

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

| ANALYTE | | | | SYST/INST | | REAGENTS | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
|----------------|----------|------------|--|-----------------|------------|--|------------|----------|-----------|----------|------|------------|---------|
| SAMPLE | METHOD | | | | | | LABS | VALUE | DEVIATION | CV | LOW | HIGH | |
| 001 ALAN AMINO | ALT/SGPT | | | CLIA TEST ID #: | 255 | EVALUATION CRITERIA: TARGET VALUE 20 % | | | | | | | |
| 2021-001 | 5 | ENZ. 37 C | | 197 | ARCHITECT | 1 | ABBOTT | 18 | 291.333 | 11.446 | 3.93 | 233.000 | 350.000 |
| 2021-001 | 10 | KINETIC 37 | | 215 | B.C DXC | 134 | BECKM.COUL | 11 | 285.727 | 5.378 | 1.88 | 229.000 | 343.000 |
| 2021-001 | 11 | MOD. IFCC | | 38 | SIEMENS DI | 143 | SIEMENS | 74 | 306.493 | 8.261 | 2.70 | 245.000 | 368.000 |
| 2021-001 | 11 | MOD. IFCC | | 184 | INTEGRA | 93 | ROCHE | 28 | 286.679 | 9.573 | 3.34 | 229.000 | 344.000 |
| 2021-001 | 11 | MOD. IFCC | | 186 | BECK. COUL | 76 | AU-BECKMAN | 26 | 259.192 | 6.737 | 2.60 | 207.000 | 311.000 |
| 2021-001 | 11 | MOD. IFCC | | 191 | RX-DAYTONA | 126 | RANDOX | 27 | 318.704 | 18.601 | 5.84 | 255.000 | 382.000 |
| 2021-001 | 11 | MOD. IFCC | | 203 | ROCHE | 93 | ROCHE | 28 | 285.704 | 6.759 | 2.37 | 229.000 | 343.000 |
| 2021-001 | 11 | MOD. IFCC | | 212 | S. D. EXL | 143 | SIEMENS | 10 | 309.100 | 14.286 | 4.62 | 247.000 | 371.000 |
| 2021-001 | 13 | ALA &aKETO | | 165 | VITROS | 63 | KODAK | 10 | 272.600 | 8.511 | 3.12 | 218.000 | 327.000 |
| 2021-001 | 13 | ALA &aKETO | | 165 | VITROS | 155 | ALTV | 128 | 274.661 | 7.643 | 2.78 | 220.000 | 330.000 |
| | | | | | | | | | | | | | |
| 2021-002 | 5 | ENZ. 37 C | | 197 | ARCHITECT | 1 | ABBOTT | 18 | 214.056 | 7.412 | 3.46 | 171.000 | 257.000 |
| 2021-002 | 10 | KINETIC 37 | | 215 | B.C DXC | 134 | BECKM.COUL | 11 | 211.182 | 3.563 | 1.69 | 169.000 | 253.000 |
| 2021-002 | 11 | MOD. IFCC | | 38 | SIEMENS DI | 143 | SIEMENS | 74 | 227.361 | 5.633 | 2.48 | 182.000 | 273.000 |
| 2021-002 | 11 | MOD. IFCC | | 184 | INTEGRA | 93 | ROCHE | 28 | 210.148 | 5.609 | 2.67 | 168.000 | 252.000 |
| 2021-002 | 11 | MOD. IFCC | | 186 | BECK. COUL | 76 | AU-BECKMAN | 26 | 189.423 | 5.315 | 2.81 | 152.000 | 227.000 |
| 2021-002 | 11 | MOD. IFCC | | 191 | RX-DAYTONA | 126 | RANDOX | 27 | 238.963 | 14.297 | 5.98 | 191.000 | 287.000 |
| 2021-002 | 11 | MOD. IFCC | | 203 | ROCHE | 93 | ROCHE | 28 | 211.704 | 5.530 | 2.61 | 169.000 | 254.000 |
| 2021-002 | 11 | MOD. IFCC | | 212 | S. D. EXL | 143 | SIEMENS | 10 | 228.800 | 9.119 | 3.99 | 183.000 | 275.000 |
| 2021-002 | 13 | ALA &aKETO | | 165 | VITROS | 63 | KODAK | 10 | 201.500 | 4.863 | 2.41 | 161.000 | 242.000 |
| 2021-002 | 13 | ALA &aKETO | | 165 | VITROS | 155 | ALTV | 128 | 203.032 | 5.682 | 2.80 | 162.000 | 244.000 |
| | | | | | | | | | | | | | |
| 2021-003 | 5 | ENZ. 37 C | | 197 | ARCHITECT | 1 | ABBOTT | 18 | 139.278 | 5.237 | 3.76 | 111.000 | 167.000 |
| 2021-003 | 10 | KINETIC 37 | | 215 | B.C DXC | 134 | BECKM.COUL | 11 | 140.818 | 2.691 | 1.91 | 113.000 | 169.000 |
| 2021-003 | 11 | MOD. IFCC | | 38 | SIEMENS DI | 143 | SIEMENS | 74 | 149.918 | 3.877 | 2.59 | 120.000 | 180.000 |
| 2021-003 | 11 | MOD. IFCC | | 184 | INTEGRA | 93 | ROCHE | 28 | 136.222 | 3.900 | 2.86 | 109.000 | 163.000 |
| 2021-003 | 11 | MOD. IFCC | | 186 | BECK. COUL | 76 | AU-BECKMAN | 26 | 123.192 | 3.659 | 2.97 | 99.000 | 148.000 |
| 2021-003 | 11 | MOD. IFCC | | 191 | RX-DAYTONA | 126 | RANDOX | 27 | 155.741 | 8.855 | 5.69 | 125.000 | 187.000 |
| 2021-003 | 11 | MOD. IFCC | | 203 | ROCHE | 93 | ROCHE | 28 | 137.429 | 3.698 | 2.69 | 110.000 | 165.000 |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

| ANALYTE | | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
|-------------------------|---------------|---------------------|--|------|---------|-----------|--------|----------|---------|------------|-------|
| SAMPLE | METHOD | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH | | |
| 2021-003 | 11 MOD. IFCC | 212 S. D. EXL | 143 SIEMENS | 10 | 150.700 | 8.112 | 5.38 | 121.000 | 181.000 | | |
| 2021-003 | 13 ALA &aKETO | 165 VITROS | 63 KODAK | 10 | 132.300 | 3.257 | 2.46 | 106.000 | 159.000 | | |
| 2021-003 | 13 ALA &aKETO | 165 VITROS | 155 ALTV | 128 | 133.465 | 3.880 | 2.91 | 107.000 | 160.000 | | |
| 001 ALAN AMINO ALT/SGPT | | CLIA TEST ID #: 255 | EVALUATION CRITERIA: TARGET VALUE 20 % | | | | | | | | |
| 2021-004 | 5 ENZ. 37 C | 197 ARCHITECT | 1 ABBOTT | 18 | 396.444 | 13.200 | 3.33 | 317.000 | 476.000 | | |
| 2021-004 | 10 KINETIC 37 | 215 B.C DXC | 134 BECKM.COUL | 11 | 376.636 | 6.919 | 1.84 | 301.000 | 452.000 | | |
| 2021-004 | 11 MOD. IFCC | 38 SIEMENS DI | 143 SIEMENS | 74 | 413.930 | 8.885 | 2.15 | 331.000 | 497.000 | | |
| 2021-004 | 11 MOD. IFCC | 184 INTEGRA | 93 ROCHE | 28 | 382.370 | 11.103 | 2.90 | 306.000 | 459.000 | | |
| 2021-004 | 11 MOD. IFCC | 186 BECK. COUL | 76 AU-BECKMAN | 26 | 350.269 | 11.798 | 3.37 | 280.000 | 420.000 | | |
| 2021-004 | 11 MOD. IFCC | 191 RX-DAYTONA | 126 RANDOX | 27 | 420.667 | 26.975 | 6.41 | 337.000 | 505.000 | | |
| 2021-004 | 11 MOD. IFCC | 203 ROCHE | 93 ROCHE | 28 | 391.370 | 9.896 | 2.53 | 313.000 | 470.000 | | |
| 2021-004 | 11 MOD. IFCC | 212 S. D. EXL | 143 SIEMENS | 10 | 415.700 | 13.617 | 3.28 | 333.000 | 499.000 | | |
| 2021-004 | 13 ALA &aKETO | 165 VITROS | 63 KODAK | 10 | 367.000 | 13.856 | 3.78 | 294.000 | 440.000 | | |
| 2021-004 | 13 ALA &aKETO | 165 VITROS | 155 ALTV | 128 | 369.159 | 10.772 | 2.92 | 295.000 | 443.000 | | |
| 2021-005 | 5 ENZ. 37 C | 197 ARCHITECT | 1 ABBOTT | 18 | 12.389 | 1.890 | 15.25 | 10.000 | 15.000 | | |
| 2021-005 | 10 KINETIC 37 | 215 B.C DXC | 134 BECKM.COUL | 11 | 23.091 | 1.083 | 4.69 | 18.000 | 28.000 | | |
| 2021-005 | 11 MOD. IFCC | 38 SIEMENS DI | 143 SIEMENS | 74 | 16.365 | 2.287 | 13.98 | 13.000 | 20.000 | | |
| 2021-005 | 11 MOD. IFCC | 184 INTEGRA | 93 ROCHE | 28 | 11.407 | 1.063 | 9.32 | 9.000 | 14.000 | | |
| 2021-005 | 11 MOD. IFCC | 186 BECK. COUL | 76 AU-BECKMAN | 26 | 10.192 | 0.556 | 5.46 | 8.000 | 12.000 | | |
| 2021-005 | 11 MOD. IFCC | 191 RX-DAYTONA | 126 RANDOX | 27 | 13.185 | 1.564 | 11.86 | 11.000 | 16.000 | | |
| 2021-005 | 11 MOD. IFCC | 203 ROCHE | 93 ROCHE | 28 | 11.607 | 0.724 | 6.24 | 9.000 | 14.000 | | |
| 2021-005 | 11 MOD. IFCC | 212 S. D. EXL | 143 SIEMENS | 10 | 16.200 | 2.315 | 14.29 | 13.000 | 19.000 | | |
| 2021-005 | 13 ALA &aKETO | 165 VITROS | 63 KODAK | 10 | 8.600 | 0.490 | 5.70 | 7.000 | 10.000 | | |
| 2021-005 | 13 ALA &aKETO | 165 VITROS | 155 ALTV | 128 | 8.714 | 0.722 | 8.29 | 7.000 | 10.000 | | |
| 002 ALBUMIN | | CLIA TEST ID #: 265 | EVALUATION CRITERIA: TARGET VALUE 10 % | | | | | | | | |
| 2021-001 | 3 DYE BI-B.G | 165 VITROS | 63 KODAK | 148 | 4.386 | 0.152 | 3.47 | 3.900 | 4.800 | | |
| 2021-001 | 3 DYE BI-B.G | 184 INTEGRA | 93 ROCHE | 36 | 4.450 | 0.132 | 2.97 | 4.000 | 4.900 | | |
| 2021-001 | 3 DYE BI-B.G | 186 BECK. COUL | 76 AU-BECKMAN | 26 | 4.235 | 0.127 | 3.00 | 3.800 | 4.700 | | |
| 2021-001 | 3 DYE BI-B.G | 191 RX-DAYTONA | 126 RANDOX | 28 | 4.314 | 0.146 | 3.38 | 3.900 | 4.700 | | |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

| ANALYTE | | | | | | | | | | | | |
|----------|---------|---------------------|-----|--|-----|------------------|-----------------|-----------------------|---------|-------------------|---------------|-------|
| SAMPLE | METHOD | SYST/INST | | REAGENTS | | NO. PART LABS | TARGET VALUE | STANDARD DEVIATION | % CV | ACCEPTABLE LOW | RANGE HIGH | |
| 2021-001 | 3 | DYE BI-B.G | 197 | ARCHITECT | 1 | ABBOTT | 21 | 4.152 | 0.122 | 2.94 | 3.700 | 4.600 |
| 2021-001 | 3 | DYE BI-B.G | 199 | Rx-IMOLA | 126 | RANDOX | 13 | 4.346 | 0.101 | 2.32 | 3.900 | 4.800 |
| 2021-001 | 3 | DYE BI-B.G | 203 | ROCHE | 93 | ROCHE | 36 | 4.443 | 0.110 | 2.48 | 4.000 | 4.900 |
| 2021-001 | 4 | DYE BI-B.P | 38 | SIEMENS DI | 143 | SIEMENS | 77 | 4.128 | 0.099 | 2.41 | 3.700 | 4.500 |
| 2021-001 | 4 | DYE BI-B.P | 212 | S. D. EXL | 143 | SIEMENS | 13 | 4.115 | 0.117 | 2.83 | 3.700 | 4.500 |
| 2021-001 | 4 | DYE BI-B.P | 215 | B.C DXC | 134 | BECKM.COUL | 10 | 4.280 | 0.087 | 2.04 | 3.900 | 4.700 |
| 002 | ALBUMIN | CLIA TEST ID #: 265 | | EVALUATION CRITERIA: TARGET VALUE 10 % | | | | | | | | |
| 2021-002 | 3 | DYE BI-B.G | 165 | VITROS | 63 | KODAK | 148 | 3.580 | 0.123 | 3.43 | 3.200 | 3.900 |
| 2021-002 | 3 | DYE BI-B.G | 184 | INTEGRA | 93 | ROCHE | 36 | 3.733 | 0.094 | 2.53 | 3.400 | 4.100 |
| 2021-002 | 3 | DYE BI-B.G | 186 | BECK. COUL | 76 | AU-BECKMAN | 26 | 3.519 | 0.096 | 2.73 | 3.200 | 3.900 |
| 2021-002 | 3 | DYE BI-B.G | 191 | RX-DAYTONA | 126 | RANDOX | 28 | 3.632 | 0.126 | 3.46 | 3.300 | 4.000 |
| 2021-002 | 3 | DYE BI-B.G | 197 | ARCHITECT | 1 | ABBOTT | 21 | 3.514 | 0.089 | 2.53 | 3.200 | 3.900 |
| 2021-002 | 3 | DYE BI-B.G | 199 | Rx-IMOLA | 126 | RANDOX | 13 | 3.608 | 0.149 | 4.13 | 3.200 | 4.000 |
| 2021-002 | 3 | DYE BI-B.G | 203 | ROCHE | 93 | ROCHE | 36 | 3.720 | 0.109 | 2.93 | 3.300 | 4.100 |
| 2021-002 | 4 | DYE BI-B.P | 38 | SIEMENS DI | 143 | SIEMENS | 77 | 3.405 | 0.087 | 2.56 | 3.100 | 3.700 |
| 2021-002 | 4 | DYE BI-B.P | 212 | S. D. EXL | 143 | SIEMENS | 13 | 3.392 | 0.092 | 2.70 | 3.100 | 3.700 |
| 2021-002 | 4 | DYE BI-B.P | 215 | B.C DXC | 134 | BECKM.COUL | 10 | 3.540 | 0.066 | 1.87 | 3.200 | 3.900 |
| 2021-003 | 3 | DYE BI-B.G | 165 | VITROS | 63 | KODAK | 148 | 2.862 | 0.095 | 3.32 | 2.600 | 3.100 |
| 2021-003 | 3 | DYE BI-B.G | 184 | INTEGRA | 93 | ROCHE | 36 | 3.053 | 0.093 | 3.04 | 2.700 | 3.400 |
| 2021-003 | 3 | DYE BI-B.G | 186 | BECK. COUL | 76 | AU-BECKMAN | 26 | 2.864 | 0.062 | 2.18 | 2.600 | 3.200 |
| 2021-003 | 3 | DYE BI-B.G | 191 | RX-DAYTONA | 126 | RANDOX | 28 | 2.968 | 0.120 | 4.03 | 2.700 | 3.300 |
| 2021-003 | 3 | DYE BI-B.G | 197 | ARCHITECT | 1 | ABBOTT | 21 | 2.852 | 0.079 | 2.78 | 2.600 | 3.100 |
| 2021-003 | 3 | DYE BI-B.G | 199 | Rx-IMOLA | 126 | RANDOX | 13 | 2.992 | 0.121 | 4.03 | 2.700 | 3.300 |
| 2021-003 | 3 | DYE BI-B.G | 203 | ROCHE | 93 | ROCHE | 36 | 3.028 | 0.102 | 3.36 | 2.700 | 3.300 |
| 2021-003 | 4 | DYE BI-B.P | 38 | SIEMENS DI | 143 | SIEMENS | 77 | 2.741 | 0.069 | 2.52 | 2.500 | 3.000 |
| 2021-003 | 4 | DYE BI-B.P | 212 | S. D. EXL | 143 | SIEMENS | 13 | 2.723 | 0.097 | 3.57 | 2.500 | 3.000 |
| 2021-003 | 4 | DYE BI-B.P | 215 | B.C DXC | 134 | BECKM.COUL | 10 | 2.860 | 0.092 | 3.20 | 2.600 | 3.100 |
| 2021-004 | 3 | DYE BI-B.G | 165 | VITROS | 63 | KODAK | 148 | 5.524 | 0.162 | 2.94 | 5.000 | 6.100 |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

| ANALYTE | | | | | | | | | | | | |
|------------------------|--------|------------|---------------------|------------|-----|--|-----------------|-----------------------|---------|-------------------|---------------|---------|
| SAMPLE | METHOD | SYST/INST | | REAGENTS | | NO. PART LABS | TARGET VALUE | STANDARD DEVIATION | % CV | ACCEPTABLE LOW | RANGE HIGH | |
| 2021-004 | 3 | DYE BI-B.G | 184 | INTEGRA | 93 | ROCHE | 36 | 5.297 | 0.159 | 3.00 | 4.800 | 5.800 |
| 2021-004 | 3 | DYE BI-B.G | 186 | BECK. COUL | 76 | AU-BECKMAN | 26 | 5.096 | 0.140 | 2.75 | 4.600 | 5.600 |
| 2021-004 | 3 | DYE BI-B.G | 191 | RX-DAYTONA | 126 | RANDOX | 28 | 5.119 | 0.147 | 2.87 | 4.600 | 5.600 |
| 2021-004 | 3 | DYE BI-B.G | 197 | ARCHITECT | 1 | ABBOTT | 21 | 5.043 | 0.153 | 3.03 | 4.500 | 5.500 |
| 2021-004 | 3 | DYE BI-B.G | 199 | Rx-IMOLA | 126 | RANDOX | 13 | 5.177 | 0.197 | 3.80 | 4.700 | 5.700 |
| 2021-004 | 3 | DYE BI-B.G | 203 | ROCHE | 93 | ROCHE | 36 | 5.329 | 0.152 | 2.86 | 4.800 | 5.900 |
| 2021-004 | 4 | DYE BI-B.P | 38 | SIEMENS DI | 143 | SIEMENS | 77 | 5.054 | 0.108 | 2.14 | 4.500 | 5.600 |
| 2021-004 | 4 | DYE BI-B.P | 212 | S. D. EXL | 143 | SIEMENS | 13 | 5.077 | 0.185 | 3.64 | 4.600 | 5.600 |
| 2021-004 | 4 | DYE BI-B.P | 215 | B.C DXC | 134 | BECKM.COUL | 10 | 5.230 | 0.100 | 1.92 | 4.700 | 5.800 |
| 002 ALBUMIN | | | CLIA TEST ID #: 265 | | | EVALUATION CRITERIA: TARGET VALUE 10 % | | | | | | |
| 2021-005 | 3 | DYE BI-B.G | 165 | VITROS | 63 | KODAK | 148 | 1.692 | 0.048 | 2.82 | 1.500 | 1.900 |
| 2021-005 | 3 | DYE BI-B.G | 184 | INTEGRA | 93 | ROCHE | 36 | 1.806 | 0.062 | 3.44 | 1.600 | 2.000 |
| 2021-005 | 3 | DYE BI-B.G | 186 | BECK. COUL | 76 | AU-BECKMAN | 26 | 1.658 | 0.063 | 3.81 | 1.500 | 1.800 |
| 2021-005 | 3 | DYE BI-B.G | 191 | RX-DAYTONA | 126 | RANDOX | 28 | 1.804 | 0.068 | 3.77 | 1.600 | 2.000 |
| 2021-005 | 3 | DYE BI-B.G | 197 | ARCHITECT | 1 | ABBOTT | 21 | 1.681 | 0.066 | 3.95 | 1.500 | 1.800 |
| 2021-005 | 3 | DYE BI-B.G | 199 | Rx-IMOLA | 126 | RANDOX | 13 | 1.808 | 0.107 | 5.93 | 1.600 | 2.000 |
| 2021-005 | 3 | DYE BI-B.G | 203 | ROCHE | 93 | ROCHE | 36 | 1.806 | 0.079 | 4.38 | 1.600 | 2.000 |
| 2021-005 | 4 | DYE BI-B.P | 38 | SIEMENS DI | 143 | SIEMENS | 77 | 1.576 | 0.053 | 3.39 | 1.400 | 1.700 |
| 2021-005 | 4 | DYE BI-B.P | 212 | S. D. EXL | 143 | SIEMENS | 13 | 1.569 | 0.072 | 4.60 | 1.400 | 1.700 |
| 2021-005 | 4 | DYE BI-B.P | 215 | B.C DXC | 134 | BECKM.COUL | 10 | 1.660 | 0.102 | 6.14 | 1.500 | 1.800 |
| 003 ALKALINE PHOSPHATE | | | CLIA TEST ID #: 275 | | | EVALUATION CRITERIA: TARGET VALUE 30 % | | | | | | |
| 2021-001 | 3 | COLORIMET. | 184 | INTEGRA | 93 | ROCHE | 30 | 236.367 | 9.621 | 4.07 | 165.000 | 307.000 |
| 2021-001 | 3 | COLORIMET. | 203 | ROCHE | 93 | ROCHE | 24 | 220.391 | 8.586 | 3.90 | 154.000 | 287.000 |
| 2021-001 | 6 | KINETIC 37 | 165 | VITROS | 63 | KODAK | 148 | 165.061 | 8.883 | 5.38 | 116.000 | 215.000 |
| 2021-001 | 6 | KINETIC 37 | 194 | BIOLIS-24S | 154 | (IDG) | 11 | 227.000 | 10.278 | 4.53 | 159.000 | 295.000 |
| 2021-001 | 6 | KINETIC 37 | 215 | B.C DXC | 134 | BECKM.COUL | 11 | 195.545 | 11.547 | 5.91 | 137.000 | 254.000 |
| 2021-001 | 8 | BOW. MC-37 | 186 | BECK. COUL | 76 | AU-BECKMAN | 27 | 205.593 | 17.182 | 8.36 | 144.000 | 267.000 |
| 2021-001 | 9 | ENZYMAT.37 | 191 | RX-DAYTONA | 126 | RANDOX | 23 | 205.522 | 18.413 | 8.96 | 144.000 | 267.000 |
| 2021-001 | 11 | Modified I | 38 | SIEMENS DI | 143 | SIEMENS | 73 | 245.000 | 9.331 | 3.81 | 172.000 | 319.000 |
| 2021-001 | 12 | P NITRO PH | 197 | ARCHITECT | 1 | ABBOTT | 12 | 227.583 | 10.251 | 4.50 | 159.000 | 296.000 |

Participant Summary

MONTH 2 OF YEAR 2021

| SPEC: 10 CHEMISTRY | | SUB: 10 ROUTINE | | GRP: 10 ROUTINE | | | | | | | | |
|--------------------|--------------------|---------------------|-----------------------------------|-----------------|------------|-----------|---------|----------|-------|------------|---------|--|
| ANALYTE | | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE | |
| SAMPLE | METHOD | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH | | | |
| 003 | ALKALINE PHOSPHATE | CLIA TEST ID #: 275 | EVALUATION CRITERIA: TARGET VALUE | 30 | 30 % | | | | | | | |
| 2021-002 | 3 | COLORIMET. | 184 INTEGRA | 93 | ROCHE | 30 | 173.700 | 9.023 | 5.19 | 122.000 | 226.000 | |
| 2021-002 | 3 | COLORIMET. | 203 ROCHE | 93 | ROCHE | 24 | 163.130 | 8.669 | 5.31 | 114.000 | 212.000 | |
| 2021-002 | 6 | KINETIC 37 | 165 VITROS | 63 | KODAK | 148 | 145.230 | 7.774 | 5.35 | 102.000 | 189.000 | |
| 2021-002 | 6 | KINETIC 37 | 194 BIOLIS-24S | 154 | (IDG) | 11 | 166.182 | 10.970 | 6.60 | 116.000 | 216.000 | |
| 2021-002 | 6 | KINETIC 37 | 215 B.C DXC | 134 | BECKM.COUL | 11 | 149.636 | 20.698 | 13.83 | 105.000 | 195.000 | |
| 2021-002 | 8 | BOW. MC-37 | 186 BECK. COUL | 76 | AU-BECKMAN | 27 | 151.148 | 11.987 | 7.93 | 106.000 | 196.000 | |
| 2021-002 | 9 | ENZYMAT.37 | 191 RX-DAYTONA | 126 | RANDOX | 23 | 152.783 | 13.657 | 8.94 | 107.000 | 199.000 | |
| 2021-002 | 11 | Modified I | 38 SIEMENS DI | 143 | SIEMENS | 73 | 181.431 | 6.000 | 3.31 | 127.000 | 236.000 | |
| 2021-002 | 12 | P NITRO PH | 197 ARCHITECT | 1 | ABBOTT | 12 | 167.667 | 6.407 | 3.82 | 117.000 | 218.000 | |
| 2021-003 | 3 | COLORIMET. | 184 INTEGRA | 93 | ROCHE | 30 | 115.967 | 5.930 | 5.11 | 81.000 | 151.000 | |
| 2021-003 | 3 | COLORIMET. | 203 ROCHE | 93 | ROCHE | 24 | 109.478 | 4.826 | 4.41 | 77.000 | 142.000 | |
| 2021-003 | 6 | KINETIC 37 | 165 VITROS | 63 | KODAK | 148 | 113.966 | 5.661 | 4.97 | 80.000 | 148.000 | |
| 2021-003 | 6 | KINETIC 37 | 194 BIOLIS-24S | 154 | (IDG) | 11 | 111.909 | 6.037 | 5.39 | 78.000 | 145.000 | |
| 2021-003 | 6 | KINETIC 37 | 215 B.C DXC | 134 | BECKM.COUL | 11 | 97.636 | 6.596 | 6.76 | 68.000 | 127.000 | |
| 2021-003 | 8 | BOW. MC-37 | 186 BECK. COUL | 76 | AU-BECKMAN | 27 | 101.519 | 7.909 | 7.79 | 71.000 | 132.000 | |
| 2021-003 | 9 | ENZYMAT.37 | 191 RX-DAYTONA | 126 | RANDOX | 23 | 103.261 | 8.911 | 8.63 | 72.000 | 134.000 | |
| 2021-003 | 11 | Modified I | 38 SIEMENS DI | 143 | SIEMENS | 73 | 121.056 | 5.259 | 4.34 | 85.000 | 157.000 | |
| 2021-003 | 12 | P NITRO PH | 197 ARCHITECT | 1 | ABBOTT | 12 | 112.750 | 4.969 | 4.41 | 79.000 | 147.000 | |
| 2021-004 | 3 | COLORIMET. | 184 INTEGRA | 93 | ROCHE | 30 | 320.500 | 13.468 | 4.20 | 224.000 | 417.000 | |
| 2021-004 | 3 | COLORIMET. | 203 ROCHE | 93 | ROCHE | 24 | 304.250 | 17.271 | 5.68 | 213.000 | 396.000 | |
| 2021-004 | 6 | KINETIC 37 | 165 VITROS | 63 | KODAK | 148 | 181.642 | 10.074 | 5.55 | 127.000 | 236.000 | |
| 2021-004 | 6 | KINETIC 37 | 194 BIOLIS-24S | 154 | (IDG) | 11 | 311.727 | 15.286 | 4.90 | 218.000 | 405.000 | |
| 2021-004 | 6 | KINETIC 37 | 215 B.C DXC | 134 | BECKM.COUL | 11 | 263.727 | 15.142 | 5.74 | 185.000 | 343.000 | |
| 2021-004 | 8 | BOW. MC-37 | 186 BECK. COUL | 76 | AU-BECKMAN | 27 | 280.259 | 21.549 | 7.69 | 196.000 | 364.000 | |
| 2021-004 | 9 | ENZYMAT.37 | 191 RX-DAYTONA | 126 | RANDOX | 23 | 275.913 | 28.601 | 10.37 | 193.000 | 359.000 | |
| 2021-004 | 11 | Modified I | 38 SIEMENS DI | 143 | SIEMENS | 73 | 337.708 | 12.788 | 3.79 | 236.000 | 439.000 | |
| 2021-004 | 12 | P NITRO PH | 197 ARCHITECT | 1 | ABBOTT | 12 | 305.583 | 14.361 | 4.70 | 214.000 | 397.000 | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPEC: 10 CHEMISTRY | | SUB: 10 ROUTINE | | GRP: 10 ROUTINE | | | | | | | | |
|--------------------|--------------------|---------------------|-----------------------------------|-----------------|------------|-----------|---------|----------|-------|------------|---------|--|
| ANALYTE | | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE | |
| SAMPLE | METHOD | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH | | | |
| 003 | ALKALINE PHOSPHATE | CLIA TEST ID #: 275 | EVALUATION CRITERIA: TARGET VALUE | 30 | 30 % | | | | | | | |
| 2021-005 | 3 | COLORIMET. | 184 INTEGRA | 93 | ROCHE | 30 | 18.931 | 1.015 | 5.36 | 13.000 | 25.000 | |
| 2021-005 | 3 | COLORIMET. | 203 ROCHE | 93 | ROCHE | 24 | 18.087 | 1.316 | 7.28 | 13.000 | 24.000 | |
| 2021-005 | 6 | KINETIC 37 | 165 VITROS | 63 | KODAK | 148 | 30.027 | 1.903 | 6.34 | 21.000 | 39.000 | |
| 2021-005 | 6 | KINETIC 37 | 194 BIOLIS-24S | 154 | (IDG) | 11 | 17.364 | 2.385 | 13.73 | 12.000 | 23.000 | |
| 2021-005 | 6 | KINETIC 37 | 215 B.C DXC | 134 | BECKM.COUL | 11 | 15.909 | 1.379 | 8.67 | 11.000 | 21.000 | |
| 2021-005 | 8 | BOW. MC-37 | 186 BECK. COUL | 76 | AU-BECKMAN | 27 | 16.407 | 1.341 | 8.17 | 11.000 | 21.000 | |
| 2021-005 | 9 | ENZYMAT.37 | 191 RX-DAYTONA | 126 | RANDOX | 23 | 17.565 | 1.740 | 9.91 | 12.000 | 23.000 | |
| 2021-005 | 11 | Modified I | 38 SIEMENS DI | 143 | SIEMENS | 73 | 19.819 | 3.151 | 15.90 | 14.000 | 26.000 | |
| 2021-005 | 12 | P NITRO PH | 197 ARCHITECT | 1 | ABBOTT | 12 | 18.667 | 0.943 | 5.05 | 13.000 | 24.000 | |
| 004 | AMYLASE | CLIA TEST ID #: 285 | | | | | | | | | | |
| 2021-001 | 3 | ENZYM. 37C | 165 VITROS | 63 | KODAK | 86 | 156.384 | 7.094 | 4.54 | 109.000 | 203.000 | |
| 2021-001 | 3 | ENZYM. 37C | 215 B.C DXC | 134 | BECKM.COUL | 11 | 220.182 | 3.486 | 1.58 | 154.000 | 286.000 | |
| 2021-001 | 4 | HYDRO ACT. | 38 SIEMENS DI | 143 | SIEMENS | 24 | 207.750 | 3.822 | 1.84 | 145.000 | 270.000 | |
| 2021-001 | 9 | ENZ/COL.37 | 184 INTEGRA | 93 | ROCHE | 10 | 216.700 | 4.691 | 2.16 | 152.000 | 282.000 | |
| 2021-001 | 9 | ENZ/COL.37 | 203 ROCHE | 93 | ROCHE | 23 | 207.087 | 4.053 | 1.96 | 145.000 | 269.000 | |
| 2021-001 | 10 | CNPG3 | 186 BECK. COUL | 76 | AU-BECKMAN | 18 | 161.833 | 10.905 | 6.74 | 113.000 | 210.000 | |
| 2021-002 | 3 | ENZYM. 37C | 165 VITROS | 63 | KODAK | 86 | 115.035 | 5.600 | 4.87 | 81.000 | 150.000 | |
| 2021-002 | 3 | ENZYM. 37C | 215 B.C DXC | 134 | BECKM.COUL | 11 | 163.364 | 2.805 | 1.72 | 114.000 | 212.000 | |
| 2021-002 | 4 | HYDRO ACT. | 38 SIEMENS DI | 143 | SIEMENS | 24 | 154.667 | 2.824 | 1.83 | 108.000 | 201.000 | |
| 2021-002 | 9 | ENZ/COL.37 | 184 INTEGRA | 93 | ROCHE | 10 | 160.500 | 2.729 | 1.70 | 112.000 | 209.000 | |
| 2021-002 | 9 | ENZ/COL.37 | 203 ROCHE | 93 | ROCHE | 23 | 153.696 | 3.700 | 2.41 | 108.000 | 200.000 | |
| 2021-002 | 10 | CNPG3 | 186 BECK. COUL | 76 | AU-BECKMAN | 18 | 119.889 | 7.370 | 6.15 | 84.000 | 156.000 | |
| 2021-003 | 3 | ENZYM. 37C | 165 VITROS | 63 | KODAK | 86 | 73.547 | 6.640 | 9.03 | 51.000 | 96.000 | |
| 2021-003 | 3 | ENZYM. 37C | 215 B.C DXC | 134 | BECKM.COUL | 11 | 109.545 | 2.311 | 2.11 | 77.000 | 142.000 | |
| 2021-003 | 4 | HYDRO ACT. | 38 SIEMENS DI | 143 | SIEMENS | 24 | 103.000 | 2.062 | 2.00 | 72.000 | 134.000 | |
| 2021-003 | 9 | ENZ/COL.37 | 184 INTEGRA | 93 | ROCHE | 10 | 107.800 | 2.040 | 1.89 | 75.000 | 140.000 | |
| 2021-003 | 9 | ENZ/COL.37 | 203 ROCHE | 93 | ROCHE | 23 | 102.957 | 1.876 | 1.82 | 72.000 | 134.000 | |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

| ANALYTE | | | | | | | | | | | | | |
|----------|---------------------|---------------------|-----|--|-----|------------------|-----------------|-----------------------|---------|-------------------|---------------|---------|--|
| SAMPLE | METHOD | SYST/INST | | REAGENTS | | NO. PART LABS | TARGET VALUE | STANDARD DEVIATION | % CV | ACCEPTABLE LOW | RANGE HIGH | | |
| 2021-003 | 10 | CNPG3 | 186 | BECK. COUL | 76 | AU-BECKMAN | 18 | 80.778 | 5.493 | 6.80 | 57.000 | 105.000 | |
| 004 | AMYLASE | CLIA TEST ID #: 285 | | EVALUATION CRITERIA: TARGET VALUE 30 % | | | | | | | | | |
| 2021-004 | 3 | ENZYM. 37C | 165 | VITROS | 63 | KODAK | 86 | 207.814 | 11.537 | 5.55 | 145.000 | 270.000 | |
| 2021-004 | 3 | ENZYM. 37C | 215 | B.C DXC | 134 | BECKM.COUL | 11 | 299.273 | 3.863 | 1.29 | 209.000 | 389.000 | |
| 2021-004 | 4 | HYDRO ACT. | 38 | SIEMENS DI | 143 | SIEMENS | 24 | 281.042 | 4.843 | 1.72 | 197.000 | 365.000 | |
| 2021-004 | 9 | ENZ/COL.37 | 184 | INTEGRA | 93 | ROCHE | 10 | 291.000 | 6.245 | 2.15 | 204.000 | 378.000 | |
| 2021-004 | 9 | ENZ/COL.37 | 203 | ROCHE | 93 | ROCHE | 23 | 282.091 | 6.201 | 2.20 | 197.000 | 367.000 | |
| 2021-004 | 10 | CNPG3 | 186 | BECK. COUL | 76 | AU-BECKMAN | 18 | 218.333 | 13.325 | 6.10 | 153.000 | 284.000 | |
| 2021-005 | 3 | ENZYM. 37C | 165 | VITROS | 63 | KODAK | 86 | 30.000 | 0.000 | 0.00 | 21.000 | 39.000 | |
| 2021-005 | 3 | ENZYM. 37C | 215 | B.C DXC | 134 | BECKM.COUL | 11 | 19.727 | 0.750 | 3.80 | 14.000 | 26.000 | |
| 2021-005 | 4 | HYDRO ACT. | 38 | SIEMENS DI | 143 | SIEMENS | 24 | 17.333 | 0.745 | 4.30 | 12.000 | 23.000 | |
| 2021-005 | 9 | ENZ/COL.37 | 184 | INTEGRA | 93 | ROCHE | 10 | 20.400 | 0.490 | 2.40 | 14.000 | 27.000 | |
| 2021-005 | 9 | ENZ/COL.37 | 203 | ROCHE | 93 | ROCHE | 23 | 19.261 | 0.529 | 2.75 | 13.000 | 25.000 | |
| 2021-005 | 10 | CNPG3 | 186 | BECK. COUL | 76 | AU-BECKMAN | 18 | 13.056 | 1.079 | 8.26 | 9.000 | 17.000 | |
| 005 | ASP. AMINO AST/SGOT | CLIA TEST ID #: 295 | | EVALUATION CRITERIA: TARGET VALUE 20 % | | | | | | | | | |
| 2021-001 | 1 | ASPAR&KETO | 165 | VITROS | 63 | KODAK | 142 | 409.688 | 12.278 | 3.00 | 328.000 | 492.000 | |
| 2021-001 | 1 | ASPAR&KETO | 194 | BIOLIS-24S | 154 | (IDG) | 11 | 285.667 | 6.549 | 2.29 | 229.000 | 343.000 | |
| 2021-001 | 1 | ASPAR&KETO | 194 | BIOLIS-24S | 154 | (IDG) | 11 | 309.273 | 29.071 | 9.40 | 247.000 | 371.000 | |
| 2021-001 | 5 | ENZYM. 37C | 38 | SIEMENS DI | 143 | SIEMENS | 78 | 318.205 | 9.300 | 2.92 | 255.000 | 382.000 | |
| 2021-001 | 5 | ENZYM. 37C | 212 | S. D. EXL | 143 | SIEMENS | 13 | 321.692 | 13.533 | 4.21 | 257.000 | 386.000 | |
| 2021-001 | 10 | KINETIC 37 | 215 | B.C DXC | 134 | BECKM.COUL | 10 | 304.700 | 6.084 | 2.00 | 244.000 | 366.000 | |
| 2021-001 | 11 | MOD. IFCC | 184 | INTEGRA | 93 | ROCHE | 30 | 325.400 | 7.898 | 2.43 | 260.000 | 390.000 | |
| 2021-001 | 11 | MOD. IFCC | 186 | BECK. COUL | 76 | AU-BECKMAN | 27 | 277.815 | 15.019 | 5.41 | 222.000 | 333.000 | |
| 2021-001 | 11 | MOD. IFCC | 191 | RX-DAYTONA | 126 | RANDOX | 28 | 348.214 | 19.514 | 5.60 | 279.000 | 418.000 | |
| 2021-001 | 11 | MOD. IFCC | 203 | ROCHE | 93 | ROCHE | 26 | 323.308 | 9.076 | 2.81 | 259.000 | 388.000 | |
| 2021-001 | 13 | NADH wo P5 | 197 | ARCHITECT | 1 | ABBOTT | 12 | 309.750 | 5.703 | 1.84 | 248.000 | 372.000 | |
| 2021-002 | 1 | ASPAR&KETO | 165 | VITROS | 63 | KODAK | 142 | 289.486 | 8.334 | 2.88 | 232.000 | 347.000 | |
| 2021-002 | 1 | ASPAR&KETO | 194 | BIOLIS-24S | 154 | (IDG) | 11 | 236.545 | 19.653 | 8.31 | 189.000 | 284.000 | |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

| ANALYTE | | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
|-------------------------|--------|------------|---------------------|--|-------|-----------|--------|----------|---------|------------|-------|
| SAMPLE | METHOD | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH | | |
| 2021-002 | 1 | ASPAR&KETO | 194 BIOLIS-24S | 154 (IDG) | 11 | 218.333 | 1.700 | 0.78 | 175.000 | 262.000 | |
| 2021-002 | 5 | ENZYMA.37C | 38 SIEMENS DI | 143 SIEMENS | 78 | 238.667 | 7.438 | 3.12 | 191.000 | 286.000 | |
| 2021-002 | 5 | ENZYMA.37C | 212 S. D. EXL | 143 SIEMENS | 13 | 239.462 | 10.689 | 4.46 | 192.000 | 287.000 | |
| 2021-002 | 10 | KINETIC 37 | 215 B.C DXC | 134 BECKM.COUL | 10 | 230.000 | 4.050 | 1.76 | 184.000 | 276.000 | |
| 2021-002 | 11 | MOD. IFCC | 184 INTEGRA | 93 ROCHE | 30 | 245.367 | 6.295 | 2.57 | 196.000 | 294.000 | |
| 2021-002 | 11 | MOD. IFCC | 186 BECK. COUL | 76 AU-BECKMAN | 27 | 207.115 | 9.390 | 4.53 | 166.000 | 249.000 | |
| 2021-002 | 11 | MOD. IFCC | 191 RX-DAYTONA | 126 RANDOX | 28 | 261.929 | 16.007 | 6.11 | 210.000 | 314.000 | |
| 2021-002 | 11 | MOD. IFCC | 203 ROCHE | 93 ROCHE | 26 | 243.080 | 7.975 | 3.28 | 194.000 | 292.000 | |
| 2021-002 | 13 | NADH wo P5 | 197 ARCHITECT | 1 ABBOTT | 12 | 231.583 | 3.774 | 1.63 | 185.000 | 278.000 | |
| 005 ASP. AMINO AST/SGOT | | | CLIA TEST ID #: 295 | EVALUATION CRITERIA: TARGET VALUE 20 % | | | | | | | |
| 2021-003 | 1 | ASPAR&KETO | 165 VITROS | 63 KODAK | 142 | 186.922 | 5.282 | 2.83 | 150.000 | 224.000 | |
| 2021-003 | 1 | ASPAR&KETO | 194 BIOLIS-24S | 154 (IDG) | 11 | 149.667 | 0.471 | 0.31 | 120.000 | 180.000 | |
| 2021-003 | 1 | ASPAR&KETO | 194 BIOLIS-24S | 154 (IDG) | 11 | 167.273 | 14.592 | 8.72 | 134.000 | 201.000 | |
| 2021-003 | 5 | ENZYMA.37C | 38 SIEMENS DI | 143 SIEMENS | 78 | 162.500 | 5.228 | 3.22 | 130.000 | 195.000 | |
| 2021-003 | 5 | ENZYMA.37C | 212 S. D. EXL | 143 SIEMENS | 13 | 162.846 | 8.475 | 5.20 | 130.000 | 195.000 | |
| 2021-003 | 10 | KINETIC 37 | 215 B.C DXC | 134 BECKM.COUL | 10 | 157.500 | 3.640 | 2.31 | 126.000 | 189.000 | |
| 2021-003 | 11 | MOD. IFCC | 184 INTEGRA | 93 ROCHE | 30 | 167.862 | 3.989 | 2.38 | 134.000 | 201.000 | |
| 2021-003 | 11 | MOD. IFCC | 186 BECK. COUL | 76 AU-BECKMAN | 27 | 142.500 | 5.271 | 3.70 | 114.000 | 171.000 | |
| 2021-003 | 11 | MOD. IFCC | 191 RX-DAYTONA | 126 RANDOX | 28 | 179.714 | 12.203 | 6.79 | 144.000 | 216.000 | |
| 2021-003 | 11 | MOD. IFCC | 203 ROCHE | 93 ROCHE | 26 | 166.192 | 4.954 | 2.98 | 133.000 | 199.000 | |
| 2021-003 | 13 | NADH wo P5 | 197 ARCHITECT | 1 ABBOTT | 12 | 160.000 | 2.858 | 1.79 | 128.000 | 192.000 | |
| 2021-004 | 1 | ASPAR&KETO | 165 VITROS | 63 KODAK | 142 | 583.149 | 26.336 | 4.52 | 467.000 | 700.000 | |
| 2021-004 | 1 | ASPAR&KETO | 194 BIOLIS-24S | 154 (IDG) | 11 | 398.273 | 22.852 | 5.74 | 319.000 | 478.000 | |
| 2021-004 | 1 | ASPAR&KETO | 194 BIOLIS-24S | 154 (IDG) | 11 | 375.000 | 13.140 | 3.50 | 300.000 | 450.000 | |
| 2021-004 | 5 | ENZYMA.37C | 38 SIEMENS DI | 143 SIEMENS | 78 | 428.513 | 13.125 | 3.06 | 343.000 | 514.000 | |
| 2021-004 | 5 | ENZYMA.37C | 212 S. D. EXL | 143 SIEMENS | 13 | 431.077 | 17.309 | 4.02 | 345.000 | 517.000 | |
| 2021-004 | 10 | KINETIC 37 | 215 B.C DXC | 134 BECKM.COUL | 10 | 395.500 | 11.138 | 2.82 | 316.000 | 475.000 | |
| 2021-004 | 11 | MOD. IFCC | 184 INTEGRA | 93 ROCHE | 30 | 425.167 | 12.450 | 2.93 | 340.000 | 510.000 | |
| 2021-004 | 11 | MOD. IFCC | 186 BECK. COUL | 76 AU-BECKMAN | 27 | 363.667 | 22.626 | 6.22 | 291.000 | 436.000 | |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

| ANALYTE | | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
|----------|---------------------|---------------------|--|--|------|----------|-----------|----------|---------|------------|-------|
| SAMPLE | METHOD | SYST/INST | REAGENTS | | LABS | VALUE | DEVIATION | CV | LOW | HIGH | |
| 2021-004 | 11 MOD. IFCC | 191 RX-DAYTONA | 126 RANDOX | | 28 | 451.500 | 26.357 | 5.84 | 361.000 | 542.000 | |
| 2021-004 | 11 MOD. IFCC | 203 ROCHE | 93 ROCHE | | 26 | 423.346 | 13.436 | 3.17 | 339.000 | 508.000 | |
| 2021-004 | 13 NADH wo P5 | 197 ARCHITECT | 1 ABBOTT | | 12 | 403.167 | 6.619 | 1.64 | 323.000 | 484.000 | |
| 005 | ASP. AMINO AST/SGOT | CLIA TEST ID #: 295 | EVALUATION CRITERIA: TARGET VALUE 20 % | | | | | | | | |
| 2021-005 | 1 ASPAR&KETO | 165 VITROS | 63 KODAK | | 142 | 38.092 | 1.231 | 3.23 | 30.000 | 46.000 | |
| 2021-005 | 1 ASPAR&KETO | 194 BIOLIS-24S | 154 (IDG) | | 11 | 30.333 | 0.943 | 3.11 | 24.000 | 36.000 | |
| 2021-005 | 1 ASPAR&KETO | 194 BIOLIS-24S | 154 (IDG) | | 11 | 32.273 | 3.768 | 11.68 | 26.000 | 39.000 | |
| 2021-005 | 5 ENZYMA.37C | 38 SIEMENS DI | 143 SIEMENS | | 78 | 34.325 | 1.834 | 5.34 | 27.000 | 41.000 | |
| 2021-005 | 5 ENZYMA.37C | 212 S. D. EXL | 143 SIEMENS | | 13 | 33.846 | 1.747 | 5.16 | 27.000 | 41.000 | |
| 2021-005 | 10 KINETIC 37 | 215 B.C DXC | 134 BECKM.COUL | | 10 | 37.000 | 1.612 | 4.36 | 30.000 | 44.000 | |
| 2021-005 | 11 MOD. IFCC | 184 INTEGRA | 93 ROCHE | | 30 | 33.833 | 1.416 | 4.19 | 27.000 | 41.000 | |
| 2021-005 | 11 MOD. IFCC | 186 BECK. COUL | 76 AU-BECKMAN | | 27 | 29.222 | 1.618 | 5.54 | 23.000 | 35.000 | |
| 2021-005 | 11 MOD. IFCC | 191 RX-DAYTONA | 126 RANDOX | | 28 | 36.407 | 2.972 | 8.16 | 29.000 | 44.000 | |
| 2021-005 | 11 MOD. IFCC | 203 ROCHE | 93 ROCHE | | 26 | 33.231 | 1.219 | 3.67 | 27.000 | 40.000 | |
| 2021-005 | 13 NADH wo P5 | 197 ARCHITECT | 1 ABBOTT | | 12 | 32.583 | 1.320 | 4.05 | 26.000 | 39.000 | |
| 006 | BILIRUBIN, TOTAL | CLIA TEST ID #: 305 | | | | | | | | | |
| 2021-001 | 1 BICHR.NO B | 194 BIOLIS-24S | 154 (IDG) | | 10 | 3.349 | 0.125 | 3.74 | 2.680 | 4.020 | |
| 2021-001 | 4 J-G WITH B | 38 SIEMENS DI | 143 SIEMENS | | 77 | 4.422 | 0.202 | 4.58 | 3.540 | 5.310 | |
| 2021-001 | 4 J-G WITH B | 186 BECK. COUL | 76 AU-BECKMAN | | 24 | 4.200 | 0.051 | 1.21 | 3.360 | 5.040 | |
| 2021-001 | 4 J-G WITH B | 186 BECK. COUL | 76 AU-BECKMAN | | 24 | 4.224 | 0.137 | 3.24 | 3.380 | 5.070 | |
| 2021-001 | 4 J-G WITH B | 191 RX-DAYTONA | 126 RANDOX | | 20 | 4.662 | 0.342 | 7.34 | 3.730 | 5.590 | |
| 2021-001 | 4 J-G WITH B | 212 S. D. EXL | 143 SIEMENS | | 10 | 4.545 | 0.384 | 8.46 | 3.640 | 5.450 | |
| 2021-001 | 4 J-G WITH B | 212 S. D. EXL | 143 SIEMENS | | 10 | 4.580 | 0.212 | 4.62 | 3.660 | 5.500 | |
| 2021-001 | 5 J-G NO BK. | 215 B.C DXC | 134 BECKM.COUL | | 11 | 4.973 | 0.166 | 3.33 | 3.980 | 5.970 | |
| 2021-001 | 7 DIAZO-DYPH | 165 VITROS | 63 KODAK | | 144 | 4.277 | 0.230 | 5.38 | 3.420 | 5.130 | |
| 2021-001 | 13 AZOBIL. | 184 INTEGRA | 93 ROCHE | | 19 | 3.983 | 0.130 | 3.26 | 3.190 | 4.780 | |
| 2021-001 | 13 AZOBIL. | 203 ROCHE | 93 ROCHE | | 23 | 4.012 | 0.141 | 3.52 | 3.210 | 4.810 | |
| 2021-001 | 18 COLORIMETR | 203 ROCHE | 93 ROCHE | | 11 | 3.917 | 0.083 | 2.11 | 3.130 | 4.700 | |
| 2021-001 | 19 DIAZO W BL | 197 ARCHITECT | 1 ABBOTT | | 12 | 4.258 | 0.164 | 3.84 | 3.410 | 5.110 | |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

| ANALYTE | | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
|----------|------------------|---------------------|--|--|------|----------|-----------|----------|-------|------------|-------|
| SAMPLE | METHOD | SYST/INST | REAGENTS | | LABS | VALUE | DEVIATION | CV | LOW | HIGH | |
| 006 | BILIRUBIN, TOTAL | CLIA TEST ID #: 305 | EVALUATION CRITERIA: TARGET VALUE 20 % | | | | | | | | |
| 2021-002 | 1 BICHR.NO B | 194 BIOLIS-24S | 154 (IDG) | | 10 | 2.429 | 0.124 | 5.11 | 1.940 | 2.910 | |
| 2021-002 | 4 J-G WITH B | 38 SIEMENS DI | 143 SIEMENS | | 77 | 3.196 | 0.168 | 5.27 | 2.560 | 3.840 | |
| 2021-002 | 4 J-G WITH B | 186 BECK. COUL | 76 AU-BECKMAN | | 24 | 3.102 | 0.102 | 3.28 | 2.480 | 3.720 | |
| 2021-002 | 4 J-G WITH B | 186 BECK. COUL | 76 AU-BECKMAN | | 24 | 3.057 | 0.081 | 2.64 | 2.450 | 3.670 | |
| 2021-002 | 4 J-G WITH B | 191 RX-DAYTONA | 126 RANDOX | | 20 | 3.415 | 0.271 | 7.92 | 2.730 | 4.100 | |
| 2021-002 | 4 J-G WITH B | 212 S. D. EXL | 143 SIEMENS | | 10 | 3.250 | 0.274 | 8.42 | 2.600 | 3.900 | |
| 2021-002 | 4 J-G WITH B | 212 S. D. EXL | 143 SIEMENS | | 10 | 3.217 | 0.111 | 3.45 | 2.570 | 3.860 | |
| 2021-002 | 5 J-G NO BK. | 215 B.C DXC | 134 BECKM.COUL | | 11 | 3.610 | 0.155 | 4.28 | 2.890 | 4.330 | |
| 2021-002 | 7 DIAZO-DYPH | 165 VITROS | 63 KODAK | | 144 | 3.055 | 0.179 | 5.85 | 2.440 | 3.670 | |
| 2021-002 | 13 AZOBIL. | 184 INTEGRA | 93 ROCHE | | 19 | 2.905 | 0.134 | 4.60 | 2.320 | 3.490 | |
| 2021-002 | 13 AZOBIL. | 203 ROCHE | 93 ROCHE | | 23 | 2.858 | 0.114 | 3.98 | 2.290 | 3.430 | |
| 2021-002 | 18 COLORIMETR | 203 ROCHE | 93 ROCHE | | 11 | 2.859 | 0.065 | 2.26 | 2.290 | 3.430 | |
| 2021-002 | 19 DIAZO W BL | 197 ARCHITECT | 1 ABBOTT | | 12 | 3.052 | 0.153 | 5.01 | 2.440 | 3.660 | |
| 2021-003 | 1 BICHR.NO B | 194 BIOLIS-24S | 154 (IDG) | | 10 | 1.518 | 0.084 | 5.50 | 1.210 | 1.820 | |
| 2021-003 | 4 J-G WITH B | 38 SIEMENS DI | 143 SIEMENS | | 77 | 1.996 | 0.095 | 4.75 | 1.600 | 2.400 | |
| 2021-003 | 4 J-G WITH B | 186 BECK. COUL | 76 AU-BECKMAN | | 24 | 1.980 | 0.029 | 1.49 | 1.580 | 2.380 | |
| 2021-003 | 4 J-G WITH B | 186 BECK. COUL | 76 AU-BECKMAN | | 24 | 2.010 | 0.070 | 3.49 | 1.610 | 2.410 | |
| 2021-003 | 4 J-G WITH B | 191 RX-DAYTONA | 126 RANDOX | | 20 | 2.174 | 0.165 | 7.60 | 1.740 | 2.610 | |
| 2021-003 | 4 J-G WITH B | 212 S. D. EXL | 143 SIEMENS | | 10 | 2.010 | 0.102 | 5.09 | 1.610 | 2.410 | |
| 2021-003 | 4 J-G WITH B | 212 S. D. EXL | 143 SIEMENS | | 10 | 2.044 | 0.182 | 8.90 | 1.640 | 2.450 | |
| 2021-003 | 5 J-G NO BK. | 215 B.C DXC | 134 BECKM.COUL | | 11 | 2.285 | 0.128 | 5.59 | 1.830 | 2.740 | |
| 2021-003 | 7 DIAZO-DYPH | 165 VITROS | 63 KODAK | | 144 | 1.906 | 0.124 | 6.50 | 1.520 | 2.290 | |
| 2021-003 | 13 AZOBIL. | 184 INTEGRA | 93 ROCHE | | 19 | 1.819 | 0.065 | 3.55 | 1.460 | 2.180 | |
| 2021-003 | 13 AZOBIL. | 203 ROCHE | 93 ROCHE | | 23 | 1.810 | 0.059 | 3.29 | 1.450 | 2.170 | |
| 2021-003 | 18 COLORIMETR | 203 ROCHE | 93 ROCHE | | 11 | 1.787 | 0.048 | 2.70 | 1.430 | 2.140 | |
| 2021-003 | 19 DIAZO W BL | 197 ARCHITECT | 1 ABBOTT | | 12 | 1.958 | 0.151 | 7.71 | 1.570 | 2.350 | |
| 2021-004 | 1 BICHR.NO B | 194 BIOLIS-24S | 154 (IDG) | | 10 | 4.578 | 0.214 | 4.67 | 3.660 | 5.490 | |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

| ANALYTE | | | | | | | | | | | | |
|----------------------|--------|------------|---------------------|------------|-----|--|-----------------|-----------------------|---------|-------------------|---------------|--------|
| SAMPLE | METHOD | SYST/INST | | REAGENTS | | NO. PART LABS | TARGET VALUE | STANDARD DEVIATION | % CV | ACCEPTABLE LOW | RANGE HIGH | |
| 2021-004 | 4 | J-G WITH B | 38 | SIEMENS DI | 143 | SIEMENS | 77 | 6.128 | 0.231 | 3.78 | 4.900 | 7.350 |
| 2021-004 | 4 | J-G WITH B | 186 | BECK. COUL | 76 | AU-BECKMAN | 24 | 5.663 | 0.122 | 2.16 | 4.530 | 6.800 |
| 2021-004 | 4 | J-G WITH B | 186 | BECK. COUL | 76 | AU-BECKMAN | 24 | 5.649 | 0.312 | 5.53 | 4.520 | 6.780 |
| 2021-004 | 4 | J-G WITH B | 191 | RX-DAYTONA | 126 | RANDOX | 20 | 6.537 | 0.456 | 6.97 | 5.230 | 7.840 |
| 2021-004 | 4 | J-G WITH B | 212 | S. D. EXL | 143 | SIEMENS | 10 | 6.373 | 0.560 | 8.79 | 5.100 | 7.650 |
| 2021-004 | 4 | J-G WITH B | 212 | S. D. EXL | 143 | SIEMENS | 10 | 6.243 | 0.270 | 4.33 | 4.990 | 7.490 |
| 2021-004 | 5 | J-G NO BK. | 215 | B.C DXC | 134 | BECKM.COUL | 11 | 6.848 | 0.204 | 2.98 | 5.480 | 8.220 |
| 2021-004 | 7 | DIAZO-DYPH | 165 | VITROS | 63 | KODAK | 144 | 5.954 | 0.292 | 4.91 | 4.760 | 7.150 |
| 2021-004 | 13 | AZOBIL. | 184 | INTEGRA | 93 | ROCHE | 19 | 5.474 | 0.165 | 3.02 | 4.380 | 6.570 |
| 2021-004 | 13 | AZOBIL. | 203 | ROCHE | 93 | ROCHE | 23 | 5.533 | 0.227 | 4.10 | 4.430 | 6.640 |
| 2021-004 | 18 | COLORIMETR | 203 | ROCHE | 93 | ROCHE | 11 | 5.480 | 0.185 | 3.38 | 4.380 | 6.580 |
| 2021-004 | 19 | DIAZO W BL | 197 | ARCHITECT | 1 | ABBOTT | 12 | 5.797 | 0.153 | 2.64 | 4.640 | 6.960 |
| 006 BILIRUBIN, TOTAL | | | CLIA TEST ID #: 305 | | | EVALUATION CRITERIA: TARGET VALUE 20 % | | | | | | |
| 2021-005 | 1 | BICHR.NO B | 194 | BIOLIS-24S | 154 | (IDG) | 10 | 0.164 | 0.042 | 25.32 | 0.130 | 0.200 |
| 2021-005 | 4 | J-G WITH B | 38 | SIEMENS DI | 143 | SIEMENS | 77 | 0.089 | 0.029 | 32.12 | 0.070 | 0.110 |
| 2021-005 | 4 | J-G WITH B | 186 | BECK. COUL | 76 | AU-BECKMAN | 24 | 0.094 | 0.012 | 12.61 | 0.080 | 0.110 |
| 2021-005 | 4 | J-G WITH B | 186 | BECK. COUL | 76 | AU-BECKMAN | 24 | 0.090 | 0.008 | 9.07 | 0.070 | 0.110 |
| 2021-005 | 4 | J-G WITH B | 191 | RX-DAYTONA | 126 | RANDOX | 20 | 0.108 | 0.042 | 39.04 | 0.090 | 0.130 |
| 2021-005 | 4 | J-G WITH B | 212 | S. D. EXL | 143 | SIEMENS | 10 | 0.087 | 0.041 | 47.68 | 0.070 | 0.100 |
| 2021-005 | 4 | J-G WITH B | 212 | S. D. EXL | 143 | SIEMENS | 10 | 0.060 | 0.029 | 49.07 | 0.050 | 0.070 |
| 2021-005 | 5 | J-G NO BK. | 215 | B.C DXC | 134 | BECKM.COUL | 11 | 0.205 | 0.080 | 39.18 | 0.160 | 0.250 |
| 2021-005 | 7 | DIAZO-DYPH | 165 | VITROS | 63 | KODAK | 144 | 0.107 | 0.027 | 24.97 | 0.090 | 0.130 |
| 2021-005 | 13 | AZOBIL. | 184 | INTEGRA | 93 | ROCHE | 19 | 0.045 | 0.053 | 118.08 | 0.040 | 0.050 |
| 2021-005 | 13 | AZOBIL. | 203 | ROCHE | 93 | ROCHE | 23 | 0.134 | 0.041 | 30.32 | 0.110 | 0.160 |
| 2021-005 | 18 | COLORIMETR | 203 | ROCHE | 93 | ROCHE | 11 | 0.150 | 0.000 | 0.00 | 0.120 | 0.180 |
| 2021-005 | 19 | DIAZO W BL | 197 | ARCHITECT | 1 | ABBOTT | 12 | 0.100 | 0.000 | 0.00 | 0.080 | 0.120 |
| 010 CALCIUM, TOTAL | | | CLIA TEST ID #: 345 | | | EVALUATION CRITERIA: TARGET VALUE 1.00 | | | | | | |
| 2021-001 | 3 | ARSEN.-III | 165 | VITROS | 63 | KODAK | 162 | 10.867 | 0.149 | 1.37 | 9.900 | 11.900 |
| 2021-001 | 3 | ARSEN.-III | 165 | VITROS | 63 | KODAK | 162 | 10.494 | 0.199 | 1.89 | 9.500 | 11.500 |
| 2021-001 | 3 | ARSEN.-III | 186 | BECK. COUL | 76 | AU-BECKMAN | 29 | 10.866 | 0.235 | 2.17 | 9.900 | 11.900 |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

| ANALYTE | | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
|----------|----------------|---------------------|-----------------------------------|------|------|----------|-----------|----------|-------|------------|-------|
| SAMPLE | METHOD | SYST/INST | REAGENTS | | LABS | VALUE | DEVIATION | CV | LOW | HIGH | |
| 2021-001 | 3 ARSEN.-III | 191 RX-DAYTONA | 126 RANDOX | | 31 | 10.829 | 0.293 | 2.71 | 9.800 | 11.800 | |
| 2021-001 | 3 ARSEN.-III | 194 BIOLIS-24S | 154 (IDG) | | 10 | 10.940 | 0.211 | 1.93 | 9.900 | 11.900 | |
| 2021-001 | 3 ARSEN.-III | 197 ARCHITECT | 1 ABBOTT | | 14 | 10.543 | 0.370 | 3.51 | 9.500 | 11.500 | |
| 2021-001 | 3 ARSEN.-III | 199 Rx-IMOLA | 126 RANDOX | | 13 | 10.908 | 0.307 | 2.82 | 9.900 | 11.900 | |
| 2021-001 | 8 CRESOLPHT. | 38 SIEMENS DI | 143 SIEMENS | | 79 | 10.524 | 0.294 | 2.79 | 9.500 | 11.500 | |
| 2021-001 | 8 CRESOLPHT. | 184 INTEGRA | 93 ROCHE | | 18 | 10.871 | 0.270 | 2.48 | 9.900 | 11.900 | |
| 2021-001 | 8 CRESOLPHT. | 203 ROCHE | 93 ROCHE | | 10 | 10.830 | 0.219 | 2.03 | 9.800 | 11.800 | |
| 2021-001 | 8 CRESOLPHT. | 212 S. D. EXL | 143 SIEMENS | | 13 | 10.446 | 0.298 | 2.85 | 9.400 | 11.400 | |
| 2021-001 | 8 CRESOLPHT. | 212 S. D. EXL | 143 SIEMENS | | 13 | 10.767 | 0.386 | 3.58 | 9.800 | 11.800 | |
| 2021-001 | 14 ELECTRODE | 215 B.C DXC | 134 BECKM.COUL | | 11 | 10.482 | 0.233 | 2.22 | 9.500 | 11.500 | |
| 2021-001 | 15 CA-NM-BAPT | 184 INTEGRA | 93 ROCHE | | 17 | 10.812 | 0.278 | 2.58 | 9.800 | 11.800 | |
| 2021-001 | 15 CA-NM-BAPT | 203 ROCHE | 93 ROCHE | | 25 | 10.846 | 0.185 | 1.70 | 9.800 | 11.800 | |
| 010 | CALCIUM, TOTAL | CLIA TEST ID #: 345 | EVALUATION CRITERIA: TARGET VALUE | 1.00 | | | | | | | |
| 2021-002 | 3 ARSEN.-III | 165 VITROS | 63 KODAK | | 162 | 9.253 | 0.185 | 2.00 | 8.300 | 10.300 | |
| 2021-002 | 3 ARSEN.-III | 165 VITROS | 63 KODAK | | 162 | 9.667 | 0.180 | 1.86 | 8.700 | 10.700 | |
| 2021-002 | 3 ARSEN.-III | 186 BECK. COUL | 76 AU-BECKMAN | | 29 | 9.418 | 0.117 | 1.24 | 8.400 | 10.400 | |
| 2021-002 | 3 ARSEN.-III | 191 RX-DAYTONA | 126 RANDOX | | 31 | 9.617 | 0.276 | 2.87 | 8.600 | 10.600 | |
| 2021-002 | 3 ARSEN.-III | 194 BIOLIS-24S | 154 (IDG) | | 10 | 9.680 | 0.160 | 1.65 | 8.700 | 10.700 | |
| 2021-002 | 3 ARSEN.-III | 197 ARCHITECT | 1 ABBOTT | | 14 | 9.164 | 0.199 | 2.17 | 8.200 | 10.200 | |
| 2021-002 | 3 ARSEN.-III | 199 Rx-IMOLA | 126 RANDOX | | 13 | 9.631 | 0.310 | 3.22 | 8.600 | 10.600 | |
| 2021-002 | 8 CRESOLPHT. | 38 SIEMENS DI | 143 SIEMENS | | 79 | 9.252 | 0.278 | 3.00 | 8.300 | 10.300 | |
| 2021-002 | 8 CRESOLPHT. | 184 INTEGRA | 93 ROCHE | | 18 | 9.539 | 0.295 | 3.09 | 8.500 | 10.500 | |
| 2021-002 | 8 CRESOLPHT. | 203 ROCHE | 93 ROCHE | | 10 | 9.590 | 0.122 | 1.27 | 8.600 | 10.600 | |
| 2021-002 | 8 CRESOLPHT. | 212 S. D. EXL | 143 SIEMENS | | 13 | 9.162 | 0.276 | 3.01 | 8.200 | 10.200 | |
| 2021-002 | 8 CRESOLPHT. | 212 S. D. EXL | 143 SIEMENS | | 13 | 9.233 | 0.205 | 2.23 | 8.200 | 10.200 | |
| 2021-002 | 14 ELECTRODE | 215 B.C DXC | 134 BECKM.COUL | | 11 | 9.209 | 0.227 | 2.47 | 8.200 | 10.200 | |
| 2021-002 | 15 CA-NM-BAPT | 184 INTEGRA | 93 ROCHE | | 17 | 9.418 | 0.281 | 2.99 | 8.400 | 10.400 | |
| 2021-002 | 15 CA-NM-BAPT | 203 ROCHE | 93 ROCHE | | 25 | 9.533 | 0.162 | 1.70 | 8.500 | 10.500 | |
| 2021-003 | 3 ARSEN.-III | 165 VITROS | 63 KODAK | | 162 | 8.600 | 0.200 | 2.33 | 7.600 | 9.600 | |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

| ANALYTE | | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
|--------------------|---------------|---------------------|--|--|------|----------|-----------|----------|--------|------------|-------|
| SAMPLE | METHOD | SYST/INST | REAGENTS | | LABS | VALUE | DEVIATION | CV | LOW | HIGH | |
| 2021-003 | 3 ARSEN.-III | 165 VITROS | 63 KODAK | | 162 | 8.101 | 0.162 | 2.00 | 7.100 | 9.100 | |
| 2021-003 | 3 ARSEN.-III | 186 BECK. COUL | 76 AU-BECKMAN | | 29 | 8.218 | 0.117 | 1.42 | 7.200 | 9.200 | |
| 2021-003 | 3 ARSEN.-III | 191 RX-DAYTONA | 126 RANDOX | | 31 | 8.442 | 0.288 | 3.41 | 7.400 | 9.400 | |
| 2021-003 | 3 ARSEN.-III | 194 BIOLIS-24S | 154 (IDG) | | 10 | 8.510 | 0.170 | 2.00 | 7.500 | 9.500 | |
| 2021-003 | 3 ARSEN.-III | 197 ARCHITECT | 1 ABBOTT | | 14 | 7.936 | 0.195 | 2.46 | 6.900 | 8.900 | |
| 2021-003 | 3 ARSEN.-III | 199 Rx-IMOLA | 126 RANDOX | | 13 | 8.554 | 0.295 | 3.45 | 7.600 | 9.600 | |
| 2021-003 | 8 CRESOLPHT. | 38 SIEMENS DI | 143 SIEMENS | | 79 | 8.128 | 0.258 | 3.17 | 7.100 | 9.100 | |
| 2021-003 | 8 CRESOLPHT. | 184 INTEGRA | 93 ROCHE | | 18 | 8.328 | 0.194 | 2.33 | 7.300 | 9.300 | |
| 2021-003 | 8 CRESOLPHT. | 203 ROCHE | 93 ROCHE | | 10 | 8.340 | 0.162 | 1.95 | 7.300 | 9.300 | |
| 2021-003 | 8 CRESOLPHT. | 212 S. D. EXL | 143 SIEMENS | | 13 | 8.062 | 0.350 | 4.34 | 7.100 | 9.100 | |
| 2021-003 | 8 CRESOLPHT. | 212 S. D. EXL | 143 SIEMENS | | 13 | 8.233 | 0.205 | 2.50 | 7.200 | 9.200 | |
| 2021-003 | 14 ELECTRODE | 215 B.C DXC | 134 BECKM.COUL | | 11 | 8.064 | 0.197 | 2.44 | 7.100 | 9.100 | |
| 2021-003 | 15 CA-NM-BAPT | 184 INTEGRA | 93 ROCHE | | 17 | 8.312 | 0.274 | 3.30 | 7.300 | 9.300 | |
| 2021-003 | 15 CA-NM-BAPT | 203 ROCHE | 93 ROCHE | | 25 | 8.324 | 0.182 | 2.18 | 7.300 | 9.300 | |
| 010 CALCIUM, TOTAL | | CLIA TEST ID #: 345 | EVALUATION CRITERIA: TARGET VALUE 1.00 | | | | | | | | |
| 2021-004 | 3 ARSEN.-III | 165 VITROS | 63 KODAK | | 162 | 11.917 | 0.255 | 2.14 | 10.900 | 12.900 | |
| 2021-004 | 3 ARSEN.-III | 165 VITROS | 63 KODAK | | 162 | 12.383 | 0.498 | 4.02 | 11.400 | 13.400 | |
| 2021-004 | 3 ARSEN.-III | 186 BECK. COUL | 76 AU-BECKMAN | | 29 | 12.525 | 0.208 | 1.66 | 11.500 | 13.500 | |
| 2021-004 | 3 ARSEN.-III | 191 RX-DAYTONA | 126 RANDOX | | 31 | 12.487 | 0.302 | 2.42 | 11.500 | 13.500 | |
| 2021-004 | 3 ARSEN.-III | 194 BIOLIS-24S | 154 (IDG) | | 10 | 12.440 | 0.233 | 1.87 | 11.400 | 13.400 | |
| 2021-004 | 3 ARSEN.-III | 197 ARCHITECT | 1 ABBOTT | | 14 | 12.286 | 0.362 | 2.95 | 11.300 | 13.300 | |
| 2021-004 | 3 ARSEN.-III | 199 Rx-IMOLA | 126 RANDOX | | 13 | 12.492 | 0.418 | 3.34 | 11.500 | 13.500 | |
| 2021-004 | 8 CRESOLPHT. | 38 SIEMENS DI | 143 SIEMENS | | 79 | 12.186 | 0.346 | 2.84 | 11.200 | 13.200 | |
| 2021-004 | 8 CRESOLPHT. | 184 INTEGRA | 93 ROCHE | | 18 | 12.389 | 0.393 | 3.17 | 11.400 | 13.400 | |
| 2021-004 | 8 CRESOLPHT. | 203 ROCHE | 93 ROCHE | | 10 | 12.480 | 0.477 | 3.82 | 11.500 | 13.500 | |
| 2021-004 | 8 CRESOLPHT. | 212 S. D. EXL | 143 SIEMENS | | 13 | 12.162 | 0.336 | 2.77 | 11.200 | 13.200 | |
| 2021-004 | 8 CRESOLPHT. | 212 S. D. EXL | 143 SIEMENS | | 13 | 12.367 | 0.125 | 1.01 | 11.400 | 13.400 | |
| 2021-004 | 14 ELECTRODE | 215 B.C DXC | 134 BECKM.COUL | | 11 | 12.018 | 0.212 | 1.77 | 11.000 | 13.000 | |
| 2021-004 | 15 CA-NM-BAPT | 184 INTEGRA | 93 ROCHE | | 17 | 12.388 | 0.307 | 2.47 | 11.400 | 13.400 | |
| 2021-004 | 15 CA-NM-BAPT | 203 ROCHE | 93 ROCHE | | 25 | 12.520 | 0.271 | 2.17 | 11.500 | 13.500 | |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

| ANALYTE | | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
|----------|----------------|---------------------|-----------------------------------|--|------|----------|-----------|----------|---------|------------|-------|
| SAMPLE | METHOD | SYST/INST | REAGENTS | | LABS | VALUE | DEVIATION | CV | LOW | HIGH | |
| 010 | CALCIUM, TOTAL | CLIA TEST ID #: 345 | EVALUATION CRITERIA: TARGET VALUE | | | 1.00 | | | | | |
| 2021-005 | 3 ARSEN.-III | 165 VITROS | 63 KODAK | | 162 | 6.600 | 0.238 | 3.61 | 5.600 | 7.600 | |
| 2021-005 | 3 ARSEN.-III | 165 VITROS | 63 KODAK | | 162 | 5.978 | 0.141 | 2.37 | 5.000 | 7.000 | |
| 2021-005 | 3 ARSEN.-III | 186 BECK. COUL | 76 AU-BECKMAN | | 29 | 6.125 | 0.102 | 1.67 | 5.100 | 7.100 | |
| 2021-005 | 3 ARSEN.-III | 191 RX-DAYTONA | 126 RANDOX | | 31 | 6.419 | 0.232 | 3.61 | 5.400 | 7.400 | |
| 2021-005 | 3 ARSEN.-III | 194 BIOLIS-24S | 154 (IDG) | | 10 | 6.510 | 0.094 | 1.45 | 5.500 | 7.500 | |
| 2021-005 | 3 ARSEN.-III | 197 ARCHITECT | 1 ABBOTT | | 14 | 5.971 | 0.148 | 2.49 | 5.000 | 7.000 | |
| 2021-005 | 3 ARSEN.-III | 199 Rx-IMOLA | 126 RANDOX | | 13 | 6.508 | 0.533 | 8.19 | 5.500 | 7.500 | |
| 2021-005 | 8 CRESOLPHT. | 38 SIEMENS DI | 143 SIEMENS | | 79 | 6.248 | 0.252 | 4.03 | 5.200 | 7.200 | |
| 2021-005 | 8 CRESOLPHT. | 184 INTEGRA | 93 ROCHE | | 18 | 6.222 | 0.155 | 2.49 | 5.200 | 7.200 | |
| 2021-005 | 8 CRESOLPHT. | 203 ROCHE | 93 ROCHE | | 10 | 6.290 | 0.151 | 2.41 | 5.300 | 7.300 | |
| 2021-005 | 8 CRESOLPHT. | 212 S. D. EXL | 143 SIEMENS | | 13 | 6.162 | 0.164 | 2.67 | 5.200 | 7.200 | |
| 2021-005 | 8 CRESOLPHT. | 212 S. D. EXL | 143 SIEMENS | | 13 | 6.133 | 0.262 | 4.28 | 5.100 | 7.100 | |
| 2021-005 | 14 ELECTRODE | 215 B.C DXC | 134 BECKM.COUL | | 11 | 6.191 | 0.150 | 2.43 | 5.200 | 7.200 | |
| 2021-005 | 15 CA-NM-BAPT | 184 INTEGRA | 93 ROCHE | | 17 | 6.200 | 0.141 | 2.28 | 5.200 | 7.200 | |
| 2021-005 | 15 CA-NM-BAPT | 203 ROCHE | 93 ROCHE | | 25 | 6.280 | 0.126 | 2.01 | 5.300 | 7.300 | |
| 011 | CHLORIDE | CLIA TEST ID #: 355 | EVALUATION CRITERIA: TARGET VALUE | | | 5 % | | | | | |
| 2021-001 | 3 ISE DILUTE | 184 INTEGRA | 93 ROCHE | | 38 | 109.026 | 2.842 | 2.61 | 104.000 | 114.000 | |
| 2021-001 | 3 ISE DILUTE | 186 BECK. COUL | 76 AU-BECKMAN | | 29 | 105.138 | 1.960 | 1.86 | 100.000 | 110.000 | |
| 2021-001 | 3 ISE DILUTE | 197 ARCHITECT | 1 ABBOTT | | 17 | 106.294 | 2.163 | 2.03 | 101.000 | 112.000 | |
| 2021-001 | 3 ISE DILUTE | 203 ROCHE | 93 ROCHE | | 38 | 104.447 | 1.727 | 1.65 | 99.000 | 110.000 | |
| 2021-001 | 3 ISE DILUTE | 215 B.C DXC | 134 BECKM.COUL | | 11 | 105.545 | 1.305 | 1.24 | 100.000 | 111.000 | |
| 2021-001 | 4 ISE UND-DI | 165 VITROS | 63 KODAK | | 102 | 105.647 | 1.892 | 1.79 | 100.000 | 111.000 | |
| 2021-001 | 4 ISE UND-DI | 165 VITROS | 156 Kit 32 | | 58 | 106.070 | 1.449 | 1.37 | 101.000 | 111.000 | |
| 2021-001 | 4 ISE UND-DI | 191 RX-DAYTONA | 126 RANDOX | | 31 | 105.267 | 2.128 | 2.02 | 100.000 | 111.000 | |
| 2021-001 | 4 ISE UND-DI | 191 RX-DAYTONA | 126 RANDOX | | 31 | 106.500 | 2.739 | 2.57 | 101.000 | 112.000 | |
| 2021-001 | 4 ISE UND-DI | 199 Rx-IMOLA | 126 RANDOX | | 13 | 105.154 | 2.348 | 2.23 | 100.000 | 110.000 | |
| 2021-001 | 9 QUICK LYTE | 38 SIEMENS DI | 143 SIEMENS | | 77 | 110.221 | 1.609 | 1.46 | 105.000 | 116.000 | |
| 2021-001 | 9 QUICK LYTE | 212 S. D. EXL | 143 SIEMENS | | 13 | 110.000 | 2.386 | 2.17 | 105.000 | 116.000 | |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

| ANALYTE | | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
|----------|--------------|---------------------|---------------------------------------|--|------|----------|-----------|----------|---------|------------|-------|
| SAMPLE | METHOD | SYST/INST | REAGENTS | | LABS | VALUE | DEVIATION | CV | LOW | HIGH | |
| 011 | CHLORIDE | CLIA TEST ID #: 355 | EVALUATION CRITERIA: TARGET VALUE 5 % | | | | | | | | |
| 2021-002 | 3 ISE DILUTE | 184 INTEGRA | 93 ROCHE | | 38 | 102.289 | 2.809 | 2.75 | 97.000 | 107.000 | |
| 2021-002 | 3 ISE DILUTE | 186 BECK. COUL | 76 AU-BECKMAN | | 29 | 99.586 | 1.672 | 1.68 | 95.000 | 105.000 | |
| 2021-002 | 3 ISE DILUTE | 197 ARCHITECT | 1 ABBOTT | | 17 | 100.941 | 1.552 | 1.54 | 96.000 | 106.000 | |
| 2021-002 | 3 ISE DILUTE | 203 ROCHE | 93 ROCHE | | 38 | 98.757 | 1.651 | 1.67 | 94.000 | 104.000 | |
| 2021-002 | 3 ISE DILUTE | 215 B.C DXC | 134 BECKM.COUL | | 11 | 100.000 | 1.809 | 1.81 | 95.000 | 105.000 | |
| 2021-002 | 4 ISE UND-DI | 165 VITROS | 63 KODAK | | 102 | 100.088 | 1.681 | 1.68 | 95.000 | 105.000 | |
| 2021-002 | 4 ISE UND-DI | 165 VITROS | 156 Kit 32 | | 58 | 100.544 | 1.623 | 1.61 | 96.000 | 106.000 | |
| 2021-002 | 4 ISE UND-DI | 191 RX-DAYTONA | 126 RANDOX | | 31 | 100.625 | 2.118 | 2.10 | 96.000 | 106.000 | |
| 2021-002 | 4 ISE UND-DI | 191 RX-DAYTONA | 126 RANDOX | | 31 | 99.333 | 2.055 | 2.07 | 94.000 | 104.000 | |
| 2021-002 | 4 ISE UND-DI | 199 Rx-IMOLA | 126 RANDOX | | 13 | 98.538 | 2.170 | 2.20 | 94.000 | 103.000 | |
| 2021-002 | 9 QUICK LYTE | 38 SIEMENS DI | 143 SIEMENS | | 77 | 103.618 | 1.581 | 1.53 | 98.000 | 109.000 | |
| 2021-002 | 9 QUICK LYTE | 212 S. D. EXL | 143 SIEMENS | | 13 | 102.538 | 2.561 | 2.50 | 97.000 | 108.000 | |
| 2021-003 | 3 ISE DILUTE | 184 INTEGRA | 93 ROCHE | | 38 | 98.026 | 2.411 | 2.46 | 93.000 | 103.000 | |
| 2021-003 | 3 ISE DILUTE | 186 BECK. COUL | 76 AU-BECKMAN | | 29 | 96.448 | 1.476 | 1.53 | 92.000 | 101.000 | |
| 2021-003 | 3 ISE DILUTE | 197 ARCHITECT | 1 ABBOTT | | 17 | 97.353 | 1.643 | 1.69 | 92.000 | 102.000 | |
| 2021-003 | 3 ISE DILUTE | 203 ROCHE | 93 ROCHE | | 38 | 94.632 | 1.661 | 1.76 | 90.000 | 99.000 | |
| 2021-003 | 3 ISE DILUTE | 215 B.C DXC | 134 BECKM.COUL | | 11 | 96.727 | 1.763 | 1.82 | 92.000 | 102.000 | |
| 2021-003 | 4 ISE UND-DI | 165 VITROS | 63 KODAK | | 102 | 96.667 | 1.751 | 1.81 | 92.000 | 102.000 | |
| 2021-003 | 4 ISE UND-DI | 165 VITROS | 156 Kit 32 | | 58 | 96.825 | 1.440 | 1.49 | 92.000 | 102.000 | |
| 2021-003 | 4 ISE UND-DI | 191 RX-DAYTONA | 126 RANDOX | | 31 | 95.200 | 1.851 | 1.94 | 90.000 | 100.000 | |
| 2021-003 | 4 ISE UND-DI | 191 RX-DAYTONA | 126 RANDOX | | 31 | 97.000 | 2.550 | 2.63 | 92.000 | 102.000 | |
| 2021-003 | 4 ISE UND-DI | 199 Rx-IMOLA | 126 RANDOX | | 13 | 94.692 | 2.090 | 2.21 | 90.000 | 99.000 | |
| 2021-003 | 9 QUICK LYTE | 38 SIEMENS DI | 143 SIEMENS | | 77 | 98.592 | 1.183 | 1.20 | 94.000 | 104.000 | |
| 2021-003 | 9 QUICK LYTE | 212 S. D. EXL | 143 SIEMENS | | 13 | 98.417 | 1.441 | 1.46 | 93.000 | 103.000 | |
| 2021-004 | 3 ISE DILUTE | 184 INTEGRA | 93 ROCHE | | 38 | 114.919 | 3.649 | 3.18 | 109.000 | 121.000 | |
| 2021-004 | 3 ISE DILUTE | 186 BECK. COUL | 76 AU-BECKMAN | | 29 | 109.828 | 2.229 | 2.03 | 104.000 | 115.000 | |
| 2021-004 | 3 ISE DILUTE | 197 ARCHITECT | 1 ABBOTT | | 17 | 110.941 | 1.893 | 1.71 | 105.000 | 116.000 | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPEC: 10 CHEMISTRY | | SUB: 10 ROUTINE | | | | GRP: 10 ROUTINE | | | | | | |
|--------------------|--------------------|---------------------|-----|------------|-----|--|-----------------|-----------------------|---------|-------------------|---------------|---------|
| ANALYTE | | | | | | | | | | | | |
| SAMPLE | METHOD | SYST/INST | | REAGENTS | | NO. PART LABS | TARGET VALUE | STANDARD DEVIATION | % CV | ACCEPTABLE LOW | RANGE HIGH | |
| 2021-004 | 3 | ISE DILUTE | 203 | ROCHE | 93 | ROCHE | 38 | 110.757 | 1.937 | 1.75 | 105.000 | 116.000 |
| 2021-004 | 3 | ISE DILUTE | 215 | B.C DXC | 134 | BECKM.COUL | 11 | 110.909 | 2.109 | 1.90 | 105.000 | 116.000 |
| 2021-004 | 4 | ISE UND-DI | 165 | VITROS | 63 | KODAK | 102 | 111.196 | 2.082 | 1.87 | 106.000 | 117.000 |
| 2021-004 | 4 | ISE UND-DI | 165 | VITROS | 156 | Kit 32 | 58 | 111.404 | 1.834 | 1.65 | 106.000 | 117.000 |
| 2021-004 | 4 | ISE UND-DI | 191 | RX-DAYTONA | 126 | RANDOX | 31 | 114.125 | 3.551 | 3.11 | 108.000 | 120.000 |
| 2021-004 | 4 | ISE UND-DI | 191 | RX-DAYTONA | 126 | RANDOX | 31 | 112.300 | 2.283 | 2.03 | 107.000 | 118.000 |
| 2021-004 | 4 | ISE UND-DI | 199 | Rx-IMOLA | 126 | RANDOX | 13 | 111.769 | 2.805 | 2.51 | 106.000 | 117.000 |
| 2021-004 | 9 | QUICK LYTE | 38 | SIEMENS DI | 143 | SIEMENS | 77 | 117.368 | 1.992 | 1.70 | 112.000 | 123.000 |
| 2021-004 | 9 | QUICK LYTE | 212 | S. D. EXL | 143 | SIEMENS | 13 | 116.615 | 2.870 | 2.46 | 111.000 | 122.000 |
| 011 | CHLORIDE | CLIA TEST ID #: 355 | | | | EVALUATION CRITERIA: TARGET VALUE 5 % | | | | | | |
| 2021-005 | 3 | ISE DILUTE | 184 | INTEGRA | 93 | ROCHE | 38 | 89.514 | 1.780 | 1.99 | 85.000 | 94.000 |
| 2021-005 | 3 | ISE DILUTE | 186 | BECK. COUL | 76 | AU-BECKMAN | 29 | 89.483 | 1.355 | 1.51 | 85.000 | 94.000 |
| 2021-005 | 3 | ISE DILUTE | 197 | ARCHITECT | 1 | ABBOTT | 17 | 90.235 | 1.699 | 1.88 | 86.000 | 95.000 |
| 2021-005 | 3 | ISE DILUTE | 203 | ROCHE | 93 | ROCHE | 38 | 87.132 | 1.989 | 2.28 | 83.000 | 91.000 |
| 2021-005 | 3 | ISE DILUTE | 215 | B.C DXC | 134 | BECKM.COUL | 11 | 89.364 | 1.553 | 1.74 | 85.000 | 94.000 |
| 2021-005 | 4 | ISE UND-DI | 165 | VITROS | 63 | KODAK | 102 | 89.772 | 1.682 | 1.87 | 85.000 | 94.000 |
| 2021-005 | 4 | ISE UND-DI | 165 | VITROS | 156 | Kit 32 | 58 | 89.897 | 1.361 | 1.51 | 85.000 | 94.000 |
| 2021-005 | 4 | ISE UND-DI | 191 | RX-DAYTONA | 126 | RANDOX | 31 | 87.387 | 2.074 | 2.37 | 83.000 | 92.000 |
| 2021-005 | 4 | ISE UND-DI | 191 | RX-DAYTONA | 126 | RANDOX | 31 | 88.500 | 2.062 | 2.33 | 84.000 | 93.000 |
| 2021-005 | 4 | ISE UND-DI | 199 | Rx-IMOLA | 126 | RANDOX | 13 | 86.308 | 1.976 | 2.29 | 82.000 | 91.000 |
| 2021-005 | 9 | QUICK LYTE | 38 | SIEMENS DI | 143 | SIEMENS | 77 | 89.382 | 1.442 | 1.61 | 85.000 | 94.000 |
| 2021-005 | 9 | QUICK LYTE | 212 | S. D. EXL | 143 | SIEMENS | 13 | 88.308 | 2.398 | 2.72 | 84.000 | 93.000 |
| 012 | CHOLESTEROL, TOTAL | CLIA TEST ID #: 365 | | | | EVALUATION CRITERIA: TARGET VALUE 10 % | | | | | | |
| 2021-001 | 1 | ENZYMATIC | 38 | SIEMENS DI | 143 | SIEMENS | 77 | 186.753 | 5.876 | 3.15 | 168.000 | 205.000 |
| 2021-001 | 1 | ENZYMATIC | 165 | VITROS | 63 | KODAK | 152 | 199.473 | 5.354 | 2.68 | 180.000 | 219.000 |
| 2021-001 | 1 | ENZYMATIC | 184 | INTEGRA | 93 | ROCHE | 20 | 194.400 | 5.267 | 2.71 | 175.000 | 214.000 |
| 2021-001 | 1 | ENZYMATIC | 191 | RX-DAYTONA | 126 | RANDOX | 34 | 204.375 | 12.185 | 5.96 | 184.000 | 225.000 |
| 2021-001 | 1 | ENZYMATIC | 191 | RX-DAYTONA | 126 | RANDOX | 34 | 202.882 | 9.196 | 4.53 | 183.000 | 223.000 |
| 2021-001 | 1 | ENZYMATIC | 197 | ARCHITECT | 1 | ABBOTT | 16 | 190.688 | 6.602 | 3.46 | 172.000 | 210.000 |
| 2021-001 | 1 | ENZYMATIC | 199 | Rx-IMOLA | 126 | RANDOX | 12 | 203.083 | 6.982 | 3.44 | 183.000 | 223.000 |

Participant Summary

MONTH 2 OF YEAR 2021

| SPEC: 10 CHEMISTRY | | SUB: 10 ROUTINE | | | | GRP: 10 ROUTINE | | | | | | |
|------------------------|--------|-----------------|---------------------|------------|-----|--|-----------------|-----------------------|---------|-------------------|---------------|---------|
| ANALYTE | | | | | | | | | | | | |
| SAMPLE | METHOD | SYST/INST | | REAGENTS | | NO. PART LABS | TARGET VALUE | STANDARD DEVIATION | % CV | ACCEPTABLE LOW | RANGE HIGH | |
| 2021-001 | 1 | ENZYMATIC | 203 | ROCHE | 93 | ROCHE | 20 | 194.400 | 3.353 | 1.72 | 175.000 | 214.000 |
| 2021-001 | 1 | ENZYMATIC | 212 | S. D. EXL | 143 | SIEMENS | 13 | 187.692 | 7.630 | 4.07 | 169.000 | 206.000 |
| 2021-001 | 1 | ENZYMATIC | 215 | B.C DXC | 134 | BECKM.COUL | 11 | 199.727 | 7.325 | 3.67 | 180.000 | 220.000 |
| 2021-001 | 8 | ENZYMATIC | 186 | BECK. COUL | 76 | AU-BECKMAN | 26 | 191.280 | 6.545 | 3.42 | 172.000 | 210.000 |
| 012 CHOLESTEROL, TOTAL | | | CLIA TEST ID #: 365 | | | EVALUATION CRITERIA: TARGET VALUE 10 % | | | | | | |
| 2021-002 | 1 | ENZYMATIC | 38 | SIEMENS DI | 143 | SIEMENS | 77 | 165.855 | 4.501 | 2.71 | 149.000 | 182.000 |
| 2021-002 | 1 | ENZYMATIC | 165 | VITROS | 63 | KODAK | 152 | 172.507 | 5.145 | 2.98 | 155.000 | 190.000 |
| 2021-002 | 1 | ENZYMATIC | 184 | INTEGRA | 93 | ROCHE | 20 | 170.450 | 4.225 | 2.48 | 153.000 | 187.000 |
| 2021-002 | 1 | ENZYMATIC | 191 | RX-DAYTONA | 126 | RANDOX | 34 | 178.618 | 8.967 | 5.02 | 161.000 | 196.000 |
| 2021-002 | 1 | ENZYMATIC | 191 | RX-DAYTONA | 126 | RANDOX | 34 | 179.125 | 9.360 | 5.23 | 161.000 | 197.000 |
| 2021-002 | 1 | ENZYMATIC | 197 | ARCHITECT | 1 | ABBOTT | 16 | 169.688 | 4.646 | 2.74 | 153.000 | 187.000 |
| 2021-002 | 1 | ENZYMATIC | 199 | Rx-IMOLA | 126 | RANDOX | 12 | 180.250 | 7.259 | 4.03 | 162.000 | 198.000 |
| 2021-002 | 1 | ENZYMATIC | 203 | ROCHE | 93 | ROCHE | 20 | 172.000 | 3.033 | 1.76 | 155.000 | 189.000 |
| 2021-002 | 1 | ENZYMATIC | 212 | S. D. EXL | 143 | SIEMENS | 13 | 165.615 | 5.485 | 3.31 | 149.000 | 182.000 |
| 2021-002 | 1 | ENZYMATIC | 215 | B.C DXC | 134 | BECKM.COUL | 11 | 176.000 | 5.427 | 3.08 | 158.000 | 194.000 |
| 2021-002 | 8 | ENZYMATIC | 186 | BECK. COUL | 76 | AU-BECKMAN | 26 | 167.769 | 5.793 | 3.45 | 151.000 | 185.000 |
| 2021-003 | 1 | ENZYMATIC | 38 | SIEMENS DI | 143 | SIEMENS | 77 | 147.909 | 4.800 | 3.25 | 133.000 | 163.000 |
| 2021-003 | 1 | ENZYMATIC | 165 | VITROS | 63 | KODAK | 152 | 148.625 | 4.459 | 3.00 | 134.000 | 163.000 |
| 2021-003 | 1 | ENZYMATIC | 184 | INTEGRA | 93 | ROCHE | 20 | 151.850 | 3.410 | 2.25 | 137.000 | 167.000 |
| 2021-003 | 1 | ENZYMATIC | 191 | RX-DAYTONA | 126 | RANDOX | 34 | 158.625 | 7.227 | 4.56 | 143.000 | 174.000 |
| 2021-003 | 1 | ENZYMATIC | 191 | RX-DAYTONA | 126 | RANDOX | 34 | 158.706 | 7.115 | 4.48 | 143.000 | 175.000 |
| 2021-003 | 1 | ENZYMATIC | 197 | ARCHITECT | 1 | ABBOTT | 16 | 150.750 | 4.054 | 2.69 | 136.000 | 166.000 |
| 2021-003 | 1 | ENZYMATIC | 199 | Rx-IMOLA | 126 | RANDOX | 12 | 157.417 | 4.481 | 2.85 | 142.000 | 173.000 |
| 2021-003 | 1 | ENZYMATIC | 203 | ROCHE | 93 | ROCHE | 20 | 151.684 | 2.028 | 1.34 | 137.000 | 167.000 |
| 2021-003 | 1 | ENZYMATIC | 212 | S. D. EXL | 143 | SIEMENS | 13 | 148.615 | 6.245 | 4.20 | 134.000 | 163.000 |
| 2021-003 | 1 | ENZYMATIC | 215 | B.C DXC | 134 | BECKM.COUL | 11 | 155.818 | 4.951 | 3.18 | 140.000 | 171.000 |
| 2021-003 | 8 | ENZYMATIC | 186 | BECK. COUL | 76 | AU-BECKMAN | 26 | 149.154 | 4.959 | 3.32 | 134.000 | 164.000 |
| 2021-004 | 1 | ENZYMATIC | 38 | SIEMENS DI | 143 | SIEMENS | 77 | 213.211 | 8.210 | 3.85 | 192.000 | 235.000 |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

| ANALYTE | | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
|------------------------|---------------|---------------------|----------------|--|------|----------|-----------|----------|---------|------------|-------|
| SAMPLE | METHOD | SYST/INST | REAGENTS | | LABS | VALUE | DEVIATION | CV | LOW | HIGH | |
| 2021-004 | 1 ENZYMATI | 165 VITROS | 63 KODAK | | 152 | 234.827 | 6.486 | 2.76 | 211.000 | 258.000 | |
| 2021-004 | 1 ENZYMATI | 184 INTEGRA | 93 ROCHE | | 20 | 219.000 | 7.348 | 3.36 | 197.000 | 241.000 | |
| 2021-004 | 1 ENZYMATI | 191 RX-DAYTONA | 126 RANDOX | | 34 | 233.382 | 10.694 | 4.58 | 210.000 | 257.000 | |
| 2021-004 | 1 ENZYMATI | 191 RX-DAYTONA | 126 RANDOX | | 34 | 243.250 | 12.627 | 5.19 | 219.000 | 268.000 | |
| 2021-004 | 1 ENZYMATI | 197 ARCHITECT | 1 ABBOTT | | 16 | 218.500 | 8.070 | 3.69 | 197.000 | 240.000 | |
| 2021-004 | 1 ENZYMATI | 199 Rx-IMOLA | 126 RANDOX | | 12 | 233.000 | 9.363 | 4.02 | 210.000 | 256.000 | |
| 2021-004 | 1 ENZYMATI | 203 ROCHE | 93 ROCHE | | 20 | 224.526 | 4.695 | 2.09 | 202.000 | 247.000 | |
| 2021-004 | 1 ENZYMATI | 212 S. D. EXL | 143 SIEMENS | | 13 | 211.077 | 7.641 | 3.62 | 190.000 | 232.000 | |
| 2021-004 | 1 ENZYMATI | 215 B.C DXC | 134 BECKM.COUL | | 11 | 230.182 | 8.277 | 3.60 | 207.000 | 253.000 | |
| 2021-004 | 8 ENZYMATI | 186 BECK. COUL | 76 AU-BECKMAN | | 26 | 219.538 | 7.592 | 3.46 | 198.000 | 241.000 | |
| 012 CHOLESTEROL, TOTAL | | CLIA TEST ID #: 365 | | EVALUATION CRITERIA: TARGET VALUE 10 % | | | | | | | |
| 2021-005 | 1 ENZYMATI | 38 SIEMENS DI | 143 SIEMENS | | 77 | 117.224 | 3.992 | 3.41 | 106.000 | 129.000 | |
| 2021-005 | 1 ENZYMATI | 165 VITROS | 63 KODAK | | 152 | 110.106 | 3.395 | 3.08 | 99.000 | 121.000 | |
| 2021-005 | 1 ENZYMATI | 184 INTEGRA | 93 ROCHE | | 20 | 117.789 | 2.284 | 1.94 | 106.000 | 130.000 | |
| 2021-005 | 1 ENZYMATI | 191 RX-DAYTONA | 126 RANDOX | | 34 | 125.750 | 4.710 | 3.75 | 113.000 | 138.000 | |
| 2021-005 | 1 ENZYMATI | 191 RX-DAYTONA | 126 RANDOX | | 34 | 124.294 | 7.567 | 6.09 | 112.000 | 137.000 | |
| 2021-005 | 1 ENZYMATI | 197 ARCHITECT | 1 ABBOTT | | 16 | 119.875 | 2.997 | 2.50 | 108.000 | 132.000 | |
| 2021-005 | 1 ENZYMATI | 199 Rx-IMOLA | 126 RANDOX | | 12 | 123.500 | 5.220 | 4.23 | 111.000 | 136.000 | |
| 2021-005 | 1 ENZYMATI | 203 ROCHE | 93 ROCHE | | 20 | 119.000 | 2.470 | 2.08 | 107.000 | 131.000 | |
| 2021-005 | 1 ENZYMATI | 212 S. D. EXL | 143 SIEMENS | | 13 | 116.462 | 4.585 | 3.94 | 105.000 | 128.000 | |
| 2021-005 | 1 ENZYMATI | 215 B.C DXC | 134 BECKM.COUL | | 11 | 119.727 | 3.493 | 2.92 | 108.000 | 132.000 | |
| 2021-005 | 8 ENZYMATI | 186 BECK. COUL | 76 AU-BECKMAN | | 26 | 116.154 | 4.203 | 3.62 | 105.000 | 128.000 | |
| 013 CHOLESTEROL, (HDL) | | CLIA TEST ID #: 375 | | EVALUATION CRITERIA: TARGET VALUE 30 % | | | | | | | |
| 2021-001 | 11 ENC.-COLO. | 165 VITROS | 63 KODAK | | 146 | 70.953 | 3.569 | 5.03 | 49.700 | 92.200 | |
| 2021-001 | 11 ENC.-COLO. | 165 VITROS | 63 KODAK | | 146 | 68.500 | 1.500 | 2.19 | 48.000 | 89.100 | |
| 2021-001 | 11 ENC.-COLO. | 184 INTEGRA | 93 ROCHE | | 32 | 70.906 | 3.232 | 4.56 | 49.600 | 92.200 | |
| 2021-001 | 11 ENC.-COLO. | 186 BECK. COUL | 76 AU-BECKMAN | | 26 | 75.952 | 4.856 | 6.39 | 53.200 | 98.700 | |
| 2021-001 | 11 ENC.-COLO. | 186 BECK. COUL | 76 AU-BECKMAN | | 26 | 65.975 | 2.406 | 3.65 | 46.200 | 85.800 | |
| 2021-001 | 11 ENC.-COLO. | 191 RX-DAYTONA | 126 RANDOX | | 32 | 68.100 | 7.492 | 11.00 | 47.700 | 88.500 | |
| 2021-001 | 11 ENC.-COLO. | 194 BIOLIS-24S | 154 (IDG) | | 11 | 44.227 | 2.209 | 4.99 | 31.000 | 57.500 | |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

| ANALYTE | | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
|------------------------|---------------|---------------------|--|--|------|----------|-----------|----------|--------|------------|-------|
| SAMPLE | METHOD | SYST/INST | REAGENTS | | LABS | VALUE | DEVIATION | CV | LOW | HIGH | |
| 2021-001 | 11 ENC.-COLO. | 199 Rx-IMOLA | 126 RANDOX | | 13 | 67.915 | 7.948 | 11.70 | 47.500 | 88.300 | |
| 2021-001 | 11 ENC.-COLO. | 203 ROCHE | 93 ROCHE | | 33 | 70.670 | 2.551 | 3.61 | 49.500 | 91.900 | |
| 2021-001 | 12 HOM-LQ.S.D | 197 ARCHITECT | 1 ABBOTT | | 18 | 71.256 | 2.625 | 3.68 | 49.900 | 92.600 | |
| 2021-001 | 12 HOM-LQ.S.D | 215 B.C DXC | 134 BECKM.COUL | | 11 | 76.645 | 2.999 | 3.91 | 53.700 | 99.600 | |
| 2021-001 | 13 AMIN.W.E.Q | 38 SIEMENS DI | 143 SIEMENS | | 76 | 62.156 | 2.602 | 4.19 | 43.500 | 80.800 | |
| 2021-001 | 13 AMIN.W.E.Q | 212 S. D. EXL | 143 SIEMENS | | 13 | 61.077 | 2.526 | 4.14 | 42.800 | 79.400 | |
| 013 CHOLESTEROL, (HDL) | | CLIA TEST ID #: 375 | EVALUATION CRITERIA: TARGET VALUE 30 % | | | | | | | | |
| 2021-002 | 11 ENC.-COLO. | 165 VITROS | 63 KODAK | | 146 | 60.500 | 1.658 | 2.74 | 42.400 | 78.700 | |
| 2021-002 | 11 ENC.-COLO. | 165 VITROS | 63 KODAK | | 146 | 62.625 | 3.212 | 5.13 | 43.800 | 81.400 | |
| 2021-002 | 11 ENC.-COLO. | 184 INTEGRA | 93 ROCHE | | 32 | 64.758 | 2.602 | 4.02 | 45.300 | 84.200 | |
| 2021-002 | 11 ENC.-COLO. | 186 BECK. COUL | 76 AU-BECKMAN | | 26 | 58.050 | 2.295 | 3.95 | 40.600 | 75.500 | |
| 2021-002 | 11 ENC.-COLO. | 186 BECK. COUL | 76 AU-BECKMAN | | 26 | 66.928 | 4.238 | 6.33 | 46.800 | 87.000 | |
| 2021-002 | 11 ENC.-COLO. | 191 RX-DAYTONA | 126 RANDOX | | 32 | 62.041 | 7.109 | 11.46 | 43.400 | 80.700 | |
| 2021-002 | 11 ENC.-COLO. | 194 BIOLIS-24S | 154 (IDG) | | 11 | 39.473 | 2.370 | 6.00 | 27.600 | 51.300 | |
| 2021-002 | 11 ENC.-COLO. | 199 Rx-IMOLA | 126 RANDOX | | 13 | 59.646 | 7.323 | 12.28 | 41.800 | 77.500 | |
| 2021-002 | 11 ENC.-COLO. | 203 ROCHE | 93 ROCHE | | 33 | 65.306 | 2.543 | 3.89 | 45.700 | 84.900 | |
| 2021-002 | 12 HOM-LQ.S.D | 197 ARCHITECT | 1 ABBOTT | | 18 | 63.883 | 2.260 | 3.54 | 44.700 | 83.000 | |
| 2021-002 | 12 HOM-LQ.S.D | 215 B.C DXC | 134 BECKM.COUL | | 11 | 67.727 | 2.327 | 3.44 | 47.400 | 88.000 | |
| 2021-002 | 13 AMIN.W.E.Q | 38 SIEMENS DI | 143 SIEMENS | | 76 | 59.753 | 2.079 | 3.48 | 41.800 | 77.700 | |
| 2021-002 | 13 AMIN.W.E.Q | 212 S. D. EXL | 143 SIEMENS | | 13 | 58.538 | 2.373 | 4.05 | 41.000 | 76.100 | |
| 2021-003 | 11 ENC.-COLO. | 165 VITROS | 63 KODAK | | 146 | 55.500 | 0.500 | 0.90 | 38.900 | 72.200 | |
| 2021-003 | 11 ENC.-COLO. | 165 VITROS | 63 KODAK | | 146 | 57.081 | 2.930 | 5.13 | 40.000 | 74.200 | |
| 2021-003 | 11 ENC.-COLO. | 184 INTEGRA | 93 ROCHE | | 32 | 60.748 | 3.044 | 5.01 | 42.500 | 79.000 | |
| 2021-003 | 11 ENC.-COLO. | 186 BECK. COUL | 76 AU-BECKMAN | | 26 | 60.244 | 4.077 | 6.77 | 42.200 | 78.300 | |
| 2021-003 | 11 ENC.-COLO. | 186 BECK. COUL | 76 AU-BECKMAN | | 26 | 52.763 | 1.806 | 3.42 | 36.900 | 68.600 | |
| 2021-003 | 11 ENC.-COLO. | 191 RX-DAYTONA | 126 RANDOX | | 32 | 56.153 | 5.763 | 10.26 | 39.300 | 73.000 | |
| 2021-003 | 11 ENC.-COLO. | 194 BIOLIS-24S | 154 (IDG) | | 11 | 35.036 | 1.406 | 4.01 | 24.500 | 45.500 | |
| 2021-003 | 11 ENC.-COLO. | 199 Rx-IMOLA | 126 RANDOX | | 13 | 54.454 | 6.623 | 12.16 | 38.100 | 70.800 | |
| 2021-003 | 11 ENC.-COLO. | 203 ROCHE | 93 ROCHE | | 33 | 60.252 | 2.642 | 4.38 | 42.200 | 78.300 | |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

| ANALYTE | | | | | | | | | | | | |
|------------------------|--------|------------|---------------------|------------|-----|--|-----------------|-----------------------|---------|-------------------|---------------|---------|
| SAMPLE | METHOD | SYST/INST | | REAGENTS | | NO. PART LABS | TARGET VALUE | STANDARD DEVIATION | % CV | ACCEPTABLE LOW | RANGE HIGH | |
| 2021-003 | 12 | HOM-LQ.S.D | 197 | ARCHITECT | 1 | ABBOTT | 18 | 57.628 | 2.278 | 3.95 | 40.300 | 74.900 |
| 2021-003 | 12 | HOM-LQ.S.D | 215 | B.C DXC | 134 | BECKM.COUL | 11 | 60.355 | 2.797 | 4.63 | 42.200 | 78.500 |
| 2021-003 | 13 | AMIN.W.E.Q | 38 | SIEMENS DI | 143 | SIEMENS | 76 | 57.561 | 1.771 | 3.08 | 40.300 | 74.800 |
| 2021-003 | 13 | AMIN.W.E.Q | 212 | S. D. EXL | 143 | SIEMENS | 13 | 57.692 | 2.197 | 3.81 | 40.400 | 75.000 |
| 013 CHOLESTEROL, (HDL) | | | CLIA TEST ID #: 375 | | | EVALUATION CRITERIA: TARGET VALUE 30 % | | | | | | |
| 2021-004 | 11 | ENC.-COLO. | 165 | VITROS | 63 | KODAK | 146 | 81.910 | 4.218 | 5.15 | 57.300 | 106.500 |
| 2021-004 | 11 | ENC.-COLO. | 165 | VITROS | 63 | KODAK | 146 | 79.250 | 1.785 | 2.25 | 55.500 | 103.000 |
| 2021-004 | 11 | ENC.-COLO. | 184 | INTEGRA | 93 | ROCHE | 32 | 76.729 | 3.704 | 4.83 | 53.700 | 99.700 |
| 2021-004 | 11 | ENC.-COLO. | 186 | BECK. COUL | 76 | AU-BECKMAN | 26 | 72.650 | 2.991 | 4.12 | 50.900 | 94.400 |
| 2021-004 | 11 | ENC.-COLO. | 186 | BECK. COUL | 76 | AU-BECKMAN | 26 | 85.464 | 5.090 | 5.96 | 59.800 | 111.100 |
| 2021-004 | 11 | ENC.-COLO. | 191 | RX-DAYTONA | 126 | RANDOX | 32 | 76.928 | 7.538 | 9.80 | 53.800 | 100.000 |
| 2021-004 | 11 | ENC.-COLO. | 194 | BIOLIS-24S | 154 | (IDG) | 11 | 50.327 | 2.932 | 5.83 | 35.200 | 65.400 |
| 2021-004 | 11 | ENC.-COLO. | 199 | Rx-IMOLA | 126 | RANDOX | 13 | 76.331 | 8.729 | 11.44 | 53.400 | 99.200 |
| 2021-004 | 11 | ENC.-COLO. | 203 | ROCHE | 93 | ROCHE | 33 | 76.936 | 2.959 | 3.85 | 53.900 | 100.000 |
| 2021-004 | 12 | HOM-LQ.S.D | 197 | ARCHITECT | 1 | ABBOTT | 18 | 80.222 | 2.839 | 3.54 | 56.200 | 104.300 |
| 2021-004 | 12 | HOM-LQ.S.D | 215 | B.C DXC | 134 | BECKM.COUL | 11 | 85.300 | 2.503 | 2.93 | 59.700 | 110.900 |
| 2021-004 | 13 | AMIN.W.E.Q | 38 | SIEMENS DI | 143 | SIEMENS | 76 | 64.619 | 3.206 | 4.96 | 45.200 | 84.000 |
| 2021-004 | 13 | AMIN.W.E.Q | 212 | S. D. EXL | 143 | SIEMENS | 13 | 63.615 | 2.403 | 3.78 | 44.500 | 82.700 |
| 2021-005 | 11 | ENC.-COLO. | 165 | VITROS | 63 | KODAK | 146 | 46.250 | 1.479 | 3.20 | 32.400 | 60.100 |
| 2021-005 | 11 | ENC.-COLO. | 165 | VITROS | 63 | KODAK | 146 | 48.205 | 2.730 | 5.66 | 33.700 | 62.700 |
| 2021-005 | 11 | ENC.-COLO. | 184 | INTEGRA | 93 | ROCHE | 32 | 50.844 | 3.060 | 6.02 | 35.600 | 66.100 |
| 2021-005 | 11 | ENC.-COLO. | 186 | BECK. COUL | 76 | AU-BECKMAN | 26 | 47.484 | 3.173 | 6.68 | 33.200 | 61.700 |
| 2021-005 | 11 | ENC.-COLO. | 186 | BECK. COUL | 76 | AU-BECKMAN | 26 | 41.063 | 1.147 | 2.79 | 28.700 | 53.400 |
| 2021-005 | 11 | ENC.-COLO. | 191 | RX-DAYTONA | 126 | RANDOX | 32 | 43.450 | 6.138 | 14.13 | 30.400 | 56.500 |
| 2021-005 | 11 | ENC.-COLO. | 194 | BIOLIS-24S | 154 | (IDG) | 11 | 26.982 | 1.780 | 6.60 | 18.900 | 35.100 |
| 2021-005 | 11 | ENC.-COLO. | 199 | Rx-IMOLA | 126 | RANDOX | 13 | 45.215 | 5.351 | 11.83 | 31.700 | 58.800 |
| 2021-005 | 11 | ENC.-COLO. | 203 | ROCHE | 93 | ROCHE | 33 | 49.909 | 1.964 | 3.93 | 34.900 | 64.900 |
| 2021-005 | 12 | HOM-LQ.S.D | 197 | ARCHITECT | 1 | ABBOTT | 18 | 45.794 | 1.828 | 3.99 | 32.100 | 59.500 |
| 2021-005 | 12 | HOM-LQ.S.D | 215 | B.C DXC | 134 | BECKM.COUL | 11 | 49.064 | 2.228 | 4.54 | 34.300 | 63.800 |

Participant Summary

MONTH 2 OF YEAR 2021

| SPEC: 10 CHEMISTRY | | SUB: 10 ROUTINE | | | | GRP: 10 ROUTINE | | | | | | | |
|--------------------------|--------|---------------------|--|----------|------------|--|-----------------|-----------------------|---------|-------------------|---------------|---------|---------|
| ANALYTE | | | | | | | | | | | | | |
| SAMPLE | METHOD | SYST/INST | | REAGENTS | | NO. PART LABS | TARGET VALUE | STANDARD DEVIATION | % CV | ACCEPTABLE LOW | RANGE HIGH | | |
| 2021-005 | 13 | AMIN.W.E.Q | | 38 | SIEMENS DI | 143 | SIEMENS | 76 | 52.349 | 1.716 | 3.28 | 36.600 | 68.100 |
| 2021-005 | 13 | AMIN.W.E.Q | | 212 | S. D. EXL | 143 | SIEMENS | 13 | 51.615 | 2.371 | 4.59 | 36.100 | 67.100 |
| 014 CREATINE KINASE (CK) | | CLIA TEST ID #: 385 | | | | EVALUATION CRITERIA: TARGET VALUE 30 % | | | | | | | |
| 2021-001 | 3 | KINETIC 37 | | 165 | VITROS | 63 | KODAK | 75 | 326.288 | 19.114 | 5.86 | 228.000 | 424.000 |
| 2021-001 | 3 | KINETIC 37 | | 186 | BECK. COUL | 76 | AU-BECKMAN | 19 | 424.368 | 13.585 | 3.20 | 297.000 | 552.000 |
| 2021-001 | 4 | OLIVER ROS | | 215 | B.C DXC | 134 | BECKM.COUL | 10 | 488.700 | 10.826 | 2.22 | 342.000 | 635.000 |
| 2021-001 | 8 | Hexokinase | | 184 | INTEGRA | 93 | ROCHE | 12 | 474.833 | 14.565 | 3.07 | 332.000 | 617.000 |
| 2021-001 | 8 | Hexokinase | | 203 | ROCHE | 93 | ROCHE | 12 | 465.750 | 12.670 | 2.72 | 326.000 | 605.000 |
| 2021-001 | 9 | SIEMENS | | 38 | SIEMENS DI | 143 | SIEMENS | 29 | 470.276 | 12.295 | 2.61 | 329.000 | 611.000 |
| 2021-002 | 3 | KINETIC 37 | | 165 | VITROS | 63 | KODAK | 75 | 259.176 | 18.977 | 7.32 | 181.000 | 337.000 |
| 2021-002 | 3 | KINETIC 37 | | 186 | BECK. COUL | 76 | AU-BECKMAN | 19 | 308.947 | 10.870 | 3.52 | 216.000 | 402.000 |
| 2021-002 | 4 | OLIVER ROS | | 215 | B.C DXC | 134 | BECKM.COUL | 10 | 360.600 | 7.813 | 2.17 | 252.000 | 469.000 |
| 2021-002 | 8 | Hexokinase | | 184 | INTEGRA | 93 | ROCHE | 12 | 351.917 | 12.606 | 3.58 | 246.000 | 457.000 |
| 2021-002 | 8 | Hexokinase | | 203 | ROCHE | 93 | ROCHE | 12 | 343.500 | 9.862 | 2.87 | 240.000 | 447.000 |
| 2021-002 | 9 | SIEMENS | | 38 | SIEMENS DI | 143 | SIEMENS | 29 | 348.276 | 10.677 | 3.07 | 244.000 | 453.000 |
| 2021-003 | 3 | KINETIC 37 | | 165 | VITROS | 63 | KODAK | 75 | 177.867 | 12.348 | 6.94 | 125.000 | 231.000 |
| 2021-003 | 3 | KINETIC 37 | | 186 | BECK. COUL | 76 | AU-BECKMAN | 19 | 202.368 | 6.745 | 3.33 | 142.000 | 263.000 |
| 2021-003 | 4 | OLIVER ROS | | 215 | B.C DXC | 134 | BECKM.COUL | 10 | 236.200 | 5.862 | 2.48 | 165.000 | 307.000 |
| 2021-003 | 8 | Hexokinase | | 184 | INTEGRA | 93 | ROCHE | 12 | 230.000 | 8.699 | 3.78 | 161.000 | 299.000 |
| 2021-003 | 8 | Hexokinase | | 203 | ROCHE | 93 | ROCHE | 12 | 225.917 | 4.856 | 2.15 | 158.000 | 294.000 |
| 2021-003 | 9 | SIEMENS | | 38 | SIEMENS DI | 143 | SIEMENS | 29 | 226.414 | 6.946 | 3.07 | 158.000 | 294.000 |
| 2021-004 | 3 | KINETIC 37 | | 165 | VITROS | 63 | KODAK | 75 | 401.405 | 24.086 | 6.00 | 281.000 | 522.000 |
| 2021-004 | 3 | KINETIC 37 | | 186 | BECK. COUL | 76 | AU-BECKMAN | 19 | 578.789 | 23.639 | 4.08 | 405.000 | 752.000 |
| 2021-004 | 4 | OLIVER ROS | | 215 | B.C DXC | 134 | BECKM.COUL | 10 | 654.600 | 18.853 | 2.88 | 458.000 | 851.000 |
| 2021-004 | 8 | Hexokinase | | 184 | INTEGRA | 93 | ROCHE | 12 | 641.500 | 19.826 | 3.09 | 449.000 | 834.000 |
| 2021-004 | 8 | Hexokinase | | 203 | ROCHE | 93 | ROCHE | 12 | 633.167 | 29.129 | 4.60 | 443.000 | 823.000 |
| 2021-004 | 9 | SIEMENS | | 38 | SIEMENS DI | 143 | SIEMENS | 29 | 638.759 | 22.057 | 3.45 | 447.000 | 830.000 |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

| ANALYTE | | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
|----------|----------------------|---------------------|-----------------------------------|--|------------------------|----------|-----------|----------|--------|------------|-------|
| SAMPLE | METHOD | SYST/INST | REAGENTS | | LABS | VALUE | DEVIATION | CV | LOW | HIGH | |
| 014 | CREATINE KINASE (CK) | CLIA TEST ID #: 385 | EVALUATION CRITERIA: TARGET VALUE | | 30 % | | | | | | |
| 2021-005 | 3 KINETIC 37 | 165 VITROS | 63 KODAK | | 75 | 20.694 | 1.350 | 6.52 | 14.000 | 27.000 | |
| 2021-005 | 3 KINETIC 37 | 186 BECK. COUL | 76 AU-BECKMAN | | 19 | 17.263 | 1.617 | 9.37 | 12.000 | 22.000 | |
| 2021-005 | 4 OLIVER ROS | 215 B.C DXC | 134 BECKM.COUL | | 10 | 22.500 | 1.204 | 5.35 | 16.000 | 29.000 | |
| 2021-005 | 8 Hexokinase | 184 INTEGRA | 93 ROCHE | | 12 | 23.083 | 1.256 | 5.44 | 16.000 | 30.000 | |
| 2021-005 | 8 Hexokinase | 203 ROCHE | 93 ROCHE | | 12 | 22.250 | 1.010 | 4.54 | 16.000 | 29.000 | |
| 2021-005 | 9 SIEMENS | 38 SIEMENS DI | 143 SIEMENS | | 29 | 20.552 | 2.737 | 13.32 | 14.000 | 27.000 | |
| 016 | CREATININE | CLIA TEST ID #: 405 | EVALUATION CRITERIA: TARGET VALUE | | 15 % OR 0.30 {GREATER} | | | | | | |
| 2021-001 | 2 AK. PIC. N | 194 BIOLIS-24S | 154 (IDG) | | 11 | 5.604 | 0.256 | 4.57 | 4.760 | 6.440 | |
| 2021-001 | 3 AK. PIC. L | 191 RX-DAYTONA | 126 RANDOX | | 21 | 4.683 | 0.344 | 7.35 | 3.980 | 5.390 | |
| 2021-001 | 6 KIN. ALK P | 184 INTEGRA | 93 ROCHE | | 23 | 5.586 | 0.201 | 3.59 | 4.750 | 6.420 | |
| 2021-001 | 6 KIN. ALK P | 186 BECK. COUL | 76 AU-BECKMAN | | 29 | 5.616 | 0.143 | 2.55 | 4.770 | 6.460 | |
| 2021-001 | 6 KIN. ALK P | 197 ARCHITECT | 1 ABBOTT | | 18 | 5.933 | 0.264 | 4.45 | 5.040 | 6.820 | |
| 2021-001 | 6 KIN. ALK P | 203 ROCHE | 93 ROCHE | | 23 | 5.649 | 0.164 | 2.90 | 4.800 | 6.500 | |
| 2021-001 | 6 KIN. ALK P | 215 B.C DXC | 134 BECKM.COUL | | 11 | 5.788 | 0.191 | 3.31 | 4.920 | 6.660 | |
| 2021-001 | 8 IDMS-CREA | 165 VITROS | 63 KODAK | | 157 | 5.428 | 0.129 | 2.38 | 4.610 | 6.240 | |
| 2021-001 | 11 IDMS Jaffe | 38 SIEMENS DI | 143 SIEMENS | | 71 | 5.868 | 0.122 | 2.08 | 4.990 | 6.750 | |
| 2021-001 | 11 IDMS Jaffe | 212 S. D. EXL | 143 SIEMENS | | 10 | 5.865 | 0.266 | 4.53 | 4.990 | 6.740 | |
| 2021-002 | 2 AK. PIC. N | 194 BIOLIS-24S | 154 (IDG) | | 11 | 4.995 | 0.109 | 2.18 | 4.250 | 5.740 | |
| 2021-002 | 3 AK. PIC. L | 191 RX-DAYTONA | 126 RANDOX | | 21 | 4.167 | 0.323 | 7.74 | 3.540 | 4.790 | |
| 2021-002 | 6 KIN. ALK P | 184 INTEGRA | 93 ROCHE | | 23 | 5.107 | 0.159 | 3.11 | 4.340 | 5.870 | |
| 2021-002 | 6 KIN. ALK P | 186 BECK. COUL | 76 AU-BECKMAN | | 29 | 4.966 | 0.141 | 2.84 | 4.220 | 5.710 | |
| 2021-002 | 6 KIN. ALK P | 197 ARCHITECT | 1 ABBOTT | | 18 | 5.213 | 0.211 | 4.06 | 4.430 | 6.000 | |
| 2021-002 | 6 KIN. ALK P | 203 ROCHE | 93 ROCHE | | 23 | 5.118 | 0.138 | 2.70 | 4.350 | 5.890 | |
| 2021-002 | 6 KIN. ALK P | 215 B.C DXC | 134 BECKM.COUL | | 11 | 5.144 | 0.153 | 2.97 | 4.370 | 5.920 | |
| 2021-002 | 8 IDMS-CREA | 165 VITROS | 63 KODAK | | 157 | 4.887 | 0.129 | 2.63 | 4.150 | 5.620 | |
| 2021-002 | 11 IDMS Jaffe | 38 SIEMENS DI | 143 SIEMENS | | 71 | 5.202 | 0.113 | 2.18 | 4.420 | 5.980 | |
| 2021-002 | 11 IDMS Jaffe | 212 S. D. EXL | 143 SIEMENS | | 10 | 5.233 | 0.219 | 4.18 | 4.450 | 6.020 | |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

| ANALYTE | | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
|----------------|---------------|---------------------|-----------------------------------|--------------|-----------|----------|-----------|----------|-------|------------|-------|
| SAMPLE | METHOD | SYST/INST | REAGENTS | | LABS | VALUE | DEVIATION | CV | LOW | HIGH | |
| 016 CREATININE | | CLIA TEST ID #: 405 | EVALUATION CRITERIA: TARGET VALUE | 15 % OR 0.30 | {GREATER} | | | | | | |
| 2021-003 | 2 AK. PIC. N | 194 BIOLIS-24S | 154 (IDG) | | 11 | 4.500 | 0.078 | 1.73 | 3.830 | 5.180 | |
| 2021-003 | 3 AK. PIC. L | 191 RX-DAYTONA | 126 RANDOX | | 21 | 3.744 | 0.270 | 7.20 | 3.180 | 4.310 | |
| 2021-003 | 6 KIN. ALK P | 184 INTEGRA | 93 ROCHE | | 23 | 4.626 | 0.144 | 3.10 | 3.930 | 5.320 | |
| 2021-003 | 6 KIN. ALK P | 186 BECK. COUL | 76 AU-BECKMAN | | 29 | 4.465 | 0.155 | 3.48 | 3.800 | 5.130 | |
| 2021-003 | 6 KIN. ALK P | 197 ARCHITECT | 1 ABBOTT | | 18 | 4.559 | 0.164 | 3.61 | 3.880 | 5.240 | |
| 2021-003 | 6 KIN. ALK P | 203 ROCHE | 93 ROCHE | | 23 | 4.637 | 0.104 | 2.24 | 3.940 | 5.330 | |
| 2021-003 | 6 KIN. ALK P | 215 B.C DXC | 134 BECKM.COUL | | 11 | 4.605 | 0.101 | 2.18 | 3.910 | 5.300 | |
| 2021-003 | 8 IDMS-CREA | 165 VITROS | 63 KODAK | | 157 | 4.359 | 0.105 | 2.42 | 3.710 | 5.010 | |
| 2021-003 | 11 IDMS Jaffe | 38 SIEMENS DI | 143 SIEMENS | | 71 | 4.666 | 0.118 | 2.52 | 3.970 | 5.370 | |
| 2021-003 | 11 IDMS Jaffe | 212 S. D. EXL | 143 SIEMENS | | 10 | 4.659 | 0.187 | 4.02 | 3.960 | 5.360 | |
| 2021-004 | 2 AK. PIC. N | 194 BIOLIS-24S | 154 (IDG) | | 11 | 6.335 | 0.122 | 1.92 | 5.390 | 7.290 | |
| 2021-004 | 3 AK. PIC. L | 191 RX-DAYTONA | 126 RANDOX | | 21 | 5.189 | 0.336 | 6.48 | 4.410 | 5.970 | |
| 2021-004 | 6 KIN. ALK P | 184 INTEGRA | 93 ROCHE | | 23 | 6.109 | 0.179 | 2.93 | 5.190 | 7.030 | |
| 2021-004 | 6 KIN. ALK P | 186 BECK. COUL | 76 AU-BECKMAN | | 29 | 6.281 | 0.145 | 2.32 | 5.340 | 7.220 | |
| 2021-004 | 6 KIN. ALK P | 197 ARCHITECT | 1 ABBOTT | | 18 | 6.865 | 0.319 | 4.64 | 5.840 | 7.890 | |
| 2021-004 | 6 KIN. ALK P | 203 ROCHE | 93 ROCHE | | 23 | 6.254 | 0.222 | 3.56 | 5.320 | 7.190 | |
| 2021-004 | 6 KIN. ALK P | 215 B.C DXC | 134 BECKM.COUL | | 11 | 6.526 | 0.231 | 3.55 | 5.550 | 7.510 | |
| 2021-004 | 8 IDMS-CREA | 165 VITROS | 63 KODAK | | 157 | 5.970 | 0.160 | 2.68 | 5.070 | 6.870 | |
| 2021-004 | 11 IDMS Jaffe | 38 SIEMENS DI | 143 SIEMENS | | 71 | 6.715 | 0.152 | 2.26 | 5.710 | 7.720 | |
| 2021-004 | 11 IDMS Jaffe | 212 S. D. EXL | 143 SIEMENS | | 10 | 6.755 | 0.240 | 3.56 | 5.740 | 7.770 | |
| 2021-005 | 2 AK. PIC. N | 194 BIOLIS-24S | 154 (IDG) | | 11 | 3.522 | 0.097 | 2.77 | 2.990 | 4.050 | |
| 2021-005 | 3 AK. PIC. L | 191 RX-DAYTONA | 126 RANDOX | | 21 | 2.968 | 0.188 | 6.35 | 2.520 | 3.410 | |
| 2021-005 | 6 KIN. ALK P | 184 INTEGRA | 93 ROCHE | | 23 | 3.669 | 0.113 | 3.08 | 3.120 | 4.220 | |
| 2021-005 | 6 KIN. ALK P | 186 BECK. COUL | 76 AU-BECKMAN | | 29 | 3.474 | 0.126 | 3.62 | 2.950 | 4.000 | |
| 2021-005 | 6 KIN. ALK P | 197 ARCHITECT | 1 ABBOTT | | 18 | 3.402 | 0.128 | 3.75 | 2.890 | 3.910 | |
| 2021-005 | 6 KIN. ALK P | 203 ROCHE | 93 ROCHE | | 23 | 3.685 | 0.119 | 3.22 | 3.130 | 4.240 | |
| 2021-005 | 6 KIN. ALK P | 215 B.C DXC | 134 BECKM.COUL | | 11 | 3.621 | 0.074 | 2.04 | 3.080 | 4.160 | |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

| ANALYTE | | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
|-------------|---------------|---------------------|--|------|---------|-----------|--------|----------|---------|------------|-------|
| SAMPLE | METHOD | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH | | |
| 2021-005 | 8 IDMS-CREA | 165 VITROS | 63 KODAK | 157 | 3.283 | 0.088 | 2.67 | 2.790 | 3.780 | | |
| 2021-005 | 11 IDMS Jaffe | 38 SIEMENS DI | 143 SIEMENS | 71 | 3.398 | 0.092 | 2.71 | 2.890 | 3.910 | | |
| 2021-005 | 11 IDMS Jaffe | 212 S. D. EXL | 143 SIEMENS | 10 | 3.377 | 0.147 | 4.34 | 2.870 | 3.880 | | |
| 017 GLUCOSE | | CLIA TEST ID #: 415 | EVALUATION CRITERIA: TARGET VALUE 10 % OR 6.00 {GREATER} | | | | | | | | |
| 2021-001 | 2 GL. OXI. E | 215 B.C DXC | 134 BECKM.COUL | 11 | 132.273 | 2.260 | 1.71 | 119.000 | 146.000 | | |
| 2021-001 | 3 GL. OXI. C | 165 VITROS | 63 KODAK | 168 | 137.711 | 3.223 | 2.34 | 124.000 | 151.000 | | |
| 2021-001 | 3 GL. OXI. C | 165 VITROS | 63 KODAK | 168 | 141.625 | 4.029 | 2.84 | 127.000 | 156.000 | | |
| 2021-001 | 3 GL. OXI. C | 213 SELECTRA P | 150 ELITECH | 10 | 136.000 | 4.050 | 2.98 | 122.000 | 150.000 | | |
| 2021-001 | 5 HEXOKINASE | 38 SIEMENS DI | 143 SIEMENS | 79 | 141.354 | 3.849 | 2.72 | 127.000 | 155.000 | | |
| 2021-001 | 5 HEXOKINASE | 186 BECK. COUL | 76 AU-BECKMAN | 29 | 135.172 | 3.455 | 2.56 | 122.000 | 149.000 | | |
| 2021-001 | 5 HEXOKINASE | 191 RX-DAYTONA | 126 RANDOX | 24 | 142.500 | 4.252 | 2.98 | 128.000 | 157.000 | | |
| 2021-001 | 5 HEXOKINASE | 203 ROCHE | 93 ROCHE | 22 | 135.682 | 2.284 | 1.68 | 122.000 | 149.000 | | |
| 2021-001 | 5 HEXOKINASE | 212 S. D. EXL | 143 SIEMENS | 13 | 141.000 | 3.464 | 2.46 | 127.000 | 155.000 | | |
| 2021-001 | 6 HEXOKI. CO | 194 BIOLIS-24S | 154 (IDG) | 11 | 130.909 | 3.476 | 2.66 | 118.000 | 144.000 | | |
| 2021-001 | 12 HEXOKINASE | 184 INTEGRA | 93 ROCHE | 26 | 140.231 | 3.786 | 2.70 | 126.000 | 154.000 | | |
| 2021-001 | 12 HEXOKINASE | 197 ARCHITECT | 1 ABBOTT | 17 | 131.882 | 3.894 | 2.95 | 119.000 | 145.000 | | |
| 2021-001 | 12 HEXOKINASE | 203 ROCHE | 93 ROCHE | 16 | 136.188 | 4.096 | 3.01 | 123.000 | 150.000 | | |
| 2021-002 | 2 GL. OXI. E | 215 B.C DXC | 134 BECKM.COUL | 11 | 107.727 | 2.490 | 2.31 | 97.000 | 119.000 | | |
| 2021-002 | 3 GL. OXI. C | 165 VITROS | 63 KODAK | 168 | 114.875 | 2.147 | 1.87 | 103.000 | 126.000 | | |
| 2021-002 | 3 GL. OXI. C | 165 VITROS | 63 KODAK | 168 | 110.826 | 2.669 | 2.41 | 100.000 | 122.000 | | |
| 2021-002 | 3 GL. OXI. C | 213 SELECTRA P | 150 ELITECH | 10 | 113.300 | 4.051 | 3.58 | 102.000 | 125.000 | | |
| 2021-002 | 5 HEXOKINASE | 38 SIEMENS DI | 143 SIEMENS | 79 | 115.747 | 3.184 | 2.75 | 104.000 | 127.000 | | |
| 2021-002 | 5 HEXOKINASE | 186 BECK. COUL | 76 AU-BECKMAN | 29 | 110.069 | 2.586 | 2.35 | 99.000 | 121.000 | | |
| 2021-002 | 5 HEXOKINASE | 191 RX-DAYTONA | 126 RANDOX | 24 | 117.000 | 3.041 | 2.60 | 105.000 | 129.000 | | |
| 2021-002 | 5 HEXOKINASE | 203 ROCHE | 93 ROCHE | 22 | 110.571 | 2.083 | 1.88 | 100.000 | 122.000 | | |
| 2021-002 | 5 HEXOKINASE | 212 S. D. EXL | 143 SIEMENS | 13 | 114.923 | 3.731 | 3.25 | 103.000 | 126.000 | | |
| 2021-002 | 6 HEXOKI. CO | 194 BIOLIS-24S | 154 (IDG) | 11 | 107.727 | 1.863 | 1.73 | 97.000 | 119.000 | | |
| 2021-002 | 12 HEXOKINASE | 184 INTEGRA | 93 ROCHE | 26 | 113.385 | 2.975 | 2.62 | 102.000 | 125.000 | | |
| 2021-002 | 12 HEXOKINASE | 197 ARCHITECT | 1 ABBOTT | 17 | 107.706 | 2.696 | 2.50 | 97.000 | 118.000 | | |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

| ANALYTE | | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
|----------|---------|---------------------|----------------|------|------------|--|---------|----------|------|------------|---------|
| SAMPLE | METHOD | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH | | |
| 2021-002 | 12 | HEXOKINASE | 203 ROCHE | 93 | ROCHE | 16 | 111.313 | 3.754 | 3.37 | 100.000 | 122.000 |
| 017 | GLUCOSE | CLIA TEST ID #: 415 | | | | EVALUATION CRITERIA: TARGET VALUE 10 % OR 6.00 {GREATER} | | | | | |
| 2021-003 | 2 | GL. OXI. E | 215 B.C DXC | 134 | BECKM.COUL | 11 | 84.273 | 2.219 | 2.63 | 76.000 | 93.000 |
| 2021-003 | 3 | GL. OXI. C | 165 VITROS | 63 | KODAK | 168 | 86.452 | 2.138 | 2.47 | 78.000 | 95.000 |
| 2021-003 | 3 | GL. OXI. C | 165 VITROS | 63 | KODAK | 168 | 91.375 | 2.118 | 2.32 | 82.000 | 101.000 |
| 2021-003 | 3 | GL. OXI. C | 213 SELECTRA P | 150 | ELITECH | 10 | 89.300 | 3.378 | 3.78 | 80.000 | 98.000 |
| 2021-003 | 5 | HEXOKINASE | 38 SIEMENS DI | 143 | SIEMENS | 79 | 91.633 | 2.659 | 2.90 | 82.000 | 101.000 |
| 2021-003 | 5 | HEXOKINASE | 186 BECK. COUL | 76 | AU-BECKMAN | 29 | 87.069 | 2.288 | 2.63 | 78.000 | 96.000 |
| 2021-003 | 5 | HEXOKINASE | 191 RX-DAYTONA | 126 | RANDOX | 24 | 93.458 | 2.415 | 2.58 | 84.000 | 103.000 |
| 2021-003 | 5 | HEXOKINASE | 203 ROCHE | 93 | ROCHE | 22 | 87.409 | 1.614 | 1.85 | 79.000 | 96.000 |
| 2021-003 | 5 | HEXOKINASE | 212 S. D. EXL | 143 | SIEMENS | 13 | 91.231 | 3.445 | 3.78 | 82.000 | 100.000 |
| 2021-003 | 6 | HEXOKI. CO | 194 BIOLIS-24S | 154 | (IDG) | 11 | 85.909 | 1.832 | 2.13 | 77.000 | 95.000 |
| 2021-003 | 12 | HEXOKINASE | 184 INTEGRA | 93 | ROCHE | 26 | 90.038 | 2.227 | 2.47 | 81.000 | 99.000 |
| 2021-003 | 12 | HEXOKINASE | 197 ARCHITECT | 1 | ABBOTT | 17 | 85.000 | 2.657 | 3.13 | 77.000 | 94.000 |
| 2021-003 | 12 | HEXOKINASE | 203 ROCHE | 93 | ROCHE | 16 | 87.813 | 2.530 | 2.88 | 79.000 | 97.000 |
| 2021-004 | 2 | GL. OXI. E | 215 B.C DXC | 134 | BECKM.COUL | 11 | 163.545 | 2.935 | 1.79 | 147.000 | 180.000 |
| 2021-004 | 3 | GL. OXI. C | 165 VITROS | 63 | KODAK | 168 | 172.000 | 8.246 | 4.79 | 155.000 | 189.000 |
| 2021-004 | 3 | GL. OXI. C | 165 VITROS | 63 | KODAK | 168 | 174.205 | 4.046 | 2.32 | 157.000 | 192.000 |
| 2021-004 | 3 | GL. OXI. C | 213 SELECTRA P | 150 | ELITECH | 10 | 169.200 | 8.376 | 4.95 | 152.000 | 186.000 |
| 2021-004 | 5 | HEXOKINASE | 38 SIEMENS DI | 143 | SIEMENS | 79 | 175.526 | 4.848 | 2.76 | 158.000 | 193.000 |
| 2021-004 | 5 | HEXOKINASE | 186 BECK. COUL | 76 | AU-BECKMAN | 29 | 167.552 | 4.207 | 2.51 | 151.000 | 184.000 |
| 2021-004 | 5 | HEXOKINASE | 191 RX-DAYTONA | 126 | RANDOX | 24 | 175.870 | 6.905 | 3.93 | 158.000 | 193.000 |
| 2021-004 | 5 | HEXOKINASE | 203 ROCHE | 93 | ROCHE | 22 | 169.273 | 3.150 | 1.86 | 152.000 | 186.000 |
| 2021-004 | 5 | HEXOKINASE | 212 S. D. EXL | 143 | SIEMENS | 13 | 174.308 | 4.158 | 2.39 | 157.000 | 192.000 |
| 2021-004 | 6 | HEXOKI. CO | 194 BIOLIS-24S | 154 | (IDG) | 11 | 163.455 | 4.356 | 2.66 | 147.000 | 180.000 |
| 2021-004 | 12 | HEXOKINASE | 184 INTEGRA | 93 | ROCHE | 26 | 173.280 | 3.985 | 2.30 | 156.000 | 191.000 |
| 2021-004 | 12 | HEXOKINASE | 197 ARCHITECT | 1 | ABBOTT | 17 | 164.471 | 5.627 | 3.42 | 148.000 | 181.000 |
| 2021-004 | 12 | HEXOKINASE | 203 ROCHE | 93 | ROCHE | 16 | 169.313 | 6.771 | 4.00 | 152.000 | 186.000 |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

| ANALYTE | | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
|----------|---------------------|---------------------|----------------|------|---------|--|--------|----------|---------|------------|-------|
| SAMPLE | METHOD | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH | | |
| 017 | GLUCOSE | CLIA TEST ID #: 415 | | | | EVALUATION CRITERIA: TARGET VALUE 10 % OR 6.00 {GREATER} | | | | | |
| 2021-005 | 2 GL. OXI. E | 215 B.C DXC | 134 BECKM.COUL | 11 | 44.636 | 1.872 | 4.19 | 39.000 | 51.000 | | |
| 2021-005 | 3 GL. OXI. C | 165 VITROS | 63 KODAK | 168 | 42.506 | 1.307 | 3.07 | 37.000 | 49.000 | | |
| 2021-005 | 3 GL. OXI. C | 165 VITROS | 63 KODAK | 168 | 49.875 | 2.368 | 4.75 | 44.000 | 56.000 | | |
| 2021-005 | 3 GL. OXI. C | 213 SELECTRA P | 150 ELITECH | 10 | 49.000 | 1.414 | 2.89 | 43.000 | 55.000 | | |
| 2021-005 | 5 HEXOKINASE | 38 SIEMENS DI | 143 SIEMENS | 79 | 50.218 | 1.788 | 3.56 | 44.000 | 56.000 | | |
| 2021-005 | 5 HEXOKINASE | 186 BECK. COUL | 76 AU-BECKMAN | 29 | 47.138 | 1.358 | 2.88 | 41.000 | 53.000 | | |
| 2021-005 | 5 HEXOKINASE | 191 RX-DAYTONA | 126 RANDOX | 24 | 53.500 | 2.041 | 3.82 | 48.000 | 60.000 | | |
| 2021-005 | 5 HEXOKINASE | 203 ROCHE | 93 ROCHE | 22 | 46.909 | 1.203 | 2.56 | 41.000 | 53.000 | | |
| 2021-005 | 5 HEXOKINASE | 212 S. D. EXL | 143 SIEMENS | 13 | 50.077 | 2.235 | 4.46 | 44.000 | 56.000 | | |
| 2021-005 | 6 HEXOKI. CO | 194 BIOLIS-24S | 154 (IDG) | 11 | 47.909 | 1.676 | 3.50 | 42.000 | 54.000 | | |
| 2021-005 | 12 HEXOKINASE | 184 INTEGRA | 93 ROCHE | 26 | 48.385 | 1.361 | 2.81 | 42.000 | 54.000 | | |
| 2021-005 | 12 HEXOKINASE | 197 ARCHITECT | 1 ABBOTT | 17 | 44.882 | 0.963 | 2.15 | 39.000 | 51.000 | | |
| 2021-005 | 12 HEXOKINASE | 203 ROCHE | 93 ROCHE | 16 | 47.125 | 1.409 | 2.99 | 41.000 | 53.000 | | |
| 018 | IRON, TOTAL | CLIA TEST ID #: 425 | | | | EVALUATION CRITERIA: TARGET VALUE 20 % | | | | | |
| 2021-001 | 4 COULOMETR. | 165 VITROS | 63 KODAK | 14 | 263.786 | 6.981 | 2.65 | 211.000 | 317.000 | | |
| 2021-002 | 4 COULOMETR. | 165 VITROS | 63 KODAK | 14 | 192.571 | 5.151 | 2.67 | 154.000 | 231.000 | | |
| 2021-003 | 4 COULOMETR. | 165 VITROS | 63 KODAK | 14 | 134.357 | 5.588 | 4.16 | 107.000 | 161.000 | | |
| 2021-004 | 4 COULOMETR. | 165 VITROS | 63 KODAK | 14 | 375.214 | 8.394 | 2.24 | 300.000 | 450.000 | | |
| 2021-005 | 4 COULOMETR. | 165 VITROS | 63 KODAK | 14 | 44.429 | 4.419 | 9.95 | 36.000 | 53.000 | | |
| 019 | LACTASE DEHY. (LDH) | CLIA TEST ID #: 435 | | | | | | | | | |
| 2021-001 | 3 KINETIC-37 | 186 BECK. COUL | 76 AU-BECKMAN | 19 | 445.526 | 32.416 | 7.28 | 356.000 | 535.000 | | |
| 2021-001 | 3 KINETIC-37 | 215 B.C DXC | 134 BECKM.COUL | 10 | 436.200 | 9.368 | 2.15 | 349.000 | 523.000 | | |
| 2021-001 | 6 NADH | 184 INTEGRA | 93 ROCHE | 14 | 548.857 | 19.071 | 3.47 | 439.000 | 659.000 | | |
| 2021-001 | 6 NADH | 203 ROCHE | 93 ROCHE | 22 | 541.190 | 15.528 | 2.87 | 433.000 | 649.000 | | |
| 2021-001 | 7 SIEMENS 37 | 38 SIEMENS DI | 143 SIEMENS | 32 | 515.313 | 19.554 | 3.79 | 412.000 | 618.000 | | |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

| ANALYTE | | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
|----------|---------------------|---------------------|--|------|---------|-----------|--------|----------|---------|------------|-------|
| SAMPLE | METHOD | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH | | |
| 2021-001 | 9 LDH1 | 165 VITROS | 63 KODAK | 69 | 633.971 | 21.673 | 3.42 | 507.000 | 761.000 | | |
| 019 | LACTASE DEHY. (LDH) | CLIA TEST ID #: 435 | EVALUATION CRITERIA: TARGET VALUE 20 % | | | | | | | | |
| 2021-002 | 3 KINETIC-37 | 186 BECK. COUL | 76 AU-BECKMAN | 19 | 332.684 | 23.353 | 7.02 | 266.000 | 399.000 | | |
| 2021-002 | 3 KINETIC-37 | 215 B.C DXC | 134 BECKM.COUL | 10 | 350.800 | 58.922 | 16.80 | 281.000 | 421.000 | | |
| 2021-002 | 6 NADH | 184 INTEGRA | 93 ROCHE | 14 | 416.786 | 13.045 | 3.13 | 333.000 | 500.000 | | |
| 2021-002 | 6 NADH | 203 ROCHE | 93 ROCHE | 22 | 405.905 | 19.454 | 4.79 | 325.000 | 487.000 | | |
| 2021-002 | 7 SIEMENS 37 | 38 SIEMENS DI | 143 SIEMENS | 32 | 388.688 | 12.593 | 3.24 | 311.000 | 466.000 | | |
| 2021-002 | 9 LDH1 | 165 VITROS | 63 KODAK | 69 | 479.191 | 11.067 | 2.31 | 383.000 | 575.000 | | |
| 2021-003 | 3 KINETIC-37 | 186 BECK. COUL | 76 AU-BECKMAN | 19 | 227.474 | 17.055 | 7.50 | 182.000 | 273.000 | | |
| 2021-003 | 3 KINETIC-37 | 215 B.C DXC | 134 BECKM.COUL | 10 | 225.800 | 6.046 | 2.68 | 181.000 | 271.000 | | |
| 2021-003 | 6 NADH | 184 INTEGRA | 93 ROCHE | 14 | 287.000 | 9.381 | 3.27 | 230.000 | 344.000 | | |
| 2021-003 | 6 NADH | 203 ROCHE | 93 ROCHE | 22 | 278.238 | 8.524 | 3.06 | 223.000 | 334.000 | | |
| 2021-003 | 7 SIEMENS 37 | 38 SIEMENS DI | 143 SIEMENS | 32 | 263.188 | 10.454 | 3.97 | 211.000 | 316.000 | | |
| 2021-003 | 9 LDH1 | 165 VITROS | 63 KODAK | 69 | 334.485 | 7.289 | 2.18 | 268.000 | 401.000 | | |
| 2021-004 | 3 KINETIC-37 | 186 BECK. COUL | 76 AU-BECKMAN | 19 | 591.842 | 46.908 | 7.93 | 473.000 | 710.000 | | |
| 2021-004 | 3 KINETIC-37 | 215 B.C DXC | 134 BECKM.COUL | 10 | 569.800 | 13.970 | 2.45 | 456.000 | 684.000 | | |
| 2021-004 | 6 NADH | 184 INTEGRA | 93 ROCHE | 14 | 720.000 | 25.315 | 3.52 | 576.000 | 864.000 | | |
| 2021-004 | 6 NADH | 203 ROCHE | 93 ROCHE | 22 | 719.190 | 27.635 | 3.84 | 575.000 | 863.000 | | |
| 2021-004 | 7 SIEMENS 37 | 38 SIEMENS DI | 143 SIEMENS | 32 | 691.563 | 20.748 | 3.00 | 553.000 | 830.000 | | |
| 2021-004 | 9 LDH1 | 165 VITROS | 63 KODAK | 69 | 823.132 | 43.802 | 5.32 | 659.000 | 988.000 | | |
| 2021-005 | 3 KINETIC-37 | 186 BECK. COUL | 76 AU-BECKMAN | 19 | 44.263 | 3.998 | 9.03 | 35.000 | 53.000 | | |
| 2021-005 | 3 KINETIC-37 | 215 B.C DXC | 134 BECKM.COUL | 10 | 45.700 | 1.676 | 3.67 | 37.000 | 55.000 | | |
| 2021-005 | 6 NADH | 184 INTEGRA | 93 ROCHE | 14 | 59.429 | 2.321 | 3.91 | 48.000 | 71.000 | | |
| 2021-005 | 6 NADH | 203 ROCHE | 93 ROCHE | 22 | 55.571 | 2.753 | 4.95 | 44.000 | 67.000 | | |
| 2021-005 | 7 SIEMENS 37 | 38 SIEMENS DI | 143 SIEMENS | 32 | 52.969 | 5.277 | 9.96 | 42.000 | 64.000 | | |
| 2021-005 | 9 LDH1 | 165 VITROS | 63 KODAK | 69 | 69.426 | 4.688 | 6.75 | 56.000 | 83.000 | | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPEC: 10 CHEMISTRY | | SUB: 10 ROUTINE | | | | GRP: 10 ROUTINE | | | | | | |
|--------------------|--------------|---------------------|------------|----------|------------|--|-----------------|-----------------------|---------|-------------------|---------------|--|
| ANALYTE | | | | | | | | | | | | |
| SAMPLE | METHOD | SYST/INST | | REAGENTS | | NO. PART LABS | TARGET VALUE | STANDARD DEVIATION | % CV | ACCEPTABLE LOW | RANGE HIGH | |
| 021 | MAGNESIUM | CLIA TEST ID #: 455 | | | | EVALUATION CRITERIA: TARGET VALUE 25 % | | | | | | |
| 2021-001 | 2 CALMAGITE | 215 | B.C DXC | 134 | BECKM.COUL | 10 | 5.070 | 0.135 | 2.65 | 3.800 | 6.300 | |
| 2021-001 | 5 COLOR./K E | 165 | VITROS | 63 | KODAK | 23 | 5.578 | 0.135 | 2.42 | 4.200 | 7.000 | |
| 2021-002 | 2 CALMAGITE | 215 | B.C DXC | 134 | BECKM.COUL | 10 | 4.410 | 0.094 | 2.14 | 3.300 | 5.500 | |
| 2021-002 | 5 COLOR./K E | 165 | VITROS | 63 | KODAK | 23 | 4.865 | 0.113 | 2.32 | 3.600 | 6.100 | |
| 2021-003 | 2 CALMAGITE | 215 | B.C DXC | 134 | BECKM.COUL | 10 | 3.890 | 0.104 | 2.68 | 2.900 | 4.900 | |
| 2021-003 | 5 COLOR./K E | 165 | VITROS | 63 | KODAK | 23 | 4.261 | 0.092 | 2.16 | 3.200 | 5.300 | |
| 2021-004 | 2 CALMAGITE | 215 | B.C DXC | 134 | BECKM.COUL | 10 | 5.920 | 0.133 | 2.24 | 4.400 | 7.400 | |
| 2021-004 | 5 COLOR./K E | 165 | VITROS | 63 | KODAK | 23 | 6.396 | 0.137 | 2.14 | 4.800 | 8.000 | |
| 2021-005 | 2 CALMAGITE | 215 | B.C DXC | 134 | BECKM.COUL | 10 | 2.870 | 0.064 | 2.23 | 2.200 | 3.600 | |
| 2021-005 | 5 COLOR./K E | 165 | VITROS | 63 | KODAK | 23 | 3.173 | 0.069 | 2.16 | 2.400 | 4.000 | |
| 022 | POTASSIUM | CLIA TEST ID #: 465 | | | | EVALUATION CRITERIA: TARGET VALUE 1.00 | | | | | | |
| 2021-001 | 3 ISE DILUT. | 184 | INTEGRA | 93 | ROCHE | 36 | 5.619 | 0.097 | 1.72 | 4.600 | 6.600 | |
| 2021-001 | 3 ISE DILUT. | 186 | BECK. COUL | 76 | AU-BECKMAN | 29 | 5.534 | 0.109 | 1.97 | 4.500 | 6.500 | |
| 2021-001 | 3 ISE DILUT. | 197 | ARCHITECT | 1 | ABBOTT | 16 | 5.588 | 0.105 | 1.89 | 4.600 | 6.600 | |
| 2021-001 | 3 ISE DILUT. | 203 | ROCHE | 93 | ROCHE | 39 | 5.626 | 0.088 | 1.56 | 4.600 | 6.600 | |
| 2021-001 | 3 ISE DILUT. | 215 | B.C DXC | 134 | BECKM.COUL | 11 | 5.600 | 0.085 | 1.52 | 4.600 | 6.600 | |
| 2021-001 | 4 ISE UNLUT. | 165 | VITROS | 63 | KODAK | 105 | 5.568 | 0.104 | 1.86 | 4.600 | 6.600 | |
| 2021-001 | 4 ISE UNLUT. | 165 | VITROS | 156 | Kit 32 | 58 | 5.598 | 0.071 | 1.27 | 4.600 | 6.600 | |
| 2021-001 | 4 ISE UNLUT. | 191 | RX-DAYTONA | 126 | RANDOX | 30 | 5.462 | 0.085 | 1.55 | 4.500 | 6.500 | |
| 2021-001 | 4 ISE UNLUT. | 199 | Rx-IMOLA | 126 | RANDOX | 13 | 5.431 | 0.107 | 1.96 | 4.400 | 6.400 | |
| 2021-001 | 6 QUICK LYTE | 38 | SIEMENS DI | 143 | SIEMENS | 77 | 5.561 | 0.083 | 1.49 | 4.600 | 6.600 | |
| 2021-001 | 6 QUICK LYTE | 212 | S. D. EXL | 143 | SIEMENS | 13 | 5.554 | 0.122 | 2.19 | 4.600 | 6.600 | |
| 2021-002 | 3 ISE DILUT. | 184 | INTEGRA | 93 | ROCHE | 36 | 4.956 | 0.093 | 1.87 | 4.000 | 6.000 | |
| 2021-002 | 3 ISE DILUT. | 186 | BECK. COUL | 76 | AU-BECKMAN | 29 | 4.883 | 0.087 | 1.79 | 3.900 | 5.900 | |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

| ANALYTE | | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
|---------------|--------------|---------------------|-----------------------------------|------|-------|-----------|--------|----------|-------|------------|-------|
| SAMPLE | METHOD | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH | | |
| 2021-002 | 3 ISE DILUT. | 197 ARCHITECT | 1 ABBOTT | 16 | 4.906 | 0.090 | 1.83 | 3.900 | 5.900 | | |
| 2021-002 | 3 ISE DILUT. | 203 ROCHE | 93 ROCHE | 39 | 4.987 | 0.080 | 1.60 | 4.000 | 6.000 | | |
| 2021-002 | 3 ISE DILUT. | 215 B.C DXC | 134 BECKM.COUL | 11 | 4.891 | 0.090 | 1.84 | 3.900 | 5.900 | | |
| 2021-002 | 4 ISE UNDIL. | 165 VITROS | 63 KODAK | 105 | 4.907 | 0.093 | 1.90 | 3.900 | 5.900 | | |
| 2021-002 | 4 ISE UNDIL. | 165 VITROS | 156 Kit 32 | 58 | 4.933 | 0.073 | 1.48 | 3.900 | 5.900 | | |
| 2021-002 | 4 ISE UNDIL. | 191 RX-DAYTONA | 126 RANDOX | 30 | 4.807 | 0.069 | 1.44 | 3.800 | 5.800 | | |
| 2021-002 | 4 ISE UNDIL. | 199 Rx-IMOLA | 126 RANDOX | 13 | 4.792 | 0.121 | 2.52 | 3.800 | 5.800 | | |
| 2021-002 | 6 QUICK LYTE | 38 SIEMENS DI | 143 SIEMENS | 77 | 4.913 | 0.082 | 1.67 | 3.900 | 5.900 | | |
| 2021-002 | 6 QUICK LYTE | 212 S. D. EXL | 143 SIEMENS | 13 | 4.885 | 0.135 | 2.76 | 3.900 | 5.900 | | |
| 022 POTASSIUM | | CLIA TEST ID #: 465 | EVALUATION CRITERIA: TARGET VALUE | | 1.00 | | | | | | |
| 2021-003 | 3 ISE DILUT. | 184 INTEGRA | 93 ROCHE | 36 | 4.400 | 0.076 | 1.72 | 3.400 | 5.400 | | |
| 2021-003 | 3 ISE DILUT. | 186 BECK. COUL | 76 AU-BECKMAN | 29 | 4.352 | 0.068 | 1.55 | 3.400 | 5.400 | | |
| 2021-003 | 3 ISE DILUT. | 197 ARCHITECT | 1 ABBOTT | 16 | 4.338 | 0.099 | 2.29 | 3.300 | 5.300 | | |
| 2021-003 | 3 ISE DILUT. | 203 ROCHE | 93 ROCHE | 39 | 4.410 | 0.084 | 1.91 | 3.400 | 5.400 | | |
| 2021-003 | 3 ISE DILUT. | 215 B.C DXC | 134 BECKM.COUL | 11 | 4.300 | 0.074 | 1.72 | 3.300 | 5.300 | | |
| 2021-003 | 4 ISE UNDIL. | 165 VITROS | 63 KODAK | 105 | 4.328 | 0.080 | 1.85 | 3.300 | 5.300 | | |
| 2021-003 | 4 ISE UNDIL. | 165 VITROS | 156 Kit 32 | 58 | 4.340 | 0.083 | 1.91 | 3.300 | 5.300 | | |
| 2021-003 | 4 ISE UNDIL. | 191 RX-DAYTONA | 126 RANDOX | 30 | 4.276 | 0.073 | 1.70 | 3.300 | 5.300 | | |
| 2021-003 | 4 ISE UNDIL. | 199 Rx-IMOLA | 126 RANDOX | 13 | 4.262 | 0.127 | 2.99 | 3.300 | 5.300 | | |
| 2021-003 | 6 QUICK LYTE | 38 SIEMENS DI | 143 SIEMENS | 77 | 4.345 | 0.062 | 1.42 | 3.300 | 5.300 | | |
| 2021-003 | 6 QUICK LYTE | 212 S. D. EXL | 143 SIEMENS | 13 | 4.323 | 0.142 | 3.29 | 3.300 | 5.300 | | |
| 2021-004 | 3 ISE DILUT. | 184 INTEGRA | 93 ROCHE | 36 | 6.369 | 0.131 | 2.05 | 5.400 | 7.400 | | |
| 2021-004 | 3 ISE DILUT. | 186 BECK. COUL | 76 AU-BECKMAN | 29 | 6.307 | 0.111 | 1.76 | 5.300 | 7.300 | | |
| 2021-004 | 3 ISE DILUT. | 197 ARCHITECT | 1 ABBOTT | 16 | 6.369 | 0.121 | 1.90 | 5.400 | 7.400 | | |
| 2021-004 | 3 ISE DILUT. | 203 ROCHE | 93 ROCHE | 39 | 6.433 | 0.116 | 1.81 | 5.400 | 7.400 | | |
| 2021-004 | 3 ISE DILUT. | 215 B.C DXC | 134 BECKM.COUL | 11 | 6.418 | 0.094 | 1.46 | 5.400 | 7.400 | | |
| 2021-004 | 4 ISE UNDIL. | 165 VITROS | 63 KODAK | 105 | 6.437 | 0.133 | 2.07 | 5.400 | 7.400 | | |
| 2021-004 | 4 ISE UNDIL. | 165 VITROS | 156 Kit 32 | 58 | 6.457 | 0.137 | 2.12 | 5.500 | 7.500 | | |
| 2021-004 | 4 ISE UNDIL. | 191 RX-DAYTONA | 126 RANDOX | 30 | 6.290 | 0.135 | 2.14 | 5.300 | 7.300 | | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPEC: 10 CHEMISTRY | | SUB: 10 ROUTINE | | | | GRP: 10 ROUTINE | | | | | | |
|--------------------|-----------|---------------------|-----|------------|-----|--|-----------------|-----------------------|---------|-------------------|---------------|---------|
| ANALYTE | | | | | | | | | | | | |
| SAMPLE | METHOD | SYST/INST | | REAGENTS | | NO. PART LABS | TARGET VALUE | STANDARD DEVIATION | % CV | ACCEPTABLE LOW | RANGE HIGH | |
| 2021-004 | 4 | ISE UNLIL. | 199 | Rx-IMOLA | 126 | RANLIX | 13 | 6.277 | 0.212 | 3.37 | 5.300 | 7.300 |
| 2021-004 | 6 | QUICK LYTE | 38 | SIEMENS DI | 143 | SIEMENS | 77 | 6.387 | 0.158 | 2.47 | 5.400 | 7.400 |
| 2021-004 | 6 | QUICK LYTE | 212 | S. D. EXL | 143 | SIEMENS | 13 | 6.346 | 0.145 | 2.28 | 5.300 | 7.300 |
| 022 | POTASSIUM | CLIA TEST ID #: 465 | | | | EVALUATION CRITERIA: TARGET VALUE 1.00 | | | | | | |
| 2021-005 | 3 | ISE DILUT. | 184 | INTEGRA | 93 | ROCHE | 36 | 3.400 | 0.067 | 1.96 | 2.400 | 4.400 |
| 2021-005 | 3 | ISE DILUT. | 186 | BECK. COUL | 76 | AU-BECKMAN | 29 | 3.410 | 0.061 | 1.78 | 2.400 | 4.400 |
| 2021-005 | 3 | ISE DILUT. | 197 | ARCHITECT | 1 | ABBOTT | 16 | 3.356 | 0.086 | 2.57 | 2.400 | 4.400 |
| 2021-005 | 3 | ISE DILUT. | 203 | ROCHE | 93 | ROCHE | 39 | 3.441 | 0.074 | 2.15 | 2.400 | 4.400 |
| 2021-005 | 3 | ISE DILUT. | 215 | B.C DXC | 134 | BECKM.COUL | 11 | 3.300 | 0.060 | 1.83 | 2.300 | 4.300 |
| 2021-005 | 4 | ISE UNLIL. | 165 | VITROS | 63 | KODAK | 105 | 3.340 | 0.065 | 1.93 | 2.300 | 4.300 |
| 2021-005 | 4 | ISE UNLIL. | 165 | VITROS | 156 | Kit 32 | 58 | 3.340 | 0.062 | 1.85 | 2.300 | 4.300 |
| 2021-005 | 4 | ISE UNLIL. | 191 | RX-DAYTONA | 126 | RANLIX | 30 | 3.353 | 0.099 | 2.96 | 2.400 | 4.400 |
| 2021-005 | 4 | ISE UNLIL. | 199 | Rx-IMOLA | 126 | RANLIX | 13 | 3.323 | 0.125 | 3.76 | 2.300 | 4.300 |
| 2021-005 | 6 | QUICK LYTE | 38 | SIEMENS DI | 143 | SIEMENS | 77 | 3.349 | 0.060 | 1.78 | 2.300 | 4.300 |
| 2021-005 | 6 | QUICK LYTE | 212 | S. D. EXL | 143 | SIEMENS | 13 | 3.331 | 0.091 | 2.73 | 2.300 | 4.300 |
| 023 | SODIUM | CLIA TEST ID #: 475 | | | | EVALUATION CRITERIA: TARGET VALUE 4.00 | | | | | | |
| 2021-001 | 3 | ISE DILUTE | 184 | INTEGRA | 93 | ROCHE | 33 | 155.406 | 2.044 | 1.32 | 151.000 | 159.000 |
| 2021-001 | 3 | ISE DILUTE | 184 | INTEGRA | 93 | ROCHE | 33 | 157.400 | 2.800 | 1.78 | 153.000 | 161.000 |
| 2021-001 | 3 | ISE DILUTE | 186 | BECK. COUL | 76 | AU-BECKMAN | 29 | 156.517 | 2.253 | 1.44 | 153.000 | 161.000 |
| 2021-001 | 3 | ISE DILUTE | 197 | ARCHITECT | 1 | ABBOTT | 17 | 157.188 | 1.810 | 1.15 | 153.000 | 161.000 |
| 2021-001 | 3 | ISE DILUTE | 203 | ROCHE | 93 | ROCHE | 31 | 156.710 | 2.143 | 1.37 | 153.000 | 161.000 |
| 2021-001 | 3 | ISE DILUTE | 215 | B.C DXC | 134 | BECKM.COUL | 11 | 155.636 | 2.267 | 1.46 | 152.000 | 160.000 |
| 2021-001 | 4 | ISE UNLIL. | 165 | VITROS | 63 | KODAK | 96 | 155.208 | 2.512 | 1.62 | 151.000 | 159.000 |
| 2021-001 | 4 | ISE UNLIL. | 165 | VITROS | 63 | KODAK | 96 | 154.333 | 3.037 | 1.97 | 150.000 | 158.000 |
| 2021-001 | 4 | ISE UNLIL. | 165 | VITROS | 156 | Kit 32 | 59 | 155.328 | 2.602 | 1.68 | 151.000 | 159.000 |
| 2021-001 | 4 | ISE UNLIL. | 191 | RX-DAYTONA | 126 | RANLIX | 25 | 155.360 | 2.464 | 1.59 | 151.000 | 159.000 |
| 2021-001 | 4 | ISE UNLIL. | 199 | Rx-IMOLA | 126 | RANLIX | 12 | 154.333 | 2.718 | 1.76 | 150.000 | 158.000 |
| 2021-001 | 6 | QUICK LYTE | 38 | SIEMENS DI | 143 | SIEMENS | 78 | 156.104 | 2.225 | 1.43 | 152.000 | 160.000 |
| 2021-001 | 6 | QUICK LYTE | 212 | S. D. EXL | 143 | SIEMENS | 13 | 155.923 | 3.540 | 2.27 | 152.000 | 160.000 |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

| ANALYTE | | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
|------------|--------------|---------------------|-----------------------------------|------|---------|-----------|--------|----------|---------|------------|-------|
| SAMPLE | METHOD | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH | | |
| 023 SODIUM | | CLIA TEST ID #: 475 | EVALUATION CRITERIA: TARGET VALUE | | 4.00 | | | | | | |
| 2021-002 | 3 ISE DILUTE | 184 INTEGRA | 93 ROCHE | 33 | 149.400 | 3.007 | 2.01 | 145.000 | 153.000 | | |
| 2021-002 | 3 ISE DILUTE | 184 INTEGRA | 93 ROCHE | 33 | 147.594 | 2.134 | 1.45 | 144.000 | 152.000 | | |
| 2021-002 | 3 ISE DILUTE | 186 BECK. COUL | 76 AU-BECKMAN | 29 | 148.828 | 1.931 | 1.30 | 145.000 | 153.000 | | |
| 2021-002 | 3 ISE DILUTE | 197 ARCHITECT | 1 ABBOTT | 17 | 149.706 | 1.741 | 1.16 | 146.000 | 154.000 | | |
| 2021-002 | 3 ISE DILUTE | 203 ROCHE | 93 ROCHE | 31 | 149.533 | 1.454 | 0.97 | 146.000 | 154.000 | | |
| 2021-002 | 3 ISE DILUTE | 215 B.C DXC | 134 BECKM.COUL | 11 | 147.818 | 2.516 | 1.70 | 144.000 | 152.000 | | |
| 2021-002 | 4 ISE UNLIL. | 165 VITROS | 63 KODAK | 96 | 146.333 | 3.300 | 2.26 | 142.000 | 150.000 | | |
| 2021-002 | 4 ISE UNLIL. | 165 VITROS | 63 KODAK | 96 | 147.125 | 2.078 | 1.41 | 143.000 | 151.000 | | |
| 2021-002 | 4 ISE UNLIL. | 165 VITROS | 156 Kit 32 | 59 | 147.102 | 2.275 | 1.55 | 143.000 | 151.000 | | |
| 2021-002 | 4 ISE UNLIL. | 191 RX-DAYTONA | 126 RANDOX | 25 | 147.080 | 2.261 | 1.54 | 143.000 | 151.000 | | |
| 2021-002 | 4 ISE UNLIL. | 199 Rx-IMOLA | 126 RANDOX | 12 | 146.083 | 1.891 | 1.29 | 142.000 | 150.000 | | |
| 2021-002 | 6 QUICK LYTE | 38 SIEMENS DI | 143 SIEMENS | 78 | 149.506 | 1.965 | 1.31 | 146.000 | 154.000 | | |
| 2021-002 | 6 QUICK LYTE | 212 S. D. EXL | 143 SIEMENS | 13 | 148.692 | 3.582 | 2.41 | 145.000 | 153.000 | | |
| 2021-003 | 3 ISE DILUTE | 184 INTEGRA | 93 ROCHE | 33 | 143.152 | 2.244 | 1.57 | 139.000 | 147.000 | | |
| 2021-003 | 3 ISE DILUTE | 184 INTEGRA | 93 ROCHE | 33 | 143.800 | 1.720 | 1.20 | 140.000 | 148.000 | | |
| 2021-003 | 3 ISE DILUTE | 186 BECK. COUL | 76 AU-BECKMAN | 29 | 144.897 | 2.074 | 1.43 | 141.000 | 149.000 | | |
| 2021-003 | 3 ISE DILUTE | 197 ARCHITECT | 1 ABBOTT | 17 | 144.588 | 1.942 | 1.34 | 141.000 | 149.000 | | |
| 2021-003 | 3 ISE DILUTE | 203 ROCHE | 93 ROCHE | 31 | 144.500 | 1.607 | 1.11 | 141.000 | 149.000 | | |
| 2021-003 | 3 ISE DILUTE | 215 B.C DXC | 134 BECKM.COUL | 11 | 142.545 | 2.350 | 1.65 | 139.000 | 147.000 | | |
| 2021-003 | 4 ISE UNLIL. | 165 VITROS | 63 KODAK | 96 | 141.642 | 2.046 | 1.44 | 138.000 | 146.000 | | |
| 2021-003 | 4 ISE UNLIL. | 165 VITROS | 63 KODAK | 96 | 141.000 | 2.160 | 1.53 | 137.000 | 145.000 | | |
| 2021-003 | 4 ISE UNLIL. | 165 VITROS | 156 Kit 32 | 59 | 141.186 | 2.119 | 1.50 | 137.000 | 145.000 | | |
| 2021-003 | 4 ISE UNLIL. | 191 RX-DAYTONA | 126 RANDOX | 25 | 141.840 | 2.587 | 1.82 | 138.000 | 146.000 | | |
| 2021-003 | 4 ISE UNLIL. | 199 Rx-IMOLA | 126 RANDOX | 12 | 141.500 | 1.803 | 1.27 | 138.000 | 146.000 | | |
| 2021-003 | 6 QUICK LYTE | 38 SIEMENS DI | 143 SIEMENS | 78 | 144.961 | 1.533 | 1.06 | 141.000 | 149.000 | | |
| 2021-003 | 6 QUICK LYTE | 212 S. D. EXL | 143 SIEMENS | 13 | 143.923 | 4.446 | 3.09 | 140.000 | 148.000 | | |
| 2021-004 | 3 ISE DILUTE | 184 INTEGRA | 93 ROCHE | 33 | 161.400 | 2.154 | 1.33 | 157.000 | 165.000 | | |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

| ANALYTE | | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
|-------------------|--------------|---------------------|--|------|---------|-----------|--------|----------|---------|------------|-------|
| SAMPLE | METHOD | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH | | |
| 2021-004 | 3 ISE DILUTE | 184 INTEGRA | 93 ROCHE | 33 | 160.364 | 2.826 | 1.76 | 156.000 | 164.000 | | |
| 2021-004 | 3 ISE DILUTE | 186 BECK. COUL | 76 AU-BECKMAN | 29 | 162.897 | 2.940 | 1.80 | 159.000 | 167.000 | | |
| 2021-004 | 3 ISE DILUTE | 197 ARCHITECT | 1 ABBOTT | 17 | 164.235 | 2.602 | 1.58 | 160.000 | 168.000 | | |
| 2021-004 | 3 ISE DILUTE | 203 ROCHE | 93 ROCHE | 31 | 163.433 | 1.927 | 1.18 | 159.000 | 167.000 | | |
| 2021-004 | 3 ISE DILUTE | 215 B.C DXC | 134 BECKM.COUL | 11 | 162.909 | 2.610 | 1.60 | 159.000 | 167.000 | | |
| 2021-004 | 4 ISE UNDIL. | 165 VITROS | 63 KODAK | 96 | 164.167 | 4.140 | 2.52 | 160.000 | 168.000 | | |
| 2021-004 | 4 ISE UNDIL. | 165 VITROS | 63 KODAK | 96 | 163.263 | 2.978 | 1.82 | 159.000 | 167.000 | | |
| 2021-004 | 4 ISE UNDIL. | 165 VITROS | 156 Kit 32 | 59 | 163.797 | 3.621 | 2.21 | 160.000 | 168.000 | | |
| 2021-004 | 4 ISE UNDIL. | 191 RX-DAYTONA | 126 RANDOX | 25 | 163.167 | 3.078 | 1.89 | 159.000 | 167.000 | | |
| 2021-004 | 4 ISE UNDIL. | 199 Rx-IMOLA | 126 RANDOX | 12 | 162.000 | 3.028 | 1.87 | 158.000 | 166.000 | | |
| 2021-004 | 6 QUICK LYTE | 38 SIEMENS DI | 143 SIEMENS | 78 | 162.342 | 2.137 | 1.32 | 158.000 | 166.000 | | |
| 2021-004 | 6 QUICK LYTE | 212 S. D. EXL | 143 SIEMENS | 13 | 161.462 | 3.795 | 2.35 | 157.000 | 165.000 | | |
| 023 SODIUM | | CLIA TEST ID #: 475 | EVALUATION CRITERIA: TARGET VALUE 4.00 | | | | | | | | |
| 2021-005 | 3 ISE DILUTE | 184 INTEGRA | 93 ROCHE | 33 | 133.212 | 2.422 | 1.82 | 129.000 | 137.000 | | |
| 2021-005 | 3 ISE DILUTE | 184 INTEGRA | 93 ROCHE | 33 | 134.000 | 2.000 | 1.49 | 130.000 | 138.000 | | |
| 2021-005 | 3 ISE DILUTE | 186 BECK. COUL | 76 AU-BECKMAN | 29 | 134.931 | 1.617 | 1.20 | 131.000 | 139.000 | | |
| 2021-005 | 3 ISE DILUTE | 197 ARCHITECT | 1 ABBOTT | 17 | 133.882 | 1.711 | 1.28 | 130.000 | 138.000 | | |
| 2021-005 | 3 ISE DILUTE | 203 ROCHE | 93 ROCHE | 31 | 134.742 | 1.999 | 1.48 | 131.000 | 139.000 | | |
| 2021-005 | 3 ISE DILUTE | 215 B.C DXC | 134 BECKM.COUL | 11 | 132.909 | 1.832 | 1.38 | 129.000 | 137.000 | | |
| 2021-005 | 4 ISE UNDIL. | 165 VITROS | 63 KODAK | 96 | 130.667 | 1.599 | 1.22 | 127.000 | 135.000 | | |
| 2021-005 | 4 ISE UNDIL. | 165 VITROS | 63 KODAK | 96 | 131.415 | 1.807 | 1.37 | 127.000 | 135.000 | | |
| 2021-005 | 4 ISE UNDIL. | 165 VITROS | 156 Kit 32 | 59 | 131.018 | 1.383 | 1.06 | 127.000 | 135.000 | | |
| 2021-005 | 4 ISE UNDIL. | 191 RX-DAYTONA | 126 RANDOX | 25 | 131.360 | 2.364 | 1.80 | 127.000 | 135.000 | | |
| 2021-005 | 4 ISE UNDIL. | 199 Rx-IMOLA | 126 RANDOX | 12 | 131.000 | 2.160 | 1.65 | 127.000 | 135.000 | | |
| 2021-005 | 6 QUICK LYTE | 38 SIEMENS DI | 143 SIEMENS | 78 | 136.091 | 1.684 | 1.24 | 132.000 | 140.000 | | |
| 2021-005 | 6 QUICK LYTE | 212 S. D. EXL | 143 SIEMENS | 13 | 134.923 | 3.269 | 2.42 | 131.000 | 139.000 | | |
| 024 TOTAL PROTEIN | | CLIA TEST ID #: 485 | EVALUATION CRITERIA: TARGET VALUE 10 % | | | | | | | | |
| 2021-001 | 1 BIURET | 38 SIEMENS DI | 143 SIEMENS | 77 | 6.717 | 0.167 | 2.48 | 6.000 | 7.400 | | |
| 2021-001 | 1 BIURET | 165 VITROS | 63 KODAK | 147 | 6.273 | 0.145 | 2.30 | 5.600 | 6.900 | | |
| 2021-001 | 1 BIURET | 184 INTEGRA | 93 ROCHE | 28 | 6.296 | 0.157 | 2.49 | 5.700 | 6.900 | | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPEC: 10 CHEMISTRY | | SUB: 10 ROUTINE | | | | GRP: 10 ROUTINE | | | | | | |
|--------------------|--------|-----------------|---------------------|------------|-----|--|-----------------|-----------------------|---------|-------------------|---------------|-------|
| ANALYTE | | | | | | | | | | | | |
| SAMPLE | METHOD | SYST/INST | | REAGENTS | | NO. PART LABS | TARGET VALUE | STANDARD DEVIATION | % CV | ACCEPTABLE LOW | RANGE HIGH | |
| 2021-001 | 1 | BIURET | 186 | BECK. COUL | 76 | AU-BECKMAN | 25 | 6.356 | 0.214 | 3.36 | 5.700 | 7.000 |
| 2021-001 | 1 | BIURET | 191 | RX-DAYTONA | 126 | RANDOX | 30 | 6.410 | 0.197 | 3.08 | 5.800 | 7.100 |
| 2021-001 | 1 | BIURET | 197 | ARCHITECT | 1 | ABBOTT | 19 | 6.458 | 0.223 | 3.46 | 5.800 | 7.100 |
| 2021-001 | 1 | BIURET | 199 | Rx-IMOLA | 126 | RANDOX | 12 | 6.558 | 0.229 | 3.49 | 5.900 | 7.200 |
| 2021-001 | 1 | BIURET | 203 | ROCHE | 93 | ROCHE | 30 | 6.410 | 0.130 | 2.03 | 5.800 | 7.100 |
| 2021-001 | 1 | BIURET | 212 | S. D. EXL | 143 | SIEMENS | 13 | 6.715 | 0.266 | 3.95 | 6.000 | 7.400 |
| 2021-001 | 1 | BIURET | 215 | B.C DXC | 134 | BECKM.COUL | 11 | 6.500 | 0.213 | 3.28 | 5.900 | 7.200 |
| 024 TOTAL PROTEIN | | | CLIA TEST ID #: 485 | | | EVALUATION CRITERIA: TARGET VALUE 10 % | | | | | | |
| 2021-002 | 1 | BIURET | 38 | SIEMENS DI | 143 | SIEMENS | 77 | 5.562 | 0.130 | 2.33 | 5.000 | 6.100 |
| 2021-002 | 1 | BIURET | 165 | VITROS | 63 | KODAK | 147 | 5.245 | 0.128 | 2.45 | 4.700 | 5.800 |
| 2021-002 | 1 | BIURET | 184 | INTEGRA | 93 | ROCHE | 28 | 5.182 | 0.151 | 2.92 | 4.700 | 5.700 |
| 2021-002 | 1 | BIURET | 186 | BECK. COUL | 76 | AU-BECKMAN | 25 | 5.232 | 0.157 | 3.00 | 4.700 | 5.800 |
| 2021-002 | 1 | BIURET | 191 | RX-DAYTONA | 126 | RANDOX | 30 | 5.313 | 0.133 | 2.51 | 4.800 | 5.800 |
| 2021-002 | 1 | BIURET | 197 | ARCHITECT | 1 | ABBOTT | 19 | 5.268 | 0.178 | 3.38 | 4.700 | 5.800 |
| 2021-002 | 1 | BIURET | 199 | Rx-IMOLA | 126 | RANDOX | 12 | 5.383 | 0.134 | 2.50 | 4.800 | 5.900 |
| 2021-002 | 1 | BIURET | 203 | ROCHE | 93 | ROCHE | 30 | 5.362 | 0.122 | 2.27 | 4.800 | 5.900 |
| 2021-002 | 1 | BIURET | 212 | S. D. EXL | 143 | SIEMENS | 13 | 5.546 | 0.210 | 3.78 | 5.000 | 6.100 |
| 2021-002 | 1 | BIURET | 215 | B.C DXC | 134 | BECKM.COUL | 11 | 5.327 | 0.142 | 2.67 | 4.800 | 5.900 |
| 2021-003 | 1 | BIURET | 38 | SIEMENS DI | 143 | SIEMENS | 77 | 4.497 | 0.127 | 2.82 | 4.000 | 4.900 |
| 2021-003 | 1 | BIURET | 165 | VITROS | 63 | KODAK | 147 | 4.272 | 0.124 | 2.91 | 3.800 | 4.700 |
| 2021-003 | 1 | BIURET | 184 | INTEGRA | 93 | ROCHE | 28 | 4.207 | 0.122 | 2.91 | 3.800 | 4.600 |
| 2021-003 | 1 | BIURET | 186 | BECK. COUL | 76 | AU-BECKMAN | 25 | 4.232 | 0.129 | 3.04 | 3.800 | 4.700 |
| 2021-003 | 1 | BIURET | 191 | RX-DAYTONA | 126 | RANDOX | 30 | 4.290 | 0.127 | 2.97 | 3.900 | 4.700 |
| 2021-003 | 1 | BIURET | 197 | ARCHITECT | 1 | ABBOTT | 19 | 4.237 | 0.156 | 3.69 | 3.800 | 4.700 |
| 2021-003 | 1 | BIURET | 199 | Rx-IMOLA | 126 | RANDOX | 12 | 4.333 | 0.103 | 2.37 | 3.900 | 4.800 |
| 2021-003 | 1 | BIURET | 203 | ROCHE | 93 | ROCHE | 30 | 4.320 | 0.098 | 2.27 | 3.900 | 4.800 |
| 2021-003 | 1 | BIURET | 212 | S. D. EXL | 143 | SIEMENS | 13 | 4.492 | 0.177 | 3.95 | 4.000 | 4.900 |
| 2021-003 | 1 | BIURET | 215 | B.C DXC | 134 | BECKM.COUL | 11 | 4.255 | 0.178 | 4.18 | 3.800 | 4.700 |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

| ANALYTE | | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
|-------------------|--------|---------------------|----------------|------|------------|--|---------|----------|------|------------|---------|
| SAMPLE | METHOD | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH | | |
| 024 TOTAL PROTEIN | | CLIA TEST ID #: 485 | | | | EVALUATION CRITERIA: TARGET VALUE 10 % | | | | | |
| 2021-004 | 1 | BIURET | 38 SIEMENS DI | 143 | SIEMENS | 77 | 8.275 | 0.199 | 2.41 | 7.400 | 9.100 |
| 2021-004 | 1 | BIURET | 165 VITROS | 63 | KODAK | 147 | 7.669 | 0.178 | 2.32 | 6.900 | 8.400 |
| 2021-004 | 1 | BIURET | 184 INTEGRA | 93 | ROCHE | 28 | 7.650 | 0.211 | 2.76 | 6.900 | 8.400 |
| 2021-004 | 1 | BIURET | 186 BECK. COUL | 76 | AU-BECKMAN | 25 | 7.748 | 0.262 | 3.39 | 7.000 | 8.500 |
| 2021-004 | 1 | BIURET | 191 RX-DAYTONA | 126 | RANDOX | 30 | 7.770 | 0.208 | 2.68 | 7.000 | 8.500 |
| 2021-004 | 1 | BIURET | 197 ARCHITECT | 1 | ABBOTT | 19 | 7.984 | 0.303 | 3.80 | 7.200 | 8.800 |
| 2021-004 | 1 | BIURET | 199 Rx-IMOLA | 126 | RANDOX | 12 | 8.000 | 0.242 | 3.02 | 7.200 | 8.800 |
| 2021-004 | 1 | BIURET | 203 ROCHE | 93 | ROCHE | 30 | 7.845 | 0.201 | 2.56 | 7.100 | 8.600 |
| 2021-004 | 1 | BIURET | 212 S. D. EXL | 143 | SIEMENS | 13 | 8.223 | 0.309 | 3.76 | 7.400 | 9.000 |
| 2021-004 | 1 | BIURET | 215 B.C DXC | 134 | BECKM.COUL | 11 | 8.000 | 0.222 | 2.77 | 7.200 | 8.800 |
| 2021-005 | 1 | BIURET | 38 SIEMENS DI | 143 | SIEMENS | 77 | 2.663 | 0.098 | 3.70 | 2.400 | 2.900 |
| 2021-005 | 1 | BIURET | 165 VITROS | 63 | KODAK | 147 | 2.563 | 0.071 | 2.75 | 2.300 | 2.800 |
| 2021-005 | 1 | BIURET | 184 INTEGRA | 93 | ROCHE | 28 | 2.493 | 0.080 | 3.20 | 2.200 | 2.700 |
| 2021-005 | 1 | BIURET | 186 BECK. COUL | 76 | AU-BECKMAN | 25 | 2.508 | 0.126 | 5.01 | 2.300 | 2.800 |
| 2021-005 | 1 | BIURET | 191 RX-DAYTONA | 126 | RANDOX | 30 | 2.580 | 0.079 | 3.07 | 2.300 | 2.800 |
| 2021-005 | 1 | BIURET | 197 ARCHITECT | 1 | ABBOTT | 19 | 2.468 | 0.134 | 5.43 | 2.200 | 2.700 |
| 2021-005 | 1 | BIURET | 199 Rx-IMOLA | 126 | RANDOX | 12 | 2.617 | 0.090 | 3.43 | 2.400 | 2.900 |
| 2021-005 | 1 | BIURET | 203 ROCHE | 93 | ROCHE | 30 | 2.573 | 0.068 | 2.64 | 2.300 | 2.800 |
| 2021-005 | 1 | BIURET | 212 S. D. EXL | 143 | SIEMENS | 13 | 2.638 | 0.121 | 4.59 | 2.400 | 2.900 |
| 2021-005 | 1 | BIURET | 215 B.C DXC | 134 | BECKM.COUL | 11 | 2.545 | 0.192 | 7.56 | 2.300 | 2.800 |
| 025 TRIGLYCERIDES | | CLIA TEST ID #: 495 | | | | EVALUATION CRITERIA: TARGET VALUE 25 % | | | | | |
| 2021-001 | 2 | ENZ. COLO. | 165 VITROS | 63 | KODAK | 150 | 215.120 | 7.964 | 3.70 | 161.000 | 269.000 |
| 2021-001 | 2 | ENZ. COLO. | 184 INTEGRA | 93 | ROCHE | 10 | 183.700 | 5.001 | 2.72 | 138.000 | 230.000 |
| 2021-001 | 2 | ENZ. COLO. | 203 ROCHE | 93 | ROCHE | 18 | 180.765 | 3.904 | 2.16 | 136.000 | 226.000 |
| 2021-001 | 4 | ENZ. (GPD) | 38 SIEMENS DI | 143 | SIEMENS | 75 | 180.676 | 4.362 | 2.41 | 136.000 | 226.000 |
| 2021-001 | 4 | ENZ. (GPD) | 212 S. D. EXL | 143 | SIEMENS | 14 | 179.000 | 4.598 | 2.57 | 134.000 | 224.000 |
| 2021-001 | 9 | GPO TRIND. | 186 BECK. COUL | 76 | AU-BECKMAN | 27 | 186.704 | 5.772 | 3.09 | 140.000 | 233.000 |
| 2021-001 | 9 | GPO TRIND. | 191 RX-DAYTONA | 126 | RANDOX | 21 | 176.048 | 8.364 | 4.75 | 132.000 | 220.000 |

Participant Summary

MONTH 2 OF YEAR 2021

| SPEC: 10 CHEMISTRY | | SUB: 10 ROUTINE | | | | GRP: 10 ROUTINE | | | | | | |
|--------------------|--------|-----------------|---------------------|------------|-----|--|-----------------|-----------------------|---------|-------------------|---------------|---------|
| ANALYTE | | | | | | | | | | | | |
| SAMPLE | METHOD | SYST/INST | | REAGENTS | | NO. PART LABS | TARGET VALUE | STANDARD DEVIATION | % CV | ACCEPTABLE LOW | RANGE HIGH | |
| 2021-001 | 9 | GPO TRIND. | 194 | BIOLIS-24S | 154 | (IDG) | 10 | 154.400 | 3.583 | 2.32 | 116.000 | 193.000 |
| 2021-001 | 9 | GPO TRIND. | 215 | B.C DXC | 134 | BECKM.COUL | 10 | 199.000 | 6.812 | 3.42 | 149.000 | 249.000 |
| 2021-001 | 10 | ENZYM. GPO | 184 | INTEGRA | 93 | ROCHE | 25 | 184.625 | 4.990 | 2.70 | 138.000 | 231.000 |
| 2021-001 | 10 | ENZYM. GPO | 203 | ROCHE | 93 | ROCHE | 20 | 179.500 | 3.775 | 2.10 | 135.000 | 224.000 |
| 2021-001 | 11 | GLY PO4 OX | 197 | ARCHITECT | 1 | ABBOTT | 11 | 180.091 | 5.501 | 3.05 | 135.000 | 225.000 |
| 025 TRIGLYCERIDES | | | CLIA TEST ID #: 495 | | | EVALUATION CRITERIA: TARGET VALUE 25 % | | | | | | |
| 2021-002 | 2 | ENZ. COLO. | 165 | VITROS | 63 | KODAK | 150 | 179.560 | 7.031 | 3.92 | 135.000 | 224.000 |
| 2021-002 | 2 | ENZ. COLO. | 184 | INTEGRA | 93 | ROCHE | 10 | 158.400 | 3.323 | 2.10 | 119.000 | 198.000 |
| 2021-002 | 2 | ENZ. COLO. | 203 | ROCHE | 93 | ROCHE | 18 | 153.824 | 3.869 | 2.52 | 115.000 | 192.000 |
| 2021-002 | 4 | ENZ. (GPD) | 38 | SIEMENS DI | 143 | SIEMENS | 75 | 151.676 | 3.662 | 2.41 | 114.000 | 190.000 |
| 2021-002 | 4 | ENZ. (GPD) | 212 | S. D. EXL | 143 | SIEMENS | 14 | 149.357 | 4.529 | 3.03 | 112.000 | 187.000 |
| 2021-002 | 9 | GPO TRIND. | 186 | BECK. COUL | 76 | AU-BECKMAN | 27 | 156.222 | 4.031 | 2.58 | 117.000 | 195.000 |
| 2021-002 | 9 | GPO TRIND. | 191 | RX-DAYTONA | 126 | RANDOX | 21 | 148.905 | 12.035 | 8.08 | 112.000 | 186.000 |
| 2021-002 | 9 | GPO TRIND. | 194 | BIOLIS-24S | 154 | (IDG) | 10 | 132.200 | 2.857 | 2.16 | 99.000 | 165.000 |
| 2021-002 | 9 | GPO TRIND. | 215 | B.C DXC | 134 | BECKM.COUL | 10 | 167.500 | 5.334 | 3.18 | 126.000 | 209.000 |
| 2021-002 | 10 | ENZYM. GPO | 184 | INTEGRA | 93 | ROCHE | 25 | 156.261 | 2.937 | 1.88 | 117.000 | 195.000 |
| 2021-002 | 10 | ENZYM. GPO | 203 | ROCHE | 93 | ROCHE | 20 | 153.850 | 3.336 | 2.17 | 115.000 | 192.000 |
| 2021-002 | 11 | GLY PO4 OX | 197 | ARCHITECT | 1 | ABBOTT | 11 | 150.727 | 4.392 | 2.91 | 113.000 | 188.000 |
| 2021-003 | 2 | ENZ. COLO. | 165 | VITROS | 63 | KODAK | 150 | 147.700 | 5.736 | 3.88 | 111.000 | 185.000 |
| 2021-003 | 2 | ENZ. COLO. | 184 | INTEGRA | 93 | ROCHE | 10 | 133.200 | 3.655 | 2.74 | 100.000 | 167.000 |
| 2021-003 | 2 | ENZ. COLO. | 203 | ROCHE | 93 | ROCHE | 18 | 129.556 | 3.685 | 2.84 | 97.000 | 162.000 |
| 2021-003 | 4 | ENZ. (GPD) | 38 | SIEMENS DI | 143 | SIEMENS | 75 | 124.307 | 3.183 | 2.56 | 93.000 | 155.000 |
| 2021-003 | 4 | ENZ. (GPD) | 212 | S. D. EXL | 143 | SIEMENS | 14 | 122.143 | 4.794 | 3.92 | 92.000 | 153.000 |
| 2021-003 | 9 | GPO TRIND. | 186 | BECK. COUL | 76 | AU-BECKMAN | 27 | 130.222 | 4.076 | 3.13 | 98.000 | 163.000 |
| 2021-003 | 9 | GPO TRIND. | 191 | RX-DAYTONA | 126 | RANDOX | 21 | 126.050 | 5.766 | 4.57 | 95.000 | 158.000 |
| 2021-003 | 9 | GPO TRIND. | 194 | BIOLIS-24S | 154 | (IDG) | 10 | 112.300 | 2.410 | 2.15 | 84.000 | 140.000 |
| 2021-003 | 9 | GPO TRIND. | 215 | B.C DXC | 134 | BECKM.COUL | 10 | 138.200 | 5.618 | 4.06 | 104.000 | 173.000 |
| 2021-003 | 10 | ENZYM. GPO | 184 | INTEGRA | 93 | ROCHE | 25 | 132.375 | 3.773 | 2.85 | 99.000 | 165.000 |
| 2021-003 | 10 | ENZYM. GPO | 203 | ROCHE | 93 | ROCHE | 20 | 129.250 | 2.947 | 2.28 | 97.000 | 162.000 |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

| ANALYTE | | | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
|----------|---------------------|---------------------|------------|---|------------|------|----------|-----------|----------|---------|------------|-------|
| SAMPLE | METHOD | SYST/INST | | REAGENTS | | LABS | VALUE | DEVIATION | CV | LOW | HIGH | |
| 2021-003 | 11 GLY PO4 OX | 197 | ARCHITECT | 1 | ABBOTT | 11 | 124.909 | 3.630 | 2.91 | 94.000 | 156.000 | |
| 025 | TRIGLYCERIDES | CLIA TEST ID #: 495 | | EVALUATION CRITERIA: TARGET VALUE 25 % | | | | | | | | |
| 2021-004 | 2 ENZ. COLO. | 165 | VITROS | 63 | KODAK | 150 | 263.033 | 10.051 | 3.82 | 197.000 | 329.000 | |
| 2021-004 | 2 ENZ. COLO. | 184 | INTEGRA | 93 | ROCHE | 10 | 216.200 | 6.615 | 3.06 | 162.000 | 270.000 | |
| 2021-004 | 2 ENZ. COLO. | 203 | ROCHE | 93 | ROCHE | 18 | 214.444 | 6.652 | 3.10 | 161.000 | 268.000 | |
| 2021-004 | 4 ENZ. (GPD) | 38 | SIEMENS DI | 143 | SIEMENS | 75 | 217.878 | 4.656 | 2.14 | 163.000 | 272.000 | |
| 2021-004 | 4 ENZ. (GPD) | 212 | S. D. EXL | 143 | SIEMENS | 14 | 216.923 | 5.980 | 2.76 | 163.000 | 271.000 | |
| 2021-004 | 9 GPO TRIND. | 186 | BECK. COUL | 76 | AU-BECKMAN | 27 | 224.593 | 6.344 | 2.82 | 168.000 | 281.000 | |
| 2021-004 | 9 GPO TRIND. | 191 | RX-DAYTONA | 126 | RANDOX | 21 | 211.238 | 9.521 | 4.51 | 158.000 | 264.000 | |
| 2021-004 | 9 GPO TRIND. | 194 | BIOLIS-24S | 154 | (IDG) | 10 | 182.800 | 5.437 | 2.97 | 137.000 | 229.000 | |
| 2021-004 | 9 GPO TRIND. | 215 | B.C DXC | 134 | BECKM.COUL | 10 | 241.000 | 8.579 | 3.56 | 181.000 | 301.000 | |
| 2021-004 | 10 ENZYM. GPO | 184 | INTEGRA | 93 | ROCHE | 25 | 216.375 | 6.244 | 2.89 | 162.000 | 270.000 | |
| 2021-004 | 10 ENZYM. GPO | 203 | ROCHE | 93 | ROCHE | 20 | 212.450 | 5.296 | 2.49 | 159.000 | 266.000 | |
| 2021-004 | 11 GLY PO4 OX | 197 | ARCHITECT | 1 | ABBOTT | 11 | 213.455 | 8.250 | 3.87 | 160.000 | 267.000 | |
| 2021-005 | 2 ENZ. COLO. | 165 | VITROS | 63 | KODAK | 150 | 89.329 | 4.157 | 4.65 | 67.000 | 112.000 | |
| 2021-005 | 2 ENZ. COLO. | 184 | INTEGRA | 93 | ROCHE | 10 | 87.600 | 1.908 | 2.18 | 66.000 | 110.000 | |
| 2021-005 | 2 ENZ. COLO. | 203 | ROCHE | 93 | ROCHE | 18 | 84.235 | 1.895 | 2.25 | 63.000 | 105.000 | |
| 2021-005 | 4 ENZ. (GPD) | 38 | SIEMENS DI | 143 | SIEMENS | 75 | 76.716 | 3.069 | 4.00 | 58.000 | 96.000 | |
| 2021-005 | 4 ENZ. (GPD) | 212 | S. D. EXL | 143 | SIEMENS | 14 | 74.357 | 3.038 | 4.09 | 56.000 | 93.000 | |
| 2021-005 | 9 GPO TRIND. | 186 | BECK. COUL | 76 | AU-BECKMAN | 27 | 82.148 | 2.337 | 2.84 | 62.000 | 103.000 | |
| 2021-005 | 9 GPO TRIND. | 191 | RX-DAYTONA | 126 | RANDOX | 21 | 81.286 | 6.415 | 7.89 | 61.000 | 102.000 | |
| 2021-005 | 9 GPO TRIND. | 194 | BIOLIS-24S | 154 | (IDG) | 10 | 77.800 | 2.676 | 3.44 | 58.000 | 97.000 | |
| 2021-005 | 9 GPO TRIND. | 215 | B.C DXC | 134 | BECKM.COUL | 10 | 93.300 | 3.466 | 3.71 | 70.000 | 117.000 | |
| 2021-005 | 10 ENZYM. GPO | 184 | INTEGRA | 93 | ROCHE | 25 | 87.083 | 3.161 | 3.63 | 65.000 | 109.000 | |
| 2021-005 | 10 ENZYM. GPO | 203 | ROCHE | 93 | ROCHE | 20 | 84.350 | 1.878 | 2.23 | 63.000 | 105.000 | |
| 2021-005 | 11 GLY PO4 OX | 197 | ARCHITECT | 1 | ABBOTT | 11 | 78.636 | 2.227 | 2.83 | 59.000 | 98.000 | |
| 026 | UREA NITROGEN (BUN) | CLIA TEST ID #: 505 | | EVALUATION CRITERIA: TARGET VALUE 9 % OR 2.00 {GREATER} | | | | | | | | |
| 2021-001 | 2 UREAS.GLDH | 38 | SIEMENS DI | 143 | SIEMENS | 79 | 34.392 | 1.216 | 3.54 | 31.000 | 37.000 | |
| 2021-001 | 2 UREAS.GLDH | 184 | INTEGRA | 93 | ROCHE | 38 | 33.684 | 1.524 | 4.52 | 31.000 | 37.000 | |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

| ANALYTE | | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
|-------------------------|--------------|---------------------|---|------|--------|-----------|--------|----------|--------|------------|-------|
| SAMPLE | METHOD | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH | | |
| 2021-001 | 2 UREAS.GLDH | 186 BECK. COUL | 76 AU-BECKMAN | 29 | 34.103 | 1.094 | 3.21 | 31.000 | 37.000 | | |
| 2021-001 | 2 UREAS.GLDH | 191 RX-DAYTONA | 126 RANDOX | 31 | 31.903 | 1.376 | 4.31 | 29.000 | 35.000 | | |
| 2021-001 | 2 UREAS.GLDH | 199 Rx-IMOLA | 126 RANDOX | 10 | 32.300 | 1.100 | 3.41 | 29.000 | 35.000 | | |
| 2021-001 | 2 UREAS.GLDH | 203 ROCHE | 93 ROCHE | 39 | 33.410 | 0.926 | 2.77 | 30.000 | 36.000 | | |
| 2021-001 | 2 UREAS.GLDH | 212 S. D. EXL | 143 SIEMENS | 13 | 33.769 | 1.846 | 5.47 | 31.000 | 37.000 | | |
| 2021-001 | 8 UREASE QUI | 165 VITROS | 63 KODAK | 164 | 31.583 | 0.708 | 2.24 | 29.000 | 34.000 | | |
| 026 UREA NITROGEN (BUN) | | CLIA TEST ID #: 505 | EVALUATION CRITERIA: TARGET VALUE 9 % OR 2.00 {GREATER} | | | | | | | | |
| 2021-002 | 2 UREAS.GLDH | 38 SIEMENS DI | 143 SIEMENS | 79 | 27.823 | 1.064 | 3.83 | 25.000 | 30.000 | | |
| 2021-002 | 2 UREAS.GLDH | 184 INTEGRA | 93 ROCHE | 38 | 27.324 | 1.164 | 4.26 | 25.000 | 30.000 | | |
| 2021-002 | 2 UREAS.GLDH | 186 BECK. COUL | 76 AU-BECKMAN | 29 | 27.655 | 0.755 | 2.73 | 25.000 | 30.000 | | |
| 2021-002 | 2 UREAS.GLDH | 191 RX-DAYTONA | 126 RANDOX | 31 | 26.355 | 1.233 | 4.68 | 24.000 | 29.000 | | |
| 2021-002 | 2 UREAS.GLDH | 199 Rx-IMOLA | 126 RANDOX | 10 | 26.700 | 1.100 | 4.12 | 24.000 | 29.000 | | |
| 2021-002 | 2 UREAS.GLDH | 203 ROCHE | 93 ROCHE | 39 | 27.132 | 1.004 | 3.70 | 25.000 | 30.000 | | |
| 2021-002 | 2 UREAS.GLDH | 212 S. D. EXL | 143 SIEMENS | 13 | 27.385 | 1.496 | 5.46 | 25.000 | 30.000 | | |
| 2021-002 | 8 UREASE QUI | 165 VITROS | 63 KODAK | 164 | 25.335 | 0.674 | 2.66 | 23.000 | 28.000 | | |
| 2021-003 | 2 UREAS.GLDH | 38 SIEMENS DI | 143 SIEMENS | 79 | 21.722 | 0.954 | 4.39 | 20.000 | 24.000 | | |
| 2021-003 | 2 UREAS.GLDH | 184 INTEGRA | 93 ROCHE | 38 | 21.421 | 1.067 | 4.98 | 19.000 | 23.000 | | |
| 2021-003 | 2 UREAS.GLDH | 186 BECK. COUL | 76 AU-BECKMAN | 29 | 21.897 | 0.661 | 3.02 | 20.000 | 24.000 | | |
| 2021-003 | 2 UREAS.GLDH | 191 RX-DAYTONA | 126 RANDOX | 31 | 20.710 | 1.197 | 5.78 | 19.000 | 23.000 | | |
| 2021-003 | 2 UREAS.GLDH | 199 Rx-IMOLA | 126 RANDOX | 10 | 21.000 | 0.775 | 3.69 | 19.000 | 23.000 | | |
| 2021-003 | 2 UREAS.GLDH | 203 ROCHE | 93 ROCHE | 39 | 21.342 | 0.619 | 2.90 | 19.000 | 23.000 | | |
| 2021-003 | 2 UREAS.GLDH | 212 S. D. EXL | 143 SIEMENS | 13 | 21.308 | 1.435 | 6.73 | 19.000 | 23.000 | | |
| 2021-003 | 8 UREASE QUI | 165 VITROS | 63 KODAK | 164 | 19.762 | 0.562 | 2.84 | 18.000 | 22.000 | | |
| 2021-004 | 2 UREAS.GLDH | 38 SIEMENS DI | 143 SIEMENS | 79 | 42.924 | 1.456 | 3.39 | 39.000 | 47.000 | | |
| 2021-004 | 2 UREAS.GLDH | 184 INTEGRA | 93 ROCHE | 38 | 41.947 | 1.959 | 4.67 | 38.000 | 46.000 | | |
| 2021-004 | 2 UREAS.GLDH | 186 BECK. COUL | 76 AU-BECKMAN | 29 | 42.517 | 1.163 | 2.74 | 39.000 | 46.000 | | |
| 2021-004 | 2 UREAS.GLDH | 191 RX-DAYTONA | 126 RANDOX | 31 | 39.613 | 1.929 | 4.87 | 36.000 | 43.000 | | |
| 2021-004 | 2 UREAS.GLDH | 199 Rx-IMOLA | 126 RANDOX | 10 | 39.800 | 1.661 | 4.17 | 36.000 | 43.000 | | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPEC: 10 CHEMISTRY | | SUB: 10 ROUTINE | | | | GRP: 10 ROUTINE | | | | | | |
|-------------------------|--------|-----------------|---------------------|------------|-----|---|-----------------|-----------------------|---------|-------------------|---------------|--------|
| ANALYTE | | | | | | | | | | | | |
| SAMPLE | METHOD | SYST/INST | | REAGENTS | | NO. PART LABS | TARGET VALUE | STANDARD DEVIATION | % CV | ACCEPTABLE LOW | RANGE HIGH | |
| 2021-004 | 2 | UREAS.GLDH | 203 | ROCHE | 93 | ROCHE | 39 | 41.974 | 1.287 | 3.07 | 38.000 | 46.000 |
| 2021-004 | 2 | UREAS.GLDH | 212 | S. D. EXL | 143 | SIEMENS | 13 | 42.538 | 2.170 | 5.10 | 39.000 | 46.000 |
| 2021-004 | 8 | UREASE QUI | 165 | VITROS | 63 | KODAK | 164 | 39.823 | 1.065 | 2.67 | 36.000 | 43.000 |
| 026 UREA NITROGEN (BUN) | | | CLIA TEST ID #: 505 | | | EVALUATION CRITERIA: TARGET VALUE 9 % OR 2.00 {GREATER} | | | | | | |
| 2021-005 | 2 | UREAS.GLDH | 38 | SIEMENS DI | 143 | SIEMENS | 79 | 11.744 | 0.741 | 6.31 | 10.000 | 14.000 |
| 2021-005 | 2 | UREAS.GLDH | 184 | INTEGRA | 93 | ROCHE | 38 | 11.526 | 0.595 | 5.17 | 10.000 | 14.000 |
| 2021-005 | 2 | UREAS.GLDH | 186 | BECK. COUL | 76 | AU-BECKMAN | 29 | 11.793 | 0.483 | 4.09 | 10.000 | 14.000 |
| 2021-005 | 2 | UREAS.GLDH | 191 | RX-DAYTONA | 126 | RANDOX | 31 | 11.400 | 0.611 | 5.36 | 9.000 | 13.000 |
| 2021-005 | 2 | UREAS.GLDH | 199 | Rx-IMOLA | 126 | RANDOX | 10 | 11.600 | 0.490 | 4.22 | 10.000 | 14.000 |
| 2021-005 | 2 | UREAS.GLDH | 203 | ROCHE | 93 | ROCHE | 39 | 11.474 | 0.499 | 4.35 | 9.000 | 13.000 |
| 2021-005 | 2 | UREAS.GLDH | 212 | S. D. EXL | 143 | SIEMENS | 13 | 11.462 | 1.009 | 8.80 | 9.000 | 13.000 |
| 2021-005 | 8 | UREASE QUI | 165 | VITROS | 63 | KODAK | 164 | 10.579 | 0.506 | 4.78 | 9.000 | 13.000 |
| 027 URIC ACID | | | CLIA TEST ID #: 515 | | | EVALUATION CRITERIA: TARGET VALUE 17 % | | | | | | |
| 2021-001 | 2 | URICASE | 38 | SIEMENS DI | 143 | SIEMENS | 44 | 8.733 | 0.248 | 2.83 | 7.200 | 10.200 |
| 2021-001 | 2 | URICASE | 165 | VITROS | 63 | KODAK | 101 | 8.789 | 0.173 | 1.97 | 7.300 | 10.300 |
| 2021-001 | 2 | URICASE | 184 | INTEGRA | 93 | ROCHE | 17 | 8.941 | 0.341 | 3.82 | 7.400 | 10.500 |
| 2021-001 | 2 | URICASE | 197 | ARCHITECT | 1 | ABBOTT | 11 | 8.855 | 0.215 | 2.43 | 7.300 | 10.400 |
| 2021-001 | 2 | URICASE | 203 | ROCHE | 93 | ROCHE | 24 | 8.550 | 0.233 | 2.72 | 7.100 | 10.000 |
| 2021-001 | 5 | URICASE 37 | 186 | BECK. COUL | 76 | AU-BECKMAN | 19 | 8.637 | 0.264 | 3.06 | 7.200 | 10.100 |
| 2021-001 | 5 | URICASE 37 | 215 | B.C DXC | 134 | BECKM.COUL | 10 | 8.280 | 0.183 | 2.21 | 6.900 | 9.700 |
| 2021-002 | 2 | URICASE | 38 | SIEMENS DI | 143 | SIEMENS | 44 | 7.025 | 0.193 | 2.75 | 5.800 | 8.200 |
| 2021-002 | 2 | URICASE | 165 | VITROS | 63 | KODAK | 101 | 7.005 | 0.133 | 1.90 | 5.800 | 8.200 |
| 2021-002 | 2 | URICASE | 184 | INTEGRA | 93 | ROCHE | 17 | 7.159 | 0.225 | 3.14 | 5.900 | 8.400 |
| 2021-002 | 2 | URICASE | 197 | ARCHITECT | 1 | ABBOTT | 11 | 7.109 | 0.124 | 1.74 | 5.900 | 8.300 |
| 2021-002 | 2 | URICASE | 203 | ROCHE | 93 | ROCHE | 24 | 6.900 | 0.174 | 2.53 | 5.700 | 8.100 |
| 2021-002 | 5 | URICASE 37 | 186 | BECK. COUL | 76 | AU-BECKMAN | 19 | 6.963 | 0.163 | 2.34 | 5.800 | 8.100 |
| 2021-002 | 5 | URICASE 37 | 215 | B.C DXC | 134 | BECKM.COUL | 10 | 6.730 | 0.135 | 2.00 | 5.600 | 7.900 |
| 2021-003 | 2 | URICASE | 38 | SIEMENS DI | 143 | SIEMENS | 44 | 5.348 | 0.154 | 2.89 | 4.400 | 6.300 |

Participant Summary

MONTH 2 OF YEAR 2021

| SPEC: 10 CHEMISTRY | | SUB: 10 ROUTINE | | GRP: 10 ROUTINE | | | | | | | | |
|--------------------------|--------------|---------------------|--|-----------------|---------|-----------|--------|----------|---------|------------|-------|--|
| ANALYTE | | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE | |
| SAMPLE | METHOD | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH | | | |
| 2021-003 | 2 URICASE | 165 VITROS | 63 KODAK | 101 | 5.398 | 0.109 | 2.02 | 4.500 | 6.300 | | | |
| 2021-003 | 2 URICASE | 184 INTEGRA | 93 ROCHE | 17 | 5.518 | 0.185 | 3.36 | 4.600 | 6.500 | | | |
| 2021-003 | 2 URICASE | 197 ARCHITECT | 1 ABBOTT | 11 | 5.473 | 0.096 | 1.76 | 4.500 | 6.400 | | | |
| 2021-003 | 2 URICASE | 203 ROCHE | 93 ROCHE | 24 | 5.292 | 0.153 | 2.88 | 4.400 | 6.200 | | | |
| 2021-003 | 5 URICASE 37 | 186 BECK. COUL | 76 AU-BECKMAN | 19 | 5.437 | 0.169 | 3.11 | 4.500 | 6.400 | | | |
| 2021-003 | 5 URICASE 37 | 215 B.C DXC | 134 BECKM.COUL | 10 | 5.230 | 0.110 | 2.10 | 4.300 | 6.100 | | | |
| 027 URIC ACID | | CLIA TEST ID #: 515 | EVALUATION CRITERIA: TARGET VALUE 17 % | | | | | | | | | |
| 2021-004 | 2 URICASE | 38 SIEMENS DI | 143 SIEMENS | 44 | 11.016 | 0.375 | 3.40 | 9.100 | 12.900 | | | |
| 2021-004 | 2 URICASE | 165 VITROS | 63 KODAK | 101 | 11.147 | 0.243 | 2.18 | 9.300 | 13.000 | | | |
| 2021-004 | 2 URICASE | 184 INTEGRA | 93 ROCHE | 17 | 11.171 | 0.382 | 3.42 | 9.300 | 13.100 | | | |
| 2021-004 | 2 URICASE | 197 ARCHITECT | 1 ABBOTT | 11 | 11.136 | 0.362 | 3.26 | 9.200 | 13.000 | | | |
| 2021-004 | 2 URICASE | 203 ROCHE | 93 ROCHE | 24 | 10.767 | 0.379 | 3.52 | 8.900 | 12.600 | | | |
| 2021-004 | 5 URICASE 37 | 186 BECK. COUL | 76 AU-BECKMAN | 19 | 10.795 | 0.268 | 2.49 | 9.000 | 12.600 | | | |
| 2021-004 | 5 URICASE 37 | 215 B.C DXC | 134 BECKM.COUL | 10 | 10.300 | 0.210 | 2.04 | 8.500 | 12.100 | | | |
| 2021-005 | 2 URICASE | 38 SIEMENS DI | 143 SIEMENS | 44 | 2.640 | 0.110 | 4.18 | 2.200 | 3.100 | | | |
| 2021-005 | 2 URICASE | 165 VITROS | 63 KODAK | 101 | 2.633 | 0.071 | 2.69 | 2.200 | 3.100 | | | |
| 2021-005 | 2 URICASE | 184 INTEGRA | 93 ROCHE | 17 | 2.700 | 0.061 | 2.27 | 2.200 | 3.200 | | | |
| 2021-005 | 2 URICASE | 197 ARCHITECT | 1 ABBOTT | 11 | 2.727 | 0.045 | 1.63 | 2.300 | 3.200 | | | |
| 2021-005 | 2 URICASE | 203 ROCHE | 93 ROCHE | 24 | 2.583 | 0.080 | 3.09 | 2.100 | 3.000 | | | |
| 2021-005 | 5 URICASE 37 | 186 BECK. COUL | 76 AU-BECKMAN | 19 | 2.763 | 0.074 | 2.68 | 2.300 | 3.200 | | | |
| 2021-005 | 5 URICASE 37 | 215 B.C DXC | 134 BECKM.COUL | 10 | 2.610 | 0.070 | 2.68 | 2.200 | 3.100 | | | |
| 135 GGT (GAMMA GLU. TRA) | | CLIA TEST ID #: 0 | EVALUATION CRITERIA: TARGET VALUE 20 % | | | | | | | | | |
| 2021-001 | 5 KINETIC 37 | 165 VITROS | 63 KODAK | 23 | 448.364 | 11.703 | 2.61 | 359.000 | 538.000 | | | |
| 2021-002 | 5 KINETIC 37 | 165 VITROS | 63 KODAK | 23 | 349.773 | 7.416 | 2.12 | 280.000 | 420.000 | | | |
| 2021-003 | 5 KINETIC 37 | 165 VITROS | 63 KODAK | 23 | 240.727 | 5.302 | 2.20 | 193.000 | 289.000 | | | |
| 2021-004 | 5 KINETIC 37 | 165 VITROS | 63 KODAK | 23 | 568.391 | 23.631 | 4.16 | 455.000 | 682.000 | | | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPEC: 10 CHEMISTRY | | SUB: 10 ROUTINE | | GRP: 10 ROUTINE | | | | | | | | |
|--------------------|----------------------|-------------------|-----------------------------------|-----------------|---------|-----------|--------|----------|---------|------------|-------|--|
| ANALYTE | | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE | |
| SAMPLE | METHOD | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH | | | |
| 135 | GGT (GAMMA GLU. TRA) | CLIA TEST ID #: 0 | EVALUATION CRITERIA: TARGET VALUE | 20 | % | | | | | | | |
| 2021-005 | 5 KINETIC 37 | 165 VITROS | 63 KODAK | 23 | 21.217 | 1.667 | 7.86 | 17.000 | 25.000 | | | |
| 136 | LACTIC ACID | | | | | | | | | | | |
| 2021-001 | 1 LACTATE-P. | 165 VITROS | 63 KODAK | 18 | 4.972 | 0.087 | 1.75 | 4.000 | 6.000 | | | |
| 2021-002 | 1 LACTATE-P. | 165 VITROS | 63 KODAK | 18 | 3.906 | 0.078 | 2.00 | 3.100 | 4.700 | | | |
| 2021-003 | 1 LACTATE-P. | 165 VITROS | 63 KODAK | 18 | 2.833 | 0.047 | 1.66 | 2.300 | 3.400 | | | |
| 2021-004 | 1 LACTATE-P. | 165 VITROS | 63 KODAK | 18 | 6.333 | 0.125 | 1.97 | 5.100 | 7.600 | | | |
| 2021-005 | 1 LACTATE-P. | 165 VITROS | 63 KODAK | 18 | 0.950 | 0.060 | 6.33 | 0.800 | 1.100 | | | |
| 137 | LIPASE | | | | | | | | | | | |
| 2021-001 | 1 COLORIMET. | 203 ROCHE | 93 ROCHE | 14 | 62.643 | 7.584 | 12.11 | 50.000 | 75.000 | | | |
| 2021-001 | 2 ENZIMATIC | 165 VITROS | 63 KODAK | 84 | 650.036 | 24.024 | 3.70 | 520.000 | 780.000 | | | |
| 2021-001 | 2 ENZIMATIC | 215 B.C DXC | 134 BECKM.COUL | 11 | 63.364 | 4.029 | 6.36 | 51.000 | 76.000 | | | |
| 2021-001 | 4 ENZ/COLOR | 186 BECK. COUL | 76 AU-BECKMAN | 16 | 66.167 | 3.532 | 5.34 | 53.000 | 79.000 | | | |
| 2021-001 | 4 ENZ/COLOR | 186 BECK. COUL | 76 AU-BECKMAN | 16 | 72.133 | 1.857 | 2.57 | 58.000 | 87.000 | | | |
| 2021-001 | 4 ENZ/COLOR | 203 ROCHE | 93 ROCHE | 14 | 62.786 | 5.833 | 9.29 | 50.000 | 75.000 | | | |
| 2021-001 | 5 SIEMENS 37 | 38 SIEMENS DI | 143 SIEMENS | 17 | 224.471 | 19.042 | 8.48 | 180.000 | 269.000 | | | |
| 2021-002 | 1 COLORIMET. | 203 ROCHE | 93 ROCHE | 14 | 49.786 | 6.349 | 12.75 | 40.000 | 60.000 | | | |
| 2021-002 | 2 ENZIMATIC | 165 VITROS | 63 KODAK | 84 | 515.928 | 18.978 | 3.68 | 413.000 | 619.000 | | | |
| 2021-002 | 2 ENZIMATIC | 215 B.C DXC | 134 BECKM.COUL | 11 | 53.091 | 2.644 | 4.98 | 42.000 | 64.000 | | | |
| 2021-002 | 4 ENZ/COLOR | 186 BECK. COUL | 76 AU-BECKMAN | 16 | 57.250 | 3.010 | 5.26 | 46.000 | 69.000 | | | |
| 2021-002 | 4 ENZ/COLOR | 186 BECK. COUL | 76 AU-BECKMAN | 16 | 52.667 | 2.134 | 4.05 | 42.000 | 63.000 | | | |
| 2021-002 | 4 ENZ/COLOR | 203 ROCHE | 93 ROCHE | 14 | 50.429 | 3.437 | 6.82 | 40.000 | 61.000 | | | |
| 2021-002 | 5 SIEMENS 37 | 38 SIEMENS DI | 143 SIEMENS | 17 | 178.059 | 17.093 | 9.60 | 142.000 | 214.000 | | | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPEC: 10 CHEMISTRY | | SUB: 10 ROUTINE | | | | GRP: 10 ROUTINE | | | | | | |
|--------------------|------------|-----------------|-------------------|------------------|-----------------------------------|-----------------------|---------|-------------------|---------------|---------|----------|--|
| ANALYTE | | | | | | | | | | | | |
| SAMPLE | METHOD | SYST/INST | REAGENTS | NO. PART LABS | TARGET VALUE | STANDARD DEVIATION | % CV | ACCEPTABLE LOW | RANGE HIGH | | | |
| 137 | LIPASE | | CLIA TEST ID #: 0 | | EVALUATION CRITERIA: TARGET VALUE | 20 % | | | | | | |
| 2021-003 | 1 | COLORIMET. | 203 ROCHE | 93 | ROCHE | 14 | 38.000 | 4.140 | 10.90 | 30.000 | 46.000 | |
| 2021-003 | 2 | ENZIMATIC | 165 VITROS | 63 | KODAK | 84 | 374.524 | 13.693 | 3.66 | 300.000 | 449.000 | |
| 2021-003 | 2 | ENZIMATIC | 215 B.C DXC | 134 | BECKM.COUL | 11 | 42.545 | 1.971 | 4.63 | 34.000 | 51.000 | |
| 2021-003 | 4 | ENZ/COLOR | 186 BECK. COUL | 76 | AU-BECKMAN | 16 | 40.000 | 1.633 | 4.08 | 32.000 | 48.000 | |
| 2021-003 | 4 | ENZ/COLOR | 186 BECK. COUL | 76 | AU-BECKMAN | 16 | 41.800 | 2.344 | 5.61 | 33.000 | 50.000 | |
| 2021-003 | 4 | ENZ/COLOR | 203 ROCHE | 93 | ROCHE | 14 | 37.857 | 2.326 | 6.14 | 30.000 | 45.000 | |
| 2021-003 | 5 | SIEMENS 37 | 38 SIEMENS DI | 143 | SIEMENS | 17 | 132.353 | 14.426 | 10.90 | 106.000 | 159.000 | |
| 2021-004 | 1 | COLORIMET. | 203 ROCHE | 93 | ROCHE | 14 | 79.143 | 10.769 | 13.61 | 63.000 | 95.000 | |
| 2021-004 | 2 | ENZIMATIC | 165 VITROS | 63 | KODAK | 84 | 843.518 | 59.660 | 7.07 | 675.000 | 1012.000 | |
| 2021-004 | 2 | ENZIMATIC | 215 B.C DXC | 134 | BECKM.COUL | 11 | 76.182 | 3.186 | 4.18 | 61.000 | 91.000 | |
| 2021-004 | 4 | ENZ/COLOR | 186 BECK. COUL | 76 | AU-BECKMAN | 16 | 95.313 | 4.510 | 4.73 | 76.000 | 114.000 | |
| 2021-004 | 4 | ENZ/COLOR | 186 BECK. COUL | 76 | AU-BECKMAN | 16 | 83.000 | 4.865 | 5.86 | 66.000 | 100.000 | |
| 2021-004 | 4 | ENZ/COLOR | 203 ROCHE | 93 | ROCHE | 14 | 78.857 | 7.558 | 9.58 | 63.000 | 95.000 | |
| 2021-004 | 5 | SIEMENS 37 | 38 SIEMENS DI | 143 | SIEMENS | 17 | 288.765 | 24.927 | 8.63 | 231.000 | 347.000 | |
| 2021-005 | 1 | COLORIMET. | 203 ROCHE | 93 | ROCHE | 14 | 15.500 | 1.296 | 8.36 | 12.000 | 19.000 | |
| 2021-005 | 2 | ENZIMATIC | 165 VITROS | 63 | KODAK | 84 | 122.720 | 4.565 | 3.72 | 98.000 | 147.000 | |
| 2021-005 | 2 | ENZIMATIC | 215 B.C DXC | 134 | BECKM.COUL | 11 | 23.273 | 1.763 | 7.57 | 19.000 | 28.000 | |
| 2021-005 | 4 | ENZ/COLOR | 186 BECK. COUL | 76 | AU-BECKMAN | 16 | 17.167 | 0.898 | 5.23 | 14.000 | 21.000 | |
| 2021-005 | 4 | ENZ/COLOR | 186 BECK. COUL | 76 | AU-BECKMAN | 16 | 15.750 | 1.953 | 12.40 | 13.000 | 19.000 | |
| 2021-005 | 4 | ENZ/COLOR | 203 ROCHE | 93 | ROCHE | 14 | 16.286 | 0.795 | 4.88 | 13.000 | 20.000 | |
| 2021-005 | 5 | SIEMENS 37 | 38 SIEMENS DI | 143 | SIEMENS | 17 | 54.059 | 9.352 | 17.30 | 43.000 | 65.000 | |
| 138 | PHOSPHORUS | | | | | | | | | | | |
| 2021-001 | 1 | PHOSPHOMO. | 38 SIEMENS DI | 143 | SIEMENS | 43 | 4.940 | 0.143 | 2.90 | 4.000 | 5.900 | |
| 2021-001 | 1 | PHOSPHOMO. | 165 VITROS | 63 | KODAK | 87 | 4.704 | 0.109 | 2.32 | 3.800 | 5.600 | |
| 2021-001 | 1 | PHOSPHOMO. | 184 INTEGRA | 93 | ROCHE | 16 | 4.825 | 0.139 | 2.88 | 3.900 | 5.800 | |
| 2021-001 | 1 | PHOSPHOMO. | 186 BECK. COUL | 76 | AU-BECKMAN | 16 | 4.694 | 0.175 | 3.73 | 3.800 | 5.600 | |
| 2021-001 | 1 | PHOSPHOMO. | 203 ROCHE | 93 | ROCHE | 32 | 4.791 | 0.142 | 2.97 | 3.800 | 5.700 | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPEC: 10 CHEMISTRY | | SUB: 10 ROUTINE | | | | GRP: 10 ROUTINE | | | | | | |
|--------------------|------------|-------------------|-----|------------|-----|--|-----------------|-----------------------|---------|-------------------|---------------|-------|
| ANALYTE | | | | | | | | | | | | |
| SAMPLE | METHOD | SYST/INST | | REAGENTS | | NO. PART LABS | TARGET VALUE | STANDARD DEVIATION | % CV | ACCEPTABLE LOW | RANGE HIGH | |
| 2021-001 | 1 | PHOSPHOMO. | 215 | B.C DXC | 134 | BECKM.COUL | 11 | 5.018 | 0.159 | 3.16 | 4.000 | 6.000 |
| 2021-001 | 2 | END POINT | 184 | INTEGRA | 93 | ROCHE | 10 | 4.760 | 0.143 | 3.00 | 3.800 | 5.700 |
| 138 | PHOSPHORUS | CLIA TEST ID #: 0 | | | | EVALUATION CRITERIA: TARGET VALUE 20 % | | | | | | |
| 2021-002 | 1 | PHOSPHOMO. | 38 | SIEMENS DI | 143 | SIEMENS | 43 | 3.974 | 0.114 | 2.88 | 3.200 | 4.800 |
| 2021-002 | 1 | PHOSPHOMO. | 165 | VITROS | 63 | KODAK | 87 | 3.909 | 0.107 | 2.73 | 3.100 | 4.700 |
| 2021-002 | 1 | PHOSPHOMO. | 184 | INTEGRA | 93 | ROCHE | 16 | 3.925 | 0.103 | 2.63 | 3.100 | 4.700 |
| 2021-002 | 1 | PHOSPHOMO. | 186 | BECK. COUL | 76 | AU-BECKMAN | 16 | 3.773 | 0.139 | 3.68 | 3.000 | 4.500 |
| 2021-002 | 1 | PHOSPHOMO. | 203 | ROCHE | 93 | ROCHE | 32 | 3.887 | 0.104 | 2.67 | 3.100 | 4.700 |
| 2021-002 | 1 | PHOSPHOMO. | 215 | B.C DXC | 134 | BECKM.COUL | 11 | 4.027 | 0.086 | 2.14 | 3.200 | 4.800 |
| 2021-002 | 2 | END POINT | 184 | INTEGRA | 93 | ROCHE | 10 | 3.820 | 0.098 | 2.56 | 3.100 | 4.600 |
| 2021-003 | 1 | PHOSPHOMO. | 38 | SIEMENS DI | 143 | SIEMENS | 43 | 3.077 | 0.094 | 3.04 | 2.500 | 3.700 |
| 2021-003 | 1 | PHOSPHOMO. | 165 | VITROS | 63 | KODAK | 87 | 3.167 | 0.081 | 2.57 | 2.500 | 3.800 |
| 2021-003 | 1 | PHOSPHOMO. | 184 | INTEGRA | 93 | ROCHE | 16 | 3.019 | 0.081 | 2.68 | 2.400 | 3.600 |
| 2021-003 | 1 | PHOSPHOMO. | 186 | BECK. COUL | 76 | AU-BECKMAN | 16 | 2.950 | 0.132 | 4.48 | 2.400 | 3.500 |
| 2021-003 | 1 | PHOSPHOMO. | 203 | ROCHE | 93 | ROCHE | 32 | 3.013 | 0.108 | 3.59 | 2.400 | 3.600 |
| 2021-003 | 1 | PHOSPHOMO. | 215 | B.C DXC | 134 | BECKM.COUL | 11 | 3.109 | 0.051 | 1.65 | 2.500 | 3.700 |
| 2021-003 | 2 | END POINT | 184 | INTEGRA | 93 | ROCHE | 10 | 3.020 | 0.117 | 3.86 | 2.400 | 3.600 |
| 2021-004 | 1 | PHOSPHOMO. | 38 | SIEMENS DI | 143 | SIEMENS | 43 | 6.138 | 0.157 | 2.56 | 4.900 | 7.400 |
| 2021-004 | 1 | PHOSPHOMO. | 165 | VITROS | 63 | KODAK | 87 | 5.883 | 0.142 | 2.42 | 4.700 | 7.100 |
| 2021-004 | 1 | PHOSPHOMO. | 184 | INTEGRA | 93 | ROCHE | 16 | 5.969 | 0.202 | 3.39 | 4.800 | 7.200 |
| 2021-004 | 1 | PHOSPHOMO. | 186 | BECK. COUL | 76 | AU-BECKMAN | 16 | 5.906 | 0.211 | 3.57 | 4.700 | 7.100 |
| 2021-004 | 1 | PHOSPHOMO. | 203 | ROCHE | 93 | ROCHE | 32 | 6.065 | 0.158 | 2.60 | 4.900 | 7.300 |
| 2021-004 | 1 | PHOSPHOMO. | 215 | B.C DXC | 134 | BECKM.COUL | 11 | 6.355 | 0.178 | 2.80 | 5.100 | 7.600 |
| 2021-004 | 2 | END POINT | 184 | INTEGRA | 93 | ROCHE | 10 | 5.940 | 0.180 | 3.03 | 4.800 | 7.100 |
| 2021-005 | 1 | PHOSPHOMO. | 38 | SIEMENS DI | 143 | SIEMENS | 43 | 1.462 | 0.095 | 6.50 | 1.200 | 1.800 |
| 2021-005 | 1 | PHOSPHOMO. | 165 | VITROS | 63 | KODAK | 87 | 1.660 | 0.088 | 5.32 | 1.300 | 2.000 |
| 2021-005 | 1 | PHOSPHOMO. | 184 | INTEGRA | 93 | ROCHE | 16 | 1.431 | 0.068 | 4.76 | 1.100 | 1.700 |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

| ANALYTE | | | | | | | | | | | | |
|----------|--------|------------|-------------------|------------|-----|--|-----------------|-----------------------|---------|-------------------|---------------|--------|
| SAMPLE | METHOD | SYST/INST | | REAGENTS | | NO. PART LABS | TARGET VALUE | STANDARD DEVIATION | % CV | ACCEPTABLE LOW | RANGE HIGH | |
| 2021-005 | 1 | PHOSPHOMO. | 186 | BECK. COUL | 76 | AU-BECKMAN | 16 | 1.406 | 0.143 | 10.20 | 1.100 | 1.700 |
| 2021-005 | 1 | PHOSPHOMO. | 203 | ROCHE | 93 | ROCHE | 32 | 1.444 | 0.090 | 6.23 | 1.200 | 1.700 |
| 2021-005 | 1 | PHOSPHOMO. | 215 | B.C DXC | 134 | BECKM.COUL | 11 | 1.427 | 0.075 | 5.25 | 1.100 | 1.700 |
| 2021-005 | 2 | END POINT | 184 | INTEGRA | 93 | ROCHE | 10 | 1.450 | 0.067 | 4.63 | 1.200 | 1.700 |
| 169 CO2 | | | CLIA TEST ID #: 0 | | | EVALUATION CRITERIA: TARGET VALUE 3 SD | | | | | | |
| 2021-001 | 1 | Generic Me | 165 | VITROS | 63 | KODAK | 18 | 25.611 | 2.085 | 8.14 | 19.000 | 32.000 |
| 2021-001 | 1 | Generic Me | 184 | INTEGRA | 93 | ROCHE | 13 | 23.769 | 2.391 | 10.06 | 17.000 | 31.000 |
| 2021-001 | 1 | Generic Me | 186 | BECK. COUL | 76 | AU-BECKMAN | 22 | 23.667 | 1.168 | 4.94 | 20.000 | 27.000 |
| 2021-001 | 1 | Generic Me | 203 | ROCHE | 93 | ROCHE | 15 | 22.733 | 1.482 | 6.52 | 18.000 | 27.000 |
| 2021-001 | 2 | ENZYMATIC | 38 | SIEMENS DI | 143 | SIEMENS | 65 | 25.662 | 2.884 | 11.24 | 17.000 | 34.000 |
| 2021-001 | 2 | ENZYMATIC | 165 | VITROS | 63 | KODAK | 77 | 24.500 | 1.881 | 7.68 | 19.000 | 30.000 |
| 2021-001 | 2 | ENZYMATIC | 165 | VITROS | 156 | Kit 32 | 52 | 24.490 | 1.243 | 5.07 | 21.000 | 28.000 |
| 2021-001 | 2 | ENZYMATIC | 203 | ROCHE | 93 | ROCHE | 14 | 23.786 | 2.335 | 9.82 | 17.000 | 31.000 |
| 2021-002 | 1 | Generic Me | 165 | VITROS | 63 | KODAK | 18 | 22.167 | 2.500 | 11.28 | 15.000 | 30.000 |
| 2021-002 | 1 | Generic Me | 184 | INTEGRA | 93 | ROCHE | 13 | 20.615 | 2.676 | 12.98 | 13.000 | 29.000 |
| 2021-002 | 1 | Generic Me | 186 | BECK. COUL | 76 | AU-BECKMAN | 22 | 20.455 | 1.876 | 9.17 | 15.000 | 26.000 |
| 2021-002 | 1 | Generic Me | 203 | ROCHE | 93 | ROCHE | 15 | 19.600 | 2.444 | 12.47 | 12.000 | 27.000 |
| 2021-002 | 2 | ENZYMATIC | 38 | SIEMENS DI | 143 | SIEMENS | 65 | 22.938 | 2.767 | 12.06 | 15.000 | 31.000 |
| 2021-002 | 2 | ENZYMATIC | 165 | VITROS | 63 | KODAK | 77 | 21.434 | 1.592 | 7.43 | 17.000 | 26.000 |
| 2021-002 | 2 | ENZYMATIC | 165 | VITROS | 156 | Kit 32 | 52 | 20.769 | 1.671 | 8.05 | 16.000 | 26.000 |
| 2021-002 | 2 | ENZYMATIC | 203 | ROCHE | 93 | ROCHE | 14 | 21.071 | 2.017 | 9.57 | 15.000 | 27.000 |
| 2021-003 | 1 | Generic Me | 165 | VITROS | 63 | KODAK | 18 | 20.056 | 2.437 | 12.15 | 13.000 | 27.000 |
| 2021-003 | 1 | Generic Me | 184 | INTEGRA | 93 | ROCHE | 13 | 18.923 | 2.730 | 14.43 | 11.000 | 27.000 |
| 2021-003 | 1 | Generic Me | 186 | BECK. COUL | 76 | AU-BECKMAN | 22 | 18.318 | 1.916 | 10.46 | 13.000 | 24.000 |
| 2021-003 | 1 | Generic Me | 203 | ROCHE | 93 | ROCHE | 15 | 17.800 | 1.869 | 10.50 | 12.000 | 23.000 |
| 2021-003 | 2 | ENZYMATIC | 38 | SIEMENS DI | 143 | SIEMENS | 65 | 20.922 | 2.624 | 12.54 | 13.000 | 29.000 |
| 2021-003 | 2 | ENZYMATIC | 165 | VITROS | 63 | KODAK | 77 | 19.145 | 1.466 | 7.66 | 15.000 | 24.000 |
| 2021-003 | 2 | ENZYMATIC | 165 | VITROS | 156 | Kit 32 | 52 | 18.392 | 1.330 | 7.23 | 14.000 | 22.000 |

Participant Summary

MONTH 2 OF YEAR 2021

| SPEC: 10 CHEMISTRY | | SUB: 10 ROUTINE | | GRP: 10 ROUTINE | | | | | | | | |
|--------------------|------------------|-----------------|-------------------|-----------------|-----------------------------------|-----------|--------|----------|-------|------------|-----------|--|
| ANALYTE | | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE | |
| SAMPLE | METHOD | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH | | | |
| 2021-003 | 2 | ENZYMATIC | 203 ROCHE | 93 | ROCHE | 14 | 19.071 | 1.534 | 8.04 | 14.000 | 24.000 | |
| 169 | CO2 | | CLIA TEST ID #: 0 | | EVALUATION CRITERIA: TARGET VALUE | 3 | SD | | | | | |
| 2021-004 | 1 | Generic Me | 165 VITROS | 63 | KODAK | 18 | 28.889 | 2.157 | 7.47 | 22.000 | 35.000 | |
| 2021-004 | 1 | Generic Me | 184 INTEGRA | 93 | ROCHE | 13 | 26.077 | 2.586 | 9.92 | 18.000 | 34.000 | |
| 2021-004 | 1 | Generic Me | 186 BECK. COUL | 76 | AU-BECKMAN | 22 | 27.045 | 2.513 | 9.29 | 20.000 | 35.000 | |
| 2021-004 | 1 | Generic Me | 203 ROCHE | 93 | ROCHE | 15 | 25.733 | 2.977 | 11.57 | 17.000 | 35.000 | |
| 2021-004 | 2 | ENZYMATIC | 38 SIEMENS DI | 143 | SIEMENS | 65 | 29.500 | 2.469 | 8.37 | 22.000 | 37.000 | |
| 2021-004 | 2 | ENZYMATIC | 165 VITROS | 63 | KODAK | 77 | 27.750 | 2.014 | 7.26 | 22.000 | 34.000 | |
| 2021-004 | 2 | ENZYMATIC | 165 VITROS | 156 | Kit 32 | 52 | 27.596 | 2.347 | 8.51 | 21.000 | 35.000 | |
| 2021-004 | 2 | ENZYMATIC | 203 ROCHE | 93 | ROCHE | 14 | 27.429 | 2.129 | 7.76 | 21.000 | 34.000 | |
| 2021-005 | 1 | Generic Me | 165 VITROS | 63 | KODAK | 18 | 16.944 | 1.682 | 9.93 | 12.000 | 22.000 | |
| 2021-005 | 1 | Generic Me | 184 INTEGRA | 93 | ROCHE | 13 | 15.000 | 1.922 | 12.81 | 9.000 | 21.000 | |
| 2021-005 | 1 | Generic Me | 186 BECK. COUL | 76 | AU-BECKMAN | 22 | 15.500 | 1.340 | 8.64 | 11.000 | 20.000 | |
| 2021-005 | 1 | Generic Me | 203 ROCHE | 93 | ROCHE | 15 | 15.267 | 1.692 | 11.08 | 10.000 | 20.000 | |
| 2021-005 | 2 | ENZYMATIC | 38 SIEMENS DI | 143 | SIEMENS | 65 | 17.500 | 1.976 | 11.29 | 12.000 | 23.000 | |
| 2021-005 | 2 | ENZYMATIC | 165 VITROS | 63 | KODAK | 77 | 16.000 | 1.459 | 9.12 | 12.000 | 20.000 | |
| 2021-005 | 2 | ENZYMATIC | 165 VITROS | 156 | Kit 32 | 52 | 15.423 | 1.276 | 8.27 | 12.000 | 19.000 | |
| 2021-005 | 2 | ENZYMATIC | 203 ROCHE | 93 | ROCHE | 14 | 16.357 | 1.445 | 8.83 | 12.000 | 21.000 | |
| 170 | DIRECT BILIRUBIN | | | | EVALUATION CRITERIA: TARGET VALUE | 3 | SD | OR | 20 | % | {GREATER} | |
| 2021-001 | 4 | JEND.-GROG | 38 SIEMENS DI | 143 | SIEMENS | 47 | 1.096 | 0.083 | 7.60 | 0.800 | 1.300 | |
| 2021-001 | 11 | SPECT. WIT | 165 VITROS | 63 | KODAK | 60 | 0.664 | 0.185 | 27.93 | 0.100 | 1.200 | |
| 2021-001 | 13 | AZOBIL.W/D | 203 ROCHE | 93 | ROCHE | 16 | 1.025 | 0.130 | 12.67 | 0.600 | 1.400 | |
| 2021-001 | 16 | DIAZO ENDP | 215 B.C DXC | 134 | BECKM.COUL | 11 | 1.109 | 0.051 | 4.64 | 0.900 | 1.300 | |
| 2021-002 | 4 | JEND.-GROG | 38 SIEMENS DI | 143 | SIEMENS | 47 | 0.815 | 0.058 | 7.15 | 0.600 | 1.000 | |
| 2021-002 | 11 | SPECT. WIT | 165 VITROS | 63 | KODAK | 60 | 0.395 | 0.148 | 37.46 | 0.000 | 0.800 | |
| 2021-002 | 13 | AZOBIL.W/D | 203 ROCHE | 93 | ROCHE | 16 | 0.780 | 0.075 | 9.59 | 0.600 | 1.000 | |
| 2021-002 | 16 | DIAZO ENDP | 215 B.C DXC | 134 | BECKM.COUL | 11 | 0.818 | 0.057 | 7.03 | 0.600 | 1.000 | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPEC: 10 CHEMISTRY | | SUB: 10 ROUTINE | | GRP: 10 ROUTINE | | | | | | | |
|--------------------|------------------|---------------------|-----------------------------------|---------------------|------------|-----------|--------|----------|---------|------------|-------|
| ANALYTE | | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
| SAMPLE | METHOD | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH | | |
| 170 | DIRECT BILIRUBIN | CLIA TEST ID #: 0 | EVALUATION CRITERIA: TARGET VALUE | 3 | SD OR 20 % | {GREATER} | | | | | |
| 2021-003 | 4 JEND.-GROG | 38 SIEMENS DI | 143 SIEMENS | 47 | 0.511 | 0.047 | 9.24 | 0.400 | 0.700 | | |
| 2021-003 | 11 SPECT. WIT | 165 VITROS | 63 KODAK | 60 | 0.119 | 0.133 | 112.41 | 0 | 0.500 | | |
| 2021-003 | 13 AZOBIL.W/D | 203 ROCHE | 93 ROCHE | 16 | 0.494 | 0.066 | 13.34 | 0.300 | 0.700 | | |
| 2021-003 | 16 DIAZO ENDP | 215 B.C DXC | 134 BECKM.COUL | 11 | 0.518 | 0.039 | 7.44 | 0.400 | 0.600 | | |
| 2021-004 | 4 JEND.-GROG | 38 SIEMENS DI | 143 SIEMENS | 47 | 1.451 | 0.096 | 6.65 | 1.200 | 1.700 | | |
| 2021-004 | 11 SPECT. WIT | 165 VITROS | 63 KODAK | 60 | 0.958 | 0.204 | 21.33 | 0.300 | 1.600 | | |
| 2021-004 | 13 AZOBIL.W/D | 203 ROCHE | 93 ROCHE | 16 | 1.306 | 0.171 | 13.11 | 0.800 | 1.800 | | |
| 2021-004 | 16 DIAZO ENDP | 215 B.C DXC | 134 BECKM.COUL | 11 | 1.400 | 0.060 | 4.31 | 1.100 | 1.700 | | |
| 2021-005 | 4 JEND.-GROG | 38 SIEMENS DI | 143 SIEMENS | 47 | 0.074 | 0.044 | 58.55 | 0 | 0.200 | | |
| 2021-005 | 11 SPECT. WIT | 165 VITROS | 63 KODAK | 60 | 0.007 | 0.025 | 370.81 | 0 | 0.100 | | |
| 2021-005 | 13 AZOBIL.W/D | 203 ROCHE | 93 ROCHE | 16 | 0.188 | 0.033 | 17.64 | 0.100 | 0.300 | | |
| 2021-005 | 16 DIAZO ENDP | 215 B.C DXC | 134 BECKM.COUL | 11 | 0.055 | 0.050 | 91.29 | 0 | 0.200 | | |
| SPEC: 10 CHEMISTRY | | SUB: 20 BLOOD GASES | | GRP: 30 BLOOD GASES | | | | | | | |
| ANALYTE | | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
| SAMPLE | METHOD | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH | | |
| 007 | BLOOD GASES-pCO2 | CLIA TEST ID #: 335 | EVALUATION CRITERIA: TARGET VALUE | 8 | % OR 5.00 | {GREATER} | | | | | |
| 2021-051 | 265 ROCHE COBA | | | 29 | 95.297 | 3.198 | 3.36 | 87.700 | 102.900 | | |
| 2021-052 | 265 ROCHE COBA | | | 29 | 53.197 | 0.852 | 1.60 | 48.200 | 58.200 | | |
| 2021-053 | 265 ROCHE COBA | | | 29 | 27.700 | 0.435 | 1.57 | 22.700 | 32.700 | | |
| 2021-054 | 265 ROCHE COBA | | | 29 | 64.041 | 1.143 | 1.79 | 58.900 | 69.200 | | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPEC: 10 CHEMISTRY | | | SUB: 20 BLOOD GASES | | | GRP: 30 BLOOD GASES | | | | | |
|--------------------|------------------|--|---------------------|-----------------------------------|------|---------------------|-----------|----------|---------|------------|-------|
| ANALYTE | | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
| SAMPLE | METHOD | | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH | |
| 007 | BLOOD GASES-pCO2 | | CLIA TEST ID #: 335 | EVALUATION CRITERIA: TARGET VALUE | 8 | % OR 5.00 | {GREATER} | | | | |
| 2021-055 | 265 ROCHE COBA | | | | 29 | 97.603 | 2.262 | 2.32 | 89.800 | 105.400 | |
| 008 | BLOOD GASES-pH | | CLIA TEST ID #: 315 | EVALUATION CRITERIA: TARGET VALUE | 0.04 | | | | | | |
| 2021-051 | 265 ROCHE COBA | | | | 29 | 7.068 | 0.008 | 0.11 | 7.028 | 7.108 | |
| 2021-052 | 265 ROCHE COBA | | | | 29 | 7.332 | 0.004 | 0.06 | 7.292 | 7.372 | |
| 2021-053 | 265 ROCHE COBA | | | | 29 | 7.574 | 0.005 | 0.06 | 7.534 | 7.614 | |
| 2021-054 | 265 ROCHE COBA | | | | 29 | 7.192 | 0.006 | 0.09 | 7.152 | 7.232 | |
| 2021-055 | 265 ROCHE COBA | | | | 29 | 7.061 | 0.006 | 0.09 | 7.021 | 7.101 | |
| 009 | BLOOD GASES-pO2 | | CLIA TEST ID #: 325 | EVALUATION CRITERIA: TARGET VALUE | 3 | SD | | | | | |
| 2021-051 | 265 ROCHE COBA | | | | 29 | 86.993 | 14.733 | 16.94 | 42.800 | 131.200 | |
| 2021-051 | 265 ROCHE COBA | | | | 29 | 98.750 | 9.377 | 9.50 | 70.600 | 126.900 | |
| 2021-052 | 265 ROCHE COBA | | | | 29 | 126.125 | 11.039 | 8.75 | 93.000 | 159.200 | |
| 2021-052 | 265 ROCHE COBA | | | | 29 | 120.761 | 4.868 | 4.03 | 106.200 | 135.400 | |
| 2021-053 | 265 ROCHE COBA | | | | 29 | 157.203 | 3.793 | 2.41 | 145.800 | 168.600 | |
| 2021-053 | 265 ROCHE COBA | | | | 29 | 156.750 | 9.216 | 5.88 | 129.100 | 184.400 | |
| 2021-054 | 265 ROCHE COBA | | | | 29 | 315.000 | 31.052 | 9.86 | 221.800 | 408.200 | |
| 2021-054 | 265 ROCHE COBA | | | | 29 | 338.734 | 11.356 | 3.35 | 304.700 | 372.800 | |
| 2021-055 | 265 ROCHE COBA | | | | 29 | 75.057 | 8.204 | 10.93 | 50.400 | 99.700 | |
| 2021-055 | 265 ROCHE COBA | | | | 29 | 91.250 | 8.212 | 9.00 | 66.600 | 115.900 | |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 30 ENDOCRINOLOGY

GRP: 40 ENDOCRINOLOGY (GEN.)

| ANALYTE | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
|--------------------------|----------------|---------------------|----------|--|-----------|------|------------|--------|
| SAMPLE | METHOD | SYST/INST | LABS | VALUE | DEVIATION | CV | LOW | HIGH |
| 029 FOLL. STIM. HOR.-FSH | | CLIA TEST ID #: 0 | | EVALUATION CRITERIA: TARGET VALUE 3 SD | | | | |
| 2021-031 | 116 ROCHE COBA | | 16 | 5.281 | 0.402 | 7.61 | 4.100 | 6.500 |
| 2021-032 | 116 ROCHE COBA | | 16 | 31.150 | 2.214 | 7.11 | 24.500 | 37.800 |
| 2021-033 | 116 ROCHE COBA | | 16 | 24.406 | 1.860 | 7.62 | 18.800 | 30.000 |
| 2021-034 | 116 ROCHE COBA | | 16 | 14.213 | 1.017 | 7.15 | 11.200 | 17.300 |
| 2021-035 | 116 ROCHE COBA | | 16 | 19.319 | 1.398 | 7.24 | 15.100 | 23.500 |
| 030 FREE THYROXINE | | CLIA TEST ID #: 545 | | | | | | |
| 2021-031 | 115 VITROS ECI | | 36 | 1.397 | 0.091 | 6.51 | 1.100 | 1.700 |
| 2021-031 | 116 ROCHE COBA | | 43 | 0.774 | 0.058 | 7.49 | 0.600 | 0.900 |
| 2021-031 | 116 ROCHE COBA | | 43 | 0.871 | 0.070 | 8.03 | 0.700 | 1.100 |
| 2021-031 | 125 B.C.ACCESS | | 42 | 0.822 | 0.061 | 7.36 | 0.600 | 1.000 |
| 2021-031 | 149 ARC i2000s | | 23 | 0.673 | 0.045 | 6.62 | 0.500 | 0.800 |
| 2021-031 | 160 SIEMENS EX | | 44 | 0.814 | 0.069 | 8.53 | 0.600 | 1.000 |
| 2021-032 | 115 VITROS ECI | | 36 | 6.991 | 0.028 | 0.40 | 6.900 | 7.100 |
| 2021-032 | 116 ROCHE COBA | | 43 | 4.243 | 0.261 | 6.15 | 3.500 | 5.000 |
| 2021-032 | 116 ROCHE COBA | | 43 | 3.774 | 0.213 | 5.64 | 3.100 | 4.400 |
| 2021-032 | 125 B.C.ACCESS | | 42 | 3.010 | 0.139 | 4.63 | 2.600 | 3.400 |
| 2021-032 | 149 ARC i2000s | | 23 | 2.813 | 0.180 | 6.40 | 2.300 | 3.400 |
| 2021-032 | 160 SIEMENS EX | | 44 | 3.909 | 0.241 | 6.17 | 3.200 | 4.600 |
| 2021-033 | 115 VITROS ECI | | 36 | 6.591 | 0.161 | 2.44 | 6.100 | 7.100 |
| 2021-033 | 116 ROCHE COBA | | 43 | 3.036 | 0.177 | 5.83 | 2.500 | 3.600 |
| 2021-033 | 116 ROCHE COBA | | 43 | 3.571 | 0.225 | 6.30 | 2.900 | 4.200 |
| 2021-033 | 125 B.C.ACCESS | | 42 | 2.615 | 0.126 | 4.82 | 2.200 | 3.000 |

Participant Summary

MONTH 2 OF YEAR 2021

| SPEC: 10 CHEMISTRY | | | SUB: 30 ENDOCRINOLOGY | | | GRP: 40 ENDOCRINOLOGY (GEN.) | | | | | |
|--------------------|------------------|------------|-----------------------|--|-----------------|------------------------------|---------|-------------------|---------------|--|--|
| ANALYTE | | | | | | | | | | | |
| SAMPLE | METHOD | SYST/INST | REAGENTS | NO. PART LABS | TARGET VALUE | STANDARD DEVIATION | % CV | ACCEPTABLE LOW | RANGE HIGH | | |
| 2021-033 | 149 | ARC i2000s | | 23 | 2.417 | 0.140 | 5.81 | 2.000 | 2.800 | | |
| 2021-033 | 160 | SIEMENS EX | | 44 | 3.132 | 0.163 | 5.22 | 2.600 | 3.600 | | |
| 030 | FREE THYROXINE | | CLIA TEST ID #: 545 | EVALUATION CRITERIA: TARGET VALUE 3 SD | | | | | | | |
| 2021-034 | 115 | VITROS ECI | | 36 | 4.453 | 0.166 | 3.72 | 4.000 | 5.000 | | |
| 2021-034 | 116 | ROCHE COBA | | 43 | 2.314 | 0.112 | 4.86 | 2.000 | 2.700 | | |
| 2021-034 | 116 | ROCHE COBA | | 43 | 1.893 | 0.097 | 5.14 | 1.600 | 2.200 | | |
| 2021-034 | 125 | B.C.ACCESS | | 42 | 1.783 | 0.088 | 4.94 | 1.500 | 2.000 | | |
| 2021-034 | 149 | ARC i2000s | | 23 | 1.530 | 0.069 | 4.49 | 1.300 | 1.700 | | |
| 2021-034 | 160 | SIEMENS EX | | 44 | 1.905 | 0.107 | 5.59 | 1.600 | 2.200 | | |
| 2021-035 | 115 | VITROS ECI | | 36 | 5.719 | 0.158 | 2.76 | 5.200 | 6.200 | | |
| 2021-035 | 116 | ROCHE COBA | | 43 | 2.488 | 0.128 | 5.13 | 2.100 | 2.900 | | |
| 2021-035 | 116 | ROCHE COBA | | 43 | 3.000 | 0.177 | 5.91 | 2.500 | 3.500 | | |
| 2021-035 | 125 | B.C.ACCESS | | 42 | 2.241 | 0.096 | 4.29 | 2.000 | 2.500 | | |
| 2021-035 | 149 | ARC i2000s | | 23 | 1.974 | 0.103 | 5.22 | 1.700 | 2.300 | | |
| 2021-035 | 160 | SIEMENS EX | | 44 | 2.511 | 0.146 | 5.83 | 2.100 | 3.000 | | |
| 032 | hCG-QUANTITATIVE | | CLIA TEST ID #: 555 | | | | | | | | |
| 2021-031 | 115 | VITROS ECI | | 18 | 2.394 | 0.024 | 0.98 | 2.300 | 2.500 | | |
| 2021-031 | 116 | ROCHE COBA | | 21 | 1.195 | 0.153 | 12.77 | 0.700 | 1.700 | | |
| 2021-031 | 125 | B.C.ACCESS | | 10 | 1.970 | 0.090 | 4.57 | 1.700 | 2.200 | | |
| 2021-032 | 115 | VITROS ECI | | 18 | 2102.372 | 99.761 | 4.75 | 1803.100 | 2401.700 | | |
| 2021-032 | 116 | ROCHE COBA | | 21 | 1303.462 | 103.959 | 7.98 | 991.600 | 1615.300 | | |
| 2021-032 | 125 | B.C.ACCESS | | 10 | 740.830 | 28.871 | 3.90 | 654.200 | 827.400 | | |
| 2021-033 | 115 | VITROS ECI | | 18 | 1525.172 | 72.599 | 4.76 | 1307.400 | 1743.000 | | |
| 2021-033 | 116 | ROCHE COBA | | 21 | 943.438 | 66.969 | 7.10 | 742.500 | 1144.300 | | |
| 2021-033 | 125 | B.C.ACCESS | | 10 | 567.120 | 32.272 | 5.69 | 470.300 | 663.900 | | |
| 2021-034 | 115 | VITROS ECI | | 18 | 693.756 | 33.919 | 4.89 | 592.000 | 795.500 | | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPEC: 10 CHEMISTRY | | SUB: 30 ENDOCRINOLOGY | | GRP: 40 ENDOCRINOLOGY (GEN.) | | | | | | |
|--------------------|------------------|-----------------------|---------------------|--|----------|-----------|-------|------------|----------|--|
| ANALYTE | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE | |
| SAMPLE | METHOD | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH | |
| 2021-034 | 116 | ROCHE COBA | | 21 | 419.219 | 26.297 | 6.27 | 340.300 | 498.100 | |
| 2021-034 | 125 | B.C.ACCESS | | 10 | 309.710 | 13.151 | 4.25 | 270.300 | 349.200 | |
| 032 | hCG-QUANTITATIVE | | CLIA TEST ID #: 555 | EVALUATION CRITERIA: TARGET VALUE 3 SD | | | | | | |
| 2021-035 | 115 | VITROS ECI | | 18 | 1106.694 | 50.084 | 4.53 | 956.400 | 1256.900 | |
| 2021-035 | 116 | ROCHE COBA | | 21 | 675.090 | 42.752 | 6.33 | 546.800 | 803.300 | |
| 2021-035 | 125 | B.C.ACCESS | | 10 | 452.680 | 23.053 | 5.09 | 383.500 | 521.800 | |
| 034 | PROGESTERONE | | CLIA TEST ID #: 0 | | | | | | | |
| 2021-031 | 116 | ROCHE COBA | | 10 | 0.480 | 0.098 | 20.41 | 0.200 | 0.800 | |
| 2021-032 | 116 | ROCHE COBA | | 10 | 30.180 | 1.513 | 5.01 | 25.600 | 34.700 | |
| 2021-033 | 116 | ROCHE COBA | | 10 | 23.690 | 1.205 | 5.08 | 20.100 | 27.300 | |
| 2021-034 | 116 | ROCHE COBA | | 10 | 12.090 | 0.430 | 3.56 | 10.800 | 13.400 | |
| 2021-035 | 116 | ROCHE COBA | | 10 | 17.930 | 0.897 | 5.00 | 15.200 | 20.600 | |
| 035 | PROLACTIN | | | | | | | | | |
| 2021-031 | 116 | ROCHE COBA | | 18 | 2.541 | 0.142 | 5.57 | 2.100 | 3.000 | |
| 2021-032 | 116 | ROCHE COBA | | 18 | 33.644 | 2.642 | 7.85 | 25.700 | 41.600 | |
| 2021-033 | 116 | ROCHE COBA | | 18 | 25.022 | 2.058 | 8.23 | 18.800 | 31.200 | |
| 2021-034 | 116 | ROCHE COBA | | 18 | 12.694 | 0.971 | 7.65 | 9.800 | 15.600 | |
| 2021-035 | 116 | ROCHE COBA | | 18 | 18.811 | 1.540 | 8.19 | 14.200 | 23.400 | |
| 037 | TESTOSTERONE | | | | | | | | | |
| 2021-031 | 116 | ROCHE COBA | | 10 | 1.090 | 0.145 | 13.26 | 0.700 | 1.500 | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPEC: 10 CHEMISTRY | | SUB: 30 ENDOCRINOLOGY | | GRP: 40 ENDOCRINOLOGY (GEN.) | | | | | | |
|--------------------|----------------------|-----------------------|--|------------------------------|--------|-----------|-------|------------|--------|--|
| ANALYTE | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE | |
| SAMPLE | METHOD | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH | |
| 037 | TESTOSTERONE | CLIA TEST ID #: 0 | EVALUATION CRITERIA: TARGET VALUE 3 SD | | | | | | | |
| 2021-032 | 116 ROCHE COBA | | | 10 | 15.170 | 0.690 | 4.55 | 13.100 | 17.200 | |
| 2021-033 | 116 ROCHE COBA | | | 10 | 12.710 | 0.797 | 6.27 | 10.300 | 15.100 | |
| 2021-034 | 116 ROCHE COBA | | | 10 | 6.710 | 0.274 | 4.08 | 5.900 | 7.500 | |
| 2021-035 | 116 ROCHE COBA | | | 10 | 9.730 | 0.514 | 5.28 | 8.200 | 11.300 | |
| 039 | THYRO. STI. HOR.-TSH | CLIA TEST ID #: 585 | | | | | | | | |
| 2021-031 | 106 TOSOH AIA | | | 14 | 0.607 | 0.088 | 14.55 | 0.300 | 0.900 | |
| 2021-031 | 115 VITROS ECI | | | 42 | 0.529 | 0.045 | 8.60 | 0.400 | 0.700 | |
| 2021-031 | 116 ROCHE COBA | | | 49 | 0.733 | 0.051 | 6.97 | 0.600 | 0.900 | |
| 2021-031 | 125 B.C.ACCESS | | | 58 | 0.521 | 0.041 | 7.82 | 0.400 | 0.600 | |
| 2021-031 | 149 ARC i2000s | | | 24 | 0.538 | 0.048 | 9.01 | 0.400 | 0.700 | |
| 2021-031 | 160 SIEMENS EX | | | 70 | 0.520 | 0.047 | 9.01 | 0.400 | 0.700 | |
| 2021-032 | 106 TOSOH AIA | | | 14 | 6.600 | 0.587 | 8.89 | 4.800 | 8.400 | |
| 2021-032 | 115 VITROS ECI | | | 42 | 6.879 | 0.246 | 3.58 | 6.100 | 7.600 | |
| 2021-032 | 116 ROCHE COBA | | | 49 | 5.608 | 0.274 | 4.88 | 4.800 | 6.400 | |
| 2021-032 | 125 B.C.ACCESS | | | 58 | 5.618 | 0.370 | 6.59 | 4.500 | 6.700 | |
| 2021-032 | 149 ARC i2000s | | | 24 | 5.588 | 0.285 | 5.10 | 4.700 | 6.400 | |
| 2021-032 | 160 SIEMENS EX | | | 70 | 4.691 | 0.307 | 6.55 | 3.800 | 5.600 | |
| 2021-033 | 106 TOSOH AIA | | | 14 | 4.950 | 0.385 | 7.78 | 3.800 | 6.100 | |
| 2021-033 | 115 VITROS ECI | | | 42 | 5.293 | 0.170 | 3.20 | 4.800 | 5.800 | |
| 2021-033 | 116 ROCHE COBA | | | 49 | 4.477 | 0.222 | 4.96 | 3.800 | 5.100 | |
| 2021-033 | 125 B.C.ACCESS | | | 58 | 4.246 | 0.292 | 6.88 | 3.400 | 5.100 | |
| 2021-033 | 149 ARC i2000s | | | 24 | 4.250 | 0.231 | 5.43 | 3.600 | 4.900 | |
| 2021-033 | 160 SIEMENS EX | | | 70 | 3.647 | 0.227 | 6.21 | 3.000 | 4.300 | |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 30 ENDOCRINOLOGY

GRP: 40 ENDOCRINOLOGY (GEN.)

| ANALYTE | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
|----------|----------------------|---------------------|-----------------------------------|----------|-----------|-----------|-------|------------|--------|
| SAMPLE | METHOD | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH |
| 039 | THYRO. STI. HOR.-TSH | CLIA TEST ID #: 585 | EVALUATION CRITERIA: TARGET VALUE | 3 | SD | | | | |
| 2021-034 | 106 TOSOH AIA | | | 14 | 2.693 | 0.215 | 8.00 | 2.000 | 3.300 |
| 2021-034 | 115 VITROS ECI | | | 42 | 2.876 | 0.111 | 3.85 | 2.500 | 3.200 |
| 2021-034 | 116 ROCHE COBA | | | 49 | 2.560 | 0.113 | 4.42 | 2.200 | 2.900 |
| 2021-034 | 125 B.C.ACCESS | | | 58 | 2.207 | 0.141 | 6.40 | 1.800 | 2.600 |
| 2021-034 | 149 ARC i2000s | | | 24 | 2.258 | 0.122 | 5.41 | 1.900 | 2.600 |
| 2021-034 | 160 SIEMENS EX | | | 70 | 2.007 | 0.115 | 5.71 | 1.700 | 2.400 |
| 2021-035 | 106 TOSOH AIA | | | 14 | 3.771 | 0.339 | 8.99 | 2.800 | 4.800 |
| 2021-035 | 115 VITROS ECI | | | 42 | 4.071 | 0.172 | 4.23 | 3.600 | 4.600 |
| 2021-035 | 116 ROCHE COBA | | | 49 | 3.547 | 0.156 | 4.39 | 3.100 | 4.000 |
| 2021-035 | 125 B.C.ACCESS | | | 58 | 3.200 | 0.238 | 7.43 | 2.500 | 3.900 |
| 2021-035 | 149 ARC i2000s | | | 24 | 3.263 | 0.163 | 4.99 | 2.800 | 3.800 |
| 2021-035 | 160 SIEMENS EX | | | 70 | 2.831 | 0.188 | 6.64 | 2.300 | 3.400 |
| 040 | THYROXINE (T4) | CLIA TEST ID #: 595 | EVALUATION CRITERIA: TARGET VALUE | 20 | % OR 1.00 | {GREATER} | | | |
| 2021-031 | 32 DADE DIME. | | | 47 | 3.094 | 0.445 | 14.39 | 2.100 | 4.100 |
| 2021-031 | 106 TOSOH AIA | | | 10 | 2.600 | 0.366 | 14.08 | 1.600 | 3.600 |
| 2021-031 | 115 VITROS ECI | | | 35 | 2.532 | 0.134 | 5.31 | 1.500 | 3.500 |
| 2021-031 | 116 ROCHE COBA | | | 46 | 2.722 | 0.216 | 7.92 | 1.700 | 3.700 |
| 2021-031 | 125 B.C.ACCESS | | | 47 | 2.247 | 0.251 | 11.16 | 1.200 | 3.200 |
| 2021-031 | 149 ARC i2000s | | | 21 | 2.076 | 0.187 | 9.03 | 1.100 | 3.100 |
| 2021-032 | 32 DADE DIME. | | | 47 | 16.352 | 0.831 | 5.08 | 13.100 | 19.600 |
| 2021-032 | 106 TOSOH AIA | | | 10 | 12.840 | 0.879 | 6.84 | 10.300 | 15.400 |
| 2021-032 | 115 VITROS ECI | | | 35 | 13.103 | 0.623 | 4.75 | 10.500 | 15.700 |
| 2021-032 | 116 ROCHE COBA | | | 46 | 13.860 | 0.779 | 5.62 | 11.100 | 16.600 |
| 2021-032 | 125 B.C.ACCESS | | | 47 | 12.691 | 0.785 | 6.19 | 10.200 | 15.200 |
| 2021-032 | 149 ARC i2000s | | | 21 | 14.624 | 0.621 | 4.25 | 11.700 | 17.500 |
| 2021-033 | 32 DADE DIME. | | | 47 | 12.751 | 0.586 | 4.60 | 10.200 | 15.300 |

Participant Summary

MONTH 2 OF YEAR 2021

| SPEC: 10 CHEMISTRY | | SUB: 30 ENDOCRINOLOGY | | GRP: 40 ENDOCRINOLOGY (GEN.) | | | | | |
|--------------------|----------------|-----------------------|---------------------|--|--------|-----------|-------|------------|--------|
| ANALYTE | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
| SAMPLE | METHOD | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH |
| 2021-033 | 106 | TOSOH AIA | | 10 | 10.870 | 0.826 | 7.60 | 8.700 | 13.000 |
| 2021-033 | 115 | VITROS ECI | | 35 | 10.631 | 0.482 | 4.53 | 8.500 | 12.800 |
| 2021-033 | 116 | ROCHE COBA | | 46 | 11.096 | 0.651 | 5.87 | 8.900 | 13.300 |
| 2021-033 | 125 | B.C.ACCESS | | 47 | 10.651 | 0.744 | 6.99 | 8.500 | 12.800 |
| 2021-033 | 149 | ARC i2000s | | 21 | 11.471 | 0.652 | 5.68 | 9.200 | 13.800 |
| 040 | THYROXINE (T4) | | CLIA TEST ID #: 595 | EVALUATION CRITERIA: TARGET VALUE 20 % OR 1.00 {GREATER} | | | | | |
| 2021-034 | 32 | DADE DIME. | | 47 | 7.411 | 0.435 | 5.87 | 5.900 | 8.900 |
| 2021-034 | 106 | TOSOH AIA | | 10 | 6.340 | 0.530 | 8.35 | 5.100 | 7.600 |
| 2021-034 | 115 | VITROS ECI | | 35 | 6.397 | 0.312 | 4.88 | 5.100 | 7.700 |
| 2021-034 | 116 | ROCHE COBA | | 46 | 6.661 | 0.453 | 6.80 | 5.300 | 8.000 |
| 2021-034 | 125 | B.C.ACCESS | | 47 | 6.736 | 0.521 | 7.73 | 5.400 | 8.100 |
| 2021-034 | 149 | ARC i2000s | | 21 | 6.262 | 0.318 | 5.09 | 5.000 | 7.500 |
| 2021-035 | 32 | DADE DIME. | | 47 | 10.032 | 0.604 | 6.02 | 8.000 | 12.000 |
| 2021-035 | 106 | TOSOH AIA | | 10 | 8.620 | 0.572 | 6.64 | 6.900 | 10.300 |
| 2021-035 | 115 | VITROS ECI | | 35 | 8.509 | 0.429 | 5.04 | 6.800 | 10.200 |
| 2021-035 | 116 | ROCHE COBA | | 46 | 8.917 | 0.609 | 6.83 | 7.100 | 10.700 |
| 2021-035 | 125 | B.C.ACCESS | | 47 | 8.834 | 0.603 | 6.82 | 7.100 | 10.600 |
| 2021-035 | 149 | ARC i2000s | | 21 | 8.871 | 0.413 | 4.66 | 7.100 | 10.600 |
| 141 | FOLATE | | CLIA TEST ID #: 0 | EVALUATION CRITERIA: TARGET VALUE 25 % | | | | | |
| 2021-031 | 115 | VITROS ECI | | 13 | 1.215 | 0.135 | 11.11 | 0.900 | 1.500 |
| 2021-031 | 116 | ROCHE COBA | | 18 | 1.011 | 0.213 | 21.08 | 0.800 | 1.300 |
| 2021-031 | 116 | ROCHE COBA | | 18 | 2.000 | 0.000 | 0.00 | 1.500 | 2.500 |
| 2021-031 | 125 | B.C.ACCESS | | 11 | 1.018 | 0.635 | 62.37 | 0.800 | 1.300 |
| 2021-031 | 125 | B.C.ACCESS | | 11 | 1.120 | 0.248 | 22.16 | 0.800 | 1.400 |
| 2021-032 | 115 | VITROS ECI | | 13 | 12.162 | 1.089 | 8.96 | 9.100 | 15.200 |
| 2021-032 | 116 | ROCHE COBA | | 18 | 9.767 | 0.930 | 9.52 | 7.300 | 12.200 |
| 2021-032 | 116 | ROCHE COBA | | 18 | 7.000 | 0.581 | 8.30 | 5.300 | 8.800 |
| 2021-032 | 125 | B.C.ACCESS | | 11 | 12.140 | 0.840 | 6.92 | 9.100 | 15.200 |

Participant Summary

MONTH 2 OF YEAR 2021

| SPEC: 10 CHEMISTRY | | SUB: 30 ENDOCRINOLOGY | | GRP: 40 ENDOCRINOLOGY (GEN.) | | | | | | |
|--------------------------|----------------|-----------------------|--|------------------------------|--------|-----------|-------|------------|--------|--|
| ANALYTE | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE | |
| SAMPLE | METHOD | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH | |
| 2021-032 | 125 B.C.ACCESS | | | 11 | 12.136 | 1.766 | 14.55 | 9.100 | 15.200 | |
| 141 FOLATE | | CLIA TEST ID #: 0 | EVALUATION CRITERIA: TARGET VALUE 25 % | | | | | | | |
| 2021-033 | 115 VITROS ECI | | | 13 | 8.569 | 0.672 | 7.84 | 6.400 | 10.700 | |
| 2021-033 | 116 ROCHE COBA | | | 18 | 5.122 | 0.473 | 9.24 | 3.800 | 6.400 | |
| 2021-033 | 116 ROCHE COBA | | | 18 | 6.533 | 0.898 | 13.75 | 4.900 | 8.200 | |
| 2021-033 | 125 B.C.ACCESS | | | 11 | 9.430 | 0.382 | 4.05 | 7.100 | 11.800 | |
| 2021-033 | 125 B.C.ACCESS | | | 11 | 8.780 | 0.440 | 5.01 | 6.600 | 11.000 | |
| 2021-034 | 115 VITROS ECI | | | 13 | 3.785 | 0.398 | 10.51 | 2.800 | 4.700 | |
| 2021-034 | 116 ROCHE COBA | | | 18 | 2.572 | 0.398 | 15.49 | 1.900 | 3.200 | |
| 2021-034 | 116 ROCHE COBA | | | 18 | 2.811 | 0.285 | 10.12 | 2.100 | 3.500 | |
| 2021-034 | 125 B.C.ACCESS | | | 11 | 4.520 | 0.098 | 2.17 | 3.400 | 5.700 | |
| 2021-034 | 125 B.C.ACCESS | | | 11 | 4.464 | 0.483 | 10.82 | 3.300 | 5.600 | |
| 2021-035 | 115 VITROS ECI | | | 13 | 6.092 | 0.570 | 9.36 | 4.600 | 7.600 | |
| 2021-035 | 116 ROCHE COBA | | | 18 | 3.867 | 0.320 | 8.27 | 2.900 | 4.800 | |
| 2021-035 | 116 ROCHE COBA | | | 18 | 4.417 | 0.700 | 15.85 | 3.300 | 5.500 | |
| 2021-035 | 125 B.C.ACCESS | | | 11 | 6.827 | 0.529 | 7.75 | 5.100 | 8.500 | |
| 2021-035 | 125 B.C.ACCESS | | | 11 | 6.580 | 0.319 | 4.84 | 4.900 | 8.200 | |
| 142 hLH (HUMAN LUT. HOR) | | | | | | | | | | |
| 2021-031 | 116 ROCHE COBA | | | 15 | 3.473 | 0.349 | 10.05 | 2.600 | 4.300 | |
| 2021-032 | 116 ROCHE COBA | | | 15 | 54.573 | 3.378 | 6.19 | 40.900 | 68.200 | |
| 2021-033 | 116 ROCHE COBA | | | 15 | 41.267 | 2.886 | 6.99 | 31.000 | 51.600 | |
| 2021-034 | 116 ROCHE COBA | | | 15 | 21.613 | 1.353 | 6.26 | 16.200 | 27.000 | |
| 2021-035 | 116 ROCHE COBA | | | 15 | 31.593 | 1.954 | 6.18 | 23.700 | 39.500 | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | SUB: 30 ENDOCRINOLOGY | | | | GRP: 40 ENDOCRINOLOGY (GEN.) | | | | | | |
|---------------------|------------------------|------------------------|------------------------|------------------|---------------------|------------------------------|-------------------|----------------|--------------|----------------|-------|-----|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART # LABS | LABS ANSW | # "SF" LABS | Score | |
| 031 hCG-QUALITATIVE | | | | | | | | | | | | |
| 2021-031 | 113 | BIO-SIGN | | 001 | 001 | 001 | 001 | 001 - NEGATIVE | 21 | 21 | 21 | 100 |
| 2021-031 | 142 | INSTANT VI | | 001 | 001 | 001 | 001 | 001 - NEGATIVE | 51 | 50 | 50 | 100 |
| 2021-031 | 142 | INSTANT VI | | 001 | 001 | 001 | 001 | 002 - POSITIVE | 51 | 1 | 50 | 0 |
| 2021-031 | 150 | AIM STEP | | 001 | 001 | 001 | 001 | 002 - POSITIVE | 82 | 1 | 81 | 0 |
| 2021-031 | 150 | AIM STEP | | 001 | 001 | 001 | 001 | 001 - NEGATIVE | 82 | 81 | 81 | 100 |
| 2021-031 | 164 | HCG Alere | | 001 | 001 | 001 | 001 | 001 - NEGATIVE | 64 | 64 | 64 | 100 |
| 2021-031 | 165 | Osom HCG C | | 001 | 001 | 001 | 001 | 001 - NEGATIVE | 19 | 18 | 18 | 100 |
| 2021-031 | 165 | Osom HCG C | | 001 | 001 | 001 | 001 | 002 - POSITIVE | 19 | 1 | 18 | 0 |
| 2021-031 | 166 | FaStep | | 001 | 001 | 001 | 001 | 001 - NEGATIVE | 12 | 12 | 12 | 100 |
| 2021-031 | 167 | Tanner Sci | | 001 | 001 | 001 | 001 | 001 - NEGATIVE | 13 | 13 | 13 | 100 |
| | | | | | | | | | | | | |
| 2021-032 | 113 | BIO-SIGN | | 002 | 002 | 002 | 002 | 002 - POSITIVE | 21 | 21 | 21 | 100 |
| 2021-032 | 142 | INSTANT VI | | 002 | 002 | 002 | 002 | 002 - POSITIVE | 51 | 51 | 51 | 100 |
| 2021-032 | 150 | AIM STEP | | 002 | 002 | 002 | 002 | 002 - POSITIVE | 82 | 82 | 82 | 100 |
| 2021-032 | 164 | HCG Alere | | 002 | 002 | 002 | 002 | 002 - POSITIVE | 64 | 64 | 64 | 100 |
| 2021-032 | 165 | Osom HCG C | | 002 | 002 | 002 | 002 | 002 - POSITIVE | 19 | 19 | 19 | 100 |
| 2021-032 | 166 | FaStep | | 002 | 002 | 002 | 002 | 002 - POSITIVE | 12 | 12 | 12 | 100 |
| 2021-032 | 167 | Tanner Sci | | 002 | 002 | 002 | 002 | 002 - POSITIVE | 13 | 13 | 13 | 100 |
| | | | | | | | | | | | | |
| 2021-033 | 113 | BIO-SIGN | | 002 | 002 | 002 | 002 | 002 - POSITIVE | 21 | 21 | 21 | 100 |
| 2021-033 | 142 | INSTANT VI | | 002 | 002 | 002 | 002 | 002 - POSITIVE | 51 | 51 | 51 | 100 |
| 2021-033 | 150 | AIM STEP | | 002 | 002 | 002 | 002 | 002 - POSITIVE | 82 | 82 | 82 | 100 |
| 2021-033 | 164 | HCG Alere | | 002 | 002 | 002 | 002 | 002 - POSITIVE | 64 | 64 | 64 | 100 |
| 2021-033 | 165 | Osom HCG C | | 002 | 002 | 002 | 002 | 002 - POSITIVE | 19 | 19 | 19 | 100 |
| 2021-033 | 166 | FaStep | | 002 | 002 | 002 | 002 | 002 - POSITIVE | 12 | 12 | 12 | 100 |
| 2021-033 | 167 | Tanner Sci | | 002 | 002 | 002 | 002 | 002 - POSITIVE | 13 | 13 | 13 | 100 |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | | SUB: 30 ENDOCRINOLOGY | | | | GRP: 40 ENDOCRINOLOGY (GEN.) | | | | |
|--------------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|------------------------------|--------------|----------------|----------------|-------|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score |
| 031 hCG-QUALITATIVE | | | | | | | | | | | |
| 2021-034 | 113 | BIO-SIGN | | 002 002 | 002 002 | | 002 - POSITIVE | 21 | 21 | 21 | 100 |
| 2021-034 | 142 | INSTANT VI | | 002 002 | 002 002 | | 002 - POSITIVE | 51 | 51 | 51 | 100 |
| 2021-034 | 150 | AIM STEP | | 002 002 | 002 002 | | 002 - POSITIVE | 82 | 82 | 82 | 100 |
| 2021-034 | 164 | HCG Alere | | 002 002 | 002 002 | | 002 - POSITIVE | 64 | 64 | 64 | 100 |
| 2021-034 | 165 | Osom HCG C | | 002 002 | 002 002 | | 002 - POSITIVE | 19 | 19 | 19 | 100 |
| 2021-034 | 166 | FaStep | | 002 002 | 002 002 | | 002 - POSITIVE | 12 | 12 | 12 | 100 |
| 2021-034 | 167 | Tanner Sci | | 002 002 | 002 002 | | 002 - POSITIVE | 13 | 13 | 13 | 100 |
| | | | | | | | | | | | |
| 2021-035 | 113 | BIO-SIGN | | 002 002 | 002 002 | | 002 - POSITIVE | 21 | 21 | 21 | 100 |
| 2021-035 | 142 | INSTANT VI | | 002 002 | 002 002 | | 002 - POSITIVE | 51 | 50 | 50 | 100 |
| 2021-035 | 142 | INSTANT VI | | 002 002 | 002 002 | | 001 - NEGATIVE | 51 | 1 | 50 | 0 |
| 2021-035 | 150 | AIM STEP | | 002 002 | 002 002 | | 002 - POSITIVE | 82 | 81 | 81 | 100 |
| 2021-035 | 150 | AIM STEP | | 002 002 | 002 002 | | 001 - NEGATIVE | 82 | 1 | 81 | 0 |
| 2021-035 | 164 | HCG Alere | | 002 002 | 002 002 | | 002 - POSITIVE | 64 | 64 | 64 | 100 |
| 2021-035 | 165 | Osom HCG C | | 002 002 | 002 002 | | 002 - POSITIVE | 19 | 18 | 18 | 100 |
| 2021-035 | 165 | Osom HCG C | | 002 002 | 002 002 | | 001 - NEGATIVE | 19 | 1 | 18 | 0 |
| 2021-035 | 166 | FaStep | | 002 002 | 002 002 | | 002 - POSITIVE | 12 | 12 | 12 | 100 |
| 2021-035 | 167 | Tanner Sci | | 002 002 | 002 002 | | 002 - POSITIVE | 13 | 13 | 13 | 100 |
| | | | | | | | | | | | |
| SPE: 10 CHEMISTRY | | | SUB: 30 ENDOCRINOLOGY | | | | GRP: 45 ENDOCRINOL.-hCG ONLY | | | | |
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score |
| 151 hCG ONLY QUALITATIVE | | | | | | | | | | | |
| 2021-021 | 018 | BIO SIGN | | 001 001 | 001 001 | | 001 - NEGATIVE | 22 | 22 | 22 | 100 |
| 2021-021 | 083 | STAMBIO | | 001 001 | 001 001 | | 001 - NEGATIVE | 10 | 10 | 10 | 100 |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | SUB: 30 ENDOCRINOLOGY | | | | GRP: 45 ENDOCRINOL.-hCG ONLY | | | | | | | |
|--------------------------|------------------------|------------------------|------------------------|------------------|---------------------|------------------------------|-------------------|--------------|----------------|----------------|-------|--|--|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | | |
| 2021-021 | 114 | INSTANT VI | | 001 001 | 001 001 | | 001 - NEGATIVE | 115 | 115 | 115 | 100 | | |
| 2021-021 | 118 | AIM STEP | | 001 001 | 001 001 | | 001 - NEGATIVE | 147 | 147 | 147 | 100 | | |
| 2021-021 | 130 | ALERE HCG | | 001 001 | 001 001 | | 001 - NEGATIVE | 94 | 94 | 94 | 100 | | |
| 2021-021 | 131 | OSOM HCG | | 001 001 | 001 001 | | 001 - NEGATIVE | 26 | 26 | 26 | 100 | | |
| 2021-021 | 133 | FaStep | | 001 001 | 001 001 | | 001 - NEGATIVE | 23 | 23 | 23 | 100 | | |
| 2021-021 | 134 | Tanner Sc. | | 001 001 | 001 001 | | 001 - NEGATIVE | 66 | 66 | 66 | 100 | | |
| 151 hCG ONLY QUALITATIVE | | | | | | | | | | | | | |
| 2021-022 | 018 | BIO SIGN | | 002 002 | 002 002 | | 002 - POSITIVE | 22 | 22 | 22 | 100 | | |
| 2021-022 | 083 | STAMBIO | | 002 002 | 002 002 | | 002 - POSITIVE | 10 | 10 | 10 | 100 | | |
| 2021-022 | 114 | INSTANT VI | | 002 002 | 002 002 | | 002 - POSITIVE | 115 | 115 | 115 | 100 | | |
| 2021-022 | 118 | AIM STEP | | 002 002 | 002 002 | | 002 - POSITIVE | 147 | 147 | 147 | 100 | | |
| 2021-022 | 130 | ALERE HCG | | 002 002 | 002 002 | | 002 - POSITIVE | 94 | 94 | 94 | 100 | | |
| 2021-022 | 131 | OSOM HCG | | 002 002 | 002 002 | | 002 - POSITIVE | 26 | 26 | 26 | 100 | | |
| 2021-022 | 133 | FaStep | | 002 002 | 002 002 | | 002 - POSITIVE | 23 | 23 | 23 | 100 | | |
| 2021-022 | 134 | Tanner Sc. | | 002 002 | 002 002 | | 002 - POSITIVE | 66 | 66 | 66 | 100 | | |
| 2021-023 | 018 | BIO SIGN | | 002 002 | 002 002 | | 002 - POSITIVE | 22 | 22 | 22 | 100 | | |
| 2021-023 | 083 | STAMBIO | | 002 002 | 002 002 | | 002 - POSITIVE | 10 | 10 | 10 | 100 | | |
| 2021-023 | 114 | INSTANT VI | | 002 002 | 002 002 | | 002 - POSITIVE | 115 | 115 | 115 | 100 | | |
| 2021-023 | 118 | AIM STEP | | 002 002 | 002 002 | | 002 - POSITIVE | 147 | 147 | 147 | 100 | | |
| 2021-023 | 130 | ALERE HCG | | 002 002 | 002 002 | | 002 - POSITIVE | 94 | 94 | 94 | 100 | | |
| 2021-023 | 131 | OSOM HCG | | 002 002 | 002 002 | | 002 - POSITIVE | 26 | 26 | 26 | 100 | | |
| 2021-023 | 133 | FaStep | | 002 002 | 002 002 | | 002 - POSITIVE | 23 | 23 | 23 | 100 | | |
| 2021-023 | 134 | Tanner Sc. | | 002 002 | 002 002 | | 002 - POSITIVE | 66 | 66 | 66 | 100 | | |
| 2021-024 | 018 | BIO SIGN | | 002 002 | 002 002 | | 002 - POSITIVE | 22 | 22 | 22 | 100 | | |
| 2021-024 | 083 | STAMBIO | | 002 002 | 002 002 | | 002 - POSITIVE | 10 | 10 | 10 | 100 | | |
| 2021-024 | 114 | INSTANT VI | | 002 002 | 002 002 | | 002 - POSITIVE | 115 | 115 | 115 | 100 | | |
| 2021-024 | 118 | AIM STEP | | 002 002 | 002 002 | | 002 - POSITIVE | 147 | 147 | 147 | 100 | | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | SUB: 30 ENDOCRINOLOGY | | | | GRP: 45 ENDOCRINOL.-hCG ONLY | | | | | | |
|--------------------------|---------------------|-----------------------|---------------------|---------------|------------------|------------------------------|----------------|-----------|-------------|-------------|-------|--|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | |
| 2021-024 | 130 | ALERE HCG | | 002 002 | 002 002 | | 002 - POSITIVE | 94 | 94 | 94 | 100 | |
| 2021-024 | 131 | OSOM HCG | | 002 002 | 002 002 | | 002 - POSITIVE | 26 | 26 | 26 | 100 | |
| 2021-024 | 133 | FaStep | | 002 002 | 002 002 | | 002 - POSITIVE | 23 | 23 | 23 | 100 | |
| 2021-024 | 134 | Tanner Sc. | | 002 002 | 002 002 | | 002 - POSITIVE | 66 | 66 | 66 | 100 | |
| 151 hCG ONLY QUALITATIVE | | | | | | | | | | | | |
| 2021-025 | 018 | BIO SIGN | | 001 001 | 001 001 | | 001 - NEGATIVE | 22 | 22 | 22 | 100 | |
| 2021-025 | 083 | STAMBIO | | 001 001 | 001 001 | | 001 - NEGATIVE | 10 | 10 | 10 | 100 | |
| 2021-025 | 114 | INSTANT VI | | 001 001 | 001 001 | | 001 - NEGATIVE | 115 | 115 | 115 | 100 | |
| 2021-025 | 118 | AIM STEP | | 001 001 | 001 001 | | 001 - NEGATIVE | 147 | 147 | 147 | 100 | |
| 2021-025 | 130 | ALERE HCG | | 001 001 | 001 001 | | 002 - POSITIVE | 94 | 1 | 93 | 0 | |
| 2021-025 | 130 | ALERE HCG | | 001 001 | 001 001 | | 001 - NEGATIVE | 94 | 93 | 93 | 100 | |
| 2021-025 | 131 | OSOM HCG | | 001 001 | 001 001 | | 001 - NEGATIVE | 26 | 26 | 26 | 100 | |
| 2021-025 | 133 | FaStep | | 001 001 | 001 001 | | 001 - NEGATIVE | 23 | 23 | 23 | 100 | |
| 2021-025 | 134 | Tanner Sc. | | 001 001 | 001 001 | | 002 - POSITIVE | 66 | 1 | 65 | 0 | |
| 2021-025 | 134 | Tanner Sc. | | 001 001 | 001 001 | | 001 - NEGATIVE | 66 | 65 | 65 | 100 | |

| SPEC: 10 CHEMISTRY | | SUB: 30 ENDOCRINOLOGY | | | | GRP: 55 ENDO.(T3 UPTAKE) | | | | | | |
|---------------------|--------|-----------------------|--|---------------|--------------|--------------------------|--------|----------------|------------|--------|--------|--|
| ANALYTE | | | | | | | | | | | | |
| SAMPLE | METHOD | SYST/INST | REAGENTS | NO. PART LABS | TARGET VALUE | STANDARD DEVIATION | % CV | ACCEPTABLE LOW | RANGE HIGH | | | |
| 173 T3 UPTAKE | | | | | | | | | | | | |
| CLIA TEST ID #: 565 | | | EVALUATION CRITERIA: TARGET VALUE 3 SD | | | | | | | | | |
| 2021-031 | 1 | %U | 84 VITROS ECI | 1 | 25-35 | 23 | 59.209 | 1.414 | 2.39 | 54.970 | 63.450 | |
| 2021-031 | 1 | %U | 91 B.C.ACCESS | 2 | 35-45 | 27 | 53.648 | 3.099 | 5.78 | 44.350 | 62.940 | |
| 2021-031 | 2 | TUV | 95 Arc i2000s | 3 | 0.7 - 1.2 | 13 | 0.522 | 0.023 | 4.44 | 0.450 | 0.590 | |
| 2021-031 | 4 | % | 32 DIMENSION | 2 | 35-45 | 49 | 42.183 | 1.779 | 4.22 | 36.850 | 47.520 | |
| 2021-031 | 4 | % | 91 B.C.ACCESS | 2 | 35-45 | 10 | 50.530 | 2.654 | 5.25 | 42.570 | 58.490 | |
| 2021-031 | 5 | TBI | 98 ROCHE COBA | 4 | 0.8-1.3 | 43 | 0.798 | 0.118 | 14.74 | 0.440 | 1.150 | |
| 2021-031 | 5 | TBI | 98 ROCHE COBA | 4 | 0.8-1.3 | 43 | 0.858 | 0.044 | 5.13 | 0.730 | 0.990 | |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 30 ENDOCRINOLOGY

GRP: 55 ENDO.(T3 UPTAKE)

| ANALYTE | | | | | | | | | | | | | |
|---------------|--------|---------------------|--|---------------|--------------|--------------------|-------|----------------|------------|--|--|--|--|
| SAMPLE | METHOD | SYST/INST | REAGENTS | NO. PART LABS | TARGET VALUE | STANDARD DEVIATION | % CV | ACCEPTABLE LOW | RANGE HIGH | | | | |
| 173 T3 UPTAKE | | CLIA TEST ID #: 565 | EVALUATION CRITERIA: TARGET VALUE 3 SD | | | | | | | | | | |
| 2021-032 | 1 %U | 84 VITROS ECI | 1 25-35 | 23 | 50.013 | 1.413 | 2.83 | 45.770 | 54.250 | | | | |
| 2021-032 | 1 %U | 91 B.C.ACCESS | 2 35-45 | 27 | 46.867 | 2.258 | 4.82 | 40.090 | 53.640 | | | | |
| 2021-032 | 2 TUV | 95 Arc i2000s | 3 0.7 - 1.2 | 13 | 1.056 | 0.030 | 2.84 | 0.970 | 1.150 | | | | |
| 2021-032 | 4 % | 32 DIMENSION | 2 35-45 | 49 | 42.356 | 2.044 | 4.83 | 36.220 | 48.490 | | | | |
| 2021-032 | 4 % | 91 B.C.ACCESS | 2 35-45 | 10 | 44.610 | 2.200 | 4.93 | 38.010 | 51.210 | | | | |
| 2021-032 | 5 TBI | 98 ROCHE COBA | 4 0.8-1.3 | 43 | 0.504 | 0.074 | 14.66 | 0.280 | 0.730 | | | | |
| 2021-032 | 5 TBI | 98 ROCHE COBA | 4 0.8-1.3 | 43 | 0.548 | 0.095 | 17.30 | 0.260 | 0.830 | | | | |
| 2021-033 | 1 %U | 84 VITROS ECI | 1 25-35 | 23 | 52.664 | 1.269 | 2.41 | 48.860 | 56.470 | | | | |
| 2021-033 | 1 %U | 91 B.C.ACCESS | 2 35-45 | 27 | 48.793 | 2.503 | 5.13 | 41.280 | 56.300 | | | | |
| 2021-033 | 2 TUV | 95 Arc i2000s | 3 0.7 - 1.2 | 13 | 0.947 | 0.040 | 4.27 | 0.830 | 1.070 | | | | |
| 2021-033 | 4 % | 32 DIMENSION | 2 35-45 | 49 | 42.010 | 1.864 | 4.44 | 36.420 | 47.600 | | | | |
| 2021-033 | 4 % | 91 B.C.ACCESS | 2 35-45 | 10 | 46.310 | 2.820 | 6.09 | 37.850 | 54.770 | | | | |
| 2021-033 | 5 TBI | 98 ROCHE COBA | 4 0.8-1.3 | 43 | 0.593 | 0.055 | 9.35 | 0.430 | 0.760 | | | | |
| 2021-033 | 5 TBI | 98 ROCHE COBA | 4 0.8-1.3 | 43 | 0.598 | 0.071 | 11.87 | 0.380 | 0.810 | | | | |
| 2021-034 | 1 %U | 84 VITROS ECI | 1 25-35 | 23 | 56.365 | 1.910 | 3.39 | 50.630 | 62.100 | | | | |
| 2021-034 | 1 %U | 91 B.C.ACCESS | 2 35-45 | 27 | 51.270 | 2.255 | 4.40 | 44.510 | 58.030 | | | | |
| 2021-034 | 2 TUV | 95 Arc i2000s | 3 0.7 - 1.2 | 13 | 0.754 | 0.025 | 3.31 | 0.680 | 0.830 | | | | |
| 2021-034 | 4 % | 32 DIMENSION | 2 35-45 | 49 | 41.684 | 1.722 | 4.13 | 36.520 | 46.850 | | | | |
| 2021-034 | 4 % | 91 B.C.ACCESS | 2 35-45 | 10 | 48.560 | 2.129 | 4.38 | 42.170 | 54.950 | | | | |
| 2021-034 | 5 TBI | 98 ROCHE COBA | 4 0.8-1.3 | 43 | 0.726 | 0.065 | 8.97 | 0.530 | 0.920 | | | | |
| 2021-034 | 5 TBI | 98 ROCHE COBA | 4 0.8-1.3 | 43 | 0.700 | 0.063 | 8.98 | 0.510 | 0.890 | | | | |
| 2021-035 | 1 %U | 84 VITROS ECI | 1 25-35 | 23 | 54.461 | 1.752 | 3.22 | 49.200 | 59.720 | | | | |
| 2021-035 | 1 %U | 91 B.C.ACCESS | 2 35-45 | 27 | 49.759 | 2.511 | 5.05 | 42.230 | 57.290 | | | | |
| 2021-035 | 2 TUV | 95 Arc i2000s | 3 0.7 - 1.2 | 13 | 0.858 | 0.028 | 3.29 | 0.770 | 0.940 | | | | |
| 2021-035 | 4 % | 32 DIMENSION | 2 35-45 | 49 | 42.263 | 1.849 | 4.37 | 36.720 | 47.810 | | | | |
| 2021-035 | 4 % | 91 B.C.ACCESS | 2 35-45 | 10 | 46.610 | 4.556 | 9.78 | 32.940 | 60.280 | | | | |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY SUB: 30 ENDOCRINOLOGY GRP: 55 ENDO.(T3 UPTAKE)

| ANALYTE | | | | | | | | | | | | | |
|----------|--------|-----------|------------|----------|---------|------------------|-----------------|-----------------------|---------|-------------------|---------------|--|--|
| SAMPLE | METHOD | SYST/INST | | REAGENTS | | NO. PART LABS | TARGET VALUE | STANDARD DEVIATION | % CV | ACCEPTABLE LOW | RANGE HIGH | | |
| 2021-035 | 5 TBI | 98 | ROCHE COBA | 4 | 0.8-1.3 | 43 | 0.658 | 0.044 | 6.75 | 0.520 | 0.790 | | |
| 2021-035 | 5 TBI | 98 | ROCHE COBA | 4 | 0.8-1.3 | 43 | 0.665 | 0.070 | 10.46 | 0.460 | 0.870 | | |

SPEC: 10 CHEMISTRY SUB: 40 TOXICOLOGY GRP: 60 TOXICOLOGY

| ANALYTE | | | | | | | | | | | | | |
|--------------|---------------|---------------------|--|--|--|------------------|-----------------|-----------------------|---------|-------------------|---------------|--|--|
| SAMPLE | METHOD | SYST/INST | | REAGENTS | | NO. PART LABS | TARGET VALUE | STANDARD DEVIATION | % CV | ACCEPTABLE LOW | RANGE HIGH | | |
| 043 DIGOXIN | | CLIA TEST ID #: 645 | | EVALUATION CRITERIA: TARGET VALUE 20 % OR 0.20 {GREATER} | | | | | | | | | |
| 2021-031 | 50 VITROS | | | | | 14 | 0.414 | 0.035 | 8.45 | 0.200 | 0.600 | | |
| 2021-032 | 50 VITROS | | | | | 14 | 1.957 | 0.140 | 7.15 | 1.600 | 2.300 | | |
| 2021-033 | 50 VITROS | | | | | 14 | 1.493 | 0.110 | 7.37 | 1.200 | 1.800 | | |
| 2021-034 | 50 VITROS | | | | | 14 | 0.793 | 0.080 | 10.07 | 0.600 | 1.000 | | |
| 2021-035 | 50 VITROS | | | | | 14 | 1.114 | 0.074 | 6.66 | 0.900 | 1.300 | | |
| 045 FERRITIN | | CLIA TEST ID #: 0 | | EVALUATION CRITERIA: TARGET VALUE 25 % | | | | | | | | | |
| 2021-031 | 50 VITROS | | | | | 15 | 15.040 | 0.689 | 4.58 | 11.300 | 18.800 | | |
| 2021-031 | 90 ROCHE COBA | | | | | 13 | 21.667 | 0.745 | 3.44 | 16.300 | 27.100 | | |
| 2021-031 | 90 ROCHE COBA | | | | | 13 | 23.615 | 2.312 | 9.79 | 17.700 | 29.500 | | |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 40 TOXICOLOGY

GRP: 60 TOXICOLOGY

| ANALYTE | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
|---------|------------|-----------|------------|--|----------|---------|-----------|-------|------------|---------|
| SAMPLE | METHOD | SYST/INST | REAGENTS | | LABS | VALUE | DEVIATION | CV | LOW | HIGH |
| 045 | FERRITIN | | | CLIA TEST ID #: 0 | | | | | | |
| | | | | EVALUATION CRITERIA: TARGET VALUE 25 % | | | | | | |
| | 2021-032 | 50 | VITROS | | 15 | 153.067 | 6.668 | 4.36 | 114.800 | 191.300 |
| | 2021-032 | 90 | ROCHE COBA | | 13 | 264.346 | 26.227 | 9.92 | 198.300 | 330.400 |
| | 2021-032 | 90 | ROCHE COBA | | 13 | 221.333 | 7.674 | 3.47 | 166.000 | 276.700 |
| | 2021-033 | 50 | VITROS | | 15 | 111.933 | 5.893 | 5.26 | 84.000 | 139.900 |
| | 2021-033 | 90 | ROCHE COBA | | 13 | 166.333 | 5.121 | 3.08 | 124.800 | 207.900 |
| | 2021-033 | 90 | ROCHE COBA | | 13 | 196.377 | 17.894 | 9.11 | 147.300 | 245.500 |
| | 2021-034 | 50 | VITROS | | 15 | 58.047 | 2.561 | 4.41 | 43.500 | 72.600 |
| | 2021-034 | 90 | ROCHE COBA | | 13 | 101.531 | 9.572 | 9.43 | 76.100 | 126.900 |
| | 2021-034 | 90 | ROCHE COBA | | 13 | 87.167 | 1.863 | 2.14 | 65.400 | 109.000 |
| | 2021-035 | 50 | VITROS | | 15 | 85.273 | 4.164 | 4.88 | 64.000 | 106.600 |
| | 2021-035 | 90 | ROCHE COBA | | 13 | 126.333 | 3.399 | 2.69 | 94.800 | 157.900 |
| | 2021-035 | 90 | ROCHE COBA | | 13 | 145.069 | 10.807 | 7.45 | 108.800 | 181.300 |
| 046 | GENTAMICIN | | | CLIA TEST ID #: 665 | | | | | | |
| | 2021-031 | 50 | VITROS | | 13 | 0.600 | 0.000 | 0.00 | 0.500 | 0.800 |
| | 2021-032 | 50 | VITROS | | 13 | 14.908 | 0.842 | 5.65 | 11.200 | 18.600 |
| | 2021-033 | 50 | VITROS | | 13 | 10.800 | 0.628 | 5.81 | 8.100 | 13.500 |
| | 2021-034 | 50 | VITROS | | 13 | 4.946 | 0.174 | 3.51 | 3.700 | 6.200 |
| | 2021-035 | 50 | VITROS | | 13 | 7.838 | 0.350 | 4.46 | 5.900 | 9.800 |
| 050 | PHENYTOIN | | | CLIA TEST ID #: 695 | | | | | | |
| | 2021-031 | 50 | VITROS | | 16 | 2.110 | 0.837 | 39.68 | 1.600 | 2.600 |
| | 2021-031 | 50 | VITROS | | 16 | 0.500 | 0.000 | 0.00 | 0.400 | 0.600 |

Participant Summary

MONTH 2 OF YEAR 2021

| SPEC: 10 CHEMISTRY | | SUB: 40 TOXICOLOGY | | GRP: 60 TOXICOLOGY | | | | | | | |
|--------------------|--------|--------------------|---------------------|--------------------|--|-----------|--------|----------|--------|------------|-------|
| ANALYTE | | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
| SAMPLE | METHOD | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH | | |
| 2021-031 | 92 | ROCHE COBA | | 10 | 0.800 | 0.000 | 0.00 | 0.600 | 1.000 | | |
| 050 PHENYTOIN | | | CLIA TEST ID #: 695 | | EVALUATION CRITERIA: TARGET VALUE 25 % | | | | | | |
| 2021-032 | 50 | VITROS | | 16 | 31.840 | 0.997 | 3.13 | 23.900 | 39.800 | | |
| 2021-032 | 50 | VITROS | | 16 | 28.313 | 1.824 | 6.44 | 21.200 | 35.400 | | |
| 2021-032 | 92 | ROCHE COBA | | 10 | 27.440 | 1.034 | 3.77 | 20.600 | 34.300 | | |
| 2021-033 | 50 | VITROS | | 16 | 20.227 | 0.753 | 3.72 | 15.200 | 25.300 | | |
| 2021-033 | 50 | VITROS | | 16 | 22.620 | 1.169 | 5.17 | 17.000 | 28.300 | | |
| 2021-033 | 92 | ROCHE COBA | | 10 | 20.120 | 0.761 | 3.78 | 15.100 | 25.200 | | |
| 2021-034 | 50 | VITROS | | 16 | 9.120 | 0.768 | 8.42 | 6.800 | 11.400 | | |
| 2021-034 | 50 | VITROS | | 16 | 9.031 | 0.512 | 5.67 | 6.800 | 11.300 | | |
| 2021-034 | 92 | ROCHE COBA | | 10 | 8.980 | 0.382 | 4.25 | 6.700 | 11.200 | | |
| 2021-035 | 50 | VITROS | | 16 | 14.320 | 0.592 | 4.14 | 10.700 | 17.900 | | |
| 2021-035 | 50 | VITROS | | 16 | 15.260 | 0.763 | 5.00 | 11.400 | 19.100 | | |
| 2021-035 | 92 | ROCHE COBA | | 10 | 14.640 | 0.642 | 4.39 | 11.000 | 18.300 | | |
| 054 THEOPHYLLINE | | | CLIA TEST ID #: 735 | | | | | | | | |
| 2021-031 | 50 | VITROS | | 13 | 2.138 | 0.389 | 18.21 | 1.600 | 2.700 | | |
| 2021-032 | 50 | VITROS | | 13 | 54.331 | 2.080 | 3.83 | 40.700 | 67.900 | | |
| 2021-033 | 50 | VITROS | | 13 | 38.762 | 1.585 | 4.09 | 29.100 | 48.500 | | |
| 2021-034 | 50 | VITROS | | 13 | 20.023 | 0.868 | 4.34 | 15.000 | 25.000 | | |
| 2021-035 | 50 | VITROS | | 13 | 30.462 | 1.292 | 4.24 | 22.800 | 38.100 | | |
| 127 VANCOMYCIN | | | CLIA TEST ID #: 0 | | | | | | | | |
| 2021-031 | 50 | VITROS | | 17 | 5.000 | 0.000 | 0.00 | 3.800 | 6.300 | | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPEC: 10 CHEMISTRY | | SUB: 40 TOXICOLOGY | | GRP: 60 TOXICOLOGY | | | | | | |
|--------------------|----------------------|--------------------|-------------------|--------------------|--|-----------|----------|--------|------------|-------|
| ANALYTE | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
| SAMPLE | METHOD | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH | |
| 127 | VANCOMYCIN | | CLIA TEST ID #: 0 | | EVALUATION CRITERIA: TARGET VALUE 25 % | | | | | |
| 2021-032 | 50 VITROS | | | 17 | 49.141 | 2.696 | 5.49 | 36.900 | 61.400 | |
| 2021-033 | 50 VITROS | | | 17 | 35.071 | 1.034 | 2.95 | 26.300 | 43.800 | |
| 2021-034 | 50 VITROS | | | 17 | 15.576 | 0.454 | 2.92 | 11.700 | 19.500 | |
| 2021-035 | 50 VITROS | | | 17 | 24.865 | 0.642 | 2.58 | 18.600 | 31.100 | |
| <hr/> | | | | | | | | | | |
| SPEC: 10 CHEMISTRY | | SUB: 50 URINALYSIS | | GRP: 70 URINALYSIS | | | | | | |
| ANALYTE | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
| SAMPLE | METHOD | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH | |
| 065 | URINA-PROTEIN QUANT. | | | | EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER} | | | | | |
| 2021-061 | 58 VITROS | | | 40 | 125.425 | 9.630 | 7.68 | 94.100 | 156.800 | |
| 2021-061 | 62 DADE DIM. | | | 44 | 114.584 | 3.381 | 2.95 | 85.900 | 143.200 | |
| 2021-061 | 79 BECK. COUL | | | 13 | 108.477 | 4.355 | 4.02 | 81.400 | 135.600 | |
| 2021-061 | 93 ARCHITECT | | | 19 | 102.847 | 2.852 | 2.77 | 77.100 | 128.600 | |
| 2021-061 | 95 INTEGRA | | | 10 | 91.350 | 5.521 | 6.04 | 68.500 | 114.200 | |
| 2021-061 | 113 ROCHE COBA | | | 28 | 95.289 | 2.490 | 2.61 | 71.500 | 119.100 | |
| 2021-061 | 139 S. EXL.200 | | | 13 | 113.046 | 2.892 | 2.56 | 84.800 | 141.300 | |
| 2021-062 | 58 VITROS | | | 40 | 8.923 | 1.206 | 13.52 | 3.900 | 13.900 | |
| 2021-062 | 62 DADE DIM. | | | 44 | 23.134 | 1.605 | 6.94 | 17.400 | 28.900 | |
| 2021-062 | 79 BECK. COUL | | | 13 | 5.225 | 0.829 | 15.86 | 0.200 | 10.200 | |
| 2021-062 | 93 ARCHITECT | | | 19 | 6.800 | 0.058 | 0.85 | 1.800 | 11.800 | |
| 2021-062 | 95 INTEGRA | | | 10 | 2.450 | 0.510 | 20.83 | 0 | 7.500 | |
| 2021-062 | 113 ROCHE COBA | | | 28 | 3.859 | 0.767 | 19.88 | 0 | 8.900 | |
| 2021-062 | 139 S. EXL.200 | | | 13 | 23.423 | 1.834 | 7.83 | 17.600 | 29.300 | |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

| ANALYTE | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
|----------|----------------------|-------------------|-----------------------------------|--------------|-----------|---------|-----------|-------|------------|---------|
| SAMPLE | METHOD | SYST/INST | REAGENTS | | LABS | VALUE | DEVIATION | CV | LOW | HIGH |
| 065 | URINA-PROTEIN QUANT. | CLIA TEST ID #: 0 | EVALUATION CRITERIA: TARGET VALUE | 25 % OR 5.00 | {GREATER} | | | | | |
| 2021-063 | 58 VITROS | | | | 40 | 150.795 | 8.440 | 5.60 | 113.100 | 188.500 |
| 2021-063 | 62 DADE DIM. | | | | 44 | 119.893 | 2.444 | 2.04 | 89.900 | 149.900 |
| 2021-063 | 79 BECK. COUL | | | | 13 | 105.808 | 6.444 | 6.09 | 79.400 | 132.300 |
| 2021-063 | 93 ARCHITECT | | | | 19 | 103.189 | 2.668 | 2.59 | 77.400 | 129.000 |
| 2021-063 | 95 INTEGRA | | | | 10 | 93.240 | 5.806 | 6.23 | 69.900 | 116.600 |
| 2021-063 | 113 ROCHE COBA | | | | 28 | 96.933 | 2.246 | 2.32 | 72.700 | 121.200 |
| 2021-063 | 139 S. EXL.200 | | | | 13 | 120.223 | 2.138 | 1.78 | 90.200 | 150.300 |
| 2021-064 | 58 VITROS | | | | 40 | 7.231 | 0.478 | 6.62 | 2.200 | 12.200 |
| 2021-064 | 62 DADE DIM. | | | | 44 | 14.832 | 1.335 | 9.00 | 9.800 | 19.800 |
| 2021-064 | 79 BECK. COUL | | | | 13 | 4.754 | 0.712 | 14.98 | 0 | 9.800 |
| 2021-064 | 93 ARCHITECT | | | | 19 | 6.839 | 0.727 | 10.64 | 1.800 | 11.800 |
| 2021-064 | 95 INTEGRA | | | | 10 | 3.390 | 0.435 | 12.82 | 0 | 8.400 |
| 2021-064 | 113 ROCHE COBA | | | | 28 | 3.870 | 0.910 | 23.51 | 0 | 8.900 |
| 2021-064 | 139 S. EXL.200 | | | | 13 | 14.462 | 1.498 | 10.36 | 9.500 | 19.500 |
| 2021-065 | 58 VITROS | | | | 40 | 142.872 | 11.004 | 7.70 | 107.200 | 178.600 |
| 2021-065 | 62 DADE DIM. | | | | 44 | 116.495 | 2.396 | 2.06 | 87.400 | 145.600 |
| 2021-065 | 79 BECK. COUL | | | | 13 | 105.908 | 5.767 | 5.45 | 79.400 | 132.400 |
| 2021-065 | 93 ARCHITECT | | | | 19 | 98.895 | 2.811 | 2.84 | 74.200 | 123.600 |
| 2021-065 | 95 INTEGRA | | | | 10 | 87.830 | 5.594 | 6.37 | 65.900 | 109.800 |
| 2021-065 | 113 ROCHE COBA | | | | 28 | 91.757 | 2.226 | 2.43 | 68.800 | 114.700 |
| 2021-065 | 139 S. EXL.200 | | | | 13 | 116.662 | 2.092 | 1.79 | 87.500 | 145.800 |
| 067 | URI-SPECIFIC GRAVITY | | EVALUATION CRITERIA: TARGET VALUE | 3 SD | | | | | | |
| 2021-061 | 11 AMES NM10S | | | | 50 | 1.024 | 0.003 | 0.30 | 1.015 | 1.033 |
| 2021-061 | 13 BAYER CLI | | | | 35 | 1.024 | 0.002 | 0.22 | 1.017 | 1.030 |
| 2021-061 | 67 URISCAN | | | | 50 | 1.024 | 0.005 | 0.45 | 1.010 | 1.037 |
| 2021-061 | 71 ATLAS | | | | 18 | 1.030 | 0.001 | 0.07 | 1.028 | 1.032 |
| 2021-061 | 72 URS-9-TECO | | | | 107 | 1.022 | 0.003 | 0.29 | 1.013 | 1.031 |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

| ANALYTE | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
|----------|----------------------|------------|-------------------|--|--------|-----------|------|------------|-------|
| SAMPLE | METHOD | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH |
| 2021-061 | 80 | ROCHE (CHE | | 37 | 1.015 | 0.000 | 0.00 | 1.015 | 1.015 |
| 2021-061 | 89 | AIMSTRIP | | 115 | 1.022 | 0.002 | 0.24 | 1.015 | 1.030 |
| 2021-061 | 94 | CLINITEK | | 103 | 1.027 | 0.022 | 2.19 | 0.959 | 1.094 |
| 2021-061 | 102 | ACON LAB | | 162 | 1.022 | 0.003 | 0.25 | 1.014 | 1.030 |
| 2021-061 | 131 | iCHEM VELO | | 26 | 1.025 | 0.001 | 0.08 | 1.022 | 1.027 |
| 2021-061 | 135 | Hybrido AU | | 14 | 1.024 | 0.001 | 0.11 | 1.021 | 1.027 |
| 2021-061 | 138 | URS-10T | | 10 | 1.022 | 0.002 | 0.24 | 1.015 | 1.029 |
| 2021-061 | 140 | MISSION A | | 66 | 1.023 | 0.003 | 0.26 | 1.015 | 1.030 |
| 2021-061 | 145 | CLINITEK | | 10 | 1.030 | 0.002 | 0.17 | 1.025 | 1.035 |
| 2021-061 | 147 | Mission120 | | 23 | 1.023 | 0.002 | 0.23 | 1.016 | 1.030 |
| 2021-061 | 148 | Mission500 | | 21 | 1.021 | 0.002 | 0.22 | 1.015 | 1.028 |
| 067 | URI-SPECIFIC GRAVITY | | CLIA TEST ID #: 0 | EVALUATION CRITERIA: TARGET VALUE 3 SD | | | | | |
| 2021-062 | 11 | AMES NM10S | | 50 | 1.014 | 0.004 | 0.41 | 1.001 | 1.026 |
| 2021-062 | 13 | BAYER CLI | | 35 | 1.015 | 0.003 | 0.32 | 1.005 | 1.024 |
| 2021-062 | 67 | URISCAN | | 50 | 1.012 | 0.006 | 0.57 | 0.995 | 1.030 |
| 2021-062 | 71 | ATLAS | | 18 | 1.030 | 0.000 | 0.05 | 1.029 | 1.032 |
| 2021-062 | 72 | URS-9-TECO | | 107 | 1.013 | 0.003 | 0.31 | 1.003 | 1.022 |
| 2021-062 | 80 | ROCHE (CHE | | 37 | 1.012 | 0.003 | 0.31 | 1.002 | 1.021 |
| 2021-062 | 89 | AIMSTRIP | | 115 | 1.015 | 0.004 | 0.38 | 1.004 | 1.027 |
| 2021-062 | 94 | CLINITEK | | 103 | 1.013 | 0.003 | 0.33 | 1.003 | 1.024 |
| 2021-062 | 102 | ACON LAB | | 162 | 1.017 | 0.004 | 0.40 | 1.004 | 1.029 |
| 2021-062 | 131 | iCHEM VELO | | 26 | 1.026 | 0.001 | 0.07 | 1.024 | 1.028 |
| 2021-062 | 135 | Hybrido AU | | 14 | 1.025 | 0.001 | 0.12 | 1.021 | 1.029 |
| 2021-062 | 138 | URS-10T | | 10 | 1.022 | 0.026 | 2.59 | 0.942 | 1.101 |
| 2021-062 | 140 | MISSION A | | 66 | 1.016 | 0.004 | 0.40 | 1.004 | 1.028 |
| 2021-062 | 145 | CLINITEK | | 10 | 1.031 | 0.001 | 0.10 | 1.028 | 1.034 |
| 2021-062 | 147 | Mission120 | | 23 | 1.018 | 0.002 | 0.24 | 1.011 | 1.025 |
| 2021-062 | 148 | Mission500 | | 21 | 1.020 | 0.000 | 0.00 | 1.020 | 1.020 |
| 2021-063 | 11 | AMES NM10S | | 50 | 1.018 | 0.003 | 0.31 | 1.008 | 1.027 |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

| ANALYTE | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
|----------|----------------------|------------|-------------------|--|--------|-----------|------|------------|-------|
| SAMPLE | METHOD | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH |
| 2021-063 | 13 | BAYER CLI | | 35 | 1.018 | 0.003 | 0.27 | 1.009 | 1.026 |
| 2021-063 | 67 | URISCAN | | 50 | 1.013 | 0.003 | 0.30 | 1.004 | 1.022 |
| 2021-063 | 71 | ATLAS | | 18 | 1.030 | 0.000 | 0.04 | 1.029 | 1.032 |
| 2021-063 | 72 | URS-9-TECO | | 107 | 1.018 | 0.003 | 0.33 | 1.008 | 1.028 |
| 2021-063 | 80 | ROCHE (CHE | | 37 | 1.012 | 0.003 | 0.27 | 1.004 | 1.020 |
| 2021-063 | 89 | AIMSTRIP | | 115 | 1.016 | 0.003 | 0.34 | 1.006 | 1.027 |
| 2021-063 | 94 | CLINITEK | | 103 | 1.018 | 0.003 | 0.25 | 1.010 | 1.026 |
| 2021-063 | 102 | ACON LAB | | 162 | 1.018 | 0.003 | 0.33 | 1.007 | 1.028 |
| 2021-063 | 131 | iCHEM VELO | | 26 | 1.028 | 0.001 | 0.10 | 1.025 | 1.032 |
| 2021-063 | 135 | Hybrido AU | | 14 | 1.029 | 0.001 | 0.12 | 1.025 | 1.032 |
| 2021-063 | 138 | URS-10T | | 10 | 1.018 | 0.003 | 0.25 | 1.010 | 1.025 |
| 2021-063 | 140 | MISSION A | | 66 | 1.017 | 0.003 | 0.33 | 1.007 | 1.028 |
| 2021-063 | 145 | CLINITEK | | 10 | 1.031 | 0.001 | 0.08 | 1.028 | 1.033 |
| 2021-063 | 147 | Mission120 | | 23 | 1.020 | 0.000 | 0.00 | 1.020 | 1.020 |
| 2021-063 | 148 | Mission500 | | 21 | 1.020 | 0.000 | 0.00 | 1.020 | 1.020 |
| 067 | URI-SPECIFIC GRAVITY | | CLIA TEST ID #: 0 | EVALUATION CRITERIA: TARGET VALUE 3 SD | | | | | |
| 2021-064 | 11 | AMES NM10S | | 50 | 1.023 | 0.003 | 0.30 | 1.014 | 1.032 |
| 2021-064 | 13 | BAYER CLI | | 35 | 1.021 | 0.004 | 0.43 | 1.008 | 1.035 |
| 2021-064 | 67 | URISCAN | | 50 | 1.022 | 0.004 | 0.35 | 1.012 | 1.033 |
| 2021-064 | 71 | ATLAS | | 18 | 1.031 | 0.002 | 0.22 | 1.024 | 1.038 |
| 2021-064 | 72 | URS-9-TECO | | 107 | 1.019 | 0.004 | 0.44 | 1.006 | 1.033 |
| 2021-064 | 80 | ROCHE (CHE | | 37 | 1.016 | 0.002 | 0.21 | 1.010 | 1.023 |
| 2021-064 | 89 | AIMSTRIP | | 115 | 1.021 | 0.003 | 0.33 | 1.011 | 1.032 |
| 2021-064 | 94 | CLINITEK | | 103 | 1.023 | 0.004 | 0.35 | 1.012 | 1.034 |
| 2021-064 | 102 | ACON LAB | | 162 | 1.022 | 0.003 | 0.29 | 1.013 | 1.031 |
| 2021-064 | 131 | iCHEM VELO | | 26 | 1.027 | 0.001 | 0.10 | 1.024 | 1.031 |
| 2021-064 | 135 | Hybrido AU | | 14 | 1.027 | 0.001 | 0.11 | 1.024 | 1.030 |
| 2021-064 | 138 | URS-10T | | 10 | 1.018 | 0.005 | 0.45 | 1.004 | 1.031 |
| 2021-064 | 140 | MISSION A | | 66 | 1.022 | 0.002 | 0.23 | 1.015 | 1.029 |
| 2021-064 | 145 | CLINITEK | | 10 | 1.033 | 0.001 | 0.11 | 1.030 | 1.037 |
| 2021-064 | 147 | Mission120 | | 23 | 1.021 | 0.002 | 0.20 | 1.015 | 1.027 |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

| ANALYTE | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
|----------|----------------------|-------------------|--|---------|-----------|-------|------------|----------|
| SAMPLE | METHOD | SYST/INST | LABS | VALUE | DEVIATION | CV | LOW | HIGH |
| 2021-064 | 148 Mission500 | | 21 | 1.023 | 0.002 | 0.24 | 1.016 | 1.030 |
| 067 | URI-SPECIFIC GRAVITY | CLIA TEST ID #: 0 | EVALUATION CRITERIA: TARGET VALUE 3 SD | | | | | |
| 2021-065 | 11 AMES NM10S | | 50 | 1.021 | 0.004 | 0.36 | 1.010 | 1.032 |
| 2021-065 | 13 BAYER CLI | | 35 | 1.020 | 0.002 | 0.17 | 1.015 | 1.025 |
| 2021-065 | 67 URISCAN | | 50 | 1.017 | 0.003 | 0.30 | 1.008 | 1.026 |
| 2021-065 | 71 ATLAS | | 18 | 1.027 | 0.002 | 0.22 | 1.020 | 1.033 |
| 2021-065 | 72 URS-9-TECO | | 107 | 1.020 | 0.003 | 0.29 | 1.011 | 1.028 |
| 2021-065 | 80 ROCHE (CHE | | 37 | 1.011 | 0.002 | 0.20 | 1.005 | 1.017 |
| 2021-065 | 89 AIMSTRIP | | 115 | 1.018 | 0.003 | 0.31 | 1.009 | 1.028 |
| 2021-065 | 94 CLINITEK | | 103 | 1.020 | 0.002 | 0.22 | 1.014 | 1.027 |
| 2021-065 | 102 ACON LAB | | 162 | 1.019 | 0.002 | 0.24 | 1.012 | 1.026 |
| 2021-065 | 131 iCHEM VELO | | 26 | 1.026 | 0.001 | 0.09 | 1.023 | 1.029 |
| 2021-065 | 135 Hybrido AU | | 14 | 1.025 | 0.001 | 0.13 | 1.021 | 1.029 |
| 2021-065 | 138 URS-10T | | 10 | 1.020 | 0.002 | 0.15 | 1.015 | 1.024 |
| 2021-065 | 140 MISSION A | | 66 | 1.018 | 0.002 | 0.25 | 1.011 | 1.026 |
| 2021-065 | 145 CLINITEK | | 10 | 1.027 | 0.001 | 0.09 | 1.024 | 1.030 |
| 2021-065 | 147 Mission120 | | 23 | 1.021 | 0.002 | 0.16 | 1.016 | 1.026 |
| 2021-065 | 148 Mission500 | | 21 | 1.020 | 0.000 | 0.00 | 1.020 | 1.020 |
| 166 | MICROALBUMIN | | EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER} | | | | | |
| 2021-061 | 58 VITROS | | 39 | 914.659 | 34.943 | 3.82 | 686.000 | 1143.300 |
| 2021-061 | 62 DADE DIM. | | 59 | 876.517 | 46.805 | 5.34 | 657.400 | 1095.600 |
| 2021-061 | 79 BECK. COUL | | 18 | 859.928 | 69.513 | 8.08 | 644.900 | 1074.900 |
| 2021-061 | 85 Rx DAYTONA | | 19 | 824.600 | 70.349 | 8.53 | 618.500 | 1030.800 |
| 2021-061 | 93 ARCHITECT | | 22 | 888.386 | 31.660 | 3.56 | 666.300 | 1110.500 |
| 2021-061 | 95 INTEGRA | | 23 | 895.935 | 32.957 | 3.68 | 672.000 | 1119.900 |
| 2021-061 | 113 ROCHE COBA | | 27 | 843.377 | 52.038 | 6.17 | 632.500 | 1054.200 |
| 2021-061 | 139 S. EXL.200 | | 22 | 900.314 | 78.560 | 8.73 | 675.200 | 1125.400 |
| 2021-062 | 58 VITROS | | 39 | 6.024 | 0.161 | 2.68 | 1.000 | 11.000 |
| 2021-062 | 62 DADE DIM. | | 59 | 2.375 | 1.064 | 44.78 | 0 | 7.400 |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

| ANALYTE | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
|----------|--------------|-------------------|--|----------|---------|-----------|--------|------------|----------|
| SAMPLE | METHOD | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH |
| 2021-062 | 79 | BECK. COUL | | 18 | 2.706 | 2.851 | 105.37 | 0 | 7.700 |
| 2021-062 | 85 | Rx DAYTONA | | 19 | 1.668 | 2.157 | 129.26 | 0 | 6.700 |
| 2021-062 | 93 | ARCHITECT | | 22 | 4.990 | 0.029 | 0.59 | 0.000 | 10.000 |
| 2021-062 | 95 | INTEGRA | | 23 | 2.695 | 0.938 | 34.81 | 0 | 7.700 |
| 2021-062 | 113 | ROCHE COBA | | 27 | 10.731 | 3.547 | 33.05 | 5.700 | 15.700 |
| 2021-062 | 139 | S. EXL.200 | | 22 | 2.668 | 1.160 | 43.49 | 0 | 7.700 |
| 166 | MICROALBUMIN | CLIA TEST ID #: 0 | EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER} | | | | | | |
| 2021-063 | 58 | VITROS | | 39 | 885.014 | 30.642 | 3.46 | 663.800 | 1106.300 |
| 2021-063 | 62 | DADE DIM. | | 59 | 881.373 | 55.639 | 6.31 | 661.000 | 1101.700 |
| 2021-063 | 79 | BECK. COUL | | 18 | 827.833 | 66.549 | 8.04 | 620.900 | 1034.800 |
| 2021-063 | 85 | Rx DAYTONA | | 19 | 834.400 | 88.879 | 10.65 | 625.800 | 1043.000 |
| 2021-063 | 93 | ARCHITECT | | 22 | 857.514 | 32.217 | 3.76 | 643.100 | 1071.900 |
| 2021-063 | 95 | INTEGRA | | 23 | 876.157 | 34.137 | 3.90 | 657.100 | 1095.200 |
| 2021-063 | 113 | ROCHE COBA | | 27 | 837.915 | 47.254 | 5.64 | 628.400 | 1047.400 |
| 2021-063 | 139 | S. EXL.200 | | 22 | 885.550 | 83.278 | 9.40 | 664.200 | 1106.900 |
| 2021-064 | 58 | VITROS | | 39 | 6.024 | 0.161 | 2.68 | 1.000 | 11.000 |
| 2021-064 | 62 | DADE DIM. | | 59 | 3.529 | 1.240 | 35.13 | 0 | 8.500 |
| 2021-064 | 79 | BECK. COUL | | 18 | 2.889 | 3.608 | 124.89 | 0 | 7.900 |
| 2021-064 | 85 | Rx DAYTONA | | 19 | 1.679 | 2.159 | 128.61 | 0 | 6.700 |
| 2021-064 | 93 | ARCHITECT | | 22 | 4.895 | 0.425 | 8.68 | 0 | 9.900 |
| 2021-064 | 95 | INTEGRA | | 23 | 2.555 | 1.215 | 47.56 | 0 | 7.600 |
| 2021-064 | 113 | ROCHE COBA | | 27 | 11.640 | 1.764 | 15.15 | 6.600 | 16.600 |
| 2021-064 | 139 | S. EXL.200 | | 22 | 3.982 | 1.244 | 31.25 | 0 | 9.000 |
| 2021-065 | 58 | VITROS | | 39 | 879.603 | 36.006 | 4.09 | 659.700 | 1099.500 |
| 2021-065 | 62 | DADE DIM. | | 59 | 865.924 | 42.526 | 4.91 | 649.400 | 1082.400 |
| 2021-065 | 79 | BECK. COUL | | 18 | 822.328 | 63.061 | 7.67 | 616.700 | 1027.900 |
| 2021-065 | 85 | Rx DAYTONA | | 19 | 800.274 | 73.875 | 9.23 | 600.200 | 1000.300 |
| 2021-065 | 93 | ARCHITECT | | 22 | 854.705 | 24.156 | 2.83 | 641.000 | 1068.400 |

Participant Summary

MONTH 2 OF YEAR 2021

| SPEC: 10 CHEMISTRY | | SUB: 50 URINALYSIS | | GRP: 70 URINALYSIS | | | | | | |
|--------------------|--------|--------------------|-------------------|--------------------|--|-----------|--------|------------|----------|--|
| ANALYTE | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE | |
| SAMPLE | METHOD | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH | |
| 2021-065 | 95 | INTEGRA | | 23 | 863.809 | 30.501 | 3.53 | 647.900 | 1079.800 | |
| 2021-065 | 113 | ROCHE COBA | | 27 | 822.619 | 47.066 | 5.72 | 617.000 | 1028.300 | |
| 2021-065 | 139 | S. EXL.200 | | 22 | 860.067 | 59.897 | 6.96 | 645.100 | 1075.100 | |
| 167 CREATININE | | | CLIA TEST ID #: 0 | | EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER} | | | | | |
| 2021-061 | 58 | VITROS | | 47 | 3.154 | 0.515 | 16.32 | 0 | 8.200 | |
| 2021-061 | 62 | DADE DIM. | | 51 | 9.322 | 5.389 | 57.81 | 4.300 | 14.300 | |
| 2021-061 | 79 | BECK. COUL | | 16 | 1.600 | 3.195 | 199.71 | 0 | 6.600 | |
| 2021-061 | 85 | Rx DAYTONA | | 11 | 0.891 | 1.529 | 171.60 | 0 | 5.900 | |
| 2021-061 | 93 | ARCHITECT | | 21 | 4.940 | 0.218 | 4.41 | 0 | 9.900 | |
| 2021-061 | 95 | INTEGRA | | 19 | 0.247 | 0.274 | 110.80 | 0 | 5.200 | |
| 2021-061 | 113 | ROCHE COBA | | 30 | 3.866 | 0.772 | 19.97 | 0 | 8.900 | |
| 2021-061 | 139 | S. EXL.200 | | 23 | 8.174 | 6.096 | 74.58 | 3.200 | 13.200 | |
| 2021-062 | 58 | VITROS | | 47 | 239.249 | 13.654 | 5.71 | 179.400 | 299.100 | |
| 2021-062 | 62 | DADE DIM. | | 51 | 235.838 | 9.989 | 4.24 | 176.900 | 294.800 | |
| 2021-062 | 79 | BECK. COUL | | 16 | 225.494 | 15.552 | 6.90 | 169.100 | 281.900 | |
| 2021-062 | 85 | Rx DAYTONA | | 11 | 225.891 | 12.731 | 5.64 | 169.400 | 282.400 | |
| 2021-062 | 93 | ARCHITECT | | 21 | 233.890 | 5.847 | 2.50 | 175.400 | 292.400 | |
| 2021-062 | 95 | INTEGRA | | 19 | 249.763 | 11.891 | 4.76 | 187.300 | 312.200 | |
| 2021-062 | 113 | ROCHE COBA | | 30 | 246.193 | 6.864 | 2.79 | 184.600 | 307.700 | |
| 2021-062 | 139 | S. EXL.200 | | 23 | 239.986 | 8.743 | 3.64 | 180.000 | 300.000 | |
| 2021-063 | 58 | VITROS | | 47 | 231.653 | 8.606 | 3.71 | 173.700 | 289.600 | |
| 2021-063 | 62 | DADE DIM. | | 51 | 229.250 | 9.092 | 3.97 | 171.900 | 286.600 | |
| 2021-063 | 79 | BECK. COUL | | 16 | 210.238 | 15.220 | 7.24 | 157.700 | 262.800 | |
| 2021-063 | 85 | Rx DAYTONA | | 11 | 220.055 | 16.976 | 7.71 | 165.000 | 275.100 | |
| 2021-063 | 93 | ARCHITECT | | 21 | 228.543 | 5.262 | 2.30 | 171.400 | 285.700 | |
| 2021-063 | 95 | INTEGRA | | 19 | 242.521 | 10.599 | 4.37 | 181.900 | 303.200 | |
| 2021-063 | 113 | ROCHE COBA | | 30 | 239.621 | 5.213 | 2.18 | 179.700 | 299.500 | |
| 2021-063 | 139 | S. EXL.200 | | 23 | 234.683 | 8.782 | 3.74 | 176.000 | 293.400 | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPEC: 10 CHEMISTRY | | SUB: 50 URINALYSIS | | GRP: 70 URINALYSIS | | | | | |
|--------------------|------------|--------------------|-----------------------------------|--------------------|-----------|-----------|--------|------------|---------|
| ANALYTE | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
| SAMPLE | METHOD | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH |
| 167 | CREATININE | CLIA TEST ID #: 0 | EVALUATION CRITERIA: TARGET VALUE | 25 | % OR 5.00 | {GREATER} | | | |
| 2021-064 | 58 | VITROS | | 47 | 3.237 | 0.218 | 6.74 | 0 | 8.200 |
| 2021-064 | 62 | DADE DIM. | | 51 | 9.304 | 5.411 | 58.16 | 4.300 | 14.300 |
| 2021-064 | 79 | BECK. COUL | | 16 | 1.563 | 3.213 | 205.66 | 0 | 6.600 |
| 2021-064 | 85 | Rx DAYTONA | | 11 | 0.682 | 1.233 | 180.80 | 0 | 5.700 |
| 2021-064 | 93 | ARCHITECT | | 21 | 4.940 | 0.218 | 4.41 | 0 | 9.900 |
| 2021-064 | 95 | INTEGRA | | 19 | 0.033 | 0.082 | 244.95 | 0 | 5.000 |
| 2021-064 | 113 | ROCHE COBA | | 30 | 3.982 | 0.487 | 12.23 | 0 | 9.000 |
| 2021-064 | 139 | S. EXL.200 | | 23 | 8.174 | 6.096 | 74.58 | 3.200 | 13.200 |
| 2021-065 | 58 | VITROS | | 47 | 226.937 | 7.276 | 3.21 | 170.200 | 283.700 |
| 2021-065 | 62 | DADE DIM. | | 51 | 233.206 | 10.944 | 4.69 | 174.900 | 291.500 |
| 2021-065 | 79 | BECK. COUL | | 16 | 222.238 | 15.295 | 6.88 | 166.700 | 277.800 |
| 2021-065 | 85 | Rx DAYTONA | | 11 | 224.864 | 19.481 | 8.66 | 168.600 | 281.100 |
| 2021-065 | 93 | ARCHITECT | | 21 | 230.795 | 5.834 | 2.53 | 173.100 | 288.500 |
| 2021-065 | 95 | INTEGRA | | 19 | 246.058 | 11.007 | 4.47 | 184.500 | 307.600 |
| 2021-065 | 113 | ROCHE COBA | | 30 | 242.353 | 6.958 | 2.87 | 181.800 | 302.900 |
| 2021-065 | 139 | S. EXL.200 | | 23 | 238.826 | 8.806 | 3.69 | 179.100 | 298.500 |

| SPE: 10 CHEMISTRY | | SUB: 50 URINALYSIS | | GRP: 70 URINALYSIS | | | | | | | | |
|--------------------------|-------------|--------------------|-------------|--------------------|----------|----------|----------|----------------|--------|------|-------|-----|
| TEST | LEVEL 1 | LEVEL 2 | LEVEL 3 | PART | REFEREE | COMMER | REPORTED | PART # | LABS # | "SF" | Score | |
| SAMPLE | RESULT CODE | RESULT CODE | RESULT CODE | LOW/HIGH | LOW/HIGH | LOW/HIGH | VALUE | LABS | ANSW | LABS | | |
| 057 URINALYSIS-BILIRUBIN | | | | | | | | | | | | |
| 2021-061 | 011 | AMES NM10S | | 057 | 057 | 057 | 057 | 057 - NEGATIVE | 50 | 50 | 50 | 100 |
| 2021-061 | 013 | BAYER CLI | | 057 | 057 | 057 | 057 | 057 - NEGATIVE | 36 | 36 | 36 | 100 |
| 2021-061 | 067 | URISCAN | | 057 | 057 | 057 | 057 | 057 - NEGATIVE | 49 | 49 | 49 | 100 |
| 2021-061 | 071 | ATLAS | | 057 | 057 | 057 | 057 | 057 - NEGATIVE | 18 | 18 | 18 | 100 |
| 2021-061 | 072 | URS-9-TECO | | 057 | 057 | 057 | 057 | 057 - NEGATIVE | 107 | 107 | 107 | 100 |
| 2021-061 | 080 | ROCHE (CHE | | 057 | 057 | 057 | 057 | 057 - NEGATIVE | 36 | 36 | 36 | 100 |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | |
|--------------------------|------------------------|------------------------|------------------------|--------------------|---------------------|--------------------|-------------------|--------------------|----------------|----------------|-------|-----|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | |
| 2021-061 | 089 | AIMSTRIP | | 057 | 057 | 057 | 057 | 057 - NEGATIVE | 115 | 115 | 115 | 100 |
| 2021-061 | 094 | CLINITEK | | 057 | 057 | 057 | 057 | 057 - NEGATIVE | 103 | 103 | 103 | 100 |
| 2021-061 | 102 | ACON LAB | | 057 | 057 | 057 | 057 | 057 - NEGATIVE | 159 | 159 | 159 | 100 |
| 2021-061 | 131 | iCHEM VELO | | 057 | 057 | 057 | 057 | 057 - NEGATIVE | 25 | 25 | 25 | 100 |
| 2021-061 | 135 | Hybrido AU | | 057 | 057 | 057 | 057 | 057 - NEGATIVE | 14 | 14 | 14 | 100 |
| 2021-061 | 140 | MISSION A | | 057 | 057 | 057 | 057 | 057 - NEGATIVE | 64 | 64 | 64 | 100 |
| 2021-061 | 145 | CLINITEK | | 057 | 057 | 057 | 057 | 057 - NEGATIVE | 10 | 10 | 10 | 100 |
| 2021-061 | 147 | Mission120 | | 057 | 057 | 057 | 057 | 057 - NEGATIVE | 25 | 25 | 25 | 100 |
| 2021-061 | 148 | Mission500 | | 057 | 057 | 057 | 057 | 057 - NEGATIVE | 24 | 24 | 24 | 100 |
| 057 URINALYSIS-BILIRUBIN | | | | | | | | | | | | |
| 2021-062 | 011 | AMES NM10S | | 057 | 057 | 057 | 057 | 057 - NEGATIVE | 50 | 50 | 50 | 100 |
| 2021-062 | 013 | BAYER CLI | | 057 | 057 | 057 | 057 | 057 - NEGATIVE | 36 | 36 | 36 | 100 |
| 2021-062 | 067 | URISCAN | | 057 | 057 | 057 | 057 | 057 - NEGATIVE | 49 | 49 | 49 | 100 |
| 2021-062 | 071 | ATLAS | | 057 | 057 | 057 | 057 | 057 - NEGATIVE | 18 | 18 | 18 | 100 |
| 2021-062 | 072 | URS-9-TECO | | 057 | 057 | 057 | 057 | 057 - NEGATIVE | 107 | 107 | 107 | 100 |
| 2021-062 | 080 | ROCHE (CHE | | 057 | 057 | 057 | 057 | 057 - NEGATIVE | 36 | 36 | 36 | 100 |
| 2021-062 | 089 | AIMSTRIP | | 057 | 057 | 057 | 057 | 057 - NEGATIVE | 115 | 115 | 115 | 100 |
| 2021-062 | 094 | CLINITEK | | 057 | 057 | 057 | 057 | 057 - NEGATIVE | 102 | 102 | 102 | 100 |
| 2021-062 | 102 | ACON LAB | | 057 | 057 | 057 | 057 | 057 - NEGATIVE | 159 | 159 | 159 | 100 |
| 2021-062 | 131 | iCHEM VELO | | 057 | 057 | 057 | 057 | 057 - NEGATIVE | 25 | 25 | 25 | 100 |
| 2021-062 | 135 | Hybrido AU | | 057 | 057 | 057 | 057 | 057 - NEGATIVE | 14 | 14 | 14 | 100 |
| 2021-062 | 140 | MISSION A | | 057 | 057 | 057 | 057 | 057 - NEGATIVE | 64 | 64 | 64 | 100 |
| 2021-062 | 145 | CLINITEK | | 057 | 057 | 057 | 057 | 057 - NEGATIVE | 10 | 10 | 10 | 100 |
| 2021-062 | 147 | Mission120 | | 057 | 057 | 057 | 057 | 057 - NEGATIVE | 25 | 25 | 25 | 100 |
| 2021-062 | 148 | Mission500 | | 057 | 057 | 057 | 057 | 057 - NEGATIVE | 24 | 24 | 24 | 100 |
| 2021-063 | 011 | AMES NM10S | | 058 | 060 | 057 | 059 | 060 - 3+ | 50 | 5 | 50 | 100 |
| 2021-063 | 011 | AMES NM10S | | 058 | 060 | 057 | 059 | 058 - TRACES, 1+ | 50 | 4 | 50 | 100 |
| 2021-063 | 011 | AMES NM10S | | 058 | 060 | 057 | 059 | 059 - 2+ | 50 | 41 | 50 | 100 |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | | | |
|-------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|--------------------|--------------|----------------|----------------|-------|--|--|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | | |
| 2021-063 | 013 | BAYER CLI | | 058 060 | 057 059 | | 060 - 3+ | 36 | 2 | 36 | 100 | | |
| 2021-063 | 013 | BAYER CLI | | 058 060 | 057 059 | | 058 - TRACES, 1+ | 36 | 7 | 36 | 100 | | |
| 2021-063 | 013 | BAYER CLI | | 058 060 | 057 059 | | 059 - 2+ | 36 | 27 | 36 | 100 | | |
| 2021-063 | 067 | URISCAN | | 057 059 | 057 059 | | 059 - 2+ | 49 | 16 | 48 | 100 | | |
| 2021-063 | 067 | URISCAN | | 057 059 | 057 059 | | 058 - TRACES, 1+ | 49 | 31 | 48 | 100 | | |
| 2021-063 | 067 | URISCAN | | 057 059 | 057 059 | | 060 - 3+ | 49 | 1 | 48 | 0 | | |
| 2021-063 | 067 | URISCAN | | 057 059 | 057 059 | | 057 - NEGATIVE | 49 | 1 | 48 | 100 | | |
| 2021-063 | 071 | ATLAS | | 057 059 | 057 059 | | 058 - TRACES, 1+ | 18 | 15 | 18 | 100 | | |
| 2021-063 | 071 | ATLAS | | 057 059 | 057 059 | | 059 - 2+ | 18 | 3 | 18 | 100 | | |
| 2021-063 | 072 | URS-9-TECO | | 058 060 | 057 059 | | 058 - TRACES, 1+ | 107 | 26 | 107 | 100 | | |
| 2021-063 | 072 | URS-9-TECO | | 058 060 | 057 059 | | 059 - 2+ | 107 | 53 | 107 | 100 | | |
| 2021-063 | 072 | URS-9-TECO | | 058 060 | 057 059 | | 057 - NEGATIVE | 107 | 7 | 107 | 100 | | |
| 2021-063 | 072 | URS-9-TECO | | 058 060 | 057 059 | | 060 - 3+ | 107 | 21 | 107 | 100 | | |
| 2021-063 | 080 | ROCHE (CHE | | 057 059 | 057 059 | | 058 - TRACES, 1+ | 36 | 34 | 36 | 100 | | |
| 2021-063 | 080 | ROCHE (CHE | | 057 059 | 057 059 | | 059 - 2+ | 36 | 2 | 36 | 100 | | |
| 2021-063 | 089 | AIMSTRIP | | 058 060 | 057 059 | | 060 - 3+ | 115 | 8 | 115 | 100 | | |
| 2021-063 | 089 | AIMSTRIP | | 058 060 | 057 059 | | 057 - NEGATIVE | 115 | 7 | 115 | 100 | | |
| 2021-063 | 089 | AIMSTRIP | | 058 060 | 057 059 | | 058 - TRACES, 1+ | 115 | 48 | 115 | 100 | | |
| 2021-063 | 089 | AIMSTRIP | | 058 060 | 057 059 | | 059 - 2+ | 115 | 52 | 115 | 100 | | |
| 2021-063 | 094 | CLINITEK | | 058 060 | 057 059 | | 059 - 2+ | 102 | 81 | 102 | 100 | | |
| 2021-063 | 094 | CLINITEK | | 058 060 | 057 059 | | 058 - TRACES, 1+ | 102 | 21 | 102 | 100 | | |
| 2021-063 | 102 | ACON LAB | | 057 059 | 057 059 | | 058 - TRACES, 1+ | 159 | 104 | 156 | 100 | | |
| 2021-063 | 102 | ACON LAB | | 057 059 | 057 059 | | 059 - 2+ | 159 | 38 | 156 | 100 | | |
| 2021-063 | 102 | ACON LAB | | 057 059 | 057 059 | | 060 - 3+ | 159 | 3 | 156 | 0 | | |
| 2021-063 | 102 | ACON LAB | | 057 059 | 057 059 | | 057 - NEGATIVE | 159 | 14 | 156 | 100 | | |
| 2021-063 | 131 | ICHEM VELO | | 057 057 | 057 059 | | 057 - NEGATIVE | 25 | 25 | 25 | 100 | | |
| 2021-063 | 135 | Hybrido AU | | 058 060 | 057 059 | | 059 - 2+ | 14 | 13 | 14 | 100 | | |
| 2021-063 | 135 | Hybrido AU | | 058 060 | 057 059 | | 060 - 3+ | 14 | 1 | 14 | 100 | | |
| 2021-063 | 140 | MISSION A | | 057 059 | 057 059 | | 057 - NEGATIVE | 64 | 5 | 64 | 100 | | |
| 2021-063 | 140 | MISSION A | | 057 059 | 057 059 | | 058 - TRACES, 1+ | 64 | 47 | 64 | 100 | | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | | |
|--------------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|--------------------|--------------|----------------|----------------|-------|--|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | |
| 2021-063 | 140 | MISSION A | | 057 059 | 057 059 | | 059 - 2+ | 64 | 12 | 64 | 100 | |
| 2021-063 | 145 | CLINITEK | | 057 057 | 057 059 | | 057 - NEGATIVE | 10 | 10 | 10 | 100 | |
| 2021-063 | 147 | Mission120 | | 057 059 | 057 059 | | 059 - 2+ | 25 | 5 | 25 | 100 | |
| 2021-063 | 147 | Mission120 | | 057 059 | 057 059 | | 058 - TRACES,1+ | 25 | 16 | 25 | 100 | |
| 2021-063 | 147 | Mission120 | | 057 059 | 057 059 | | 057 - NEGATIVE | 25 | 4 | 25 | 100 | |
| 2021-063 | 148 | Mission500 | | 057 059 | 057 059 | | 059 - 2+ | 24 | 5 | 24 | 100 | |
| 2021-063 | 148 | Mission500 | | 057 059 | 057 059 | | 058 - TRACES,1+ | 24 | 19 | 24 | 100 | |
| 057 URINALYSIS-BILIRUBIN | | | | | | | | | | | | |
| 2021-064 | 011 | AMES NM10S | | 057 057 | 057 057 | | 057 - NEGATIVE | 50 | 50 | 50 | 100 | |
| 2021-064 | 013 | BAYER CLI | | 057 057 | 057 057 | | 057 - NEGATIVE | 36 | 36 | 36 | 100 | |
| 2021-064 | 067 | URISCAN | | 057 057 | 057 057 | | 057 - NEGATIVE | 49 | 49 | 49 | 100 | |
| 2021-064 | 071 | ATLAS | | 057 057 | 057 057 | | 057 - NEGATIVE | 18 | 18 | 18 | 100 | |
| 2021-064 | 072 | URS-9-TECO | | 057 057 | 057 057 | | 057 - NEGATIVE | 107 | 107 | 107 | 100 | |
| 2021-064 | 080 | ROCHE (CHE | | 057 057 | 057 057 | | 057 - NEGATIVE | 36 | 36 | 36 | 100 | |
| 2021-064 | 089 | AIMSTRIP | | 057 057 | 057 057 | | 057 - NEGATIVE | 115 | 115 | 115 | 100 | |
| 2021-064 | 094 | CLINITEK | | 057 057 | 057 057 | | 057 - NEGATIVE | 102 | 102 | 102 | 100 | |
| 2021-064 | 102 | ACON LAB | | 057 057 | 057 057 | | 057 - NEGATIVE | 159 | 159 | 159 | 100 | |
| 2021-064 | 131 | iCHEM VELO | | 057 057 | 057 057 | | 057 - NEGATIVE | 25 | 25 | 25 | 100 | |
| 2021-064 | 135 | Hybrido AU | | 057 057 | 057 057 | | 057 - NEGATIVE | 14 | 14 | 14 | 100 | |
| 2021-064 | 140 | MISSION A | | 057 057 | 057 057 | | 057 - NEGATIVE | 64 | 64 | 64 | 100 | |
| 2021-064 | 145 | CLINITEK | | 057 057 | 057 057 | | 057 - NEGATIVE | 10 | 10 | 10 | 100 | |
| 2021-064 | 147 | Mission120 | | 057 057 | 057 057 | | 057 - NEGATIVE | 25 | 25 | 25 | 100 | |
| 2021-064 | 148 | Mission500 | | 057 057 | 057 057 | | 057 - NEGATIVE | 24 | 24 | 24 | 100 | |
| 2021-065 | 011 | AMES NM10S | | 057 057 | 057 057 | | 057 - NEGATIVE | 50 | 50 | 50 | 100 | |
| 2021-065 | 013 | BAYER CLI | | 057 057 | 057 057 | | 057 - NEGATIVE | 36 | 36 | 36 | 100 | |
| 2021-065 | 067 | URISCAN | | 057 057 | 057 057 | | 057 - NEGATIVE | 49 | 49 | 49 | 100 | |
| 2021-065 | 071 | ATLAS | | 057 057 | 057 057 | | 057 - NEGATIVE | 18 | 18 | 18 | 100 | |
| 2021-065 | 072 | URS-9-TECO | | 057 057 | 057 057 | | 057 - NEGATIVE | 107 | 107 | 107 | 100 | |

Participant Summary

MONTH 2 OF YEAR 2021

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score |
|------------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|-------------------|--------------|----------------|----------------|-------|
| 2021-065 | 080 | ROCHE (CHE | | 057 057 | 057 057 | | 057 - NEGATIVE | 36 | 36 | 36 | 100 |
| 2021-065 | 089 | AIMSTRIP | | 057 057 | 057 057 | | 057 - NEGATIVE | 115 | 115 | 115 | 100 |
| 2021-065 | 094 | CLINITEK | | 057 057 | 057 057 | | 057 - NEGATIVE | 102 | 102 | 102 | 100 |
| 2021-065 | 102 | ACON LAB | | 057 057 | 057 057 | | 057 - NEGATIVE | 159 | 159 | 159 | 100 |
| 2021-065 | 131 | iCHEM VELO | | 057 057 | 057 057 | | 057 - NEGATIVE | 25 | 25 | 25 | 100 |
| 2021-065 | 135 | Hybrido AU | | 057 057 | 057 057 | | 057 - NEGATIVE | 14 | 14 | 14 | 100 |
| 2021-065 | 140 | MISSION A | | 057 057 | 057 057 | | 057 - NEGATIVE | 64 | 64 | 64 | 100 |
| 2021-065 | 145 | CLINITEK | | 057 057 | 057 057 | | 057 - NEGATIVE | 10 | 10 | 10 | 100 |
| 2021-065 | 147 | Mission120 | | 057 057 | 057 057 | | 057 - NEGATIVE | 25 | 25 | 25 | 100 |
| 2021-065 | 148 | Mission500 | | 057 057 | 057 057 | | 057 - NEGATIVE | 24 | 24 | 24 | 100 |
| 058 URINALYSIS-GLUCOSE | | | | | | | | | | | |
| 2021-061 | 011 | AMES NM10S | | 076 078 | 076 078 | | 076 - 500mg/dl2+ | 50 | 14 | 50 | 100 |
| 2021-061 | 011 | AMES NM10S | | 076 078 | 076 078 | | 077 - 1000mg/dl | 50 | 34 | 50 | 100 |
| 2021-061 | 011 | AMES NM10S | | 076 078 | 076 078 | | 078 - 2000mg/dl | 50 | 2 | 50 | 100 |
| 2021-061 | 013 | BAYER CLI | | 076 078 | 076 078 | | 075 - 250mg/dl-+ | 35 | 3 | 32 | 0 |
| 2021-061 | 013 | BAYER CLI | | 076 078 | 076 078 | | 077 - 1000mg/dl | 35 | 19 | 32 | 100 |
| 2021-061 | 013 | BAYER CLI | | 076 078 | 076 078 | | 076 - 500mg/dl2+ | 35 | 13 | 32 | 100 |
| 2021-061 | 067 | URISCAN | | 077 078 | 076 078 | | 078 - 2000mg/dl | 49 | 39 | 49 | 100 |
| 2021-061 | 067 | URISCAN | | 077 078 | 076 078 | | 077 - 1000mg/dl | 49 | 10 | 49 | 100 |
| 2021-061 | 071 | ATLAS | | 076 078 | 076 078 | | 076 - 500mg/dl2+ | 18 | 1 | 18 | 100 |
| 2021-061 | 071 | ATLAS | | 076 078 | 076 078 | | 077 - 1000mg/dl | 18 | 16 | 18 | 100 |
| 2021-061 | 071 | ATLAS | | 076 078 | 076 078 | | 078 - 2000mg/dl | 18 | 1 | 18 | 100 |
| 2021-061 | 072 | URS-9-TECO | | 076 078 | 076 078 | | 077 - 1000mg/dl | 108 | 57 | 107 | 100 |
| 2021-061 | 072 | URS-9-TECO | | 076 078 | 076 078 | | 075 - 250mg/dl-+ | 108 | 1 | 107 | 0 |
| 2021-061 | 072 | URS-9-TECO | | 076 078 | 076 078 | | 078 - 2000mg/dl | 108 | 15 | 107 | 100 |
| 2021-061 | 072 | URS-9-TECO | | 076 078 | 076 078 | | 076 - 500mg/dl2+ | 108 | 35 | 107 | 100 |
| 2021-061 | 080 | ROCHE (CHE | | 076 078 | 076 078 | | 077 - 1000mg/dl | 37 | 35 | 37 | 100 |
| 2021-061 | 080 | ROCHE (CHE | | 076 078 | 076 078 | | 078 - 2000mg/dl | 37 | 2 | 37 | 100 |
| 2021-061 | 089 | AIMSTRIP | | 075 077 | 076 078 | | 077 - 1000mg/dl | 115 | 39 | 115 | 100 |
| 2021-061 | 089 | AIMSTRIP | | 075 077 | 076 078 | | 078 - 2000mg/dl | 115 | 3 | 115 | 100 |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | | | | |
|------------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|-------------------|--------------|----------------|----------------|-------|--|--|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | | |
| 2021-061 | 089 | AIMSTRIP | | 075 077 | 076 078 | | 075 - 250mg/dl-+ | 115 | 2 | 115 | 100 | | |
| 2021-061 | 089 | AIMSTRIP | | 075 077 | 076 078 | | 076 - 500mg/dl2+ | 115 | 71 | 115 | 100 | | |
| 2021-061 | 094 | CLINITEK | | 076 078 | 076 078 | | 075 - 250mg/dl-+ | 102 | 1 | 101 | 0 | | |
| 2021-061 | 094 | CLINITEK | | 076 078 | 076 078 | | 078 - 2000mg/dl | 102 | 1 | 101 | 100 | | |
| 2021-061 | 094 | CLINITEK | | 076 078 | 076 078 | | 076 - 500mg/dl2+ | 102 | 31 | 101 | 100 | | |
| 2021-061 | 094 | CLINITEK | | 076 078 | 076 078 | | 077 - 1000mg/dl | 102 | 69 | 101 | 100 | | |
| 2021-061 | 102 | ACON LAB | | 075 077 | 076 078 | | 077 - 1000mg/dl | 161 | 59 | 161 | 100 | | |
| 2021-061 | 102 | ACON LAB | | 075 077 | 076 078 | | 076 - 500mg/dl2+ | 161 | 102 | 161 | 100 | | |
| 2021-061 | 131 | iCHEM VELO | | 075 077 | 076 078 | | 076 - 500mg/dl2+ | 26 | 24 | 26 | 100 | | |
| 2021-061 | 131 | iCHEM VELO | | 075 077 | 076 078 | | 077 - 1000mg/dl | 26 | 2 | 26 | 100 | | |
| 2021-061 | 135 | Hybrido AU | | 077 078 | 076 078 | | 077 - 1000mg/dl | 14 | 6 | 14 | 100 | | |
| 2021-061 | 135 | Hybrido AU | | 077 078 | 076 078 | | 078 - 2000mg/dl | 14 | 8 | 14 | 100 | | |
| 2021-061 | 138 | URS-10T | | 076 078 | 076 078 | | 076 - 500mg/dl2+ | 10 | 2 | 9 | 100 | | |
| 2021-061 | 138 | URS-10T | | 076 078 | 076 078 | | 077 - 1000mg/dl | 10 | 7 | 9 | 100 | | |
| 2021-061 | 138 | URS-10T | | 076 078 | 076 078 | | 074 - TRACES | 10 | 1 | 9 | 0 | | |
| 2021-061 | 140 | MISSION A | | 076 078 | 076 078 | | 073 - NEGATIVE | 64 | 1 | 63 | 0 | | |
| 2021-061 | 140 | MISSION A | | 076 078 | 076 078 | | 076 - 500mg/dl2+ | 64 | 17 | 63 | 100 | | |
| 2021-061 | 140 | MISSION A | | 076 078 | 076 078 | | 078 - 2000mg/dl | 64 | 6 | 63 | 100 | | |
| 2021-061 | 140 | MISSION A | | 076 078 | 076 078 | | 077 - 1000mg/dl | 64 | 40 | 63 | 100 | | |
| 2021-061 | 145 | CLINITEK | | 076 078 | 076 078 | | 077 - 1000mg/dl | 10 | 9 | 10 | 100 | | |
| 2021-061 | 145 | CLINITEK | | 076 078 | 076 078 | | 078 - 2000mg/dl | 10 | 1 | 10 | 100 | | |
| 2021-061 | 147 | Mission120 | | 076 078 | 076 078 | | 078 - 2000mg/dl | 23 | 1 | 23 | 100 | | |
| 2021-061 | 147 | Mission120 | | 076 078 | 076 078 | | 077 - 1000mg/dl | 23 | 19 | 23 | 100 | | |
| 2021-061 | 147 | Mission120 | | 076 078 | 076 078 | | 076 - 500mg/dl2+ | 23 | 3 | 23 | 100 | | |
| 2021-061 | 148 | Mission500 | | 076 078 | 076 078 | | 077 - 1000mg/dl | 25 | 14 | 25 | 100 | | |
| 2021-061 | 148 | Mission500 | | 076 078 | 076 078 | | 076 - 500mg/dl2+ | 25 | 11 | 25 | 100 | | |
| 058 URINALYSIS-GLUCOSE | | | | | | | | | | | | | |
| 2021-062 | 011 | AMES NM10S | | 076 078 | 076 078 | | 076 - 500mg/dl2+ | 50 | 16 | 50 | 100 | | |
| 2021-062 | 011 | AMES NM10S | | 076 078 | 076 078 | | 077 - 1000mg/dl | 50 | 32 | 50 | 100 | | |
| 2021-062 | 011 | AMES NM10S | | 076 078 | 076 078 | | 078 - 2000mg/dl | 50 | 2 | 50 | 100 | | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | | | |
|-------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|--------------------|--------------|----------------|----------------|-------|--|--|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | | |
| 2021-062 | 013 | BAYER CLI | | 076 078 | 076 078 | | 076 - 500mg/dl2+ | 35 | 15 | 35 | 100 | | |
| 2021-062 | 013 | BAYER CLI | | 076 078 | 076 078 | | 077 - 1000mg/dl | 35 | 20 | 35 | 100 | | |
| 2021-062 | 067 | URISCAN | | 077 078 | 076 078 | | 078 - 2000mg/dl | 49 | 34 | 49 | 100 | | |
| 2021-062 | 067 | URISCAN | | 077 078 | 076 078 | | 077 - 1000mg/dl | 49 | 13 | 49 | 100 | | |
| 2021-062 | 067 | URISCAN | | 077 078 | 076 078 | | 076 - 500mg/dl2+ | 49 | 2 | 49 | 100 | | |
| 2021-062 | 071 | ATLAS | | 075 077 | 076 078 | | 076 - 500mg/dl2+ | 18 | 16 | 18 | 100 | | |
| 2021-062 | 071 | ATLAS | | 075 077 | 076 078 | | 077 - 1000mg/dl | 18 | 2 | 18 | 100 | | |
| 2021-062 | 072 | URS-9-TECO | | 076 078 | 076 078 | | 078 - 2000mg/dl | 108 | 14 | 102 | 100 | | |
| 2021-062 | 072 | URS-9-TECO | | 076 078 | 076 078 | | 075 - 250mg/dl-+ | 108 | 6 | 102 | 0 | | |
| 2021-062 | 072 | URS-9-TECO | | 076 078 | 076 078 | | 076 - 500mg/dl2+ | 108 | 32 | 102 | 100 | | |
| 2021-062 | 072 | URS-9-TECO | | 076 078 | 076 078 | | 077 - 1000mg/dl | 108 | 56 | 102 | 100 | | |
| 2021-062 | 080 | ROCHE (CHE | | 076 078 | 076 078 | | 076 - 500mg/dl2+ | 37 | 1 | 33 | 100 | | |
| 2021-062 | 080 | ROCHE (CHE | | 076 078 | 076 078 | | 077 - 1000mg/dl | 37 | 31 | 33 | 100 | | |
| 2021-062 | 080 | ROCHE (CHE | | 076 078 | 076 078 | | 078 - 2000mg/dl | 37 | 1 | 33 | 100 | | |
| 2021-062 | 080 | ROCHE (CHE | | 076 078 | 076 078 | | 075 - 250mg/dl-+ | 37 | 4 | 33 | 0 | | |
| 2021-062 | 089 | AIMSTRIP | | 075 077 | 076 078 | | 077 - 1000mg/dl | 115 | 47 | 115 | 100 | | |
| 2021-062 | 089 | AIMSTRIP | | 075 077 | 076 078 | | 075 - 250mg/dl-+ | 115 | 2 | 115 | 100 | | |
| 2021-062 | 089 | AIMSTRIP | | 075 077 | 076 078 | | 078 - 2000mg/dl | 115 | 2 | 115 | 100 | | |
| 2021-062 | 089 | AIMSTRIP | | 075 077 | 076 078 | | 076 - 500mg/dl2+ | 115 | 64 | 115 | 100 | | |
| 2021-062 | 094 | CLINITEK | | 076 078 | 076 078 | | 078 - 2000mg/dl | 102 | 1 | 102 | 100 | | |
| 2021-062 | 094 | CLINITEK | | 076 078 | 076 078 | | 076 - 500mg/dl2+ | 102 | 35 | 102 | 100 | | |
| 2021-062 | 094 | CLINITEK | | 076 078 | 076 078 | | 077 - 1000mg/dl | 102 | 66 | 102 | 100 | | |
| 2021-062 | 102 | ACON LAB | | 075 077 | 076 078 | | 075 - 250mg/dl-+ | 161 | 3 | 161 | 100 | | |
| 2021-062 | 102 | ACON LAB | | 075 077 | 076 078 | | 078 - 2000mg/dl | 161 | 2 | 161 | 100 | | |
| 2021-062 | 102 | ACON LAB | | 075 077 | 076 078 | | 077 - 1000mg/dl | 161 | 75 | 161 | 100 | | |
| 2021-062 | 102 | ACON LAB | | 075 077 | 076 078 | | 076 - 500mg/dl2+ | 161 | 81 | 161 | 100 | | |
| 2021-062 | 131 | iCHEM VELO | | 075 077 | 076 078 | | 077 - 1000mg/dl | 26 | 2 | 26 | 100 | | |
| 2021-062 | 131 | iCHEM VELO | | 075 077 | 076 078 | | 076 - 500mg/dl2+ | 26 | 24 | 26 | 100 | | |
| 2021-062 | 135 | Hybrido AU | | 076 078 | 076 078 | | 077 - 1000mg/dl | 14 | 9 | 14 | 100 | | |
| 2021-062 | 135 | Hybrido AU | | 076 078 | 076 078 | | 078 - 2000mg/dl | 14 | 5 | 14 | 100 | | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | | |
|------------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|--------------------|--------------|----------------|----------------|-------|--|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | |
| 2021-062 | 138 | URS-10T | | 076 078 | 076 078 | | 076 - 500mg/dl2+ | 10 | 3 | 10 | 100 | |
| 2021-062 | 138 | URS-10T | | 076 078 | 076 078 | | 078 - 2000mg/dl | 10 | 1 | 10 | 100 | |
| 2021-062 | 138 | URS-10T | | 076 078 | 076 078 | | 077 - 1000mg/dl | 10 | 6 | 10 | 100 | |
| 2021-062 | 140 | MISSION A | | 076 078 | 076 078 | | 076 - 500mg/dl2+ | 64 | 15 | 63 | 100 | |
| 2021-062 | 140 | MISSION A | | 076 078 | 076 078 | | 075 - 250mg/dl-+ | 64 | 1 | 63 | 0 | |
| 2021-062 | 140 | MISSION A | | 076 078 | 076 078 | | 078 - 2000mg/dl | 64 | 10 | 63 | 100 | |
| 2021-062 | 140 | MISSION A | | 076 078 | 076 078 | | 077 - 1000mg/dl | 64 | 38 | 63 | 100 | |
| 2021-062 | 145 | CLINITEK | | 075 077 | 076 078 | | 076 - 500mg/dl2+ | 10 | 7 | 10 | 100 | |
| 2021-062 | 145 | CLINITEK | | 075 077 | 076 078 | | 077 - 1000mg/dl | 10 | 3 | 10 | 100 | |
| 2021-062 | 147 | Mission120 | | 076 078 | 076 078 | | 078 - 2000mg/dl | 23 | 6 | 23 | 100 | |
| 2021-062 | 147 | Mission120 | | 076 078 | 076 078 | | 077 - 1000mg/dl | 23 | 15 | 23 | 100 | |
| 2021-062 | 147 | Mission120 | | 076 078 | 076 078 | | 076 - 500mg/dl2+ | 23 | 2 | 23 | 100 | |
| 2021-062 | 148 | Mission500 | | 076 078 | 076 078 | | 076 - 500mg/dl2+ | 25 | 6 | 25 | 100 | |
| 2021-062 | 148 | Mission500 | | 076 078 | 076 078 | | 077 - 1000mg/dl | 25 | 19 | 25 | 100 | |
| 058 URINALYSIS-GLUCOSE | | | | | | | | | | | | |
| 2021-063 | 011 | AMES NM10S | | 073 073 | 073 073 | | 073 - NEGATIVE | 50 | 50 | 50 | 100 | |
| 2021-063 | 013 | BAYER CLI | | 073 073 | 073 073 | | 073 - NEGATIVE | 35 | 35 | 35 | 100 | |
| 2021-063 | 067 | URISCAN | | 073 073 | 073 073 | | 073 - NEGATIVE | 49 | 49 | 49 | 100 | |
| 2021-063 | 071 | ATLAS | | 073 073 | 073 073 | | 073 - NEGATIVE | 18 | 18 | 18 | 100 | |
| 2021-063 | 072 | URS-9-TECO | | 073 073 | 073 073 | | 073 - NEGATIVE | 108 | 108 | 108 | 100 | |
| 2021-063 | 080 | ROCHE (CHE | | 073 073 | 073 073 | | 073 - NEGATIVE | 37 | 37 | 37 | 100 | |
| 2021-063 | 089 | AIMSTRIP | | 073 073 | 073 073 | | 075 - 250mg/dl-+ | 115 | 1 | 114 | 0 | |
| 2021-063 | 089 | AIMSTRIP | | 073 073 | 073 073 | | 073 - NEGATIVE | 115 | 114 | 114 | 100 | |
| 2021-063 | 094 | CLINITEK | | 073 073 | 073 073 | | 073 - NEGATIVE | 102 | 102 | 102 | 100 | |
| 2021-063 | 102 | ACON LAB | | 073 073 | 073 073 | | 073 - NEGATIVE | 161 | 161 | 161 | 100 | |
| 2021-063 | 131 | iCHEM VELO | | 073 073 | 073 073 | | 073 - NEGATIVE | 26 | 26 | 26 | 100 | |
| 2021-063 | 135 | Hybrido AU | | 073 073 | 073 073 | | 073 - NEGATIVE | 14 | 14 | 14 | 100 | |
| 2021-063 | 138 | URS-10T | | 073 073 | 073 073 | | 078 - 2000mg/dl | 10 | 1 | 9 | 0 | |
| 2021-063 | 138 | URS-10T | | 073 073 | 073 073 | | 073 - NEGATIVE | 10 | 9 | 9 | 100 | |
| 2021-063 | 140 | MISSION A | | 073 073 | 073 073 | | 073 - NEGATIVE | 64 | 64 | 64 | 100 | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | | | |
|------------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|-------------------|--------------|----------------|----------------|-------|--|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | |
| 2021-063 | 145 | CLINITEK | | 073 073 | 073 073 | | 073 - NEGATIVE | 10 | 10 | 10 | 100 | |
| 2021-063 | 147 | Mission120 | | 073 073 | 073 073 | | 073 - NEGATIVE | 23 | 23 | 23 | 100 | |
| 2021-063 | 148 | Mission500 | | 073 073 | 073 073 | | 073 - NEGATIVE | 25 | 25 | 25 | 100 | |
| 058 URINALYSIS-GLUCOSE | | | | | | | | | | | | |
| 2021-064 | 011 | AMES NM10S | | 073 075 | 074 076 | | 075 - 250mg/dl-+ | 50 | 18 | 50 | 100 | |
| 2021-064 | 011 | AMES NM10S | | 073 075 | 074 076 | | 076 - 500mg/dl2+ | 50 | 1 | 50 | 100 | |
| 2021-064 | 011 | AMES NM10S | | 073 075 | 074 076 | | 073 - NEGATIVE | 50 | 2 | 50 | 100 | |
| 2021-064 | 011 | AMES NM10S | | 073 075 | 074 076 | | 074 - TRACES | 50 | 29 | 50 | 100 | |
| 2021-064 | 013 | BAYER CLI | | 073 075 | 074 076 | | 075 - 250mg/dl-+ | 35 | 14 | 35 | 100 | |
| 2021-064 | 013 | BAYER CLI | | 073 075 | 074 076 | | 073 - NEGATIVE | 35 | 1 | 35 | 100 | |
| 2021-064 | 013 | BAYER CLI | | 073 075 | 074 076 | | 074 - TRACES | 35 | 20 | 35 | 100 | |
| 2021-064 | 067 | URISCAN | | | 074 076 | | 076 - 500mg/dl2+ | 49 | 15 | 39 | 100 | |
| 2021-064 | 067 | URISCAN | | | 074 076 | | 073 - NEGATIVE | 49 | 1 | 39 | 0 | |
| 2021-064 | 067 | URISCAN | | | 074 076 | | 077 - 1000mg/dl | 49 | 7 | 39 | 0 | |
| 2021-064 | 067 | URISCAN | | | 074 076 | | 074 - TRACES | 49 | 3 | 39 | 100 | |
| 2021-064 | 067 | URISCAN | | | 074 076 | | 075 - 250mg/dl-+ | 49 | 21 | 39 | 100 | |
| 2021-064 | 067 | URISCAN | | | 074 076 | | 078 - 2000mg/dl | 49 | 2 | 39 | 0 | |
| 2021-064 | 071 | ATLAS | | 075 077 | 074 076 | | 076 - 500mg/dl2+ | 18 | 11 | 18 | 100 | |
| 2021-064 | 071 | ATLAS | | 075 077 | 074 076 | | 077 - 1000mg/dl | 18 | 6 | 18 | 100 | |
| 2021-064 | 071 | ATLAS | | 075 077 | 074 076 | | 075 - 250mg/dl-+ | 18 | 1 | 18 | 100 | |
| 2021-064 | 072 | URS-9-TECO | | | 074 076 | | 076 - 500mg/dl2+ | 108 | 2 | 84 | 100 | |
| 2021-064 | 072 | URS-9-TECO | | | 074 076 | | 073 - NEGATIVE | 108 | 22 | 84 | 0 | |
| 2021-064 | 072 | URS-9-TECO | | | 074 076 | | 077 - 1000mg/dl | 108 | 2 | 84 | 0 | |
| 2021-064 | 072 | URS-9-TECO | | | 074 076 | | 074 - TRACES | 108 | 38 | 84 | 100 | |
| 2021-064 | 072 | URS-9-TECO | | | 074 076 | | 075 - 250mg/dl-+ | 108 | 44 | 84 | 100 | |
| 2021-064 | 080 | ROCHE (CHE | | 076 078 | 074 076 | | 078 - 2000mg/dl | 37 | 1 | 37 | 100 | |
| 2021-064 | 080 | ROCHE (CHE | | 076 078 | 074 076 | | 075 - 250mg/dl-+ | 37 | 1 | 37 | 100 | |
| 2021-064 | 080 | ROCHE (CHE | | 076 078 | 074 076 | | 077 - 1000mg/dl | 37 | 35 | 37 | 100 | |
| 2021-064 | 089 | AIMSTRIP | | 074 076 | 074 076 | | 074 - TRACES | 115 | 33 | 114 | 100 | |
| 2021-064 | 089 | AIMSTRIP | | 074 076 | 074 076 | | 073 - NEGATIVE | 115 | 1 | 114 | 0 | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | | | |
|------------------------|---------------------|---------------------|---------------------|---------------|------------------|--------------------|------------------|-----------|-------------|-------------|-------|--|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | |
| 2021-064 | 089 | AIMSTRIP | | 074 076 | 074 076 | | 075 - 250mg/dl-+ | 115 | 81 | 114 | 100 | |
| 2021-064 | 094 | CLINITEK | | 073 075 | 074 076 | | 073 - NEGATIVE | 102 | 2 | 102 | 100 | |
| 2021-064 | 094 | CLINITEK | | 073 075 | 074 076 | | 074 - TRACES | 102 | 59 | 102 | 100 | |
| 2021-064 | 094 | CLINITEK | | 073 075 | 074 076 | | 075 - 250mg/dl-+ | 102 | 41 | 102 | 100 | |
| 2021-064 | 102 | ACON LAB | | 074 076 | 074 076 | | 075 - 250mg/dl-+ | 161 | 133 | 158 | 100 | |
| 2021-064 | 102 | ACON LAB | | 074 076 | 074 076 | | 073 - NEGATIVE | 161 | 3 | 158 | 0 | |
| 2021-064 | 102 | ACON LAB | | 074 076 | 074 076 | | 074 - TRACES | 161 | 25 | 158 | 100 | |
| 2021-064 | 131 | iCHEM VELO | | 075 077 | 074 076 | | 077 - 1000mg/dl | 26 | 2 | 26 | 100 | |
| 2021-064 | 131 | iCHEM VELO | | 075 077 | 074 076 | | 076 - 500mg/dl2+ | 26 | 24 | 26 | 100 | |
| 2021-064 | 135 | Hybrido AU | | 076 078 | 074 076 | | 077 - 1000mg/dl | 14 | 9 | 14 | 100 | |
| 2021-064 | 135 | Hybrido AU | | 076 078 | 074 076 | | 078 - 2000mg/dl | 14 | 5 | 14 | 100 | |
| 2021-064 | 138 | URS-10T | | 074 076 | 074 076 | | 075 - 250mg/dl-+ | 10 | 4 | 8 | 100 | |
| 2021-064 | 138 | URS-10T | | 074 076 | 074 076 | | 074 - TRACES | 10 | 3 | 8 | 100 | |
| 2021-064 | 138 | URS-10T | | 074 076 | 074 076 | | 076 - 500mg/dl2+ | 10 | 1 | 8 | 100 | |
| 2021-064 | 138 | URS-10T | | 074 076 | 074 076 | | 073 - NEGATIVE | 10 | 2 | 8 | 0 | |
| 2021-064 | 140 | MISSION A | | 074 076 | 074 076 | | 074 - TRACES | 64 | 5 | 64 | 100 | |
| 2021-064 | 140 | MISSION A | | 074 076 | 074 076 | | 075 - 250mg/dl-+ | 64 | 59 | 64 | 100 | |
| 2021-064 | 145 | CLINITEK | | 076 078 | 074 076 | | 076 - 500mg/dl2+ | 10 | 4 | 10 | 100 | |
| 2021-064 | 145 | CLINITEK | | 076 078 | 074 076 | | 077 - 1000mg/dl | 10 | 6 | 10 | 100 | |
| 2021-064 | 147 | Mission120 | | 074 076 | 074 076 | | 075 - 250mg/dl-+ | 23 | 23 | 23 | 100 | |
| 2021-064 | 148 | Mission500 | | 074 076 | 074 076 | | 075 - 250mg/dl-+ | 25 | 25 | 25 | 100 | |
| 058 URINALYSIS-GLUCOSE | | | | | | | | | | | | |
| 2021-065 | 011 | AMES NM10S | | 073 073 | 073 073 | | 073 - NEGATIVE | 50 | 50 | 50 | 100 | |
| 2021-065 | 013 | BAYER CLI | | 073 073 | 073 073 | | 073 - NEGATIVE | 35 | 35 | 35 | 100 | |
| 2021-065 | 067 | URISCAN | | 073 073 | 073 073 | | 075 - 250mg/dl-+ | 49 | 1 | 48 | 0 | |
| 2021-065 | 067 | URISCAN | | 073 073 | 073 073 | | 073 - NEGATIVE | 49 | 48 | 48 | 100 | |
| 2021-065 | 071 | ATLAS | | 073 073 | 073 073 | | 073 - NEGATIVE | 18 | 18 | 18 | 100 | |
| 2021-065 | 072 | URS-9-TECO | | 073 073 | 073 073 | | 073 - NEGATIVE | 108 | 108 | 108 | 100 | |
| 2021-065 | 080 | ROCHE (CHE | | 073 073 | 073 073 | | 073 - NEGATIVE | 37 | 37 | 37 | 100 | |
| 2021-065 | 089 | AIMSTRIP | | 073 073 | 073 073 | | 073 - NEGATIVE | 115 | 115 | 115 | 100 | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | | | |
|--------------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|-------------------|--------------|----------------|----------------|-------|--|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | |
| 2021-065 | 094 | CLINITEK | | 073 073 | 073 073 | | 073 - NEGATIVE | 102 | 102 | 102 | 100 | |
| 2021-065 | 102 | ACON LAB | | 073 073 | 073 073 | | 073 - NEGATIVE | 161 | 161 | 161 | 100 | |
| 2021-065 | 131 | iCHEM VELO | | 073 073 | 073 073 | | 073 - NEGATIVE | 26 | 26 | 26 | 100 | |
| 2021-065 | 135 | Hybrido AU | | 073 073 | 073 073 | | 073 - NEGATIVE | 14 | 14 | 14 | 100 | |
| 2021-065 | 138 | URS-10T | | 073 073 | 073 073 | | 073 - NEGATIVE | 10 | 10 | 10 | 100 | |
| 2021-065 | 140 | MISSION A | | 073 073 | 073 073 | | 073 - NEGATIVE | 64 | 64 | 64 | 100 | |
| 2021-065 | 145 | CLINITEK | | 073 073 | 073 073 | | 073 - NEGATIVE | 10 | 10 | 10 | 100 | |
| 2021-065 | 147 | Mission120 | | 073 073 | 073 073 | | 073 - NEGATIVE | 23 | 23 | 23 | 100 | |
| 2021-065 | 148 | Mission500 | | 073 073 | 073 073 | | 073 - NEGATIVE | 25 | 25 | 25 | 100 | |
| 059 URINALYS.HG.OR BLOOD | | | | | | | | | | | | |
| 2021-061 | 011 | AMES NM10S | | 068 069 | 068 069 | | 069 - POS.(3+) | 50 | 47 | 50 | 100 | |
| 2021-061 | 011 | AMES NM10S | | 068 069 | 068 069 | | 068 - POS.(1-2+) | 50 | 3 | 50 | 100 | |
| 2021-061 | 013 | BAYER CLI | | 068 069 | 068 069 | | 068 - POS.(1-2+) | 35 | 1 | 35 | 100 | |
| 2021-061 | 013 | BAYER CLI | | 068 069 | 068 069 | | 069 - POS.(3+) | 35 | 34 | 35 | 100 | |
| 2021-061 | 067 | URISCAN | | 068 069 | 068 069 | | 069 - POS.(3+) | 49 | 44 | 49 | 100 | |
| 2021-061 | 067 | URISCAN | | 068 069 | 068 069 | | 068 - POS.(1-2+) | 49 | 5 | 49 | 100 | |
| 2021-061 | 071 | ATLAS | | 068 069 | 068 069 | | 069 - POS.(3+) | 18 | 17 | 17 | 100 | |
| 2021-061 | 071 | ATLAS | | 068 069 | 068 069 | | 066 - NEGATIVE | 18 | 1 | 17 | 0 | |
| 2021-061 | 072 | URS-9-TECO | | 068 069 | 068 069 | | 068 - POS.(1-2+) | 108 | 9 | 108 | 100 | |
| 2021-061 | 072 | URS-9-TECO | | 068 069 | 068 069 | | 069 - POS.(3+) | 108 | 99 | 108 | 100 | |
| 2021-061 | 080 | ROCHE (CHE | | 068 069 | 068 069 | | 068 - POS.(1-2+) | 37 | 2 | 37 | 100 | |
| 2021-061 | 080 | ROCHE (CHE | | 068 069 | 068 069 | | 069 - POS.(3+) | 37 | 35 | 37 | 100 | |
| 2021-061 | 089 | AIMSTRIP | | 068 069 | 068 069 | | 069 - POS.(3+) | 115 | 113 | 115 | 100 | |
| 2021-061 | 089 | AIMSTRIP | | 068 069 | 068 069 | | 068 - POS.(1-2+) | 115 | 2 | 115 | 100 | |
| 2021-061 | 094 | CLINITEK | | 068 069 | 068 069 | | 069 - POS.(3+) | 102 | 99 | 102 | 100 | |
| 2021-061 | 094 | CLINITEK | | 068 069 | 068 069 | | 068 - POS.(1-2+) | 102 | 3 | 102 | 100 | |
| 2021-061 | 102 | ACON LAB | | 068 069 | 068 069 | | 069 - POS.(3+) | 162 | 157 | 162 | 100 | |
| 2021-061 | 102 | ACON LAB | | 068 069 | 068 069 | | 068 - POS.(1-2+) | 162 | 5 | 162 | 100 | |
| 2021-061 | 131 | iCHEM VELO | | 068 069 | 068 069 | | 069 - POS.(3+) | 26 | 24 | 26 | 100 | |
| 2021-061 | 131 | iCHEM VELO | | 068 069 | 068 069 | | 068 - POS.(1-2+) | 26 | 2 | 26 | 100 | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | | | | |
|--------------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|-------------------|--------------|----------------|----------------|-------|--|--|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | | |
| 2021-061 | 135 | Hybrido AU | | 068 069 | 068 069 | | 069 - POS.(3+)) | 14 | 14 | 14 | 100 | | |
| 2021-061 | 138 | URS-10T | | 068 069 | 068 069 | | 069 - POS.(3+)) | 10 | 10 | 10 | 100 | | |
| 2021-061 | 140 | MISSION A | | 068 069 | 068 069 | | 069 - POS.(3+)) | 65 | 63 | 65 | 100 | | |
| 2021-061 | 140 | MISSION A | | 068 069 | 068 069 | | 068 - POS.(1-2+) | 65 | 2 | 65 | 100 | | |
| 2021-061 | 145 | CLINITEK | | 068 069 | 068 069 | | 069 - POS.(3+)) | 10 | 10 | 10 | 100 | | |
| 2021-061 | 147 | Mission120 | | 068 069 | 068 069 | | 069 - POS.(3+)) | 23 | 23 | 23 | 100 | | |
| 2021-061 | 148 | Mission500 | | 068 069 | 068 069 | | 069 - POS.(3+)) | 23 | 22 | 23 | 100 | | |
| 2021-061 | 148 | Mission500 | | 068 069 | 068 069 | | 068 - POS.(1-2+) | 23 | 1 | 23 | 100 | | |
| 059 URINALYS.HG.OR BLOOD | | | | | | | | | | | | | |
| 2021-062 | 011 | AMES NM10S | | 066 066 | 066 066 | | 066 - NEGATIVE | 50 | 50 | 50 | 100 | | |
| 2021-062 | 013 | BAYER CLI | | 066 066 | 066 066 | | 066 - NEGATIVE | 35 | 35 | 35 | 100 | | |
| 2021-062 | 067 | URISCAN | | 066 066 | 066 066 | | 067 - TRACES | 49 | 1 | 48 | 0 | | |
| 2021-062 | 067 | URISCAN | | 066 066 | 066 066 | | 066 - NEGATIVE | 49 | 48 | 48 | 100 | | |
| 2021-062 | 071 | ATLAS | | 066 066 | 066 066 | | 066 - NEGATIVE | 18 | 18 | 18 | 100 | | |
| 2021-062 | 072 | URS-9-TECO | | 066 066 | 066 066 | | 066 - NEGATIVE | 108 | 108 | 108 | 100 | | |
| 2021-062 | 080 | ROCHE (CHE | | 066 066 | 066 066 | | 066 - NEGATIVE | 37 | 37 | 37 | 100 | | |
| 2021-062 | 089 | AIMSTRIP | | 066 066 | 066 066 | | 066 - NEGATIVE | 115 | 115 | 115 | 100 | | |
| 2021-062 | 094 | CLINITEK | | 066 066 | 066 066 | | 066 - NEGATIVE | 102 | 101 | 101 | 100 | | |
| 2021-062 | 094 | CLINITEK | | 066 066 | 066 066 | | 067 - TRACES | 102 | 1 | 101 | 0 | | |
| 2021-062 | 102 | ACON LAB | | 066 066 | 066 066 | | 067 - TRACES | 162 | 1 | 161 | 0 | | |
| 2021-062 | 102 | ACON LAB | | 066 066 | 066 066 | | 066 - NEGATIVE | 162 | 161 | 161 | 100 | | |
| 2021-062 | 131 | iCHEM VELO | | 066 066 | 066 066 | | 066 - NEGATIVE | 26 | 26 | 26 | 100 | | |
| 2021-062 | 135 | Hybrido AU | | 066 066 | 066 066 | | 066 - NEGATIVE | 14 | 14 | 14 | 100 | | |
| 2021-062 | 138 | URS-10T | | 066 066 | 066 066 | | 066 - NEGATIVE | 10 | 10 | 10 | 100 | | |
| 2021-062 | 140 | MISSION A | | 066 066 | 066 066 | | 066 - NEGATIVE | 65 | 65 | 65 | 100 | | |
| 2021-062 | 145 | CLINITEK | | 066 066 | 066 066 | | 066 - NEGATIVE | 10 | 10 | 10 | 100 | | |
| 2021-062 | 147 | Mission120 | | 066 066 | 066 066 | | 066 - NEGATIVE | 23 | 23 | 23 | 100 | | |
| 2021-062 | 148 | Mission500 | | 066 066 | 066 066 | | 066 - NEGATIVE | 23 | 23 | 23 | 100 | | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | | |
|--------------------------|---------------------|---------------------|---------------------|---------------|------------------|--------------------|------------------|-----------|-------------|-------------|-------|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score |
| 059 URINALYS.HG.OR BLOOD | | | | | | | | | | | |
| 2021-063 | 011 AMES NM10S | | | 068 069 | 068 069 | | 068 - POS.(1-2+) | 50 | 11 | 50 | 100 |
| 2021-063 | 011 AMES NM10S | | | 068 069 | 068 069 | | 069 - POS.(3+) | 50 | 39 | 50 | 100 |
| 2021-063 | 013 BAYER CLI | | | 068 069 | 068 069 | | 068 - POS.(1-2+) | 35 | 2 | 34 | 100 |
| 2021-063 | 013 BAYER CLI | | | 068 069 | 068 069 | | 069 - POS.(3+) | 35 | 32 | 34 | 100 |
| 2021-063 | 013 BAYER CLI | | | 068 069 | 068 069 | | 066 - NEGATIVE | 35 | 1 | 34 | 0 |
| 2021-063 | 067 URISCAN | | | 068 069 | 068 069 | | 068 - POS.(1-2+) | 49 | 6 | 49 | 100 |
| 2021-063 | 067 URISCAN | | | 068 069 | 068 069 | | 069 - POS.(3+) | 49 | 43 | 49 | 100 |
| 2021-063 | 071 ATLAS | | | 068 069 | 068 069 | | 069 - POS.(3+) | 18 | 18 | 18 | 100 |
| 2021-063 | 072 URS-9-TECO | | | 068 069 | 068 069 | | 069 - POS.(3+) | 108 | 78 | 108 | 100 |
| 2021-063 | 072 URS-9-TECO | | | 068 069 | 068 069 | | 068 - POS.(1-2+) | 108 | 30 | 108 | 100 |
| 2021-063 | 080 ROCHE (CHE | | | 068 069 | 068 069 | | 069 - POS.(3+) | 37 | 33 | 37 | 100 |
| 2021-063 | 080 ROCHE (CHE | | | 068 069 | 068 069 | | 068 - POS.(1-2+) | 37 | 4 | 37 | 100 |
| 2021-063 | 089 AIMSTRIP | | | 068 069 | 068 069 | | 069 - POS.(3+) | 115 | 111 | 114 | 100 |
| 2021-063 | 089 AIMSTRIP | | | 068 069 | 068 069 | | 066 - NEGATIVE | 115 | 1 | 114 | 0 |
| 2021-063 | 089 AIMSTRIP | | | 068 069 | 068 069 | | 068 - POS.(1-2+) | 115 | 3 | 114 | 100 |
| 2021-063 | 094 CLINITEK | | | 068 069 | 068 069 | | 068 - POS.(1-2+) | 102 | 15 | 102 | 100 |
| 2021-063 | 094 CLINITEK | | | 068 069 | 068 069 | | 069 - POS.(3+) | 102 | 87 | 102 | 100 |
| 2021-063 | 102 ACON LAB | | | 068 069 | 068 069 | | 068 - POS.(1-2+) | 162 | 4 | 161 | 100 |
| 2021-063 | 102 ACON LAB | | | 068 069 | 068 069 | | 066 - NEGATIVE | 162 | 1 | 161 | 0 |
| 2021-063 | 102 ACON LAB | | | 068 069 | 068 069 | | 069 - POS.(3+) | 162 | 157 | 161 | 100 |
| 2021-063 | 131 iCHEM VELO | | | 067 069 | 068 069 | | 068 - POS.(1-2+) | 26 | 24 | 26 | 100 |
| 2021-063 | 131 iCHEM VELO | | | 067 069 | 068 069 | | 067 - TRACES | 26 | 1 | 26 | 100 |
| 2021-063 | 131 iCHEM VELO | | | 067 069 | 068 069 | | 069 - POS.(3+) | 26 | 1 | 26 | 100 |
| 2021-063 | 135 Hybrido AU | | | 067 069 | 068 069 | | 068 - POS.(1-2+) | 14 | 14 | 14 | 100 |
| 2021-063 | 138 URS-10T | | | 068 069 | 068 069 | | 069 - POS.(3+) | 10 | 8 | 10 | 100 |
| 2021-063 | 138 URS-10T | | | 068 069 | 068 069 | | 068 - POS.(1-2+) | 10 | 2 | 10 | 100 |
| 2021-063 | 140 MISSION A | | | 068 069 | 068 069 | | 068 - POS.(1-2+) | 65 | 1 | 65 | 100 |
| 2021-063 | 140 MISSION A | | | 068 069 | 068 069 | | 069 - POS.(3+) | 65 | 64 | 65 | 100 |
| 2021-063 | 145 CLINITEK | | | 067 069 | 068 069 | | 068 - POS.(1-2+) | 10 | 7 | 10 | 100 |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | | |
|--------------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|--------------------|--------------|----------------|----------------|-------|--|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | |
| 2021-063 | 145 | CLINITEK | | 067 069 | 068 069 | | 069 - POS.(3+)) | 10 | 3 | 10 | 100 | |
| 2021-063 | 147 | Mission120 | | 068 069 | 068 069 | | 069 - POS.(3+)) | 23 | 23 | 23 | 100 | |
| 2021-063 | 148 | Mission500 | | 068 069 | 068 069 | | 069 - POS.(3+)) | 23 | 22 | 23 | 100 | |
| 2021-063 | 148 | Mission500 | | 068 069 | 068 069 | | 068 - POS.(1-2+) | 23 | 1 | 23 | 100 | |
| 059 URINALYS.HG.OR BLOOD | | | | | | | | | | | | |
| 2021-064 | 011 | AMES NM10S | | 066 066 | 066 066 | | 067 - TRACES | 50 | 1 | 49 | 0 | |
| 2021-064 | 011 | AMES NM10S | | 066 066 | 066 066 | | 066 - NEGATIVE | 50 | 49 | 49 | 100 | |
| 2021-064 | 013 | BAYER CLI | | 066 066 | 066 066 | | 066 - NEGATIVE | 35 | 35 | 35 | 100 | |
| 2021-064 | 067 | URISCAN | | 066 066 | 066 066 | | 069 - POS.(3+)) | 49 | 1 | 48 | 0 | |
| 2021-064 | 067 | URISCAN | | 066 066 | 066 066 | | 066 - NEGATIVE | 49 | 48 | 48 | 100 | |
| 2021-064 | 071 | ATLAS | | 066 066 | 066 066 | | 066 - NEGATIVE | 18 | 18 | 18 | 100 | |
| 2021-064 | 072 | URS-9-TECO | | 066 066 | 066 066 | | 066 - NEGATIVE | 108 | 108 | 108 | 100 | |
| 2021-064 | 080 | ROCHE (CHE | | 066 066 | 066 066 | | 066 - NEGATIVE | 37 | 37 | 37 | 100 | |
| 2021-064 | 089 | AIMSTRIP | | 066 066 | 066 066 | | 066 - NEGATIVE | 115 | 115 | 115 | 100 | |
| 2021-064 | 094 | CLINITEK | | 066 066 | 066 066 | | 066 - NEGATIVE | 102 | 102 | 102 | 100 | |
| 2021-064 | 102 | ACON LAB | | 066 066 | 066 066 | | 066 - NEGATIVE | 162 | 162 | 162 | 100 | |
| 2021-064 | 131 | iCHEM VELO | | 066 066 | 066 066 | | 066 - NEGATIVE | 26 | 26 | 26 | 100 | |
| 2021-064 | 135 | Hybrido AU | | 066 066 | 066 066 | | 066 - NEGATIVE | 14 | 14 | 14 | 100 | |
| 2021-064 | 138 | URS-10T | | 066 066 | 066 066 | | 066 - NEGATIVE | 10 | 10 | 10 | 100 | |
| 2021-064 | 140 | MISSION A | | 066 066 | 066 066 | | 066 - NEGATIVE | 65 | 65 | 65 | 100 | |
| 2021-064 | 145 | CLINITEK | | 066 066 | 066 066 | | 066 - NEGATIVE | 10 | 10 | 10 | 100 | |
| 2021-064 | 147 | Mission120 | | 066 066 | 066 066 | | 066 - NEGATIVE | 23 | 23 | 23 | 100 | |
| 2021-064 | 148 | Mission500 | | 066 066 | 066 066 | | 066 - NEGATIVE | 23 | 23 | 23 | 100 | |
| 2021-065 | 011 | AMES NM10S | | 068 069 | 068 069 | | 069 - POS.(3+)) | 50 | 49 | 50 | 100 | |
| 2021-065 | 011 | AMES NM10S | | 068 069 | 068 069 | | 068 - POS.(1-2+) | 50 | 1 | 50 | 100 | |
| 2021-065 | 013 | BAYER CLI | | 068 069 | 068 069 | | 069 - POS.(3+)) | 35 | 35 | 35 | 100 | |
| 2021-065 | 067 | URISCAN | | 068 069 | 068 069 | | 066 - NEGATIVE | 49 | 1 | 48 | 0 | |
| 2021-065 | 067 | URISCAN | | 068 069 | 068 069 | | 069 - POS.(3+)) | 49 | 46 | 48 | 100 | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | | | | |
|------------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|-------------------|--------------|----------------|----------------|-------|-----|-----|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | | |
| 2021-065 | 067 | URISCAN | | 068 | 069 | 068 | 069 | 068 | - POS.(1-2+) | 49 | 2 | 48 | 100 |
| 2021-065 | 071 | ATLAS | | 068 | 069 | 068 | 069 | 069 | - POS.(3+) | 18 | 18 | 18 | 100 |
| 2021-065 | 072 | URS-9-TECO | | 068 | 069 | 068 | 069 | 068 | - POS.(1-2+) | 108 | 9 | 107 | 100 |
| 2021-065 | 072 | URS-9-TECO | | 068 | 069 | 068 | 069 | 066 | - NEGATIVE | 108 | 1 | 107 | 0 |
| 2021-065 | 072 | URS-9-TECO | | 068 | 069 | 068 | 069 | 069 | - POS.(3+) | 108 | 98 | 107 | 100 |
| 2021-065 | 080 | ROCHE (CHE | | 068 | 069 | 068 | 069 | 069 | - POS.(3+) | 37 | 35 | 37 | 100 |
| 2021-065 | 080 | ROCHE (CHE | | 068 | 069 | 068 | 069 | 068 | - POS.(1-2+) | 37 | 2 | 37 | 100 |
| 2021-065 | 089 | AIMSTRIP | | 068 | 069 | 068 | 069 | 069 | - POS.(3+) | 115 | 112 | 115 | 100 |
| 2021-065 | 089 | AIMSTRIP | | 068 | 069 | 068 | 069 | 068 | - POS.(1-2+) | 115 | 3 | 115 | 100 |
| 2021-065 | 094 | CLINITEK | | 068 | 069 | 068 | 069 | 068 | - POS.(1-2+) | 102 | 1 | 102 | 100 |
| 2021-065 | 094 | CLINITEK | | 068 | 069 | 068 | 069 | 069 | - POS.(3+) | 102 | 101 | 102 | 100 |
| 2021-065 | 102 | ACON LAB | | 068 | 069 | 068 | 069 | 069 | - POS.(3+) | 162 | 160 | 162 | 100 |
| 2021-065 | 102 | ACON LAB | | 068 | 069 | 068 | 069 | 068 | - POS.(1-2+) | 162 | 2 | 162 | 100 |
| 2021-065 | 131 | iCHEM VELO | | 068 | 069 | 068 | 069 | 069 | - POS.(3+) | 26 | 24 | 26 | 100 |
| 2021-065 | 131 | iCHEM VELO | | 068 | 069 | 068 | 069 | 068 | - POS.(1-2+) | 26 | 2 | 26 | 100 |
| 2021-065 | 135 | Hybrido AU | | 068 | 069 | 068 | 069 | 069 | - POS.(3+) | 14 | 13 | 14 | 100 |
| 2021-065 | 135 | Hybrido AU | | 068 | 069 | 068 | 069 | 068 | - POS.(1-2+) | 14 | 1 | 14 | 100 |
| 2021-065 | 138 | URS-10T | | 068 | 069 | 068 | 069 | 069 | - POS.(3+) | 10 | 10 | 10 | 100 |
| 2021-065 | 140 | MISSION A | | 068 | 069 | 068 | 069 | 068 | - POS.(1-2+) | 65 | 1 | 65 | 100 |
| 2021-065 | 140 | MISSION A | | 068 | 069 | 068 | 069 | 069 | - POS.(3+) | 65 | 64 | 65 | 100 |
| 2021-065 | 145 | CLINITEK | | 068 | 069 | 068 | 069 | 069 | - POS.(3+) | 10 | 10 | 10 | 100 |
| 2021-065 | 147 | Mission120 | | 068 | 069 | 068 | 069 | 069 | - POS.(3+) | 23 | 23 | 23 | 100 |
| 2021-065 | 148 | Mission500 | | 068 | 069 | 068 | 069 | 068 | - POS.(1-2+) | 23 | 1 | 23 | 100 |
| 2021-065 | 148 | Mission500 | | 068 | 069 | 068 | 069 | 069 | - POS.(3+) | 23 | 22 | 23 | 100 |
| 060 URINALYSIS-KETONES | | | | | | | | | | | | | |
| 2021-061 | 011 | AMES NM10S | | 090 | 090 | 090 | 090 | 090 | - NEGATIVE | 50 | 50 | 50 | 100 |
| 2021-061 | 013 | BAYER CLI | | 090 | 090 | 090 | 090 | 090 | - NEGATIVE | 35 | 35 | 35 | 100 |
| 2021-061 | 067 | URISCAN | | 090 | 090 | 090 | 090 | 090 | - NEGATIVE | 49 | 49 | 49 | 100 |
| 2021-061 | 071 | ATLAS | | 090 | 090 | 090 | 090 | 090 | - NEGATIVE | 18 | 18 | 18 | 100 |
| 2021-061 | 072 | URS-9-TECO | | 090 | 090 | 090 | 090 | 091 | - TRACE | 108 | 1 | 107 | 0 |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | | | |
|------------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|--------------------|--------------|----------------|----------------|-------|-----|-----|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | | |
| 2021-061 | 072 | URS-9-TECO | | 090 | 090 | 090 | 090 | 090 | - NEGATIVE | 108 | 107 | 107 | 100 |
| 2021-061 | 080 | ROCHE (CHE | | 090 | 090 | 090 | 090 | 090 | - NEGATIVE | 37 | 37 | 37 | 100 |
| 2021-061 | 089 | AIMSTRIP | | 090 | 090 | 090 | 090 | 090 | - NEGATIVE | 115 | 115 | 115 | 100 |
| 2021-061 | 094 | CLINITEK | | 090 | 090 | 090 | 090 | 090 | - NEGATIVE | 102 | 102 | 102 | 100 |
| 2021-061 | 102 | ACON LAB | | 090 | 090 | 090 | 090 | 090 | - NEGATIVE | 161 | 161 | 161 | 100 |
| 2021-061 | 131 | iCHEM VELO | | 090 | 090 | 090 | 090 | 090 | - NEGATIVE | 26 | 26 | 26 | 100 |
| 2021-061 | 135 | Hybrido AU | | 090 | 090 | 090 | 090 | 090 | - NEGATIVE | 14 | 14 | 14 | 100 |
| 2021-061 | 138 | URS-10T | | 090 | 090 | 090 | 090 | 090 | - NEGATIVE | 10 | 10 | 10 | 100 |
| 2021-061 | 140 | MISSION A | | 090 | 090 | 090 | 090 | 090 | - NEGATIVE | 65 | 65 | 65 | 100 |
| 2021-061 | 145 | CLINITEK | | 090 | 090 | 090 | 090 | 090 | - NEGATIVE | 10 | 10 | 10 | 100 |
| 2021-061 | 147 | Mission120 | | 090 | 090 | 090 | 090 | 090 | - NEGATIVE | 23 | 23 | 23 | 100 |
| 2021-061 | 148 | Mission500 | | 090 | 090 | 090 | 090 | 090 | - NEGATIVE | 24 | 24 | 24 | 100 |
| 060 URINALYSIS-KETONES | | | | | | | | | | | | | |
| 2021-062 | 011 | AMES NM10S | | 090 | 090 | 090 | 090 | 090 | - NEGATIVE | 50 | 50 | 50 | 100 |
| 2021-062 | 013 | BAYER CLI | | 090 | 090 | 090 | 090 | 090 | - NEGATIVE | 35 | 35 | 35 | 100 |
| 2021-062 | 067 | URISCAN | | 090 | 090 | 090 | 090 | 090 | - NEGATIVE | 49 | 49 | 49 | 100 |
| 2021-062 | 071 | ATLAS | | 090 | 090 | 090 | 090 | 090 | - NEGATIVE | 18 | 18 | 18 | 100 |
| 2021-062 | 072 | URS-9-TECO | | 090 | 090 | 090 | 090 | 090 | 091 - TRACE | 108 | 1 | 107 | 0 |
| 2021-062 | 072 | URS-9-TECO | | 090 | 090 | 090 | 090 | 090 | - NEGATIVE | 108 | 107 | 107 | 100 |
| 2021-062 | 080 | ROCHE (CHE | | 090 | 090 | 090 | 090 | 090 | - NEGATIVE | 37 | 37 | 37 | 100 |
| 2021-062 | 089 | AIMSTRIP | | 090 | 090 | 090 | 090 | 090 | - NEGATIVE | 115 | 115 | 115 | 100 |
| 2021-062 | 094 | CLINITEK | | 090 | 090 | 090 | 090 | 090 | - NEGATIVE | 102 | 102 | 102 | 100 |
| 2021-062 | 102 | ACON LAB | | 090 | 090 | 090 | 090 | 090 | - NEGATIVE | 161 | 161 | 161 | 100 |
| 2021-062 | 131 | iCHEM VELO | | 090 | 090 | 090 | 090 | 090 | - NEGATIVE | 26 | 26 | 26 | 100 |
| 2021-062 | 135 | Hybrido AU | | 090 | 090 | 090 | 090 | 090 | - NEGATIVE | 14 | 14 | 14 | 100 |
| 2021-062 | 138 | URS-10T | | 090 | 090 | 090 | 090 | 090 | - NEGATIVE | 10 | 10 | 10 | 100 |
| 2021-062 | 140 | MISSION A | | 090 | 090 | 090 | 090 | 090 | - NEGATIVE | 65 | 65 | 65 | 100 |
| 2021-062 | 145 | CLINITEK | | 090 | 090 | 090 | 090 | 090 | - NEGATIVE | 10 | 10 | 10 | 100 |
| 2021-062 | 147 | Mission120 | | 090 | 090 | 090 | 090 | 090 | - NEGATIVE | 23 | 23 | 23 | 100 |
| 2021-062 | 148 | Mission500 | | 090 | 090 | 090 | 090 | 090 | - NEGATIVE | 24 | 24 | 24 | 100 |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | | | | |
|------------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|-------------------|--------------|----------------|----------------|-------|--|--|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | | |
| 060 URINALYSIS-KETONES | | | | | | | | | | | | | |
| 2021-063 | 011 | AMES NM10S | | 093 094 | 093 094 | | 093 - MOD. (2+) | 50 | 1 | 49 | 100 | | |
| 2021-063 | 011 | AMES NM10S | | 093 094 | 093 094 | | 092 - SMALL (1+) | 50 | 1 | 49 | 0 | | |
| 2021-063 | 011 | AMES NM10S | | 093 094 | 093 094 | | 094 - LARGE-3-4+ | 50 | 48 | 49 | 100 | | |
| 2021-063 | 013 | BAYER CLI | | 093 094 | 093 094 | | 094 - LARGE-3-4+ | 35 | 33 | 35 | 100 | | |
| 2021-063 | 013 | BAYER CLI | | 093 094 | 093 094 | | 093 - MOD. (2+) | 35 | 2 | 35 | 100 | | |
| 2021-063 | 067 | URISCAN | | 093 094 | 093 094 | | 093 - MOD. (2+) | 49 | 14 | 49 | 100 | | |
| 2021-063 | 067 | URISCAN | | 093 094 | 093 094 | | 094 - LARGE-3-4+ | 49 | 35 | 49 | 100 | | |
| 2021-063 | 071 | ATLAS | | 093 094 | 093 094 | | 094 - LARGE-3-4+ | 18 | 18 | 18 | 100 | | |
| 2021-063 | 072 | URS-9-TECO | | 093 094 | 093 094 | | 094 - LARGE-3-4+ | 108 | 103 | 108 | 100 | | |
| 2021-063 | 072 | URS-9-TECO | | 093 094 | 093 094 | | 093 - MOD. (2+) | 108 | 5 | 108 | 100 | | |
| 2021-063 | 080 | ROCHE (CHE | | 093 094 | 093 094 | | 094 - LARGE-3-4+ | 37 | 32 | 37 | 100 | | |
| 2021-063 | 080 | ROCHE (CHE | | 093 094 | 093 094 | | 093 - MOD. (2+) | 37 | 5 | 37 | 100 | | |
| 2021-063 | 089 | AIMSTRIP | | 093 094 | 093 094 | | 093 - MOD. (2+) | 115 | 1 | 113 | 100 | | |
| 2021-063 | 089 | AIMSTRIP | | 093 094 | 093 094 | | 092 - SMALL (1+) | 115 | 2 | 113 | 0 | | |
| 2021-063 | 089 | AIMSTRIP | | 093 094 | 093 094 | | 094 - LARGE-3-4+ | 115 | 112 | 113 | 100 | | |
| 2021-063 | 094 | CLINITEK | | 093 094 | 093 094 | | 093 - MOD. (2+) | 102 | 3 | 102 | 100 | | |
| 2021-063 | 094 | CLINITEK | | 093 094 | 093 094 | | 094 - LARGE-3-4+ | 102 | 99 | 102 | 100 | | |
| 2021-063 | 102 | ACON LAB | | 093 094 | 093 094 | | 090 - NEGATIVE | 161 | 1 | 160 | 0 | | |
| 2021-063 | 102 | ACON LAB | | 093 094 | 093 094 | | 093 - MOD. (2+) | 161 | 5 | 160 | 100 | | |
| 2021-063 | 102 | ACON LAB | | 093 094 | 093 094 | | 094 - LARGE-3-4+ | 161 | 155 | 160 | 100 | | |
| 2021-063 | 131 | iCHEM VELO | | 092 094 | 093 094 | | 093 - MOD. (2+) | 26 | 15 | 26 | 100 | | |
| 2021-063 | 131 | iCHEM VELO | | 092 094 | 093 094 | | 094 - LARGE-3-4+ | 26 | 11 | 26 | 100 | | |
| 2021-063 | 135 | Hybrido AU | | 093 094 | 093 094 | | 094 - LARGE-3-4+ | 14 | 14 | 14 | 100 | | |
| 2021-063 | 138 | URS-10T | | 093 094 | 093 094 | | 093 - MOD. (2+) | 10 | 1 | 10 | 100 | | |
| 2021-063 | 138 | URS-10T | | 093 094 | 093 094 | | 094 - LARGE-3-4+ | 10 | 9 | 10 | 100 | | |
| 2021-063 | 140 | MISSION A | | 093 094 | 093 094 | | 094 - LARGE-3-4+ | 65 | 65 | 65 | 100 | | |
| 2021-063 | 145 | CLINITEK | | 093 094 | 093 094 | | 094 - LARGE-3-4+ | 10 | 10 | 10 | 100 | | |
| 2021-063 | 147 | Mission120 | | 093 094 | 093 094 | | 094 - LARGE-3-4+ | 23 | 23 | 23 | 100 | | |
| 2021-063 | 148 | Mission500 | | 093 094 | 093 094 | | 094 - LARGE-3-4+ | 24 | 24 | 24 | 100 | | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | | | | |
|------------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|-------------------|--------------|----------------|----------------|-------|--|--|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | | |
| 060 URINALYSIS-KETONES | | | | | | | | | | | | | |
| 2021-064 | 011 | AMES NM10S | | 092 094 | 092 094 | | 093 - MOD. (2+) | 50 | 33 | 50 | 100 | | |
| 2021-064 | 011 | AMES NM10S | | 092 094 | 092 094 | | 092 - SMALL (1+) | 50 | 9 | 50 | 100 | | |
| 2021-064 | 011 | AMES NM10S | | 092 094 | 092 094 | | 094 - LARGE-3-4+ | 50 | 8 | 50 | 100 | | |
| 2021-064 | 013 | BAYER CLI | | 092 094 | 092 094 | | 093 - MOD. (2+) | 35 | 24 | 34 | 100 | | |
| 2021-064 | 013 | BAYER CLI | | 092 094 | 092 094 | | 090 - NEGATIVE | 35 | 1 | 34 | 0 | | |
| 2021-064 | 013 | BAYER CLI | | 092 094 | 092 094 | | 094 - LARGE-3-4+ | 35 | 2 | 34 | 100 | | |
| 2021-064 | 013 | BAYER CLI | | 092 094 | 092 094 | | 092 - SMALL (1+) | 35 | 8 | 34 | 100 | | |
| 2021-064 | 067 | URISCAN | | 092 094 | 092 094 | | 094 - LARGE-3-4+ | 49 | 5 | 48 | 100 | | |
| 2021-064 | 067 | URISCAN | | 092 094 | 092 094 | | 093 - MOD. (2+) | 49 | 41 | 48 | 100 | | |
| 2021-064 | 067 | URISCAN | | 092 094 | 092 094 | | 092 - SMALL (1+) | 49 | 2 | 48 | 100 | | |
| 2021-064 | 067 | URISCAN | | 092 094 | 092 094 | | 090 - NEGATIVE | 49 | 1 | 48 | 0 | | |
| 2021-064 | 071 | ATLAS | | 092 094 | 092 094 | | 093 - MOD. (2+) | 18 | 18 | 18 | 100 | | |
| 2021-064 | 072 | URS-9-TECO | | 092 094 | 092 094 | | 094 - LARGE-3-4+ | 108 | 24 | 107 | 100 | | |
| 2021-064 | 072 | URS-9-TECO | | 092 094 | 092 094 | | 090 - NEGATIVE | 108 | 1 | 107 | 0 | | |
| 2021-064 | 072 | URS-9-TECO | | 092 094 | 092 094 | | 092 - SMALL (1+) | 108 | 6 | 107 | 100 | | |
| 2021-064 | 072 | URS-9-TECO | | 092 094 | 092 094 | | 093 - MOD. (2+) | 108 | 77 | 107 | 100 | | |
| 2021-064 | 080 | ROCHE (CHE | | 092 094 | 092 094 | | 093 - MOD. (2+) | 37 | 19 | 37 | 100 | | |
| 2021-064 | 080 | ROCHE (CHE | | 092 094 | 092 094 | | 092 - SMALL (1+) | 37 | 9 | 37 | 100 | | |
| 2021-064 | 080 | ROCHE (CHE | | 092 094 | 092 094 | | 094 - LARGE-3-4+ | 37 | 9 | 37 | 100 | | |
| 2021-064 | 089 | AIMSTRIP | | 092 094 | 092 094 | | 090 - NEGATIVE | 115 | 1 | 114 | 0 | | |
| 2021-064 | 089 | AIMSTRIP | | 092 094 | 092 094 | | 093 - MOD. (2+) | 115 | 60 | 114 | 100 | | |
| 2021-064 | 089 | AIMSTRIP | | 092 094 | 092 094 | | 092 - SMALL (1+) | 115 | 18 | 114 | 100 | | |
| 2021-064 | 089 | AIMSTRIP | | 092 094 | 092 094 | | 094 - LARGE-3-4+ | 115 | 36 | 114 | 100 | | |
| 2021-064 | 094 | CLINITEK | | 092 094 | 092 094 | | 092 - SMALL (1+) | 102 | 23 | 101 | 100 | | |
| 2021-064 | 094 | CLINITEK | | 092 094 | 092 094 | | 093 - MOD. (2+) | 102 | 76 | 101 | 100 | | |
| 2021-064 | 094 | CLINITEK | | 092 094 | 092 094 | | 091 - TRACE | 102 | 1 | 101 | 0 | | |
| 2021-064 | 094 | CLINITEK | | 092 094 | 092 094 | | 094 - LARGE-3-4+ | 102 | 2 | 101 | 100 | | |
| 2021-064 | 102 | ACON LAB | | 092 094 | 092 094 | | 094 - LARGE-3-4+ | 161 | 57 | 160 | 100 | | |
| 2021-064 | 102 | ACON LAB | | 092 094 | 092 094 | | 090 - NEGATIVE | 161 | 1 | 160 | 0 | | |

Participant Summary

MONTH 2 OF YEAR 2021

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score |
|------------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|-------------------|--------------|----------------|----------------|-------|
| 2021-064 | 102 | ACON LAB | | 092 094 | 092 094 | | 092 - SMALL (1+) | 161 | 11 | 160 | 100 |
| 2021-064 | 102 | ACON LAB | | 092 094 | 092 094 | | 093 - MOD. (2+) | 161 | 92 | 160 | 100 |
| 2021-064 | 131 | iCHEM VELO | | 091 093 | 092 094 | | 093 - MOD. (2+) | 26 | 6 | 26 | 100 |
| 2021-064 | 131 | iCHEM VELO | | 091 093 | 092 094 | | 092 - SMALL (1+) | 26 | 20 | 26 | 100 |
| 2021-064 | 135 | Hybrido AU | | 092 094 | 092 094 | | 093 - MOD. (2+) | 14 | 14 | 14 | 100 |
| 2021-064 | 138 | URS-10T | | 092 094 | 092 094 | | 094 - LARGE-3-4+ | 10 | 2 | 10 | 100 |
| 2021-064 | 138 | URS-10T | | 092 094 | 092 094 | | 092 - SMALL (1+) | 10 | 1 | 10 | 100 |
| 2021-064 | 138 | URS-10T | | 092 094 | 092 094 | | 093 - MOD. (2+) | 10 | 7 | 10 | 100 |
| 2021-064 | 140 | MISSION A | | 093 094 | 092 094 | | 093 - MOD. (2+) | 65 | 20 | 65 | 100 |
| 2021-064 | 140 | MISSION A | | 093 094 | 092 094 | | 092 - SMALL (1+) | 65 | 1 | 65 | 100 |
| 2021-064 | 140 | MISSION A | | 093 094 | 092 094 | | 094 - LARGE-3-4+ | 65 | 44 | 65 | 100 |
| 2021-064 | 145 | CLINITEK | | 092 094 | 092 094 | | 093 - MOD. (2+) | 10 | 9 | 10 | 100 |
| 2021-064 | 145 | CLINITEK | | 092 094 | 092 094 | | 092 - SMALL (1+) | 10 | 1 | 10 | 100 |
| 2021-064 | 147 | Mission120 | | 093 094 | 092 094 | | 094 - LARGE-3-4+ | 23 | 23 | 23 | 100 |
| 2021-064 | 148 | Mission500 | | 092 094 | 092 094 | | 094 - LARGE-3-4+ | 24 | 11 | 24 | 100 |
| 2021-064 | 148 | Mission500 | | 092 094 | 092 094 | | 093 - MOD. (2+) | 24 | 12 | 24 | 100 |
| 2021-064 | 148 | Mission500 | | 092 094 | 092 094 | | 092 - SMALL (1+) | 24 | 1 | 24 | 100 |
| 060 URINALYSIS-KETONES | | | | | | | | | | | |
| 2021-065 | 011 | AMES NM10S | | 090 090 | 090 090 | | 090 - NEGATIVE | 50 | 49 | 49 | 100 |
| 2021-065 | 011 | AMES NM10S | | 090 090 | 090 090 | | 094 - LARGE-3-4+ | 50 | 1 | 49 | 0 |
| 2021-065 | 013 | BAYER CLI | | 090 090 | 090 090 | | 090 - NEGATIVE | 35 | 35 | 35 | 100 |
| 2021-065 | 067 | URISCAN | | 090 090 | 090 090 | | 094 - LARGE-3-4+ | 49 | 1 | 46 | 0 |
| 2021-065 | 067 | URISCAN | | 090 090 | 090 090 | | 092 - SMALL (1+) | 49 | 1 | 46 | 0 |
| 2021-065 | 067 | URISCAN | | 090 090 | 090 090 | | 093 - MOD. (2+) | 49 | 1 | 46 | 0 |
| 2021-065 | 067 | URISCAN | | 090 090 | 090 090 | | 090 - NEGATIVE | 49 | 46 | 46 | 100 |
| 2021-065 | 071 | ATLAS | | 090 090 | 090 090 | | 090 - NEGATIVE | 18 | 18 | 18 | 100 |
| 2021-065 | 072 | URS-9-TECO | | 090 090 | 090 090 | | 090 - NEGATIVE | 108 | 108 | 108 | 100 |
| 2021-065 | 080 | ROCHE (CHE | | 090 090 | 090 090 | | 090 - NEGATIVE | 37 | 37 | 37 | 100 |
| 2021-065 | 089 | AIMSTRIP | | 090 090 | 090 090 | | 094 - LARGE-3-4+ | 115 | 1 | 114 | 0 |
| 2021-065 | 089 | AIMSTRIP | | 090 090 | 090 090 | | 090 - NEGATIVE | 115 | 114 | 114 | 100 |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | | | |
|------------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|--------------------|--------------|----------------|----------------|-------|--|--|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | | |
| 2021-065 | 094 | CLINITEK | | 090 090 | 090 090 | | 091 - TRACE | 102 | 1 | 101 | 0 | | |
| 2021-065 | 094 | CLINITEK | | 090 090 | 090 090 | | 090 - NEGATIVE | 102 | 101 | 101 | 100 | | |
| 2021-065 | 102 | ACON LAB | | 090 090 | 090 090 | | 090 - NEGATIVE | 161 | 161 | 161 | 100 | | |
| 2021-065 | 131 | iCHEM VELO | | 090 090 | 090 090 | | 090 - NEGATIVE | 26 | 26 | 26 | 100 | | |
| 2021-065 | 135 | Hybrido AU | | 090 090 | 090 090 | | 090 - NEGATIVE | 14 | 14 | 14 | 100 | | |
| 2021-065 | 138 | URS-10T | | 090 090 | 090 090 | | 090 - NEGATIVE | 10 | 10 | 10 | 100 | | |
| 2021-065 | 140 | MISSION A | | 090 090 | 090 090 | | 090 - NEGATIVE | 65 | 65 | 65 | 100 | | |
| 2021-065 | 145 | CLINITEK | | 090 090 | 090 090 | | 090 - NEGATIVE | 10 | 10 | 10 | 100 | | |
| 2021-065 | 147 | Mission120 | | 090 090 | 090 090 | | 090 - NEGATIVE | 23 | 23 | 23 | 100 | | |
| 2021-065 | 148 | Mission500 | | 090 090 | 090 090 | | 090 - NEGATIVE | 24 | 24 | 24 | 100 | | |
| 061 URINALYSIS-NITRATE | | | | | | | | | | | | | |
| 2021-061 | 011 | AMES NM10S | | 070 070 | 070 070 | | 070 - NEGATIVE | 50 | 50 | 50 | 100 | | |
| 2021-061 | 013 | BAYER CLI | | 070 070 | 070 070 | | 070 - NEGATIVE | 36 | 36 | 36 | 100 | | |
| 2021-061 | 067 | URISCAN | | 070 070 | 070 070 | | 070 - NEGATIVE | 49 | 49 | 49 | 100 | | |
| 2021-061 | 071 | ATLAS | | 070 070 | 070 070 | | 070 - NEGATIVE | 18 | 18 | 18 | 100 | | |
| 2021-061 | 072 | URS-9-TECO | | 070 070 | 070 070 | | 070 - NEGATIVE | 107 | 107 | 107 | 100 | | |
| 2021-061 | 080 | ROCHE (CHE | | 070 070 | 070 070 | | 070 - NEGATIVE | 37 | 37 | 37 | 100 | | |
| 2021-061 | 089 | AIMSTRIP | | 070 070 | 070 070 | | 070 - NEGATIVE | 115 | 115 | 115 | 100 | | |
| 2021-061 | 094 | CLINITEK | | 070 070 | 070 070 | | 070 - NEGATIVE | 102 | 102 | 102 | 100 | | |
| 2021-061 | 102 | ACON LAB | | 070 070 | 070 070 | | 070 - NEGATIVE | 161 | 161 | 161 | 100 | | |
| 2021-061 | 131 | iCHEM VELO | | 070 070 | 070 070 | | 070 - NEGATIVE | 26 | 26 | 26 | 100 | | |
| 2021-061 | 135 | Hybrido AU | | 070 070 | 070 070 | | 070 - NEGATIVE | 14 | 14 | 14 | 100 | | |
| 2021-061 | 138 | URS-10T | | 070 070 | 070 070 | | 070 - NEGATIVE | 10 | 10 | 10 | 100 | | |
| 2021-061 | 140 | MISSION A | | 070 070 | 070 070 | | 070 - NEGATIVE | 65 | 65 | 65 | 100 | | |
| 2021-061 | 145 | CLINITEK | | 070 070 | 070 070 | | 070 - NEGATIVE | 10 | 10 | 10 | 100 | | |
| 2021-061 | 147 | Mission120 | | 070 070 | 070 070 | | 070 - NEGATIVE | 23 | 23 | 23 | 100 | | |
| 2021-061 | 148 | Mission500 | | 070 070 | 070 070 | | 070 - NEGATIVE | 24 | 24 | 24 | 100 | | |
| 2021-062 | 011 | AMES NM10S | | 070 070 | 070 070 | | 070 - NEGATIVE | 50 | 50 | 50 | 100 | | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | | |
|------------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|--------------------|--------------|----------------|----------------|-------|--|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | |
| 2021-062 | 013 | BAYER CLI | | 070 | 070 | 070 | 070 | 36 | 36 | 36 | 100 | |
| 2021-062 | 067 | URISCAN | | 070 | 070 | 070 | 070 | 49 | 49 | 49 | 100 | |
| 2021-062 | 071 | ATLAS | | 070 | 070 | 070 | 070 | 18 | 18 | 18 | 100 | |
| 2021-062 | 072 | URS-9-TECO | | 070 | 070 | 070 | 070 | 107 | 107 | 107 | 100 | |
| 2021-062 | 080 | ROCHE (CHE | | 070 | 070 | 070 | 070 | 37 | 37 | 37 | 100 | |
| 2021-062 | 089 | AIMSTRIP | | 070 | 070 | 070 | 070 | 115 | 115 | 115 | 100 | |
| 2021-062 | 094 | CLINITEK | | 070 | 070 | 070 | 070 | 102 | 102 | 102 | 100 | |
| 2021-062 | 102 | ACON LAB | | 070 | 070 | 070 | 070 | 161 | 161 | 161 | 100 | |
| 2021-062 | 131 | iCHEM VELO | | 070 | 070 | 070 | 070 | 26 | 26 | 26 | 100 | |
| 2021-062 | 135 | Hybrido AU | | 070 | 070 | 070 | 070 | 14 | 14 | 14 | 100 | |
| 2021-062 | 138 | URS-10T | | 070 | 070 | 070 | 070 | 10 | 10 | 10 | 100 | |
| 2021-062 | 140 | MISSION A | | 070 | 070 | 070 | 070 | 65 | 65 | 65 | 100 | |
| 2021-062 | 145 | CLINITEK | | 070 | 070 | 070 | 070 | 10 | 10 | 10 | 100 | |
| 2021-062 | 147 | Mission120 | | 070 | 070 | 070 | 070 | 23 | 23 | 23 | 100 | |
| 2021-062 | 148 | Mission500 | | 070 | 070 | 070 | 070 | 24 | 24 | 24 | 100 | |
| 061 URINALYSIS-NITRATE | | | | | | | | | | | | |
| 2021-063 | 011 | AMES NMI0S | | 070 | 070 | 070 | 070 | 50 | 50 | 50 | 100 | |
| 2021-063 | 013 | BAYER CLI | | 070 | 070 | 070 | 070 | 36 | 36 | 36 | 100 | |
| 2021-063 | 067 | URISCAN | | 070 | 070 | 070 | 070 | 49 | 49 | 49 | 100 | |
| 2021-063 | 071 | ATLAS | | 070 | 070 | 070 | 070 | 18 | 18 | 18 | 100 | |
| 2021-063 | 072 | URS-9-TECO | | 070 | 070 | 070 | 070 | 107 | 107 | 107 | 100 | |
| 2021-063 | 080 | ROCHE (CHE | | 070 | 070 | 070 | 070 | 37 | 37 | 37 | 100 | |
| 2021-063 | 089 | AIMSTRIP | | 070 | 070 | 070 | 070 | 115 | 115 | 115 | 100 | |
| 2021-063 | 094 | CLINITEK | | 070 | 070 | 070 | 070 | 102 | 102 | 102 | 100 | |
| 2021-063 | 102 | ACON LAB | | 070 | 070 | 070 | 070 | 161 | 161 | 161 | 100 | |
| 2021-063 | 131 | iCHEM VELO | | 070 | 070 | 070 | 070 | 26 | 26 | 26 | 100 | |
| 2021-063 | 135 | Hybrido AU | | 070 | 070 | 070 | 070 | 14 | 14 | 14 | 100 | |
| 2021-063 | 138 | URS-10T | | 070 | 070 | 070 | 070 | 10 | 10 | 10 | 100 | |
| 2021-063 | 140 | MISSION A | | 070 | 070 | 070 | 070 | 65 | 65 | 65 | 100 | |
| 2021-063 | 145 | CLINITEK | | 070 | 070 | 070 | 070 | 10 | 10 | 10 | 100 | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | | | | |
|------------------------|---------------------|---------------------|---------------------|---------------|------------------|--------------------|-----------------|-----------|-------------|-------------|-------|--|--|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | | |
| 2021-063 | 147 | Mission120 | | 070 070 | 070 070 | | 070 - NEGATIVE | 23 | 23 | 23 | 100 | | |
| 2021-063 | 148 | Mission500 | | 070 070 | 070 070 | | 070 - NEGATIVE | 24 | 24 | 24 | 100 | | |
| 061 URINALYSIS-NITRATE | | | | | | | | | | | | | |
| 2021-064 | 011 | AMES NM10S | | 071 072 | 071 072 | | 072 - POSITIVE | 50 | 50 | 50 | 100 | | |
| 2021-064 | 013 | BAYER CLI | | 071 072 | 071 072 | | 072 - POSITIVE | 36 | 36 | 36 | 100 | | |
| 2021-064 | 067 | URISCAN | | 071 072 | 071 072 | | 070 - NEGATIVE | 49 | 1 | 48 | 0 | | |
| 2021-064 | 067 | URISCAN | | 071 072 | 071 072 | | 072 - POSITIVE | 49 | 48 | 48 | 100 | | |
| 2021-064 | 071 | ATLAS | | 071 072 | 071 072 | | 072 - POSITIVE | 18 | 18 | 18 | 100 | | |
| 2021-064 | 072 | URS-9-TECO | | 071 072 | 071 072 | | 071 - WEAK POS. | 107 | 1 | 106 | 100 | | |
| 2021-064 | 072 | URS-9-TECO | | 071 072 | 071 072 | | 070 - NEGATIVE | 107 | 1 | 106 | 0 | | |
| 2021-064 | 072 | URS-9-TECO | | 071 072 | 071 072 | | 072 - POSITIVE | 107 | 105 | 106 | 100 | | |
| 2021-064 | 080 | ROCHE (CHE | | 071 072 | 071 072 | | 072 - POSITIVE | 37 | 37 | 37 | 100 | | |
| 2021-064 | 089 | AIMSTRIP | | 071 072 | 071 072 | | 072 - POSITIVE | 115 | 115 | 115 | 100 | | |
| 2021-064 | 094 | CLINITEK | | 071 072 | 071 072 | | 072 - POSITIVE | 102 | 102 | 102 | 100 | | |
| 2021-064 | 102 | ACON LAB | | 071 072 | 071 072 | | 070 - NEGATIVE | 161 | 1 | 160 | 0 | | |
| 2021-064 | 102 | ACON LAB | | 071 072 | 071 072 | | 072 - POSITIVE | 161 | 159 | 160 | 100 | | |
| 2021-064 | 102 | ACON LAB | | 071 072 | 071 072 | | 071 - WEAK POS. | 161 | 1 | 160 | 100 | | |
| 2021-064 | 131 | iCHEM VELO | | 071 072 | 071 072 | | 072 - POSITIVE | 26 | 26 | 26 | 100 | | |
| 2021-064 | 135 | Hybrido AU | | 071 072 | 071 072 | | 072 - POSITIVE | 14 | 14 | 14 | 100 | | |
| 2021-064 | 138 | URS-10T | | 071 072 | 071 072 | | 072 - POSITIVE | 10 | 10 | 10 | 100 | | |
| 2021-064 | 140 | MISSION A | | 071 072 | 071 072 | | 072 - POSITIVE | 65 | 65 | 65 | 100 | | |
| 2021-064 | 145 | CLINITEK | | 071 072 | 071 072 | | 072 - POSITIVE | 10 | 10 | 10 | 100 | | |
| 2021-064 | 147 | Mission120 | | 071 072 | 071 072 | | 072 - POSITIVE | 23 | 23 | 23 | 100 | | |
| 2021-064 | 148 | Mission500 | | 071 072 | 071 072 | | 072 - POSITIVE | 24 | 24 | 24 | 100 | | |
| 2021-065 | 011 | AMES NM10S | | 070 070 | 070 070 | | 070 - NEGATIVE | 50 | 50 | 50 | 100 | | |
| 2021-065 | 013 | BAYER CLI | | 070 070 | 070 070 | | 070 - NEGATIVE | 36 | 36 | 36 | 100 | | |
| 2021-065 | 067 | URISCAN | | 070 070 | 070 070 | | 070 - NEGATIVE | 49 | 48 | 48 | 100 | | |
| 2021-065 | 067 | URISCAN | | 070 070 | 070 070 | | 072 - POSITIVE | 49 | 1 | 48 | 0 | | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | | | | |
|-------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|-------------------|--------------|----------------|----------------|-------|-----|-----|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | | |
| 2021-065 | 071 | ATLAS | | 070 | 070 | 070 | 070 | 070 | - NEGATIVE | 18 | 18 | 18 | 100 |
| 2021-065 | 072 | URS-9-TECO | | 070 | 070 | 070 | 070 | 070 | - NEGATIVE | 107 | 107 | 107 | 100 |
| 2021-065 | 080 | ROCHE (CHE | | 070 | 070 | 070 | 070 | 070 | - NEGATIVE | 37 | 37 | 37 | 100 |
| 2021-065 | 089 | AIMSTRIP | | 070 | 070 | 070 | 070 | 070 | - NEGATIVE | 115 | 115 | 115 | 100 |
| 2021-065 | 094 | CLINITEK | | 070 | 070 | 070 | 070 | 070 | - NEGATIVE | 102 | 102 | 102 | 100 |
| 2021-065 | 102 | ACON LAB | | 070 | 070 | 070 | 070 | 070 | - NEGATIVE | 161 | 161 | 161 | 100 |
| 2021-065 | 131 | iCHEM VELO | | 070 | 070 | 070 | 070 | 070 | - NEGATIVE | 26 | 26 | 26 | 100 |
| 2021-065 | 135 | Hybrido AU | | 070 | 070 | 070 | 070 | 070 | - NEGATIVE | 14 | 14 | 14 | 100 |
| 2021-065 | 138 | URS-10T | | 070 | 070 | 070 | 070 | 070 | - NEGATIVE | 10 | 10 | 10 | 100 |
| 2021-065 | 140 | MISSION A | | 070 | 070 | 070 | 070 | 070 | - NEGATIVE | 65 | 65 | 65 | 100 |
| 2021-065 | 145 | CLINITEK | | 070 | 070 | 070 | 070 | 070 | - NEGATIVE | 10 | 10 | 10 | 100 |
| 2021-065 | 147 | Mission120 | | 070 | 070 | 070 | 070 | 070 | - NEGATIVE | 23 | 23 | 23 | 100 |
| 2021-065 | 148 | Mission500 | | 070 | 070 | 070 | 070 | 070 | - NEGATIVE | 24 | 24 | 24 | 100 |
| 062 URINALYSIS-pH | | | | | | | | | | | | | |
| 2021-061 | 011 | AMES NM10S | | 084 | 088 | 083 | 087 | 085 | - 6.5 | 50 | 11 | 50 | 100 |
| 2021-061 | 011 | AMES NM10S | | 084 | 088 | 083 | 087 | 086 | - 7.0 | 50 | 39 | 50 | 100 |
| 2021-061 | 013 | BAYER CLI | | 084 | 088 | 083 | 087 | 085 | - 6.5 | 36 | 7 | 36 | 100 |
| 2021-061 | 013 | BAYER CLI | | 084 | 088 | 083 | 087 | 086 | - 7.0 | 36 | 29 | 36 | 100 |
| 2021-061 | 067 | URISCAN | | 083 | 087 | 083 | 087 | 085 | - 6.5 | 49 | 35 | 49 | 100 |
| 2021-061 | 067 | URISCAN | | 083 | 087 | 083 | 087 | 084 | - 6.0 | 49 | 14 | 49 | 100 |
| 2021-061 | 071 | ATLAS | | 083 | 087 | 083 | 087 | 085 | - 6.5 | 18 | 18 | 18 | 100 |
| 2021-061 | 072 | URS-9-TECO | | 083 | 087 | 083 | 087 | 085 | - 6.5 | 107 | 70 | 107 | 100 |
| 2021-061 | 072 | URS-9-TECO | | 083 | 087 | 083 | 087 | 084 | - 6.0 | 107 | 8 | 107 | 100 |
| 2021-061 | 072 | URS-9-TECO | | 083 | 087 | 083 | 087 | 086 | - 7.0 | 107 | 29 | 107 | 100 |
| 2021-061 | 080 | ROCHE (CHE | | 083 | 087 | 083 | 087 | 084 | - 6.0 | 37 | 1 | 37 | 100 |
| 2021-061 | 080 | ROCHE (CHE | | 083 | 087 | 083 | 087 | 085 | - 6.5 | 37 | 35 | 37 | 100 |
| 2021-061 | 080 | ROCHE (CHE | | 083 | 087 | 083 | 087 | 086 | - 7.0 | 37 | 1 | 37 | 100 |
| 2021-061 | 089 | AIMSTRIP | | 083 | 087 | 083 | 087 | 082 | - 5.0 | 115 | 1 | 114 | 0 |
| 2021-061 | 089 | AIMSTRIP | | 083 | 087 | 083 | 087 | 086 | - 7.0 | 115 | 50 | 114 | 100 |
| 2021-061 | 089 | AIMSTRIP | | 083 | 087 | 083 | 087 | 084 | - 6.0 | 115 | 11 | 114 | 100 |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | | | | |
|-------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|--------------------|--------------|----------------|----------------|-------|-----|-----|-----|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | | | |
| 2021-061 | 089 | AIMSTRIP | | 083 | 087 | 083 | 087 | 085 | - | 6.5 | 115 | 53 | 114 | 100 |
| 2021-061 | 094 | CLINITEK | | 084 | 088 | 083 | 087 | 084 | - | 6.0 | 102 | 1 | 102 | 100 |
| 2021-061 | 094 | CLINITEK | | 084 | 088 | 083 | 087 | 083 | - | 5.5 | 102 | 1 | 102 | 100 |
| 2021-061 | 094 | CLINITEK | | 084 | 088 | 083 | 087 | 085 | - | 6.5 | 102 | 19 | 102 | 100 |
| 2021-061 | 094 | CLINITEK | | 084 | 088 | 083 | 087 | 086 | - | 7.0 | 102 | 81 | 102 | 100 |
| 2021-061 | 102 | ACON LAB | | 083 | 087 | 083 | 087 | 086 | - | 7.0 | 161 | 35 | 161 | 100 |
| 2021-061 | 102 | ACON LAB | | 083 | 087 | 083 | 087 | 085 | - | 6.5 | 161 | 100 | 161 | 100 |
| 2021-061 | 102 | ACON LAB | | 083 | 087 | 083 | 087 | 084 | - | 6.0 | 161 | 26 | 161 | 100 |
| 2021-061 | 131 | iCHEM VELO | | 082 | 086 | 083 | 087 | 084 | - | 6.0 | 26 | 25 | 26 | 100 |
| 2021-061 | 131 | iCHEM VELO | | 082 | 086 | 083 | 087 | 086 | - | 7.0 | 26 | 1 | 26 | 100 |
| 2021-061 | 135 | Hybrido AU | | 084 | 088 | 083 | 087 | 085 | - | 6.5 | 14 | 6 | 14 | 100 |
| 2021-061 | 135 | Hybrido AU | | 084 | 088 | 083 | 087 | 086 | - | 7.0 | 14 | 8 | 14 | 100 |
| 2021-061 | 138 | URS-10T | | 083 | 087 | 083 | 087 | 086 | - | 7.0 | 10 | 3 | 10 | 100 |
| 2021-061 | 138 | URS-10T | | 083 | 087 | 083 | 087 | 085 | - | 6.5 | 10 | 7 | 10 | 100 |
| 2021-061 | 140 | MISSION A | | 083 | 087 | 083 | 087 | 085 | - | 6.5 | 65 | 51 | 65 | 100 |
| 2021-061 | 140 | MISSION A | | 083 | 087 | 083 | 087 | 084 | - | 6.0 | 65 | 10 | 65 | 100 |
| 2021-061 | 140 | MISSION A | | 083 | 087 | 083 | 087 | 086 | - | 7.0 | 65 | 4 | 65 | 100 |
| 2021-061 | 145 | CLINITEK | | 083 | 087 | 083 | 087 | 085 | - | 6.5 | 10 | 10 | 10 | 100 |
| 2021-061 | 147 | Mission120 | | 083 | 087 | 083 | 087 | 085 | - | 6.5 | 23 | 23 | 23 | 100 |
| 2021-061 | 148 | Mission500 | | 083 | 087 | 083 | 087 | 085 | - | 6.5 | 24 | 24 | 24 | 100 |
| 062 URINALYSIS-pH | | | | | | | | | | | | | | |
| 2021-062 | 011 | AMES NM10S | | 086 | 088 | 086 | 088 | 087 | - | 7.5 | 50 | 7 | 50 | 100 |
| 2021-062 | 011 | AMES NM10S | | 086 | 088 | 086 | 088 | 088 | - | 8.0OR MORE | 50 | 43 | 50 | 100 |
| 2021-062 | 013 | BAYER CLI | | 086 | 088 | 086 | 088 | 088 | - | 8.0OR MORE | 36 | 27 | 36 | 100 |
| 2021-062 | 013 | BAYER CLI | | 086 | 088 | 086 | 088 | 087 | - | 7.5 | 36 | 9 | 36 | 100 |
| 2021-062 | 067 | URISCAN | | 085 | 088 | 086 | 088 | 088 | - | 8.0OR MORE | 49 | 18 | 49 | 100 |
| 2021-062 | 067 | URISCAN | | 085 | 088 | 086 | 088 | 087 | - | 7.5 | 49 | 31 | 49 | 100 |
| 2021-062 | 071 | ATLAS | | 085 | 088 | 086 | 088 | 087 | - | 7.5 | 18 | 13 | 18 | 100 |
| 2021-062 | 071 | ATLAS | | 085 | 088 | 086 | 088 | 088 | - | 8.0OR MORE | 18 | 5 | 18 | 100 |
| 2021-062 | 072 | URS-9-TECO | | 085 | 088 | 086 | 088 | 085 | - | 6.5 | 107 | 2 | 106 | 100 |

Participant Summary

MONTH 2 OF YEAR 2021

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score |
|----------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|-------------------|--------------|----------------|----------------|-------|
| 2021-062 | 072 | URS-9-TECO | | 085 088 | 086 088 | | 087 - 7.5 | 107 | 70 | 106 | 100 |
| 2021-062 | 072 | URS-9-TECO | | 085 088 | 086 088 | | 084 - 6.0 | 107 | 1 | 106 | 0 |
| 2021-062 | 072 | URS-9-TECO | | 085 088 | 086 088 | | 088 - 8.0OR MORE | 107 | 20 | 106 | 100 |
| 2021-062 | 072 | URS-9-TECO | | 085 088 | 086 088 | | 086 - 7.0 | 107 | 14 | 106 | 100 |
| 2021-062 | 080 | ROCHE (CHE | | 086 088 | 086 088 | | 086 - 7.0 | 37 | 5 | 37 | 100 |
| 2021-062 | 080 | ROCHE (CHE | | 086 088 | 086 088 | | 088 - 8.0OR MORE | 37 | 32 | 37 | 100 |
| 2021-062 | 089 | AIMSTRIP | | 086 088 | 086 088 | | 088 - 8.0OR MORE | 115 | 87 | 115 | 100 |
| 2021-062 | 089 | AIMSTRIP | | 086 088 | 086 088 | | 087 - 7.5 | 115 | 27 | 115 | 100 |
| 2021-062 | 089 | AIMSTRIP | | 086 088 | 086 088 | | 086 - 7.0 | 115 | 1 | 115 | 100 |
| 2021-062 | 094 | CLINITEK | | 086 088 | 086 088 | | 088 - 8.0OR MORE | 102 | 83 | 102 | 100 |
| 2021-062 | 094 | CLINITEK | | 086 088 | 086 088 | | 087 - 7.5 | 102 | 17 | 102 | 100 |
| 2021-062 | 094 | CLINITEK | | 086 088 | 086 088 | | 086 - 7.0 | 102 | 2 | 102 | 100 |
| 2021-062 | 102 | ACON LAB | | 086 088 | 086 088 | | 088 - 8.0OR MORE | 161 | 136 | 161 | 100 |
| 2021-062 | 102 | ACON LAB | | 086 088 | 086 088 | | 087 - 7.5 | 161 | 25 | 161 | 100 |
| 2021-062 | 131 | iCHEM VELO | | 086 088 | 086 088 | | 086 - 7.0 | 26 | 9 | 26 | 100 |
| 2021-062 | 131 | iCHEM VELO | | 086 088 | 086 088 | | 088 - 8.0OR MORE | 26 | 17 | 26 | 100 |
| 2021-062 | 135 | Hybrido AU | | 086 088 | 086 088 | | 087 - 7.5 | 14 | 1 | 14 | 100 |
| 2021-062 | 135 | Hybrido AU | | 086 088 | 086 088 | | 088 - 8.0OR MORE | 14 | 13 | 14 | 100 |
| 2021-062 | 138 | URS-10T | | 085 088 | 086 088 | | 087 - 7.5 | 10 | 7 | 10 | 100 |
| 2021-062 | 138 | URS-10T | | 085 088 | 086 088 | | 086 - 7.0 | 10 | 1 | 10 | 100 |
| 2021-062 | 138 | URS-10T | | 085 088 | 086 088 | | 088 - 8.0OR MORE | 10 | 2 | 10 | 100 |
| 2021-062 | 140 | MISSION A | | 086 088 | 086 088 | | 088 - 8.0OR MORE | 65 | 50 | 65 | 100 |
| 2021-062 | 140 | MISSION A | | 086 088 | 086 088 | | 087 - 7.5 | 65 | 15 | 65 | 100 |
| 2021-062 | 145 | CLINITEK | | 086 088 | 086 088 | | 088 - 8.0OR MORE | 10 | 8 | 10 | 100 |
| 2021-062 | 145 | CLINITEK | | 086 088 | 086 088 | | 087 - 7.5 | 10 | 2 | 10 | 100 |
| 2021-062 | 147 | Mission120 | | 086 088 | 086 088 | | 087 - 7.5 | 23 | 6 | 23 | 100 |
| 2021-062 | 147 | Mission120 | | 086 088 | 086 088 | | 088 - 8.0OR MORE | 23 | 17 | 23 | 100 |
| 2021-062 | 148 | Mission500 | | 086 088 | 086 088 | | 087 - 7.5 | 24 | 2 | 24 | 100 |
| 2021-062 | 148 | Mission500 | | 086 088 | 086 088 | | 088 - 8.0OR MORE | 24 | 22 | 24 | 100 |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | | |
|-------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|-------------------|--------------|----------------|----------------|-------|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score |
| 062 URINALYSIS-pH | | | | | | | | | | | |
| 2021-063 | 011 | AMES NM10S | | 086 088 | 086 088 | | 088 - 8.00R MORE | 50 | 41 | 50 | 100 |
| 2021-063 | 011 | AMES NM10S | | 086 088 | 086 088 | | 087 - 7.5 | 50 | 9 | 50 | 100 |
| 2021-063 | 013 | BAYER CLI | | 086 088 | 086 088 | | 087 - 7.5 | 36 | 13 | 36 | 100 |
| 2021-063 | 013 | BAYER CLI | | 086 088 | 086 088 | | 088 - 8.00R MORE | 36 | 23 | 36 | 100 |
| 2021-063 | 067 | URISCAN | | 085 088 | 086 088 | | 087 - 7.5 | 49 | 42 | 49 | 100 |
| 2021-063 | 067 | URISCAN | | 085 088 | 086 088 | | 086 - 7.0 | 49 | 3 | 49 | 100 |
| 2021-063 | 067 | URISCAN | | 085 088 | 086 088 | | 088 - 8.00R MORE | 49 | 4 | 49 | 100 |
| 2021-063 | 071 | ATLAS | | 085 088 | 086 088 | | 088 - 8.00R MORE | 18 | 1 | 18 | 100 |
| 2021-063 | 071 | ATLAS | | 085 088 | 086 088 | | 087 - 7.5 | 18 | 17 | 18 | 100 |
| 2021-063 | 072 | URS-9-TECO | | 085 088 | 086 088 | | 087 - 7.5 | 107 | 67 | 107 | 100 |
| 2021-063 | 072 | URS-9-TECO | | 085 088 | 086 088 | | 086 - 7.0 | 107 | 29 | 107 | 100 |
| 2021-063 | 072 | URS-9-TECO | | 085 088 | 086 088 | | 088 - 8.00R MORE | 107 | 9 | 107 | 100 |
| 2021-063 | 072 | URS-9-TECO | | 085 088 | 086 088 | | 085 - 6.5 | 107 | 2 | 107 | 100 |
| 2021-063 | 080 | ROCHE (CHE | | 086 088 | 086 088 | | 088 - 8.00R MORE | 37 | 28 | 37 | 100 |
| 2021-063 | 080 | ROCHE (CHE | | 086 088 | 086 088 | | 086 - 7.0 | 37 | 9 | 37 | 100 |
| 2021-063 | 089 | AIMSTRIP | | 086 088 | 086 088 | | 087 - 7.5 | 115 | 41 | 115 | 100 |
| 2021-063 | 089 | AIMSTRIP | | 086 088 | 086 088 | | 088 - 8.00R MORE | 115 | 74 | 115 | 100 |
| 2021-063 | 094 | CLINITEK | | 086 088 | 086 088 | | 087 - 7.5 | 102 | 24 | 102 | 100 |
| 2021-063 | 094 | CLINITEK | | 086 088 | 086 088 | | 088 - 8.00R MORE | 102 | 77 | 102 | 100 |
| 2021-063 | 094 | CLINITEK | | 086 088 | 086 088 | | 086 - 7.0 | 102 | 1 | 102 | 100 |
| 2021-063 | 102 | ACON LAB | | 086 088 | 086 088 | | 087 - 7.5 | 161 | 54 | 161 | 100 |
| 2021-063 | 102 | ACON LAB | | 086 088 | 086 088 | | 088 - 8.00R MORE | 161 | 107 | 161 | 100 |
| 2021-063 | 131 | iCHEM VELO | | 084 088 | 086 088 | | 086 - 7.0 | 26 | 24 | 26 | 100 |
| 2021-063 | 131 | iCHEM VELO | | 084 088 | 086 088 | | 088 - 8.00R MORE | 26 | 2 | 26 | 100 |
| 2021-063 | 135 | Hybrido AU | | 086 088 | 086 088 | | 088 - 8.00R MORE | 14 | 13 | 14 | 100 |
| 2021-063 | 135 | Hybrido AU | | 086 088 | 086 088 | | 087 - 7.5 | 14 | 1 | 14 | 100 |
| 2021-063 | 138 | URS-10T | | 085 088 | 086 088 | | 086 - 7.0 | 10 | 2 | 10 | 100 |
| 2021-063 | 138 | URS-10T | | 085 088 | 086 088 | | 087 - 7.5 | 10 | 8 | 10 | 100 |
| 2021-063 | 140 | MISSION A | | 086 088 | 086 088 | | 087 - 7.5 | 65 | 19 | 65 | 100 |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | | | |
|-------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|-------------------|--------------|----------------|----------------|-------|--|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | |
| 2021-063 | 140 | MISSION A | | 086 088 | 086 088 | | 088 - 8.00R MORE | 65 | 46 | 65 | 100 | |
| 2021-063 | 145 | CLINITEK | | 085 088 | 086 088 | | 088 - 8.00R MORE | 10 | 4 | 10 | 100 | |
| 2021-063 | 145 | CLINITEK | | 085 088 | 086 088 | | 087 - 7.5 | 10 | 6 | 10 | 100 | |
| 2021-063 | 147 | Mission120 | | 086 088 | 086 088 | | 088 - 8.00R MORE | 23 | 12 | 23 | 100 | |
| 2021-063 | 147 | Mission120 | | 086 088 | 086 088 | | 087 - 7.5 | 23 | 11 | 23 | 100 | |
| 2021-063 | 148 | Mission500 | | 086 088 | 086 088 | | 087 - 7.5 | 24 | 3 | 24 | 100 | |
| 2021-063 | 148 | Mission500 | | 086 088 | 086 088 | | 088 - 8.00R MORE | 24 | 21 | 24 | 100 | |
| 062 URINALYSIS-pH | | | | | | | | | | | | |
| 2021-064 | 011 | AMES NM10S | | 080 084 | 080 084 | | 083 - 5.5 | 50 | 15 | 50 | 100 | |
| 2021-064 | 011 | AMES NM10S | | 080 084 | 080 084 | | 084 - 6.0 | 50 | 4 | 50 | 100 | |
| 2021-064 | 011 | AMES NM10S | | 080 084 | 080 084 | | 082 - 5.0 | 50 | 31 | 50 | 100 | |
| 2021-064 | 013 | BAYER CLI | | 080 084 | 080 084 | | 083 - 5.5 | 36 | 15 | 35 | 100 | |
| 2021-064 | 013 | BAYER CLI | | 080 084 | 080 084 | | 085 - 6.5 | 36 | 1 | 35 | 0 | |
| 2021-064 | 013 | BAYER CLI | | 080 084 | 080 084 | | 082 - 5.0 | 36 | 20 | 35 | 100 | |
| 2021-064 | 067 | URISCAN | | 080 084 | 080 084 | | 082 - 5.0 | 49 | 42 | 48 | 100 | |
| 2021-064 | 067 | URISCAN | | 080 084 | 080 084 | | 086 - 7.0 | 49 | 1 | 48 | 0 | |
| 2021-064 | 067 | URISCAN | | 080 084 | 080 084 | | 083 - 5.5 | 49 | 5 | 48 | 100 | |
| 2021-064 | 067 | URISCAN | | 080 084 | 080 084 | | 084 - 6.0 | 49 | 1 | 48 | 100 | |
| 2021-064 | 071 | ATLAS | | 080 084 | 080 084 | | 082 - 5.0 | 18 | 14 | 18 | 100 | |
| 2021-064 | 071 | ATLAS | | 080 084 | 080 084 | | 083 - 5.5 | 18 | 4 | 18 | 100 | |
| 2021-064 | 072 | URS-9-TECO | | 082 086 | 080 084 | | 084 - 6.0 | 107 | 60 | 107 | 100 | |
| 2021-064 | 072 | URS-9-TECO | | 082 086 | 080 084 | | 083 - 5.5 | 107 | 20 | 107 | 100 | |
| 2021-064 | 072 | URS-9-TECO | | 082 086 | 080 084 | | 082 - 5.0 | 107 | 17 | 107 | 100 | |
| 2021-064 | 072 | URS-9-TECO | | 082 086 | 080 084 | | 085 - 6.5 | 107 | 10 | 107 | 100 | |
| 2021-064 | 080 | ROCHE (CHE | | 080 084 | 080 084 | | 082 - 5.0 | 37 | 36 | 37 | 100 | |
| 2021-064 | 080 | ROCHE (CHE | | 080 084 | 080 084 | | 084 - 6.0 | 37 | 1 | 37 | 100 | |
| 2021-064 | 089 | AIMSTRIP | | 080 084 | 080 084 | | 084 - 6.0 | 115 | 9 | 114 | 100 | |
| 2021-064 | 089 | AIMSTRIP | | 080 084 | 080 084 | | 083 - 5.5 | 115 | 34 | 114 | 100 | |
| 2021-064 | 089 | AIMSTRIP | | 080 084 | 080 084 | | 082 - 5.0 | 115 | 71 | 114 | 100 | |
| 2021-064 | 089 | AIMSTRIP | | 080 084 | 080 084 | | 085 - 6.5 | 115 | 1 | 114 | 0 | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | | |
|-------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|-------------------|--------------|----------------|----------------|-------|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score |
| 2021-064 | 094 | CLINITEK | | 081 085 | 080 084 | | 082 - 5.0 | 102 | 41 | 102 | 100 |
| 2021-064 | 094 | CLINITEK | | 081 085 | 080 084 | | 084 - 6.0 | 102 | 8 | 102 | 100 |
| 2021-064 | 094 | CLINITEK | | 081 085 | 080 084 | | 083 - 5.5 | 102 | 53 | 102 | 100 |
| 2021-064 | 102 | ACON LAB | | 082 086 | 080 084 | | 083 - 5.5 | 161 | 43 | 161 | 100 |
| 2021-064 | 102 | ACON LAB | | 082 086 | 080 084 | | 084 - 6.0 | 161 | 67 | 161 | 100 |
| 2021-064 | 102 | ACON LAB | | 082 086 | 080 084 | | 082 - 5.0 | 161 | 51 | 161 | 100 |
| 2021-064 | 131 | iCHEM VELO | | 080 084 | 080 084 | | 082 - 5.0 | 26 | 26 | 26 | 100 |
| 2021-064 | 135 | Hybrido AU | | 080 084 | 080 084 | | 082 - 5.0 | 14 | 14 | 14 | 100 |
| 2021-064 | 138 | URS-10T | | 081 085 | 080 084 | | 084 - 6.0 | 10 | 3 | 10 | 100 |
| 2021-064 | 138 | URS-10T | | 081 085 | 080 084 | | 083 - 5.5 | 10 | 3 | 10 | 100 |
| 2021-064 | 138 | URS-10T | | 081 085 | 080 084 | | 085 - 6.5 | 10 | 1 | 10 | 100 |
| 2021-064 | 138 | URS-10T | | 081 085 | 080 084 | | 082 - 5.0 | 10 | 3 | 10 | 100 |
| 2021-064 | 140 | MISSION A | | 081 085 | 080 084 | | 084 - 6.0 | 65 | 17 | 65 | 100 |
| 2021-064 | 140 | MISSION A | | 081 085 | 080 084 | | 083 - 5.5 | 65 | 28 | 65 | 100 |
| 2021-064 | 140 | MISSION A | | 081 085 | 080 084 | | 082 - 5.0 | 65 | 20 | 65 | 100 |
| 2021-064 | 145 | CLINITEK | | 080 084 | 080 084 | | 082 - 5.0 | 10 | 10 | 10 | 100 |
| 2021-064 | 147 | Mission120 | | 081 085 | 080 084 | | 082 - 5.0 | 23 | 11 | 23 | 100 |
| 2021-064 | 147 | Mission120 | | 081 085 | 080 084 | | 083 - 5.5 | 23 | 12 | 23 | 100 |
| 2021-064 | 148 | Mission500 | | 082 086 | 080 084 | | 082 - 5.0 | 24 | 1 | 24 | 100 |
| 2021-064 | 148 | Mission500 | | 082 086 | 080 084 | | 083 - 5.5 | 24 | 6 | 24 | 100 |
| 2021-064 | 148 | Mission500 | | 082 086 | 080 084 | | 084 - 6.0 | 24 | 17 | 24 | 100 |
| 062 URINALYSIS-pH | | | | | | | | | | | |
| 2021-065 | 011 | AMES NM10S | | 085 088 | 084 088 | | 086 - 7.0 | 50 | 7 | 50 | 100 |
| 2021-065 | 011 | AMES NM10S | | 085 088 | 084 088 | | 087 - 7.5 | 50 | 43 | 50 | 100 |
| 2021-065 | 013 | BAYER CLI | | 085 088 | 084 088 | | 087 - 7.5 | 36 | 26 | 36 | 100 |
| 2021-065 | 013 | BAYER CLI | | 085 088 | 084 088 | | 086 - 7.0 | 36 | 10 | 36 | 100 |
| 2021-065 | 067 | URISCAN | | 084 088 | 084 088 | | 082 - 5.0 | 49 | 1 | 48 | 0 |
| 2021-065 | 067 | URISCAN | | 084 088 | 084 088 | | 085 - 6.5 | 49 | 2 | 48 | 100 |
| 2021-065 | 067 | URISCAN | | 084 088 | 084 088 | | 086 - 7.0 | 49 | 44 | 48 | 100 |
| 2021-065 | 067 | URISCAN | | 084 088 | 084 088 | | 087 - 7.5 | 49 | 2 | 48 | 100 |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | | |
|-------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|-------------------|--------------|----------------|----------------|-------|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score |
| 2021-065 | 071 | ATLAS | | 085 088 | 084 088 | | 087 - 7.5 | 18 | 11 | 18 | 100 |
| 2021-065 | 071 | ATLAS | | 085 088 | 084 088 | | 086 - 7.0 | 18 | 7 | 18 | 100 |
| 2021-065 | 072 | URS-9-TECO | | 084 088 | 084 088 | | 085 - 6.5 | 107 | 2 | 107 | 100 |
| 2021-065 | 072 | URS-9-TECO | | 084 088 | 084 088 | | 087 - 7.5 | 107 | 6 | 107 | 100 |
| 2021-065 | 072 | URS-9-TECO | | 084 088 | 084 088 | | 086 - 7.0 | 107 | 99 | 107 | 100 |
| 2021-065 | 080 | ROCHE (CHE | | 084 088 | 084 088 | | 086 - 7.0 | 37 | 37 | 37 | 100 |
| 2021-065 | 089 | AIMSTRIP | | 084 088 | 084 088 | | 087 - 7.5 | 115 | 50 | 115 | 100 |
| 2021-065 | 089 | AIMSTRIP | | 084 088 | 084 088 | | 086 - 7.0 | 115 | 61 | 115 | 100 |
| 2021-065 | 089 | AIMSTRIP | | 084 088 | 084 088 | | 088 - 8.0OR MORE | 115 | 1 | 115 | 100 |
| 2021-065 | 089 | AIMSTRIP | | 084 088 | 084 088 | | 085 - 6.5 | 115 | 3 | 115 | 100 |
| 2021-065 | 094 | CLINITEK | | 085 088 | 084 088 | | 087 - 7.5 | 102 | 80 | 102 | 100 |
| 2021-065 | 094 | CLINITEK | | 085 088 | 084 088 | | 086 - 7.0 | 102 | 22 | 102 | 100 |
| 2021-065 | 102 | ACON LAB | | 084 088 | 084 088 | | 086 - 7.0 | 161 | 122 | 161 | 100 |
| 2021-065 | 102 | ACON LAB | | 084 088 | 084 088 | | 085 - 6.5 | 161 | 1 | 161 | 100 |
| 2021-065 | 102 | ACON LAB | | 084 088 | 084 088 | | 087 - 7.5 | 161 | 38 | 161 | 100 |
| 2021-065 | 131 | icHEM VELO | | 084 088 | 084 088 | | 086 - 7.0 | 26 | 26 | 26 | 100 |
| 2021-065 | 135 | Hybrido AU | | 085 088 | 084 088 | | 086 - 7.0 | 14 | 1 | 14 | 100 |
| 2021-065 | 135 | Hybrido AU | | 085 088 | 084 088 | | 087 - 7.5 | 14 | 13 | 14 | 100 |
| 2021-065 | 138 | URS-10T | | 084 088 | 084 088 | | 086 - 7.0 | 10 | 9 | 10 | 100 |
| 2021-065 | 138 | URS-10T | | 084 088 | 084 088 | | 087 - 7.5 | 10 | 1 | 10 | 100 |
| 2021-065 | 140 | MISSION A | | 084 088 | 084 088 | | 087 - 7.5 | 65 | 13 | 65 | 100 |
| 2021-065 | 140 | MISSION A | | 084 088 | 084 088 | | 086 - 7.0 | 65 | 51 | 65 | 100 |
| 2021-065 | 140 | MISSION A | | 084 088 | 084 088 | | 088 - 8.0OR MORE | 65 | 1 | 65 | 100 |
| 2021-065 | 145 | CLINITEK | | 085 088 | 084 088 | | 087 - 7.5 | 10 | 8 | 10 | 100 |
| 2021-065 | 145 | CLINITEK | | 085 088 | 084 088 | | 086 - 7.0 | 10 | 2 | 10 | 100 |
| 2021-065 | 147 | Mission120 | | 084 088 | 084 088 | | 086 - 7.0 | 23 | 21 | 23 | 100 |
| 2021-065 | 147 | Mission120 | | 084 088 | 084 088 | | 087 - 7.5 | 23 | 2 | 23 | 100 |
| 2021-065 | 148 | Mission500 | | 084 088 | 084 088 | | 087 - 7.5 | 24 | 1 | 24 | 100 |
| 2021-065 | 148 | Mission500 | | 084 088 | 084 088 | | 086 - 7.0 | 24 | 23 | 24 | 100 |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | | | | |
|-------------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|-------------------|--------------|----------------|----------------|-------|--|--|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | | |
| 064 URIN-PROTEIN QUALI. | | | | | | | | | | | | | |
| 2021-061 | 011 | AMES NM10S | | 053 055 | 053 055 | | 056 - 4+ | 51 | 1 | 50 | 0 | | |
| 2021-061 | 011 | AMES NM10S | | 053 055 | 053 055 | | 053 - 1+ | 51 | 5 | 50 | 100 | | |
| 2021-061 | 011 | AMES NM10S | | 053 055 | 053 055 | | 054 - 2+ | 51 | 32 | 50 | 100 | | |
| 2021-061 | 011 | AMES NM10S | | 053 055 | 053 055 | | 055 - 3+ | 51 | 13 | 50 | 100 | | |
| 2021-061 | 013 | BAYER CLI | | 053 055 | 053 055 | | 052 - TRACES | 35 | 1 | 34 | 0 | | |
| 2021-061 | 013 | BAYER CLI | | 053 055 | 053 055 | | 053 - 1+ | 35 | 2 | 34 | 100 | | |
| 2021-061 | 013 | BAYER CLI | | 053 055 | 053 055 | | 054 - 2+ | 35 | 25 | 34 | 100 | | |
| 2021-061 | 013 | BAYER CLI | | 053 055 | 053 055 | | 055 - 3+ | 35 | 7 | 34 | 100 | | |
| 2021-061 | 067 | URISCAN | | 053 055 | 053 055 | | 055 - 3+ | 49 | 1 | 49 | 100 | | |
| 2021-061 | 067 | URISCAN | | 053 055 | 053 055 | | 053 - 1+ | 49 | 12 | 49 | 100 | | |
| 2021-061 | 067 | URISCAN | | 053 055 | 053 055 | | 054 - 2+ | 49 | 36 | 49 | 100 | | |
| 2021-061 | 071 | ATLAS | | 053 055 | 053 055 | | 053 - 1+ | 18 | 1 | 18 | 100 | | |
| 2021-061 | 071 | ATLAS | | 053 055 | 053 055 | | 054 - 2+ | 18 | 17 | 18 | 100 | | |
| 2021-061 | 072 | URS-9-TECO | | 053 055 | 053 055 | | 055 - 3+ | 108 | 26 | 108 | 100 | | |
| 2021-061 | 072 | URS-9-TECO | | 053 055 | 053 055 | | 053 - 1+ | 108 | 6 | 108 | 100 | | |
| 2021-061 | 072 | URS-9-TECO | | 053 055 | 053 055 | | 054 - 2+ | 108 | 76 | 108 | 100 | | |
| 2021-061 | 080 | ROCHE (CHE | | 053 055 | 053 055 | | 055 - 3+ | 37 | 11 | 37 | 100 | | |
| 2021-061 | 080 | ROCHE (CHE | | 053 055 | 053 055 | | 054 - 2+ | 37 | 26 | 37 | 100 | | |
| 2021-061 | 089 | AIMSTRIP | | 053 055 | 053 055 | | 054 - 2+ | 114 | 97 | 112 | 100 | | |
| 2021-061 | 089 | AIMSTRIP | | 053 055 | 053 055 | | 056 - 4+ | 114 | 2 | 112 | 0 | | |
| 2021-061 | 089 | AIMSTRIP | | 053 055 | 053 055 | | 055 - 3+ | 114 | 13 | 112 | 100 | | |
| 2021-061 | 089 | AIMSTRIP | | 053 055 | 053 055 | | 053 - 1+ | 114 | 2 | 112 | 100 | | |
| 2021-061 | 094 | CLINITEK | | 053 055 | 053 055 | | 055 - 3+ | 102 | 9 | 101 | 100 | | |
| 2021-061 | 094 | CLINITEK | | 053 055 | 053 055 | | 056 - 4+ | 102 | 1 | 101 | 0 | | |
| 2021-061 | 094 | CLINITEK | | 053 055 | 053 055 | | 054 - 2+ | 102 | 87 | 101 | 100 | | |
| 2021-061 | 094 | CLINITEK | | 053 055 | 053 055 | | 053 - 1+ | 102 | 5 | 101 | 100 | | |
| 2021-061 | 102 | ACON LAB | | 053 055 | 053 055 | | 053 - 1+ | 160 | 5 | 156 | 100 | | |
| 2021-061 | 102 | ACON LAB | | 053 055 | 053 055 | | 054 - 2+ | 160 | 130 | 156 | 100 | | |
| 2021-061 | 102 | ACON LAB | | 053 055 | 053 055 | | 056 - 4+ | 160 | 3 | 156 | 0 | | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | | |
|-------------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|--------------------|--------------|----------------|----------------|-------|--|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | |
| 2021-061 | 102 | ACON LAB | | 053 055 | 053 055 | | 052 - TRACES | 160 | 1 | 156 | 0 | |
| 2021-061 | 102 | ACON LAB | | 053 055 | 053 055 | | 055 - 3+ | 160 | 21 | 156 | 100 | |
| 2021-061 | 131 | iCHEM VELO | | 053 055 | 053 055 | | 054 - 2+ | 26 | 25 | 26 | 100 | |
| 2021-061 | 131 | iCHEM VELO | | 053 055 | 053 055 | | 055 - 3+ | 26 | 1 | 26 | 100 | |
| 2021-061 | 135 | Hybrido AU | | 053 055 | 053 055 | | 054 - 2+ | 14 | 14 | 14 | 100 | |
| 2021-061 | 138 | URS-10T | | 053 055 | 053 055 | | 055 - 3+ | 10 | 3 | 10 | 100 | |
| 2021-061 | 138 | URS-10T | | 053 055 | 053 055 | | 053 - 1+ | 10 | 1 | 10 | 100 | |
| 2021-061 | 138 | URS-10T | | 053 055 | 053 055 | | 054 - 2+ | 10 | 6 | 10 | 100 | |
| 2021-061 | 140 | MISSION A | | 053 055 | 053 055 | | 054 - 2+ | 65 | 53 | 65 | 100 | |
| 2021-061 | 140 | MISSION A | | 053 055 | 053 055 | | 053 - 1+ | 65 | 5 | 65 | 100 | |
| 2021-061 | 140 | MISSION A | | 053 055 | 053 055 | | 055 - 3+ | 65 | 7 | 65 | 100 | |
| 2021-061 | 145 | CLINITEK | | 053 055 | 053 055 | | 055 - 3+ | 10 | 1 | 10 | 100 | |
| 2021-061 | 145 | CLINITEK | | 053 055 | 053 055 | | 054 - 2+ | 10 | 9 | 10 | 100 | |
| 2021-061 | 147 | Mission120 | | 053 055 | 053 055 | | 054 - 2+ | 23 | 21 | 23 | 100 | |
| 2021-061 | 147 | Mission120 | | 053 055 | 053 055 | | 053 - 1+ | 23 | 2 | 23 | 100 | |
| 2021-061 | 148 | Mission500 | | 053 055 | 053 055 | | 053 - 1+ | 24 | 2 | 24 | 100 | |
| 2021-061 | 148 | Mission500 | | 053 055 | 053 055 | | 054 - 2+ | 24 | 19 | 24 | 100 | |
| 2021-061 | 148 | Mission500 | | 053 055 | 053 055 | | 055 - 3+ | 24 | 3 | 24 | 100 | |
| 064 URIN-PROTEIN QUALI. | | | | | | | | | | | | |
| 2021-062 | 011 | AMES NM10S | | 051 051 | 051 051 | | 051 - NEGATIVE | 51 | 51 | 51 | 100 | |
| 2021-062 | 013 | BAYER CLI | | 051 051 | 051 051 | | 051 - NEGATIVE | 35 | 35 | 35 | 100 | |
| 2021-062 | 067 | URISCAN | | 051 051 | 051 051 | | 051 - NEGATIVE | 49 | 48 | 48 | 100 | |
| 2021-062 | 067 | URISCAN | | 051 051 | 051 051 | | 052 - TRACES | 49 | 1 | 48 | 0 | |
| 2021-062 | 071 | ATLAS | | 051 051 | 051 051 | | 051 - NEGATIVE | 18 | 18 | 18 | 100 | |
| 2021-062 | 072 | URS-9-TECO | | 051 051 | 051 051 | | 052 - TRACES | 108 | 1 | 107 | 0 | |
| 2021-062 | 072 | URS-9-TECO | | 051 051 | 051 051 | | 051 - NEGATIVE | 108 | 107 | 107 | 100 | |
| 2021-062 | 080 | ROCHE (CHE | | 051 051 | 051 051 | | 051 - NEGATIVE | 37 | 36 | 36 | 100 | |
| 2021-062 | 080 | ROCHE (CHE | | 051 051 | 051 051 | | 052 - TRACES | 37 | 1 | 36 | 0 | |
| 2021-062 | 089 | AIMSTRIP | | 051 051 | 051 051 | | 052 - TRACES | 114 | 1 | 112 | 0 | |
| 2021-062 | 089 | AIMSTRIP | | 051 051 | 051 051 | | 054 - 2+ | 114 | 1 | 112 | 0 | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | | | |
|-------------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|-------------------|--------------|----------------|----------------|-------|--|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | |
| 2021-062 | 089 | AIMSTRIP | | 051 051 | 051 051 | | 051 - NEGATIVE | 114 | 112 | 112 | 100 | |
| 2021-062 | 094 | CLINITEK | | 051 051 | 051 051 | | 051 - NEGATIVE | 102 | 101 | 101 | 100 | |
| 2021-062 | 094 | CLINITEK | | 051 051 | 051 051 | | 052 - TRACES | 102 | 1 | 101 | 0 | |
| 2021-062 | 102 | ACON LAB | | 051 051 | 051 051 | | 051 - NEGATIVE | 160 | 156 | 156 | 100 | |
| 2021-062 | 102 | ACON LAB | | 051 051 | 051 051 | | 053 - 1+ | 160 | 1 | 156 | 0 | |
| 2021-062 | 102 | ACON LAB | | 051 051 | 051 051 | | 052 - TRACES | 160 | 3 | 156 | 0 | |
| 2021-062 | 131 | iCHEM VELO | | 051 051 | 051 051 | | 051 - NEGATIVE | 26 | 26 | 26 | 100 | |
| 2021-062 | 135 | Hybrido AU | | 051 051 | 051 051 | | 051 - NEGATIVE | 14 | 14 | 14 | 100 | |
| 2021-062 | 138 | URS-10T | | 051 051 | 051 051 | | 051 - NEGATIVE | 10 | 10 | 10 | 100 | |
| 2021-062 | 140 | MISSION A | | 051 051 | 051 051 | | 051 - NEGATIVE | 65 | 63 | 63 | 100 | |
| 2021-062 | 140 | MISSION A | | 051 051 | 051 051 | | 052 - TRACES | 65 | 2 | 63 | 0 | |
| 2021-062 | 145 | CLINITEK | | 051 051 | 051 051 | | 051 - NEGATIVE | 10 | 10 | 10 | 100 | |
| 2021-062 | 147 | Mission120 | | 051 051 | 051 051 | | 051 - NEGATIVE | 23 | 22 | 22 | 100 | |
| 2021-062 | 147 | Mission120 | | 051 051 | 051 051 | | 052 - TRACES | 23 | 1 | 22 | 0 | |
| 2021-062 | 148 | Mission500 | | 051 051 | 051 051 | | 052 - TRACES | 24 | 2 | 22 | 0 | |
| 2021-062 | 148 | Mission500 | | 051 051 | 051 051 | | 051 - NEGATIVE | 24 | 22 | 22 | 100 | |
| 064 URIN-PROTEIN QUALI. | | | | | | | | | | | | |
| 2021-063 | 011 | AMES NM10S | | 053 055 | 053 055 | | 055 - 3+ | 51 | 22 | 50 | 100 | |
| 2021-063 | 011 | AMES NM10S | | 053 055 | 053 055 | | 056 - 4+ | 51 | 1 | 50 | 0 | |
| 2021-063 | 011 | AMES NM10S | | 053 055 | 053 055 | | 054 - 2+ | 51 | 27 | 50 | 100 | |
| 2021-063 | 011 | AMES NM10S | | 053 055 | 053 055 | | 053 - 1+ | 51 | 1 | 50 | 100 | |
| 2021-063 | 013 | BAYER CLI | | 053 055 | 053 055 | | 055 - 3+ | 35 | 14 | 34 | 100 | |
| 2021-063 | 013 | BAYER CLI | | 053 055 | 053 055 | | 054 - 2+ | 35 | 20 | 34 | 100 | |
| 2021-063 | 013 | BAYER CLI | | 053 055 | 053 055 | | 052 - TRACES | 35 | 1 | 34 | 0 | |
| 2021-063 | 067 | URISCAN | | 053 055 | 053 055 | | 055 - 3+ | 49 | 8 | 49 | 100 | |
| 2021-063 | 067 | URISCAN | | 053 055 | 053 055 | | 054 - 2+ | 49 | 41 | 49 | 100 | |
| 2021-063 | 071 | ATLAS | | 053 055 | 053 055 | | 053 - 1+ | 18 | 1 | 18 | 100 | |
| 2021-063 | 071 | ATLAS | | 053 055 | 053 055 | | 054 - 2+ | 18 | 17 | 18 | 100 | |
| 2021-063 | 072 | URS-9-TECO | | 053 055 | 053 055 | | 056 - 4+ | 108 | 2 | 106 | 0 | |
| 2021-063 | 072 | URS-9-TECO | | 053 055 | 053 055 | | 055 - 3+ | 108 | 50 | 106 | 100 | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | | | |
|-------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|--------------------|--------------|----------------|----------------|-------|-----|-----|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | | |
| 2021-063 | 072 | URS-9-TECO | | 053 | 055 | 053 | 055 | 053 | - 1+ | 108 | 1 | 106 | 100 |
| 2021-063 | 072 | URS-9-TECO | | 053 | 055 | 053 | 055 | 054 | - 2+ | 108 | 55 | 106 | 100 |
| 2021-063 | 080 | ROCHE (CHE | | 053 | 055 | 053 | 055 | 053 | - 1+ | 37 | 1 | 37 | 100 |
| 2021-063 | 080 | ROCHE (CHE | | 053 | 055 | 053 | 055 | 054 | - 2+ | 37 | 27 | 37 | 100 |
| 2021-063 | 080 | ROCHE (CHE | | 053 | 055 | 053 | 055 | 055 | - 3+ | 37 | 9 | 37 | 100 |
| 2021-063 | 089 | AIMSTRIP | | 053 | 055 | 053 | 055 | 056 | - 4+ | 114 | 4 | 110 | 0 |
| 2021-063 | 089 | AIMSTRIP | | 053 | 055 | 053 | 055 | 054 | - 2+ | 114 | 57 | 110 | 100 |
| 2021-063 | 089 | AIMSTRIP | | 053 | 055 | 053 | 055 | 053 | - 1+ | 114 | 2 | 110 | 100 |
| 2021-063 | 089 | AIMSTRIP | | 053 | 055 | 053 | 055 | 055 | - 3+ | 114 | 51 | 110 | 100 |
| 2021-063 | 094 | CLINITEK | | 053 | 055 | 053 | 055 | 054 | - 2+ | 102 | 81 | 100 | 100 |
| 2021-063 | 094 | CLINITEK | | 053 | 055 | 053 | 055 | 056 | - 4+ | 102 | 2 | 100 | 0 |
| 2021-063 | 094 | CLINITEK | | 053 | 055 | 053 | 055 | 055 | - 3+ | 102 | 15 | 100 | 100 |
| 2021-063 | 094 | CLINITEK | | 053 | 055 | 053 | 055 | 053 | - 1+ | 102 | 4 | 100 | 100 |
| 2021-063 | 102 | ACON LAB | | 053 | 055 | 053 | 055 | 053 | - 1+ | 160 | 2 | 154 | 100 |
| 2021-063 | 102 | ACON LAB | | 053 | 055 | 053 | 055 | 054 | - 2+ | 160 | 90 | 154 | 100 |
| 2021-063 | 102 | ACON LAB | | 053 | 055 | 053 | 055 | 056 | - 4+ | 160 | 5 | 154 | 0 |
| 2021-063 | 102 | ACON LAB | | 053 | 055 | 053 | 055 | 052 | - TRACES | 160 | 1 | 154 | 0 |
| 2021-063 | 102 | ACON LAB | | 053 | 055 | 053 | 055 | 055 | - 3+ | 160 | 62 | 154 | 100 |
| 2021-063 | 131 | iCHEM VELO | | 053 | 055 | 053 | 055 | 055 | - 3+ | 26 | 5 | 26 | 100 |
| 2021-063 | 131 | iCHEM VELO | | 053 | 055 | 053 | 055 | 054 | - 2+ | 26 | 21 | 26 | 100 |
| 2021-063 | 135 | Hybrido AU | | 053 | 055 | 053 | 055 | 054 | - 2+ | 14 | 14 | 14 | 100 |
| 2021-063 | 138 | URS-10T | | 054 | 056 | 053 | 055 | 051 | - NEGATIVE | 10 | 1 | 9 | 0 |
| 2021-063 | 138 | URS-10T | | 054 | 056 | 053 | 055 | 055 | - 3+ | 10 | 6 | 9 | 100 |
| 2021-063 | 138 | URS-10T | | 054 | 056 | 053 | 055 | 054 | - 2+ | 10 | 3 | 9 | 100 |
| 2021-063 | 140 | MISSION A | | 053 | 055 | 053 | 055 | 055 | - 3+ | 65 | 12 | 64 | 100 |
| 2021-063 | 140 | MISSION A | | 053 | 055 | 053 | 055 | 054 | - 2+ | 65 | 48 | 64 | 100 |
| 2021-063 | 140 | MISSION A | | 053 | 055 | 053 | 055 | 053 | - 1+ | 65 | 4 | 64 | 100 |
| 2021-063 | 140 | MISSION A | | 053 | 055 | 053 | 055 | 056 | - 4+ | 65 | 1 | 64 | 0 |
| 2021-063 | 145 | CLINITEK | | 054 | 056 | 053 | 055 | 055 | - 3+ | 10 | 5 | 10 | 100 |
| 2021-063 | 145 | CLINITEK | | 054 | 056 | 053 | 055 | 054 | - 2+ | 10 | 5 | 10 | 100 |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | | |
|-------------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|--------------------|--------------|----------------|----------------|-------|--|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | |
| 2021-063 | 147 | Mission120 | | 053 055 | 053 055 | | 053 - 1+ | 23 | 1 | 23 | 100 | |
| 2021-063 | 147 | Mission120 | | 053 055 | 053 055 | | 054 - 2+ | 23 | 20 | 23 | 100 | |
| 2021-063 | 147 | Mission120 | | 053 055 | 053 055 | | 055 - 3+ | 23 | 2 | 23 | 100 | |
| 2021-063 | 148 | Mission500 | | 054 056 | 053 055 | | 054 - 2+ | 24 | 10 | 24 | 100 | |
| 2021-063 | 148 | Mission500 | | 054 056 | 053 055 | | 053 - 1+ | 24 | 1 | 24 | 100 | |
| 2021-063 | 148 | Mission500 | | 054 056 | 053 055 | | 056 - 4+ | 24 | 2 | 24 | 100 | |
| 2021-063 | 148 | Mission500 | | 054 056 | 053 055 | | 055 - 3+ | 24 | 11 | 24 | 100 | |
| 064 URIN-PROTEIN QUALI. | | | | | | | | | | | | |
| 2021-064 | 011 | AMES NM10S | | 051 051 | 051 051 | | 051 - NEGATIVE | 51 | 51 | 51 | 100 | |
| 2021-064 | 013 | BAYER CLI | | 051 051 | 051 051 | | 051 - NEGATIVE | 35 | 35 | 35 | 100 | |
| 2021-064 | 067 | URISCAN | | 051 051 | 051 051 | | 053 - 1+ | 49 | 1 | 48 | 0 | |
| 2021-064 | 067 | URISCAN | | 051 051 | 051 051 | | 051 - NEGATIVE | 49 | 48 | 48 | 100 | |
| 2021-064 | 071 | ATLAS | | 051 051 | 051 051 | | 051 - NEGATIVE | 18 | 18 | 18 | 100 | |
| 2021-064 | 072 | URS-9-TECO | | 051 051 | 051 051 | | 051 - NEGATIVE | 108 | 107 | 107 | 100 | |
| 2021-064 | 072 | URS-9-TECO | | 051 051 | 051 051 | | 055 - 3+ | 108 | 1 | 107 | 0 | |
| 2021-064 | 080 | ROCHE (CHE | | 051 051 | 051 051 | | 051 - NEGATIVE | 37 | 37 | 37 | 100 | |
| 2021-064 | 089 | AIMSTRIP | | 051 051 | 051 051 | | 051 - NEGATIVE | 114 | 114 | 114 | 100 | |
| 2021-064 | 094 | CLINITEK | | 051 051 | 051 051 | | 051 - NEGATIVE | 102 | 101 | 101 | 100 | |
| 2021-064 | 094 | CLINITEK | | 051 051 | 051 051 | | 052 - TRACES | 102 | 1 | 101 | 0 | |
| 2021-064 | 102 | ACON LAB | | 051 051 | 051 051 | | 051 - NEGATIVE | 160 | 160 | 160 | 100 | |
| 2021-064 | 131 | ICHEM VELO | | 051 051 | 051 051 | | 051 - NEGATIVE | 26 | 26 | 26 | 100 | |
| 2021-064 | 135 | Hybrido AU | | 051 051 | 051 051 | | 051 - NEGATIVE | 14 | 14 | 14 | 100 | |
| 2021-064 | 138 | URS-10T | | 051 051 | 051 051 | | 051 - NEGATIVE | 10 | 10 | 10 | 100 | |
| 2021-064 | 140 | MISSION A | | 051 051 | 051 051 | | 051 - NEGATIVE | 65 | 65 | 65 | 100 | |
| 2021-064 | 145 | CLINITEK | | 051 051 | 051 051 | | 052 - TRACES | 10 | 1 | 9 | 0 | |
| 2021-064 | 145 | CLINITEK | | 051 051 | 051 051 | | 051 - NEGATIVE | 10 | 9 | 9 | 100 | |
| 2021-064 | 147 | Mission120 | | 051 051 | 051 051 | | 051 - NEGATIVE | 23 | 23 | 23 | 100 | |
| 2021-064 | 148 | Mission500 | | 051 051 | 051 051 | | 051 - NEGATIVE | 24 | 24 | 24 | 100 | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | | | |
|-------------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|-------------------|----------------|----------------|----------------|-------|-----|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | |
| 064 URIN-PROTEIN QUALI. | | | | | | | | | | | | |
| 2021-065 | 011 | AMES NM10S | | 053 | 055 | 053 | 055 | 055 - 3+ | 51 | 21 | 50 | 100 |
| 2021-065 | 011 | AMES NM10S | | 053 | 055 | 053 | 055 | 054 - 2+ | 51 | 28 | 50 | 100 |
| 2021-065 | 011 | AMES NM10S | | 053 | 055 | 053 | 055 | 053 - 1+ | 51 | 1 | 50 | 100 |
| 2021-065 | 011 | AMES NM10S | | 053 | 055 | 053 | 055 | 056 - 4+ | 51 | 1 | 50 | 0 |
| 2021-065 | 013 | BAYER CLI | | 053 | 055 | 053 | 055 | 055 - 3+ | 35 | 10 | 34 | 100 |
| 2021-065 | 013 | BAYER CLI | | 053 | 055 | 053 | 055 | 054 - 2+ | 35 | 24 | 34 | 100 |
| 2021-065 | 013 | BAYER CLI | | 053 | 055 | 053 | 055 | 052 - TRACES | 35 | 1 | 34 | 0 |
| 2021-065 | 067 | URISCAN | | 053 | 055 | 053 | 055 | 054 - 2+ | 49 | 43 | 48 | 100 |
| 2021-065 | 067 | URISCAN | | 053 | 055 | 053 | 055 | 053 - 1+ | 49 | 1 | 48 | 100 |
| 2021-065 | 067 | URISCAN | | 053 | 055 | 053 | 055 | 055 - 3+ | 49 | 4 | 48 | 100 |
| 2021-065 | 067 | URISCAN | | 053 | 055 | 053 | 055 | 051 - NEGATIVE | 49 | 1 | 48 | 0 |
| 2021-065 | 071 | ATLAS | | 053 | 055 | 053 | 055 | 053 - 1+ | 18 | 1 | 18 | 100 |
| 2021-065 | 071 | ATLAS | | 053 | 055 | 053 | 055 | 054 - 2+ | 18 | 17 | 18 | 100 |
| 2021-065 | 072 | URS-9-TECO | | 053 | 055 | 053 | 055 | 056 - 4+ | 108 | 4 | 104 | 0 |
| 2021-065 | 072 | URS-9-TECO | | 053 | 055 | 053 | 055 | 055 - 3+ | 108 | 43 | 104 | 100 |
| 2021-065 | 072 | URS-9-TECO | | 053 | 055 | 053 | 055 | 053 - 1+ | 108 | 5 | 104 | 100 |
| 2021-065 | 072 | URS-9-TECO | | 053 | 055 | 053 | 055 | 054 - 2+ | 108 | 56 | 104 | 100 |
| 2021-065 | 080 | ROCHE (CHE | | 053 | 055 | 053 | 055 | 055 - 3+ | 37 | 12 | 37 | 100 |
| 2021-065 | 080 | ROCHE (CHE | | 053 | 055 | 053 | 055 | 054 - 2+ | 37 | 25 | 37 | 100 |
| 2021-065 | 089 | AIMSTRIP | | 053 | 055 | 053 | 055 | 053 - 1+ | 114 | 2 | 110 | 100 |
| 2021-065 | 089 | AIMSTRIP | | 053 | 055 | 053 | 055 | 054 - 2+ | 114 | 76 | 110 | 100 |
| 2021-065 | 089 | AIMSTRIP | | 053 | 055 | 053 | 055 | 056 - 4+ | 114 | 4 | 110 | 0 |
| 2021-065 | 089 | AIMSTRIP | | 053 | 055 | 053 | 055 | 055 - 3+ | 114 | 32 | 110 | 100 |
| 2021-065 | 094 | CLINITEK | | 053 | 055 | 053 | 055 | 051 - NEGATIVE | 102 | 1 | 101 | 0 |
| 2021-065 | 094 | CLINITEK | | 053 | 055 | 053 | 055 | 054 - 2+ | 102 | 83 | 101 | 100 |
| 2021-065 | 094 | CLINITEK | | 053 | 055 | 053 | 055 | 053 - 1+ | 102 | 4 | 101 | 100 |
| 2021-065 | 094 | CLINITEK | | 053 | 055 | 053 | 055 | 055 - 3+ | 102 | 14 | 101 | 100 |
| 2021-065 | 102 | ACON LAB | | 053 | 055 | 053 | 055 | 054 - 2+ | 160 | 103 | 155 | 100 |
| 2021-065 | 102 | ACON LAB | | 053 | 055 | 053 | 055 | 053 - 1+ | 160 | 2 | 155 | 100 |

Participant Summary

MONTH 2 OF YEAR 2021

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score |
|--------------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|-------------------|--------------|----------------|----------------|-------|
| 2021-065 | 102 | ACON LAB | | 053 055 | 053 055 | | 055 - 3+ | 160 | 50 | 155 | 100 |
| 2021-065 | 102 | ACON LAB | | 053 055 | 053 055 | | 056 - 4+ | 160 | 4 | 155 | 0 |
| 2021-065 | 102 | ACON LAB | | 053 055 | 053 055 | | 052 - TRACES | 160 | 1 | 155 | 0 |
| 2021-065 | 131 | iCHEM VELO | | 053 055 | 053 055 | | 055 - 3+ | 26 | 3 | 26 | 100 |
| 2021-065 | 131 | iCHEM VELO | | 053 055 | 053 055 | | 054 - 2+ | 26 | 23 | 26 | 100 |
| 2021-065 | 135 | Hybrido AU | | 053 055 | 053 055 | | 054 - 2+ | 14 | 14 | 14 | 100 |
| 2021-065 | 138 | URS-10T | | 054 056 | 053 055 | | 054 - 2+ | 10 | 4 | 10 | 100 |
| 2021-065 | 138 | URS-10T | | 054 056 | 053 055 | | 055 - 3+ | 10 | 6 | 10 | 100 |
| 2021-065 | 140 | MISSION A | | 053 055 | 053 055 | | 053 - 1+ | 65 | 3 | 65 | 100 |
| 2021-065 | 140 | MISSION A | | 053 055 | 053 055 | | 054 - 2+ | 65 | 52 | 65 | 100 |
| 2021-065 | 140 | MISSION A | | 053 055 | 053 055 | | 055 - 3+ | 65 | 10 | 65 | 100 |
| 2021-065 | 145 | CLINITEK | | 054 056 | 053 055 | | 055 - 3+ | 10 | 6 | 10 | 100 |
| 2021-065 | 145 | CLINITEK | | 054 056 | 053 055 | | 054 - 2+ | 10 | 4 | 10 | 100 |
| 2021-065 | 147 | Mission120 | | 053 055 | 053 055 | | 054 - 2+ | 23 | 22 | 23 | 100 |
| 2021-065 | 147 | Mission120 | | 053 055 | 053 055 | | 053 - 1+ | 23 | 1 | 23 | 100 |
| 2021-065 | 148 | Mission500 | | 053 055 | 053 055 | | 056 - 4+ | 24 | 1 | 23 | 0 |
| 2021-065 | 148 | Mission500 | | 053 055 | 053 055 | | 055 - 3+ | 24 | 7 | 23 | 100 |
| 2021-065 | 148 | Mission500 | | 053 055 | 053 055 | | 053 - 1+ | 24 | 1 | 23 | 100 |
| 2021-065 | 148 | Mission500 | | 053 055 | 053 055 | | 054 - 2+ | 24 | 15 | 23 | 100 |
| 066 URINAL.-UROBILINOGEN | | | | | | | | | | | |
| 2021-061 | 011 | AMES NM10S | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 51 | 51 | 51 | 100 |
| 2021-061 | 013 | BAYER CLI | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 35 | 35 | 35 | 100 |
| 2021-061 | 067 | URISCAN | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 49 | 49 | 49 | 100 |
| 2021-061 | 071 | ATLAS | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 18 | 18 | 18 | 100 |
| 2021-061 | 072 | URS-9-TECO | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 108 | 108 | 108 | 100 |
| 2021-061 | 080 | ROCHE (CHE | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 37 | 37 | 37 | 100 |
| 2021-061 | 089 | AIMSTRIP | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 114 | 114 | 114 | 100 |
| 2021-061 | 094 | CLINITEK | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 103 | 103 | 103 | 100 |
| 2021-061 | 102 | ACON LAB | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 159 | 159 | 159 | 100 |
| 2021-061 | 131 | iCHEM VELO | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 26 | 26 | 26 | 100 |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | | |
|--------------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|--------------------|--------------|----------------|----------------|-------|--|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | |
| 2021-061 | 135 | Hybrido AU | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 14 | 14 | 14 | 100 | |
| 2021-061 | 138 | URS-10T | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 10 | 10 | 10 | 100 | |
| 2021-061 | 140 | MISSION A | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 65 | 65 | 65 | 100 | |
| 2021-061 | 145 | CLINITEK | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 10 | 10 | 10 | 100 | |
| 2021-061 | 147 | Mission120 | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 23 | 23 | 23 | 100 | |
| 2021-061 | 148 | Mission500 | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 24 | 24 | 24 | 100 | |
| 066 URINAL.-UROBILINOGEN | | | | | | | | | | | | |
| 2021-062 | 011 | AMES NM10S | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 51 | 51 | 51 | 100 | |
| 2021-062 | 013 | BAYER CLI | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 35 | 35 | 35 | 100 | |
| 2021-062 | 067 | URISCAN | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 49 | 49 | 49 | 100 | |
| 2021-062 | 071 | ATLAS | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 18 | 18 | 18 | 100 | |
| 2021-062 | 072 | URS-9-TECO | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 108 | 108 | 108 | 100 | |
| 2021-062 | 080 | ROCHE (CHE | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 37 | 37 | 37 | 100 | |
| 2021-062 | 089 | AIMSTRIP | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 114 | 114 | 114 | 100 | |
| 2021-062 | 094 | CLINITEK | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 103 | 103 | 103 | 100 | |
| 2021-062 | 102 | ACON LAB | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 159 | 159 | 159 | 100 | |
| 2021-062 | 131 | iCHEM VELO | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 26 | 26 | 26 | 100 | |
| 2021-062 | 135 | Hybrido AU | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 14 | 14 | 14 | 100 | |
| 2021-062 | 138 | URS-10T | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 10 | 10 | 10 | 100 | |
| 2021-062 | 140 | MISSION A | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 65 | 65 | 65 | 100 | |
| 2021-062 | 145 | CLINITEK | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 10 | 10 | 10 | 100 | |
| 2021-062 | 147 | Mission120 | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 23 | 23 | 23 | 100 | |
| 2021-062 | 148 | Mission500 | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 24 | 24 | 24 | 100 | |
| 2021-063 | 011 | AMES NM10S | | 061 063 | 061 063 | | 061 - NORMAL,NEG | 51 | 5 | 51 | 100 | |
| 2021-063 | 011 | AMES NM10S | | 061 063 | 061 063 | | 062 - 2 | 51 | 29 | 51 | 100 | |
| 2021-063 | 011 | AMES NM10S | | 061 063 | 061 063 | | 063 - 4 | 51 | 17 | 51 | 100 | |
| 2021-063 | 013 | BAYER CLI | | | 061 063 | | 063 - 4 | 35 | 4 | 35 | 100 | |
| 2021-063 | 013 | BAYER CLI | | | 061 063 | | 062 - 2 | 35 | 13 | 35 | 100 | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | | SUB: 50 URINALYSIS | | | GRP: 70 URINALYSIS | | | | | | |
|-------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|-------------------|--------------|----------------|----------------|-------|--|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | |
| 2021-063 | 013 | BAYER CLI | | | 061 063 | | 061 - NORMAL,NEG | 35 | 18 | 35 | 100 | |
| 2021-063 | 067 | URISCAN | | | 061 063 | | 064 - 8 | 49 | 2 | 47 | 0 | |
| 2021-063 | 067 | URISCAN | | | 061 063 | | 061 - NORMAL,NEG | 49 | 12 | 47 | 100 | |
| 2021-063 | 067 | URISCAN | | | 061 063 | | 063 - 4 | 49 | 28 | 47 | 100 | |
| 2021-063 | 067 | URISCAN | | | 061 063 | | 062 - 2 | 49 | 7 | 47 | 100 | |
| 2021-063 | 071 | ATLAS | | 061 063 | 061 063 | | 063 - 4 | 18 | 5 | 18 | 100 | |
| 2021-063 | 071 | ATLAS | | 061 063 | 061 063 | | 062 - 2 | 18 | 13 | 18 | 100 | |
| 2021-063 | 072 | URS-9-TECO | | 061 063 | 061 063 | | 061 - NORMAL,NEG | 108 | 21 | 107 | 100 | |
| 2021-063 | 072 | URS-9-TECO | | 061 063 | 061 063 | | 063 - 4 | 108 | 28 | 107 | 100 | |
| 2021-063 | 072 | URS-9-TECO | | 061 063 | 061 063 | | 062 - 2 | 108 | 58 | 107 | 100 | |
| 2021-063 | 072 | URS-9-TECO | | 061 063 | 061 063 | | 064 - 8 | 108 | 1 | 107 | 0 | |
| 2021-063 | 080 | ROCHE (CHE | | 061 061 | 061 063 | | 061 - NORMAL,NEG | 37 | 35 | 37 | 100 | |
| 2021-063 | 080 | ROCHE (CHE | | 061 061 | 061 063 | | 062 - 2 | 37 | 2 | 37 | 100 | |
| 2021-063 | 089 | AIMSTRIP | | | 061 063 | | 064 - 8 | 114 | 1 | 113 | 0 | |
| 2021-063 | 089 | AIMSTRIP | | | 061 063 | | 061 - NORMAL,NEG | 114 | 65 | 113 | 100 | |
| 2021-063 | 089 | AIMSTRIP | | | 061 063 | | 063 - 4 | 114 | 6 | 113 | 100 | |
| 2021-063 | 089 | AIMSTRIP | | | 061 063 | | 062 - 2 | 114 | 42 | 113 | 100 | |
| 2021-063 | 094 | CLINITEK | | 061 063 | 061 063 | | 061 - NORMAL,NEG | 103 | 13 | 103 | 100 | |
| 2021-063 | 094 | CLINITEK | | 061 063 | 061 063 | | 062 - 2 | 103 | 54 | 103 | 100 | |
| 2021-063 | 094 | CLINITEK | | 061 063 | 061 063 | | 063 - 4 | 103 | 36 | 103 | 100 | |
| 2021-063 | 102 | ACON LAB | | 061 061 | 061 063 | | 061 - NORMAL,NEG | 159 | 134 | 159 | 100 | |
| 2021-063 | 102 | ACON LAB | | 061 061 | 061 063 | | 063 - 4 | 159 | 1 | 159 | 100 | |
| 2021-063 | 102 | ACON LAB | | 061 061 | 061 063 | | 062 - 2 | 159 | 24 | 159 | 100 | |
| 2021-063 | 131 | icHEM VELO | | 062 064 | 061 063 | | 063 - 4 | 26 | 25 | 26 | 100 | |
| 2021-063 | 131 | icHEM VELO | | 062 064 | 061 063 | | 062 - 2 | 26 | 1 | 26 | 100 | |
| 2021-063 | 135 | Hybrido AU | | 061 063 | 061 063 | | 061 - NORMAL,NEG | 14 | 2 | 14 | 100 | |
| 2021-063 | 135 | Hybrido AU | | 061 063 | 061 063 | | 062 - 2 | 14 | 12 | 14 | 100 | |
| 2021-063 | 138 | URS-10T | | 061 063 | 061 063 | | 061 - NORMAL,NEG | 10 | 3 | 9 | 100 | |
| 2021-063 | 138 | URS-10T | | 061 063 | 061 063 | | 064 - 8 | 10 | 1 | 9 | 0 | |
| 2021-063 | 138 | URS-10T | | 061 063 | 061 063 | | 063 - 4 | 10 | 2 | 9 | 100 | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | | |
|--------------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|--------------------|--------------|----------------|----------------|-------|--|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | |
| 2021-063 | 138 | URS-10T | | 061 063 | 061 063 | | 062 - 2 | 10 | 4 | 9 | 100 | |
| 2021-063 | 140 | MISSION A | | 061 061 | 061 063 | | 061 - NORMAL,NEG | 65 | 55 | 65 | 100 | |
| 2021-063 | 140 | MISSION A | | 061 061 | 061 063 | | 063 - 4 | 65 | 1 | 65 | 100 | |
| 2021-063 | 140 | MISSION A | | 061 061 | 061 063 | | 062 - 2 | 65 | 9 | 65 | 100 | |
| 2021-063 | 145 | CLINITEK | | 061 063 | 061 063 | | 062 - 2 | 10 | 8 | 10 | 100 | |
| 2021-063 | 145 | CLINITEK | | 061 063 | 061 063 | | 061 - NORMAL,NEG | 10 | 2 | 10 | 100 | |
| 2021-063 | 147 | Mission120 | | 061 061 | 061 063 | | 062 - 2 | 23 | 1 | 23 | 100 | |
| 2021-063 | 147 | Mission120 | | 061 061 | 061 063 | | 061 - NORMAL,NEG | 23 | 22 | 23 | 100 | |
| 2021-063 | 148 | Mission500 | | 061 061 | 061 063 | | 061 - NORMAL,NEG | 24 | 21 | 24 | 100 | |
| 2021-063 | 148 | Mission500 | | 061 061 | 061 063 | | 063 - 4 | 24 | 1 | 24 | 100 | |
| 2021-063 | 148 | Mission500 | | 061 061 | 061 063 | | 062 - 2 | 24 | 2 | 24 | 100 | |
| 066 URINAL.-UROBILINOGEN | | | | | | | | | | | | |
| 2021-064 | 011 | AMES NM10S | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 51 | 51 | 51 | 100 | |
| 2021-064 | 013 | BAYER CLI | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 35 | 35 | 35 | 100 | |
| 2021-064 | 067 | URISCAN | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 49 | 49 | 49 | 100 | |
| 2021-064 | 071 | ATLAS | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 18 | 18 | 18 | 100 | |
| 2021-064 | 072 | URS-9-TECO | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 108 | 108 | 108 | 100 | |
| 2021-064 | 080 | ROCHE (CHE | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 37 | 37 | 37 | 100 | |
| 2021-064 | 089 | AIMSTRIP | | 061 061 | 061 061 | | 062 - 2 | 114 | 2 | 112 | 0 | |
| 2021-064 | 089 | AIMSTRIP | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 114 | 112 | 112 | 100 | |
| 2021-064 | 094 | CLINITEK | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 103 | 102 | 102 | 100 | |
| 2021-064 | 094 | CLINITEK | | 061 061 | 061 061 | | 062 - 2 | 103 | 1 | 102 | 0 | |
| 2021-064 | 102 | ACON LAB | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 159 | 159 | 159 | 100 | |
| 2021-064 | 131 | iCHEM VELO | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 26 | 26 | 26 | 100 | |
| 2021-064 | 135 | Hybrido AU | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 14 | 14 | 14 | 100 | |
| 2021-064 | 138 | URS-10T | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 10 | 10 | 10 | 100 | |
| 2021-064 | 140 | MISSION A | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 65 | 65 | 65 | 100 | |
| 2021-064 | 145 | CLINITEK | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 10 | 10 | 10 | 100 | |
| 2021-064 | 147 | Mission120 | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 23 | 23 | 23 | 100 | |
| 2021-064 | 148 | Mission500 | | 061 061 | 061 061 | | 061 - NORMAL,NEG | 24 | 24 | 24 | 100 | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | | |
|--------------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|--------------------|------------------|----------------|----------------|-------|-----|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | |
| 066 URINAL.-UROBILINOGEN | | | | | | | | | | | | |
| 2021-065 | 011 | AMES NM10S | | 061 | 061 | 061 | 061 | 061 - NORMAL,NEG | 51 | 51 | 51 | 100 |
| 2021-065 | 013 | BAYER CLI | | 061 | 061 | 061 | 061 | 061 - NORMAL,NEG | 35 | 35 | 35 | 100 |
| 2021-065 | 067 | URISCAN | | 061 | 061 | 061 | 061 | 061 - NORMAL,NEG | 49 | 49 | 49 | 100 |
| 2021-065 | 071 | ATLAS | | 061 | 061 | 061 | 061 | 061 - NORMAL,NEG | 18 | 18 | 18 | 100 |
| 2021-065 | 072 | URS-9-TECO | | 061 | 061 | 061 | 061 | 061 - NORMAL,NEG | 108 | 108 | 108 | 100 |
| 2021-065 | 080 | ROCHE (CHE | | 061 | 061 | 061 | 061 | 061 - NORMAL,NEG | 37 | 37 | 37 | 100 |
| 2021-065 | 089 | AIMSTRIP | | 061 | 061 | 061 | 061 | 061 - NORMAL,NEG | 114 | 114 | 114 | 100 |
| 2021-065 | 094 | CLINITEK | | 061 | 061 | 061 | 061 | 061 - NORMAL,NEG | 103 | 102 | 102 | 100 |
| 2021-065 | 094 | CLINITEK | | 061 | 061 | 061 | 061 | 062 - 2 | 103 | 1 | 102 | 0 |
| 2021-065 | 102 | ACON LAB | | 061 | 061 | 061 | 061 | 061 - NORMAL,NEG | 159 | 159 | 159 | 100 |
| 2021-065 | 131 | iCHEM VELO | | 061 | 061 | 061 | 061 | 061 - NORMAL,NEG | 26 | 26 | 26 | 100 |
| 2021-065 | 135 | Hybrido AU | | 061 | 061 | 061 | 061 | 061 - NORMAL,NEG | 14 | 14 | 14 | 100 |
| 2021-065 | 138 | URS-10T | | 061 | 061 | 061 | 061 | 061 - NORMAL,NEG | 10 | 10 | 10 | 100 |
| 2021-065 | 140 | MISSION A | | 061 | 061 | 061 | 061 | 061 - NORMAL,NEG | 65 | 65 | 65 | 100 |
| 2021-065 | 145 | CLINITEK | | 061 | 061 | 061 | 061 | 061 - NORMAL,NEG | 10 | 10 | 10 | 100 |
| 2021-065 | 147 | Mission120 | | 061 | 061 | 061 | 061 | 061 - NORMAL,NEG | 23 | 23 | 23 | 100 |
| 2021-065 | 148 | Mission500 | | 061 | 061 | 061 | 061 | 061 - NORMAL,NEG | 24 | 24 | 24 | 100 |
| 184 URINALYSIS LEUKOCYTE | | | | | | | | | | | | |
| 2021-061 | | | | 001 | 001 | 001 | 001 | 001 - Negative | 16 | 16 | 16 | 100 |
| 2021-061 | 011 | AMES NM10S | | 001 | 001 | 001 | 001 | 001 - Negative | 47 | 47 | 47 | 100 |
| 2021-061 | 013 | BAYER CLI | | 001 | 001 | 001 | 001 | 001 - Negative | 35 | 35 | 35 | 100 |
| 2021-061 | 067 | URISCAN | | 001 | 001 | 001 | 001 | 001 - Negative | 49 | 49 | 49 | 100 |
| 2021-061 | 071 | ATLAS | | 001 | 001 | 001 | 001 | 001 - Negative | 17 | 17 | 17 | 100 |
| 2021-061 | 072 | URS-9-TECO | | 001 | 001 | 001 | 001 | 001 - Negative | 98 | 98 | 98 | 100 |
| 2021-061 | 080 | ROCHE (CHE | | 001 | 001 | 001 | 001 | 001 - Negative | 34 | 34 | 34 | 100 |
| 2021-061 | 089 | AIMSTRIP | | 001 | 001 | 001 | 001 | 001 - Negative | 112 | 112 | 112 | 100 |
| 2021-061 | 094 | CLINITEK | | 001 | 001 | 001 | 001 | 001 - Negative | 102 | 102 | 102 | 100 |
| 2021-061 | 102 | ACON LAB | | 001 | 001 | 001 | 001 | 001 - Negative | 143 | 143 | 143 | 100 |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | | | |
|--------------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|-------------------|--------------|----------------|----------------|-------|--|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | |
| 2021-061 | 131 | iCHEM VELO | | 001 001 | 001 001 | | 001 - Negative | 26 | 26 | 26 | 100 | |
| 2021-061 | 135 | Hybrido AU | | 001 001 | 001 001 | | 001 - Negative | 14 | 14 | 14 | 100 | |
| 2021-061 | 138 | URS-10T | | 001 001 | 001 001 | | 001 - Negative | 10 | 10 | 10 | 100 | |
| 2021-061 | 140 | MISSION A | | 001 001 | 001 001 | | 001 - Negative | 74 | 74 | 74 | 100 | |
| 2021-061 | 145 | CLINITEK | | 001 001 | 001 001 | | 001 - Negative | 10 | 10 | 10 | 100 | |
| 2021-061 | 147 | Mission120 | | 001 001 | 001 001 | | 005 - Large | 23 | 1 | 22 | 0 | |
| 2021-061 | 147 | Mission120 | | 001 001 | 001 001 | | 001 - Negative | 23 | 22 | 22 | 100 | |
| 2021-061 | 148 | Mission500 | | 001 001 | 001 001 | | 001 - Negative | 23 | 23 | 23 | 100 | |
| 184 URINALYSIS LEUKOCYTE | | | | | | | | | | | | |
| 2021-062 | | | | 001 001 | 001 001 | | 001 - Negative | 16 | 16 | 16 | 100 | |
| 2021-062 | 011 | AMES NM10S | | 001 001 | 001 001 | | 001 - Negative | 47 | 47 | 47 | 100 | |
| 2021-062 | 013 | BAYER CLI | | 001 001 | 001 001 | | 001 - Negative | 35 | 35 | 35 | 100 | |
| 2021-062 | 067 | URISCAN | | 001 001 | 001 001 | | 001 - Negative | 49 | 49 | 49 | 100 | |
| 2021-062 | 071 | ATLAS | | 001 001 | 001 001 | | 001 - Negative | 17 | 17 | 17 | 100 | |
| 2021-062 | 072 | URS-9-TECO | | 001 001 | 001 001 | | 001 - Negative | 98 | 98 | 98 | 100 | |
| 2021-062 | 080 | ROCHE (CHE | | 001 001 | 001 001 | | 001 - Negative | 34 | 34 | 34 | 100 | |
| 2021-062 | 089 | AIMSTRIP | | 001 001 | 001 001 | | 002 - Traces | 112 | 1 | 111 | 0 | |
| 2021-062 | 089 | AIMSTRIP | | 001 001 | 001 001 | | 001 - Negative | 112 | 111 | 111 | 100 | |
| 2021-062 | 094 | CLINITEK | | 001 001 | 001 001 | | 001 - Negative | 102 | 102 | 102 | 100 | |
| 2021-062 | 102 | ACON LAB | | 001 001 | 001 001 | | 001 - Negative | 143 | 143 | 143 | 100 | |
| 2021-062 | 131 | iCHEM VELO | | 001 001 | 001 001 | | 001 - Negative | 26 | 26 | 26 | 100 | |
| 2021-062 | 135 | Hybrido AU | | 001 001 | 001 001 | | 001 - Negative | 14 | 14 | 14 | 100 | |
| 2021-062 | 138 | URS-10T | | 001 001 | 001 001 | | 001 - Negative | 10 | 10 | 10 | 100 | |
| 2021-062 | 140 | MISSION A | | 001 001 | 001 001 | | 001 - Negative | 74 | 73 | 73 | 100 | |
| 2021-062 | 140 | MISSION A | | 001 001 | 001 001 | | 004 - Moderate | 74 | 1 | 73 | 0 | |
| 2021-062 | 145 | CLINITEK | | 001 001 | 001 001 | | 001 - Negative | 10 | 10 | 10 | 100 | |
| 2021-062 | 147 | Mission120 | | 001 001 | 001 001 | | 001 - Negative | 23 | 23 | 23 | 100 | |
| 2021-062 | 148 | Mission500 | | 001 001 | 001 001 | | 001 - Negative | 23 | 23 | 23 | 100 | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | | |
|--------------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|-------------------|--------------|----------------|----------------|-------|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score |
| 184 URINALYSIS LEUKOCYTE | | | | | | | | | | | |
| 2021-063 | | | | 001 001 | 001 001 | | 001 - Negative | 16 | 16 | 16 | 100 |
| 2021-063 | 011 AMES NM10S | | | 001 001 | 001 001 | | 001 - Negative | 47 | 47 | 47 | 100 |
| 2021-063 | 013 BAYER CLI | | | 001 001 | 001 001 | | 001 - Negative | 35 | 35 | 35 | 100 |
| 2021-063 | 067 URISCAN | | | 001 001 | 001 001 | | 001 - Negative | 49 | 49 | 49 | 100 |
| 2021-063 | 071 ATLAS | | | 001 001 | 001 001 | | 001 - Negative | 17 | 17 | 17 | 100 |
| 2021-063 | 072 URS-9-TECO | | | 001 001 | 001 001 | | 001 - Negative | 98 | 98 | 98 | 100 |
| 2021-063 | 080 ROCHE (CHE | | | 001 001 | 001 001 | | 001 - Negative | 34 | 34 | 34 | 100 |
| 2021-063 | 089 AIMSTRIP | | | 001 001 | 001 001 | | 001 - Negative | 112 | 112 | 112 | 100 |
| 2021-063 | 094 CLINITEK | | | 001 001 | 001 001 | | 001 - Negative | 102 | 102 | 102 | 100 |
| 2021-063 | 102 ACON LAB | | | 001 001 | 001 001 | | 001 - Negative | 143 | 143 | 143 | 100 |
| 2021-063 | 131 iCHEM VELO | | | 001 001 | 001 001 | | 001 - Negative | 26 | 26 | 26 | 100 |
| 2021-063 | 135 Hybrid0 AU | | | 001 001 | 001 001 | | 001 - Negative | 14 | 14 | 14 | 100 |
| 2021-063 | 138 URS-10T | | | 001 001 | 001 001 | | 001 - Negative | 10 | 10 | 10 | 100 |
| 2021-063 | 140 MISSION A | | | 001 001 | 001 001 | | 001 - Negative | 74 | 74 | 74 | 100 |
| 2021-063 | 145 CLINITEK | | | 001 001 | 001 001 | | 001 - Negative | 10 | 10 | 10 | 100 |
| 2021-063 | 147 Mission120 | | | 001 001 | 001 001 | | 001 - Negative | 23 | 23 | 23 | 100 |
| 2021-063 | 148 Mission500 | | | 001 001 | 001 001 | | 001 - Negative | 23 | 23 | 23 | 100 |
| 2021-064 | | | | 002 004 | 003 005 | | 004 - Moderate | 16 | 6 | 16 | 100 |
| 2021-064 | | | | 002 004 | 003 005 | | 005 - Large | 16 | 2 | 16 | 100 |
| 2021-064 | | | | 002 004 | 003 005 | | 003 - Small | 16 | 8 | 16 | 100 |
| 2021-064 | 011 AMES NM10S | | | 002 004 | 003 005 | | 005 - Large | 47 | 1 | 47 | 100 |
| 2021-064 | 011 AMES NM10S | | | 002 004 | 003 005 | | 004 - Moderate | 47 | 7 | 47 | 100 |
| 2021-064 | 011 AMES NM10S | | | 002 004 | 003 005 | | 003 - Small | 47 | 39 | 47 | 100 |
| 2021-064 | 013 BAYER CLI | | | 002 004 | 003 005 | | 005 - Large | 35 | 2 | 35 | 100 |
| 2021-064 | 013 BAYER CLI | | | 002 004 | 003 005 | | 004 - Moderate | 35 | 8 | 35 | 100 |
| 2021-064 | 013 BAYER CLI | | | 002 004 | 003 005 | | 003 - Small | 35 | 25 | 35 | 100 |
| 2021-064 | 067 URISCAN | | | 003 005 | 003 005 | | 001 - Negative | 49 | 1 | 48 | 0 |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | | | |
|-------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|-------------------|--------------|----------------|----------------|-------|--|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | |
| 2021-064 | 067 | URISCAN | | 003 005 | 003 005 | | 003 - Small | 49 | 8 | 48 | 100 | |
| 2021-064 | 067 | URISCAN | | 003 005 | 003 005 | | 005 - Large | 49 | 16 | 48 | 100 | |
| 2021-064 | 067 | URISCAN | | 003 005 | 003 005 | | 004 - Moderate | 49 | 24 | 48 | 100 | |
| 2021-064 | 071 | ATLAS | | 003 005 | 003 005 | | 004 - Moderate | 17 | 15 | 17 | 100 | |
| 2021-064 | 071 | ATLAS | | 003 005 | 003 005 | | 003 - Small | 17 | 1 | 17 | 100 | |
| 2021-064 | 071 | ATLAS | | 003 005 | 003 005 | | 005 - Large | 17 | 1 | 17 | 100 | |
| 2021-064 | 072 | URS-9-TECO | | 003 005 | 003 005 | | 003 - Small | 98 | 28 | 97 | 100 | |
| 2021-064 | 072 | URS-9-TECO | | 003 005 | 003 005 | | 002 - Traces | 98 | 1 | 97 | 0 | |
| 2021-064 | 072 | URS-9-TECO | | 003 005 | 003 005 | | 005 - Large | 98 | 5 | 97 | 100 | |
| 2021-064 | 072 | URS-9-TECO | | 003 005 | 003 005 | | 004 - Moderate | 98 | 64 | 97 | 100 | |
| 2021-064 | 080 | ROCHE (CHE | | 004 005 | 003 005 | | 004 - Moderate | 34 | 5 | 34 | 100 | |
| 2021-064 | 080 | ROCHE (CHE | | 004 005 | 003 005 | | 003 - Small | 34 | 1 | 34 | 100 | |
| 2021-064 | 080 | ROCHE (CHE | | 004 005 | 003 005 | | 005 - Large | 34 | 28 | 34 | 100 | |
| 2021-064 | 089 | AIMSTRIP | | 002 004 | 003 005 | | 001 - Negative | 112 | 1 | 111 | 0 | |
| 2021-064 | 089 | AIMSTRIP | | 002 004 | 003 005 | | 004 - Moderate | 112 | 34 | 111 | 100 | |
| 2021-064 | 089 | AIMSTRIP | | 002 004 | 003 005 | | 003 - Small | 112 | 73 | 111 | 100 | |
| 2021-064 | 089 | AIMSTRIP | | 002 004 | 003 005 | | 002 - Traces | 112 | 3 | 111 | 100 | |
| 2021-064 | 089 | AIMSTRIP | | 002 004 | 003 005 | | 005 - Large | 112 | 1 | 111 | 100 | |
| 2021-064 | 094 | CLINITEK | | 002 004 | 003 005 | | 003 - Small | 102 | 88 | 102 | 100 | |
| 2021-064 | 094 | CLINITEK | | 002 004 | 003 005 | | 005 - Large | 102 | 1 | 102 | 100 | |
| 2021-064 | 094 | CLINITEK | | 002 004 | 003 005 | | 004 - Moderate | 102 | 13 | 102 | 100 | |
| 2021-064 | 102 | ACON LAB | | 002 004 | 003 005 | | 004 - Moderate | 143 | 69 | 143 | 100 | |
| 2021-064 | 102 | ACON LAB | | 002 004 | 003 005 | | 003 - Small | 143 | 72 | 143 | 100 | |
| 2021-064 | 102 | ACON LAB | | 002 004 | 003 005 | | 005 - Large | 143 | 1 | 143 | 100 | |
| 2021-064 | 102 | ACON LAB | | 002 004 | 003 005 | | 002 - Traces | 143 | 1 | 143 | 100 | |
| 2021-064 | 131 | iCHEM VELO | | 004 005 | 003 005 | | 004 - Moderate | 26 | 1 | 26 | 100 | |
| 2021-064 | 131 | iCHEM VELO | | 004 005 | 003 005 | | 005 - Large | 26 | 25 | 26 | 100 | |
| 2021-064 | 135 | Hybrido AU | | 004 005 | 003 005 | | 005 - Large | 14 | 14 | 14 | 100 | |
| 2021-064 | 138 | URS-10T | | 003 005 | 003 005 | | 003 - Small | 10 | 3 | 10 | 100 | |
| 2021-064 | 138 | URS-10T | | 003 005 | 003 005 | | 004 - Moderate | 10 | 7 | 10 | 100 | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | | | |
|--------------------------|------------------------|------------------------|------------------------|------------------|---------------------|--------------------|-------------------|--------------|----------------|----------------|-------|--|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | |
| 2021-064 | 140 | MISSION A | | 002 004 | 003 005 | | 005 - Large | 74 | 2 | 73 | 100 | |
| 2021-064 | 140 | MISSION A | | 002 004 | 003 005 | | 002 - Traces | 74 | 4 | 73 | 100 | |
| 2021-064 | 140 | MISSION A | | 002 004 | 003 005 | | 004 - Moderate | 74 | 27 | 73 | 100 | |
| 2021-064 | 140 | MISSION A | | 002 004 | 003 005 | | 001 - Negative | 74 | 1 | 73 | 0 | |
| 2021-064 | 140 | MISSION A | | 002 004 | 003 005 | | 003 - Small | 74 | 40 | 73 | 100 | |
| 2021-064 | 145 | CLINITEK | | 003 005 | 003 005 | | 005 - Large | 10 | 1 | 10 | 100 | |
| 2021-064 | 145 | CLINITEK | | 003 005 | 003 005 | | 004 - Moderate | 10 | 9 | 10 | 100 | |
| 2021-064 | 147 | Mission120 | | 002 004 | 003 005 | | 004 - Moderate | 23 | 5 | 21 | 100 | |
| 2021-064 | 147 | Mission120 | | 002 004 | 003 005 | | 002 - Traces | 23 | 1 | 21 | 100 | |
| 2021-064 | 147 | Mission120 | | 002 004 | 003 005 | | 003 - Small | 23 | 15 | 21 | 100 | |
| 2021-064 | 147 | Mission120 | | 002 004 | 003 005 | | 001 - Negative | 23 | 2 | 21 | 0 | |
| 2021-064 | 148 | Mission500 | | 003 005 | 003 005 | | 004 - Moderate | 23 | 15 | 23 | 100 | |
| 2021-064 | 148 | Mission500 | | 003 005 | 003 005 | | 003 - Small | 23 | 8 | 23 | 100 | |
| 184 URINALYSIS LEUKOCYTE | | | | | | | | | | | | |
| 2021-065 | | | | 001 001 | 001 001 | | 001 - Negative | 16 | 16 | 16 | 100 | |
| 2021-065 | 011 | AMES NM10S | | 001 001 | 001 001 | | 001 - Negative | 47 | 47 | 47 | 100 | |
| 2021-065 | 013 | BAYER CLI | | 001 001 | 001 001 | | 001 - Negative | 35 | 35 | 35 | 100 | |
| 2021-065 | 067 | URISCAN | | 001 001 | 001 001 | | 004 - Moderate | 49 | 1 | 48 | 0 | |
| 2021-065 | 067 | URISCAN | | 001 001 | 001 001 | | 001 - Negative | 49 | 48 | 48 | 100 | |
| 2021-065 | 071 | ATLAS | | 001 001 | 001 001 | | 001 - Negative | 17 | 17 | 17 | 100 | |
| 2021-065 | 072 | URS-9-TECO | | 001 001 | 001 001 | | 001 - Negative | 98 | 98 | 98 | 100 | |
| 2021-065 | 080 | ROCHE (CHE | | 001 001 | 001 001 | | 001 - Negative | 34 | 34 | 34 | 100 | |
| 2021-065 | 089 | AIMSTRIP | | 001 001 | 001 001 | | 001 - Negative | 112 | 112 | 112 | 100 | |
| 2021-065 | 094 | CLINITEK | | 001 001 | 001 001 | | 001 - Negative | 102 | 102 | 102 | 100 | |
| 2021-065 | 102 | ACON LAB | | 001 001 | 001 001 | | 001 - Negative | 143 | 143 | 143 | 100 | |
| 2021-065 | 131 | iCHEM VELO | | 001 001 | 001 001 | | 001 - Negative | 26 | 26 | 26 | 100 | |
| 2021-065 | 135 | Hybrido AU | | 001 001 | 001 001 | | 001 - Negative | 14 | 14 | 14 | 100 | |
| 2021-065 | 138 | URS-10T | | 001 001 | 001 001 | | 001 - Negative | 10 | 10 | 10 | 100 | |
| 2021-065 | 140 | MISSION A | | 001 001 | 001 001 | | 001 - Negative | 74 | 73 | 73 | 100 | |
| 2021-065 | 140 | MISSION A | | 001 001 | 001 001 | | 002 - Traces | 74 | 1 | 73 | 0 | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | | SUB: 50 URINALYSIS | | | | GRP: 70 URINALYSIS | | | | | |
|------------------------|---------------------|---------------------|---------------------|---------------|------------------|-----------------|------------------------|-----------|-------------|-------------|-------|--|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | |
| 2021-065 | 145 | CLINITEK | | 001 001 | 001 001 | | 001 - Negative | 10 | 10 | 10 | 100 | |
| 2021-065 | 147 | Mission120 | | 001 001 | 001 001 | | 001 - Negative | 23 | 23 | 23 | 100 | |
| 2021-065 | 148 | Mission500 | | 001 001 | 001 001 | | 001 - Negative | 23 | 23 | 23 | 100 | |
| SPE: 10 CHEMISTRY | | | SUB: 50 URINALYSIS | | | | GRP: 80 PREGNANCY TEST | | | | | |
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | |
| 063 URI-PREGNANCY TEST | | | | | | | | | | | | |
| 2021-061 | 091 | AIM STEP | | 001 001 | 001 001 | | 002 - POSITIVE | 35 | 1 | 34 | 0 | |
| 2021-061 | 091 | AIM STEP | | 001 001 | 001 001 | | 001 - NEGATIVE | 35 | 34 | 34 | 100 | |
| 2021-061 | 101 | HCG Alere | | 001 001 | 001 001 | | 001 - NEGATIVE | 24 | 24 | 24 | 100 | |
| 2021-062 | 091 | AIM STEP | | 001 001 | 001 001 | | 001 - NEGATIVE | 35 | 35 | 35 | 100 | |
| 2021-062 | 101 | HCG Alere | | 001 001 | 001 001 | | 001 - NEGATIVE | 24 | 24 | 24 | 100 | |
| 2021-063 | 091 | AIM STEP | | 002 002 | 002 002 | | 002 - POSITIVE | 35 | 35 | 35 | 100 | |
| 2021-063 | 101 | HCG Alere | | 002 002 | 002 002 | | 002 - POSITIVE | 24 | 24 | 24 | 100 | |
| 2021-064 | 091 | AIM STEP | | 001 001 | 001 001 | | 001 - NEGATIVE | 35 | 35 | 35 | 100 | |
| 2021-064 | 101 | HCG Alere | | 001 001 | 001 001 | | 001 - NEGATIVE | 24 | 24 | 24 | 100 | |
| 2021-065 | 091 | AIM STEP | | 002 002 | 002 002 | | 002 - POSITIVE | 35 | 35 | 35 | 100 | |
| 2021-065 | 101 | HCG Alere | | 002 002 | 002 002 | | 002 - POSITIVE | 24 | 24 | 24 | 100 | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | SUB: 50 URINALYSIS | | | GRP: 75 URINALYSIS SEDIMENT | | | | | | |
|-----------------------|------------------------|------------------------|------------------------|------------------|-----------------------------|--------------------|-------------------|--------------|----------------|----------------|-------|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score |
| 150 URINAL.- SEDIMENT | | | | | | | | | | | |
| 2021-071 | | | | | 009 | 009 | 007 - WHITE CELL | 869 | 2 | 867 | 0 |
| 2021-071 | | | | | 009 | 009 | 009 - LEUKOCYTE | 869 | 867 | 867 | 100 |
| 2021-072 | | | | | 040 | 040 | 040 - S. haemat. | 869 | 865 | 865 | 100 |
| 2021-072 | | | | | 040 | 040 | 003 - GRANULAR C | 869 | 2 | 865 | 0 |
| 2021-072 | | | | | 040 | 040 | 039 - E. vermic. | 869 | 2 | 865 | 0 |
| 2021-073 | | | | | 046 | 046 | 046 - DECOY CELL | 866 | 822 | 822 | 100 |
| 2021-073 | | | | | 046 | 046 | 010 - RENAL TUB. | 866 | 26 | 822 | 0 |
| 2021-073 | | | | | 046 | 046 | 033 - OVAL FAT B | 866 | 11 | 822 | 0 |
| 2021-073 | | | | | 046 | 046 | 047 - SIGNET RIN | 866 | 1 | 822 | 0 |
| 2021-073 | | | | | 046 | 046 | 035 - POLLEN GR. | 866 | 1 | 822 | 0 |
| 2021-073 | | | | | 046 | 046 | 040 - S. haemat. | 866 | 2 | 822 | 0 |
| 2021-073 | | | | | 046 | 046 | 003 - GRANULAR C | 866 | 1 | 822 | 0 |
| 2021-073 | | | | | 046 | 046 | 012 - TRANSITIO. | 866 | 1 | 822 | 0 |
| 2021-073 | | | | | 046 | 046 | 009 - LEUKOCYTE | 866 | 1 | 822 | 0 |
| 2021-074 | | | | | 003 | 003 | 003 - GRANULAR C | 869 | 863 | 863 | 100 |
| 2021-074 | | | | | 003 | 003 | 002 - FATTY CAST | 869 | 3 | 863 | 0 |
| 2021-074 | | | | | 003 | 003 | 046 - DECOY CELL | 869 | 3 | 863 | 0 |
| 2021-075 | | | | | 017 | 017 | 023 - URIC ACID | 870 | 1 | 869 | 0 |
| 2021-075 | | | | | 017 | 017 | 017 - CYSTINE C. | 870 | 869 | 869 | 100 |

Participant Summary

MONTH 2 OF YEAR 2021

| SPE: 10 CHEMISTRY | | SUB: 60 SPECIAL TESTS | | | | GRP: 98 OCCULT BLOOD | | | | | | | | |
|------------------------|------------------------|------------------------|------------------------|------------------|---------------------|----------------------|-------------------|----------------|----------------|----------------|-------|-----|--|--|
| TEST SAMPLE | LEVEL 1 RESULT CODE | LEVEL 2 RESULT CODE | LEVEL 3 RESULT CODE | PART LOW/HIGH | REFEREE LOW/HIGH | COMMER LOW/HIGH | REPORTED VALUE | PART LABS | # LABS ANSW | # "SF" LABS | Score | | | |
| 154 FECAL OCCULT BLOOD | | | | | | | | | | | | | | |
| 2021-081 | 001 | PEROXIDASE | | 002 | 002 | 002 | 002 | 002 - POSITIVE | 435 | 435 | 435 | 100 | | |
| 2021-081 | 002 | INMMUASSAY | | 002 | 002 | 002 | 002 | 002 - POSITIVE | 690 | 688 | 688 | 100 | | |
| 2021-081 | 002 | INMMUASSAY | | 002 | 002 | 002 | 002 | 001 - NEGATIVE | 690 | 2 | 688 | 0 | | |
| 2021-082 | 001 | PEROXIDASE | | 001 | 001 | 001 | 001 | 001 - NEGATIVE | 435 | 435 | 435 | 100 | | |
| 2021-082 | 002 | INMMUASSAY | | 001 | 001 | 001 | 001 | 002 - POSITIVE | 690 | 1 | 689 | 0 | | |
| 2021-082 | 002 | INMMUASSAY | | 001 | 001 | 001 | 001 | 001 - NEGATIVE | 690 | 689 | 689 | 100 | | |
| 2021-083 | 001 | PEROXIDASE | | 002 | 002 | 002 | 002 | 002 - POSITIVE | 435 | 434 | 434 | 100 | | |
| 2021-083 | 001 | PEROXIDASE | | 002 | 002 | 002 | 002 | 001 - NEGATIVE | 435 | 1 | 434 | 0 | | |
| 2021-083 | 002 | INMMUASSAY | | 002 | 002 | 002 | 002 | 001 - NEGATIVE | 690 | 1 | 689 | 0 | | |
| 2021-083 | 002 | INMMUASSAY | | 002 | 002 | 002 | 002 | 002 - POSITIVE | 690 | 689 | 689 | 100 | | |
| 2021-084 | 001 | PEROXIDASE | | 001 | 001 | 001 | 001 | 001 - NEGATIVE | 435 | 435 | 435 | 100 | | |
| 2021-084 | 002 | INMMUASSAY | | 001 | 001 | 001 | 001 | 001 - NEGATIVE | 690 | 688 | 688 | 100 | | |
| 2021-084 | 002 | INMMUASSAY | | 001 | 001 | 001 | 001 | 002 - POSITIVE | 690 | 2 | 688 | 0 | | |
| 2021-085 | 001 | PEROXIDASE | | 002 | 002 | 002 | 002 | 002 - POSITIVE | 435 | 431 | 431 | 100 | | |
| 2021-085 | 001 | PEROXIDASE | | 002 | 002 | 002 | 002 | 001 - NEGATIVE | 435 | 4 | 431 | 0 | | |
| 2021-085 | 002 | INMMUASSAY | | 002 | 002 | 002 | 002 | 001 - NEGATIVE | 690 | 6 | 684 | 0 | | |
| 2021-085 | 002 | INMMUASSAY | | 002 | 002 | 002 | 002 | 002 - POSITIVE | 690 | 684 | 684 | 100 | | |
| SPEC: 10 CHEMISTRY | | SUB: 60 SPECIAL TESTS | | | | GRP: 90 SPECIAL TEST | | | | | | | | |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 60 SPECIAL TESTS

GRP: 90 SPECIAL TEST

| ANALYTE | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
|----------|----------------------|-------------------|-----------------------------------|----------|------------|-----------|-------|------------|--------|
| SAMPLE | METHOD | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH |
| 068 | CARCINOE. ANTIG. CEA | CLIA TEST ID #: 0 | EVALUATION CRITERIA: TARGET VALUE | 3 | SD OR 25 % | {LOWER} | | | |
| 2021-031 | 29 VITROS | | | 11 | 0.427 | 0.062 | 14.43 | 0.300 | 0.500 |
| 2021-031 | 38 ROCHE E | | | 21 | 0.724 | 0.148 | 20.41 | 0.500 | 0.900 |
| 2021-031 | 44 BECK.COUL. | | | 17 | 0.531 | 0.046 | 8.72 | 0.400 | 0.700 |
| 2021-031 | 50 ARC | | | 10 | 0.514 | 0.035 | 6.80 | 0.400 | 0.600 |
| 2021-032 | 29 VITROS | | | 11 | 28.418 | 0.694 | 2.44 | 26.300 | 30.500 |
| 2021-032 | 38 ROCHE E | | | 21 | 25.881 | 1.327 | 5.13 | 21.900 | 29.900 |
| 2021-032 | 44 BECK.COUL. | | | 17 | 32.471 | 1.688 | 5.20 | 27.400 | 37.500 |
| 2021-032 | 50 ARC | | | 10 | 31.490 | 1.879 | 5.97 | 25.900 | 37.100 |
| 2021-033 | 29 VITROS | | | 11 | 20.236 | 0.464 | 2.29 | 18.800 | 21.600 |
| 2021-033 | 38 ROCHE E | | | 21 | 19.229 | 0.920 | 4.78 | 16.500 | 22.000 |
| 2021-033 | 44 BECK.COUL. | | | 17 | 22.629 | 1.454 | 6.42 | 18.300 | 27.000 |
| 2021-033 | 50 ARC | | | 10 | 22.610 | 0.712 | 3.15 | 20.500 | 24.700 |
| 2021-034 | 29 VITROS | | | 11 | 9.155 | 0.300 | 3.27 | 8.300 | 10.100 |
| 2021-034 | 38 ROCHE E | | | 21 | 9.357 | 0.408 | 4.36 | 8.100 | 10.600 |
| 2021-034 | 44 BECK.COUL. | | | 17 | 10.288 | 0.516 | 5.01 | 8.700 | 11.800 |
| 2021-034 | 50 ARC | | | 10 | 10.350 | 0.476 | 4.60 | 8.900 | 11.800 |
| 2021-035 | 29 VITROS | | | 11 | 14.491 | 0.406 | 2.80 | 13.300 | 15.700 |
| 2021-035 | 38 ROCHE E | | | 21 | 14.214 | 0.620 | 4.36 | 12.400 | 16.100 |
| 2021-035 | 44 BECK.COUL. | | | 17 | 16.247 | 0.948 | 5.83 | 13.400 | 19.100 |
| 2021-035 | 50 ARC | | | 10 | 16.360 | 0.853 | 5.22 | 13.800 | 18.900 |
| 069 | PROS. SPEC-ANTIG-PSA | | | | | | | | |
| 2021-031 | 29 VITROS | | | 38 | 0.224 | 0.108 | 47.95 | 0.200 | 0.300 |
| 2021-031 | 36 TOSOH AIA | | | 13 | 0.175 | 0.043 | 24.74 | 0.100 | 0.200 |
| 2021-031 | 38 ROCHE E | | | 46 | 0.200 | 0.000 | 0.00 | 0.200 | 0.200 |
| 2021-031 | 39 DIMENS.RXL | | | 50 | 0.160 | 0.049 | 30.62 | 0.100 | 0.200 |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 60 SPECIAL TESTS

GRP: 90 SPECIAL TEST

| ANALYTE | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
|----------|----------------------|-------------------|-----------------------------------|----------|------------|-----------|-------|------------|--------|
| SAMPLE | METHOD | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH |
| 2021-031 | 44 | BECK.COUL. | | 51 | 0.182 | 0.038 | 20.91 | 0.100 | 0.200 |
| 2021-031 | 50 | ARC | | 18 | 0.100 | 0.000 | 0.00 | 0.100 | 0.100 |
| 2021-031 | 57 | S. EXL 200 | | 20 | 0.165 | 0.048 | 28.91 | 0.100 | 0.200 |
| 069 | PROS. SPEC-ANTIG-PSA | CLIA TEST ID #: 0 | EVALUATION CRITERIA: TARGET VALUE | 3 | SD OR 25 % | {LOWER} | | | |
| 2021-032 | 29 | VITROS | | 38 | 20.845 | 0.948 | 4.55 | 18.000 | 23.700 |
| 2021-032 | 36 | TOSOH AIA | | 13 | 21.917 | 1.241 | 5.66 | 18.200 | 25.600 |
| 2021-032 | 38 | ROCHE E | | 46 | 26.872 | 2.144 | 7.98 | 20.400 | 33.300 |
| 2021-032 | 39 | DIMENS.RXL | | 50 | 24.778 | 1.359 | 5.48 | 20.700 | 28.900 |
| 2021-032 | 44 | BECK.COUL. | | 51 | 28.433 | 1.690 | 5.94 | 23.400 | 33.500 |
| 2021-032 | 50 | ARC | | 18 | 21.228 | 1.587 | 7.48 | 16.500 | 26.000 |
| 2021-032 | 57 | S. EXL 200 | | 20 | 24.485 | 1.492 | 6.10 | 20.000 | 29.000 |
| 2021-033 | 29 | VITROS | | 38 | 15.129 | 0.695 | 4.60 | 13.000 | 17.200 |
| 2021-033 | 36 | TOSOH AIA | | 13 | 15.950 | 1.034 | 6.48 | 12.800 | 19.100 |
| 2021-033 | 38 | ROCHE E | | 46 | 19.750 | 1.530 | 7.75 | 15.200 | 24.300 |
| 2021-033 | 39 | DIMENS.RXL | | 50 | 18.018 | 0.986 | 5.47 | 15.100 | 21.000 |
| 2021-033 | 44 | BECK.COUL. | | 51 | 20.731 | 0.920 | 4.44 | 18.000 | 23.500 |
| 2021-033 | 50 | ARC | | 18 | 15.183 | 0.692 | 4.56 | 13.100 | 17.300 |
| 2021-033 | 57 | S. EXL 200 | | 20 | 17.755 | 1.010 | 5.69 | 14.700 | 20.800 |
| 2021-034 | 29 | VITROS | | 38 | 7.250 | 0.328 | 4.53 | 6.300 | 8.200 |
| 2021-034 | 36 | TOSOH AIA | | 13 | 7.583 | 0.501 | 6.61 | 6.100 | 9.100 |
| 2021-034 | 38 | ROCHE E | | 46 | 9.280 | 0.631 | 6.80 | 7.400 | 11.200 |
| 2021-034 | 39 | DIMENS.RXL | | 50 | 8.421 | 0.450 | 5.34 | 7.100 | 9.800 |
| 2021-034 | 44 | BECK.COUL. | | 51 | 9.654 | 0.499 | 5.17 | 8.200 | 11.200 |
| 2021-034 | 50 | ARC | | 18 | 7.017 | 0.446 | 6.36 | 5.700 | 8.400 |
| 2021-034 | 57 | S. EXL 200 | | 20 | 8.275 | 0.536 | 6.47 | 6.700 | 9.900 |
| 2021-035 | 29 | VITROS | | 38 | 11.163 | 0.524 | 4.70 | 9.600 | 12.700 |
| 2021-035 | 36 | TOSOH AIA | | 13 | 11.775 | 0.828 | 7.03 | 9.300 | 14.300 |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 60 SPECIAL TESTS

GRP: 90 SPECIAL TEST

| ANALYTE | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
|------------------|--------|-------------------|--|------|----------|-----------|----------|---------|------------|-------|
| SAMPLE | METHOD | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH | |
| 2021-035 | 38 | ROCHE E | | 46 | 14.417 | 1.108 | 7.69 | 11.100 | 17.700 | |
| 2021-035 | 39 | DIMENS.RXL | | 50 | 13.296 | 0.711 | 5.34 | 11.200 | 15.400 | |
| 2021-035 | 44 | BECK.COUL. | | 51 | 14.952 | 0.802 | 5.36 | 12.500 | 17.400 | |
| 2021-035 | 50 | ARC | | 18 | 11.006 | 0.603 | 5.48 | 9.200 | 12.800 | |
| 2021-035 | 57 | S. EXL 200 | | 20 | 12.935 | 0.833 | 6.44 | 10.400 | 15.400 | |
| 071 VITAMIN B 12 | | CLIA TEST ID #: 0 | EVALUATION CRITERIA: TARGET VALUE 3 SD OR 25 % {LOWER} | | | | | | | |
| 2021-031 | 29 | VITROS | | 24 | 264.304 | 6.590 | 2.49 | 245.000 | 284.000 | |
| 2021-031 | 38 | ROCHE E | | 27 | 202.704 | 38.811 | 19.15 | 152.000 | 253.000 | |
| 2021-031 | 44 | BECK.COUL. | | 24 | 160.875 | 16.974 | 10.55 | 121.000 | 201.000 | |
| 2021-031 | 50 | ARC | | 17 | 220.938 | 15.974 | 7.23 | 173.000 | 269.000 | |
| 2021-031 | 57 | S. EXL 200 | | 10 | 332.500 | 22.491 | 6.76 | 265.000 | 400.000 | |
| 2021-032 | 29 | VITROS | | 24 | 757.958 | 81.888 | 10.80 | 568.000 | 947.000 | |
| 2021-032 | 38 | ROCHE E | | 27 | 975.923 | 171.965 | 17.62 | 732.000 | 1220.000 | |
| 2021-032 | 44 | BECK.COUL. | | 24 | 697.958 | 66.032 | 9.46 | 523.000 | 872.000 | |
| 2021-032 | 50 | ARC | | 17 | 953.813 | 56.967 | 5.97 | 783.000 | 1125.000 | |
| 2021-032 | 57 | S. EXL 200 | | 10 | 924.700 | 30.916 | 3.34 | 832.000 | 1017.000 | |
| 2021-033 | 29 | VITROS | | 24 | 694.667 | 76.039 | 10.95 | 521.000 | 868.000 | |
| 2021-033 | 38 | ROCHE E | | 27 | 756.654 | 66.264 | 8.76 | 567.000 | 946.000 | |
| 2021-033 | 44 | BECK.COUL. | | 24 | 544.125 | 45.631 | 8.39 | 408.000 | 680.000 | |
| 2021-033 | 50 | ARC | | 17 | 741.500 | 47.538 | 6.41 | 599.000 | 884.000 | |
| 2021-033 | 57 | S. EXL 200 | | 10 | 749.100 | 23.923 | 3.19 | 677.000 | 821.000 | |
| 2021-034 | 29 | VITROS | | 24 | 441.667 | 24.682 | 5.59 | 368.000 | 516.000 | |
| 2021-034 | 38 | ROCHE E | | 27 | 419.889 | 62.476 | 14.88 | 315.000 | 525.000 | |
| 2021-034 | 44 | BECK.COUL. | | 24 | 327.708 | 25.183 | 7.68 | 252.000 | 403.000 | |
| 2021-034 | 50 | ARC | | 17 | 440.824 | 28.153 | 6.39 | 356.000 | 525.000 | |
| 2021-034 | 57 | S. EXL 200 | | 10 | 511.500 | 23.256 | 4.55 | 442.000 | 581.000 | |

Participant Summary

MONTH 2 OF YEAR 2021

| SPEC: 10 CHEMISTRY | | | SUB: 60 SPECIAL TESTS | | | GRP: 90 SPECIAL TEST | | | | |
|--------------------|---------------|-------------------|-----------------------------------|------|------------|----------------------|----------|---------|------------|-------|
| ANALYTE | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
| SAMPLE | METHOD | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH | |
| 071 VITAMIN B 12 | | CLIA TEST ID #: 0 | EVALUATION CRITERIA: TARGET VALUE | 3 | SD OR 25 % | {LOWER} | | | | |
| 2021-035 | 29 VITROS | | | 24 | 558.958 | 51.788 | 9.27 | 419.000 | 699.000 | |
| 2021-035 | 38 ROCHE E | | | 27 | 587.231 | 51.254 | 8.73 | 440.000 | 734.000 | |
| 2021-035 | 44 BECK.COUL. | | | 24 | 438.208 | 36.068 | 8.23 | 330.000 | 546.000 | |
| 2021-035 | 50 ARC | | | 17 | 583.176 | 34.505 | 5.92 | 480.000 | 687.000 | |
| 2021-035 | 57 S. EXL 200 | | | 10 | 622.200 | 34.278 | 5.51 | 519.000 | 725.000 | |

| SPEC: 10 CHEMISTRY | | | SUB: 60 SPECIAL TESTS | | | GRP: 95 GLYCOHEMOGLOBINE | | | | |
|---------------------|---------------|-----------|-----------------------|------|----------|--------------------------|----------|-------|------------|-------|
| ANALYTE | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
| SAMPLE | METHOD | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH | |
| 146 GLYCOHEMOGLOBIN | | | | | | | | | | |
| 2021-041 | 2 DCA-2000 | | | 10 | 6.220 | 0.299 | 4.81 | 5.300 | 7.100 | |
| 2021-041 | 12 COBAS/INT. | | | 29 | 5.914 | 0.328 | 5.54 | 4.900 | 6.900 | |
| 2021-041 | 14 IMMUNOTUR. | | | 10 | 6.140 | 0.408 | 6.64 | 4.900 | 7.400 | |
| 2021-041 | 22 VITROS | | | 42 | 5.721 | 0.152 | 2.66 | 5.300 | 6.200 | |
| 2021-041 | 30 DAYTONA | | | 13 | 6.254 | 0.669 | 10.69 | 4.700 | 7.800 | |
| 2021-041 | 31 IMMUNOTURB | | | 32 | 5.622 | 0.375 | 6.67 | 4.500 | 6.700 | |
| 2021-041 | 40 SIEMENS DI | | | 80 | 5.973 | 0.289 | 4.83 | 5.100 | 6.800 | |
| 2021-041 | 46 ARCHITECT | | | 15 | 5.627 | 0.161 | 2.86 | 5.100 | 6.100 | |
| 2021-042 | 2 DCA-2000 | | | 10 | 7.220 | 0.260 | 3.60 | 6.400 | 8.000 | |
| 2021-042 | 12 COBAS/INT. | | | 29 | 6.914 | 0.275 | 3.98 | 6.100 | 7.700 | |
| 2021-042 | 14 IMMUNOTUR. | | | 10 | 7.260 | 0.498 | 6.86 | 5.800 | 8.800 | |
| 2021-042 | 22 VITROS | | | 42 | 6.905 | 0.215 | 3.12 | 6.300 | 7.600 | |
| 2021-042 | 30 DAYTONA | | | 13 | 7.069 | 0.439 | 6.21 | 5.800 | 8.400 | |
| 2021-042 | 31 IMMUNOTURB | | | 32 | 6.878 | 0.290 | 4.22 | 6.000 | 7.700 | |
| 2021-042 | 40 SIEMENS DI | | | 80 | 7.015 | 0.206 | 2.93 | 6.400 | 7.600 | |
| 2021-042 | 46 ARCHITECT | | | 15 | 6.573 | 0.148 | 2.25 | 6.100 | 7.000 | |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 60 SPECIAL TESTS

GRP: 95 GLYCOHEMOGLOBINE

| ANALYTE | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
|----------|-----------------|-------------------|-----------------------------------|------|------------|-----------|----------|--------|------------|-------|
| SAMPLE | METHOD | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH | |
| 146 | GLYCOHEMOGLOBIN | CLIA TEST ID #: 0 | EVALUATION CRITERIA: TARGET VALUE | 3 | SD OR 25 % | {LOWER} | | | | |
| 2021-043 | 2 | DCA-2000 | | 10 | 11.360 | 0.390 | 3.44 | 10.200 | 12.500 | |
| 2021-043 | 12 | COBAS/INT. | | 29 | 11.200 | 0.396 | 3.53 | 10.000 | 12.400 | |
| 2021-043 | 14 | IMMUNOTUR. | | 10 | 11.520 | 0.992 | 8.61 | 8.600 | 14.400 | |
| 2021-043 | 22 | VITROS | | 42 | 10.907 | 0.323 | 2.96 | 9.900 | 11.900 | |
| 2021-043 | 30 | DAYTONA | | 13 | 12.054 | 0.749 | 6.21 | 9.800 | 14.300 | |
| 2021-043 | 31 | IMMUNOTURB | | 32 | 11.075 | 0.502 | 4.53 | 9.600 | 12.600 | |
| 2021-043 | 40 | SIEMENS DI | | 80 | 11.010 | 0.294 | 2.67 | 10.100 | 11.900 | |
| 2021-043 | 46 | ARCHITECT | | 15 | 10.436 | 0.134 | 1.29 | 10.000 | 10.800 | |
| 2021-044 | 2 | DCA-2000 | | 10 | 6.230 | 0.380 | 6.09 | 5.100 | 7.400 | |
| 2021-044 | 12 | COBAS/INT. | | 29 | 5.952 | 0.333 | 5.59 | 5.000 | 7.000 | |
| 2021-044 | 14 | IMMUNOTUR. | | 10 | 5.990 | 0.288 | 4.81 | 5.100 | 6.900 | |
| 2021-044 | 22 | VITROS | | 42 | 5.690 | 0.141 | 2.48 | 5.300 | 6.100 | |
| 2021-044 | 30 | DAYTONA | | 13 | 6.146 | 0.323 | 5.25 | 5.200 | 7.100 | |
| 2021-044 | 31 | IMMUNOTURB | | 32 | 5.584 | 0.303 | 5.42 | 4.700 | 6.500 | |
| 2021-044 | 40 | SIEMENS DI | | 80 | 5.976 | 0.264 | 4.41 | 5.200 | 6.800 | |
| 2021-044 | 46 | ARCHITECT | | 15 | 5.627 | 0.144 | 2.55 | 5.200 | 6.100 | |
| 2021-045 | 2 | DCA-2000 | | 10 | 7.130 | 0.210 | 2.95 | 6.500 | 7.800 | |
| 2021-045 | 12 | COBAS/INT. | | 29 | 6.907 | 0.209 | 3.02 | 6.300 | 7.500 | |
| 2021-045 | 14 | IMMUNOTUR. | | 10 | 7.230 | 0.443 | 6.12 | 5.900 | 8.600 | |
| 2021-045 | 22 | VITROS | | 42 | 6.924 | 0.185 | 2.67 | 6.400 | 7.500 | |
| 2021-045 | 30 | DAYTONA | | 13 | 7.085 | 0.709 | 10.01 | 5.300 | 8.900 | |
| 2021-045 | 31 | IMMUNOTURB | | 32 | 6.916 | 0.277 | 4.01 | 6.100 | 7.700 | |
| 2021-045 | 40 | SIEMENS DI | | 80 | 7.058 | 0.160 | 2.27 | 6.600 | 7.500 | |
| 2021-045 | 46 | ARCHITECT | | 15 | 6.580 | 0.142 | 2.16 | 6.200 | 7.000 | |

Participant Summary

MONTH 2 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 60 SPECIAL TESTS

GRP: 99 Vitamin D

| ANALYTE | | | | | NO. PART | TARGET | STANDARD | % | ACCEPTABLE | RANGE |
|---------------|--------|-------------------|-----------------------------------|------|----------|-----------|----------|--------|------------|-------|
| SAMPLE | METHOD | SYST/INST | REAGENTS | LABS | VALUE | DEVIATION | CV | LOW | HIGH | |
| 178 Vitamin D | | CLIA TEST ID #: 0 | EVALUATION CRITERIA: TARGET VALUE | 20 % | | | | | | |
| 2021-261 | 3 | VITROS | | 35 | 23.147 | 4.367 | 18.86 | 19.000 | 28.000 | |
| 2021-261 | 5 | ROCHE E | | 34 | 21.412 | 2.991 | 13.97 | 17.000 | 26.000 | |
| 2021-261 | 9 | BECK.COUL. | | 44 | 29.250 | 2.506 | 8.57 | 23.000 | 35.000 | |
| 2021-261 | 11 | ARC | | 17 | 27.500 | 1.541 | 5.60 | 22.000 | 33.000 | |
| 2021-261 | 25 | S. DIME | | 21 | 21.810 | 1.500 | 6.88 | 17.000 | 26.000 | |
| 2021-262 | 3 | VITROS | | 35 | 42.382 | 5.816 | 13.72 | 34.000 | 51.000 | |
| 2021-262 | 5 | ROCHE E | | 34 | 33.364 | 3.338 | 10.00 | 27.000 | 40.000 | |
| 2021-262 | 9 | BECK.COUL. | | 44 | 47.591 | 3.222 | 6.77 | 38.000 | 57.000 | |
| 2021-262 | 11 | ARC | | 17 | 45.500 | 2.151 | 4.73 | 36.000 | 55.000 | |
| 2021-262 | 25 | S. DIME | | 21 | 33.905 | 2.091 | 6.17 | 27.000 | 41.000 | |
| 2021-263 | 3 | VITROS | | 35 | 80.118 | 6.493 | 8.10 | 64.000 | 96.000 | |
| 2021-263 | 5 | ROCHE E | | 34 | 50.441 | 7.570 | 15.01 | 40.000 | 61.000 | |
| 2021-263 | 9 | BECK.COUL. | | 44 | 79.767 | 5.052 | 6.33 | 64.000 | 96.000 | |
| 2021-263 | 11 | ARC | | 17 | 73.000 | 2.598 | 3.56 | 58.000 | 88.000 | |
| 2021-263 | 25 | S. DIME | | 21 | 53.476 | 2.921 | 5.46 | 43.000 | 64.000 | |
| 2021-264 | 3 | VITROS | | 35 | 32.333 | 3.723 | 11.51 | 26.000 | 39.000 | |
| 2021-264 | 5 | ROCHE E | | 34 | 24.091 | 2.575 | 10.69 | 19.000 | 29.000 | |
| 2021-264 | 9 | BECK.COUL. | | 44 | 33.932 | 2.666 | 7.86 | 27.000 | 41.000 | |
| 2021-264 | 11 | ARC | | 17 | 32.063 | 1.749 | 5.45 | 26.000 | 38.000 | |
| 2021-264 | 25 | S. DIME | | 21 | 24.857 | 1.612 | 6.49 | 20.000 | 30.000 | |
| 2021-265 | 3 | VITROS | | 35 | 57.818 | 4.865 | 8.41 | 46.000 | 69.000 | |
| 2021-265 | 5 | ROCHE E | | 34 | 41.588 | 5.683 | 13.67 | 33.000 | 50.000 | |
| 2021-265 | 9 | BECK.COUL. | | 44 | 64.182 | 4.371 | 6.81 | 51.000 | 77.000 | |
| 2021-265 | 11 | ARC | | 17 | 55.706 | 10.720 | 19.24 | 45.000 | 67.000 | |
| 2021-265 | 25 | S. DIME | | 21 | 44.143 | 2.436 | 5.52 | 35.000 | 53.000 | |

4/19/2021

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 122 (122)
DATE : 4/19/2021
TIME : 11:41:58

Participant Summary

MONTH 2 OF YEAR 2021